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Abstract 
Use of medications, including psychotropics, is common during pregnancy. Indeed, many 
women might be in need of pharmacotherapy during pregnancy in order to ensure maternal-
fetal health. However, discordant findings or lack of information about neonatal and maternal 
safety after use of psychotropics, in particular antidepressants, have so far posed significant 
challenges on practicing clinicians when assessing the risk of pharmacotherapy versus the risk 
RIQRWPHGLFDWHGPDWHUQDOLOOQHVV,QDGGLWLRQZRPHQ¶VXQUHDOLVWLFULVNSHUFHSWLRQRIH[SRVXUH
WRDQWLGHSUHVVDQWVGXULQJSUHJQDQF\DQGLQGLYLGXDOV¶EHOLHIVDERXWSUHVFULEHGPHGLFLQHVPD\
influence ZRPHQ¶VDGKHUHQFHWRQHHGHGPHGLFDWLRQVGXULQJSUHJQDQF\ 
Thus, the aims of this doctoral work were: I) to explore from a multinational perspective 
patterns of and factors associated with use of medications during pregnancy, with particular 
focus on psychotropics for treatment of depression and/or anxiety; II) to investigate patterns of 
and associations between use of psychotropics and other relevant medications in the time 
around pregnancy and eating disorders; III) to explore patterns of and risk factors for low 
adherence to psychotropics during pregnancy; IV) to determine whether gestational exposure 
to antidepressants increases the risk of obstetric bleeding complications during pregnancy and 
postpartum.     
In order to address these research questions, data from two studies were utilized. The 
Multinational Medication Use in Pregnancy Study, providing information about psychiatric 
and other disorders during pregnancy, related medications use and adherence during 
pregnancy as reported by participating women, was used to address aims nos. I and III. The 
Norwegian Mother and Child Cohort Study, comprising information on medication exposures 
and maternal characteristics during pregnancy, linked to the Medical Birth Registry of Norway 
providing information about birth outcomes, were utilized to address aims nos. II and IV. 
Study I showed that about eight out of ten women used at least one medication during the 
course of the pregnancy, whereas five out of ten did so during the first trimester. There was a 
high degree of self-medication with OTC drugs (67%) during pregnancy. About 3% of women 
reported use of psychotropic medications during pregnancy, mostly SSRIs. Disadvantaged 
women (e.g. single or divorced, older, with low education, smokers and alcohol consumers 

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during pregnancy) or with an unplanned pregnancy were more likely to use psychotropics 
during pregnancy. 
Study II showed that use of psychotropics is high among women with eating disorders before, 
during, and after pregnancy, particularly among women with AN or EDNOS-P. Having BN 
was found to be significantly directly associated with use (1.8-fold magnitude) and incident 
use (2.3-fold magnitude) of psychotropics during pregnancy. Having AN or EDNOS-P were 
found to be significantly directly associated with use of anxiolytics/sedatives postpartum (5.1- 
and 6.8-fold risk magnitude, respectively). 
In study III, about 5% of the sample reported having a psychiatric disorder during pregnancy, 
mainly depression and/or anxiety, and within this group about 50% presented symptoms of 
depression. Of the women with a psychiatric disorder, 62% were medicated with 
psychotropics during pregnancy. About one out of two women medicated with psychotropics 
demonstrated low adherence during pregnancy. Risk factors for low medication adherence 
were smoking in pregnancy, ongoing symptoms of depression, elevated antidepressant risk 
perceptionDQGZRPHQ¶VLQGLYLGXDOEHOLHIVDERut their prescribed psychotropics. 
Study IV showed that exposure to antidepressants during the first or second trimester is not 
associated with an increased likelihood of vaginal bleeding in early or midpregnancy, 
respectively. Contrarily, women with depressive symptoms but not exposed to antidepressants 
during pregnancy had a moderate significant increased likelihood to experience these 
outcomes. Exposure to SSRIs/SNRIs between gestational week 30 and childbirth did not 
confer any increased odds for postpartum hemorrhage, compared to non-exposure; however, 
exposure to TCAs/OADs during this time window conferred a significant 3.8-fold increased 
odds of postpartum hemorrhage overall, but low statistical power impeded the analysis by 
mode of delivery. 
The findings of this work highlight the need to increase awareness among healthcare providers 
that a large proportion of pregnant women will be in need of tailored evidence-based 
information about the fetal and maternal risks of medication exposures during pregnancy, but 
also about the risk of untreated psychiatric illness during pregnancy and postpartum. 
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1. Introduction 
³Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less´ 
- Marie Curie 
Medication use in pregnancy has become an important public health concern in the latest years. 
Indeed, the mean age of women at first birth has dramatically increased in most developed 
countries,1 which implies higher potential risks of obstetric and perinatal complications, and 
not least a higher likelihood that women will be suffering from chronic disorders already at 
conception.2 Similarly, the burden of depression and other mental health conditions is on the 
rise globally, especially among women, and pregnancy is not a protective factor against their 
occurrence.3,4 In all these instances, pharmacotherapy may be needed, even during pregnancy. 
Pharmacotherapy during pregnancy however involves weighing the possible risk of fetal 
exposure to medication against the potential adverse effects of untreated maternal illness to 
both the mother and child. To guide such decisions, it is critical to provide sound data about 
patterns of and factors associated with medication use in pregnancy, and not least their safety 
in pregnancy.   
1.1 Lesson learned from the past and ethical considerations  
Nearly every pregnant woman has faced the dilemma whether to take or not to take a 
medication during pregnancy because of fear of harming her unborn child. The rationale 
behind such fear is multifaceted and is triggered by several factors such as health care 
SURIHVVLRQDOV¶KHVLWDWLRQLQDGYLVLQJDQGSUHVFULELQJQHHGHGPHGLFDWLRQVWRSUHJQDQWZRPHQ
medication labeling, lack of tailored evidence-based teratogenic counseling, receipt of 
conflicting information from different sources, and most importantly uncertainty about the 
safety profile of most marketed medications in human pregnancy.5-9  
7KH³WKDOLGRPLGHGLVDVWHU´IURPWKHHDUO\¶VKDVFHUWDLQO\FRQWULEXWHGWRVXFKDVFHQDULRDQG
shaped a strong common belief that women should not be exposed to anything during 
pregnancy, especially not medications, as they could potentially harm the fetus.  The 
³WKDOLGRPLGHGLVDVWHU´UHSUHVHQWVWKHPRVWXQWRZDUGHYHQWLQWKHKLVWRU\RIUHSURGXFWLYHKHDOWK

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which shattered the P\WK WKDW WKHUHZDV D ³SODFHQWDO EDUULHU´ WKURXJKZKLFK QRWKLQJ FRXOG
FURVV7KDOLGRPLGHZDVDPHGLFDWLRQOLFHQVHGLQWKHODWH¶VDVVHGDWLYHDQGDQWL-nausea drug 
that could be safely used in pregnancy.10 ,Q WKH HDUO\ ¶V 'UV 0F%ULGH DQG /HQ]
independently reported an increase in the incidence of infants with severe congenital 
anomalies after exposure in utero to thalidomide,11,12 which was then withdrawn from the 
market. By this time, however, more than 10,000 children had been born with major 
thalidomide-related malformations.10 Approximately one out of three women taking 
thalidomide during the first trimester of pregnancy gave birth to a child with congenital 
anomalies.13 These mainly included amelia or phocomelia of extremities, and resulted from 
repeated use as well as from single intake during the critical period within the 27th to the 40th 
day of gestation.14  
The abovementioned disaster gave rise to increased caution and reticence among 
pharmaceutical manufacturers in carrying out clinical studies including pregnant women, and 
the Food and Drug Administration (FDA) in the USA even promulgated new Ethics Research 
Guidelines supporting the exclusion of women in childbearing age from clinical studies 
investigating new medications.15 In the years that followed, other drugs, such as isotretinoin 
and valproic acid, were correctly shown to be teratogenic, whereas other were wrongly alleged 
to be so, for instance the anti-emetic Bendectin® (doxylamine and pyridoxine). Although 
subsequent sound studies unsupported the allegations against Bendectin®,16 they anyhow 
reinforced the general concern and unrealistic elevated perception of teratogenic risk of 
marketed medications, which sometimes even led women to terminate a wanted pregnancy.17 
In 1992, the FDA urged the need of more studies of gender differences in prescription drug 
testing,18 which represented an important shift in clinical research. The current International 
Ethical Guidelines for Biomedical Research Involving Human Subjects also provides guidance 
LQKRZFOLQLFDO UHVHDUFK LQSUHJQDQWZRPHQVKRXOGEHFDUULHGRXW VWDWLQJ WKDW³Research in 
this population should be performed only if it is relevant to the particular health needs of a 
pregnant woman or her fetus, or to the health needs of pregnant women in general, and, when 
appropriate, if it is supported by reliable evidence from animal experiments, particularly as to 
risks of teratogenicity and mutagenicity´19 These principles are also emphasized in the 
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Guidelines for inclusion of women in medical research ± Gender as variable in all medical 
research, edited by the National Ethics Committee for medical research in Norway.20 
The value of preclinical testing of medications in pregnant animals is somewhat limited since 
teratogenicity in animals does not always predict teratogenicity in humans, or the converse. 
For instance, thalidomide was not found to exert teratogenic effects in rats but it did cause 
malformations similar to those seen in humans in New Zealand white rabbits, highlighting the 
importance of species-specific mechanisms in teratogenicity.21  
Since no studies of teratogenicity or of other adverse perinatal outcomes can be conducted 
during embryogenesis in humans, most medications are put into the market without their 
safety profile in human pregnancy being established. So far, few medications have been 
shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on 
fetal and child development still has to be determined for most of drugs.13 Now it is time ³to 
understand more´ DERXW SDWWHUQV RI XVH DQG VDIHW\ RI PHGLFDWLRQV LQ SUHJQDQF\ VR WKDW 
practicing clinicians and pregnant women ³PD\IHDUOHVV´DQGWKXVHQVXUHUDWLRQDOHDQGVDIH
medication use among pregnant women worldwide.  
1.2 Introduction to maternal disorders and medication use 
in pregnancy 
³$IWHUWKHGLVDVWHUVRIWKHSDVWLWLVZRUU\LQJWKLQNLQJ 
\RXPD\KDYHWRWDNHPHGLFDWLRQDWDOOLQSUHJQDQF\´ 
- A 36-year-old woman from the  
United Kingdom, 39 weeks pregnant - 
Pregnancy encompasses PDQ\ ELRORJLFDO DQG SV\FKRORJLFDO FKDQJHV LQ D ZRPDQ¶V ERG\
These physiological changes are often the cause of numerous short-term ailments such as 
nausea and vomiting, heartburn, headache or pelvic girdle pain, just to mention some, and may 
also increase DZRPDQ¶VVXVFHSWLELOLW\WRXULQDU\WUDFWLQIHFWLRQV87,V)RULQVWDQFHQDXVHD
and vomiting are estimated to affect 75% of pregnant women, whereas UTIs are expected to 
complicate 7-10% of the pregnancies.22,23 Women with preexisting disorders do also get 
pregnant, and not least delayed childbearing is associated with increased risk of obstetrical 
complications such as gestational diabetes, preeclampsia, or hypertension.2 Hence, for most of 

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these disorders, either short or long-term, pharmacotherapy during pregnancy may be required 
to ensure maternal-fetal health. 
Several studies have shown that medication use is common during pregnancy. Daw et al.24 
have recently systematically reviewed all pregnancy drug utilization studies performed in 
developed countries and found that prescription drug use in pregnancy was highest in France 
(93%) and Germany (85%) and lowest in Northern European countries (44-47%). Most of the 
studies included in the systematic review used automated databases as source of information 
about drug utilization. However, in this latter review it was also pointed out that difference in 
study designs, calculation of length of pregnancy, and restriction or not to pregnancies ending 
in live births, impeded objective comparisons across the various studies.24 The last cooperative 
study collecting data uniformly in various countries was carried out in 1987.25  
Individual studies across Europe identified different estimates of prescribed medication use, 
ranging from 27% in Serbia to 46% in Finland, 48% in Italy, 57% in Norway, 79% in The 
Netherlands and 93% in France.26-31 In the USA, use of medications, either prescribed or 
purchased over-the-counter (OTC), occurred in 89% of all pregnancies.32 Overall, paracetamol 
(acetaminophen) is the most commonly used medication in pregnancy, followed by 
medication for the alimentary tract and metabolism (e.g., antacids, laxatives, and antiemetics), 
antibiotics, anti-asthmatics and psychotropics.30,33-35 In Norway, the most recent study 
utilizing patients as source of information about medication use in pregnancy (via self-
completed questionnaires), was carried out in the period 2008-2010;36 it was found that 58% 
of women used psychotropics and/or analgesic medications during pregnancy, with analgesics 
being the most common drug group (56%). Among the women who reported using analgesics 
prior to pregnancy, 71% also did so during pregnancy.36 
Most of the recent studies on medication use in pregnancy stem from automated databases 
analyses that are often limited to prescription-only medications. In fact, the available literature 
about the extent and typology of OTC medication used in pregnancy is not extensive. Werler 
et al.37 found that use of OTC is common in pregnancy, with 65%, 18% and 15% of women 
reporting use of paracetamol, ibuprofen, and pseudoephedrine, respectively, during pregnancy. 
Another study38 among Hispanic women residing in the USA found that the self-reported rate 


ϭϮ
of OTC drug use during pregnancy was 23%, while higher estimates were observed by 
Refuerzo et al. (63%).39 In the latter study, paracetamol, antacids and ibuprofen were the most 
commonly reported OTC drugs (37%, 26% and 10%, respectively).39  
Several studies have also attempted to estimate the prevalence of use of medications with a 
potential for fetal harm among pregnant women.26,40-42 In the study by Andrade et al.,40 for 
instance, 1.1% of women in the USA were exposed to a teratogenic medication during 
gestation based on the assessment of clinical teratologists, most commonly fluconazole, 
carbamazepine, prophylthiouracil and tetracycline. A recent study43 examined the prevalence 
and fetal risks of medications most commonly used specifically during the first trimester of 
pregnancy. There were 54 medications used by more than 0.5% of the pregnant population 
during the first trimester, and among these only two drugs (promethazine and doxylamine) had 
³JRRG WR H[FHOOHQW´ GDWD DYDLODEOH WR DVVHVV WKHLU WHratogenic risks in human pregnancy 
according to the Teratology Information System (TERIS); the majority of the remaining 
PHGLFDWLRQVKDG³YHU\OLPLWHGWRIDLU´GDWDDERXWWKHLUWHUDWRJHQLFULVNV 
1.3 Psychiatric disorders and related pharmacotherapy 
during pregnancy 
1.3.1 The burden of psychiatric disorders in pregnancy 
Psychiatric disorders such as depression, anxiety and eating disorders, are important illnesses 
primarily affecting the childbearing-age female population, and pregnancy is not a protective 
factor against their onset.4 Depression and anxiety constitute the most common psychiatric 
disorders in pregnancy. Studies have shown that between 8.5% and 11.0% of women may 
experience depression during pregnancy, with variations according to time of gestation.44 
However, when we deal with symptoms of depression rather than diagnosis of major or minor 
depression, the prevalence estimates rise to 25%,45 with peaks especially in the second and 
third trimester.46,47 Anxiety disorders, which are highly comorbid to depression, account for 
8.5% of the pregnancies.48 However, prevalence estimates of anxiety disorders may vary from 
study to study, both related to the gestational time when women were assessed and to the 
screening/diagnostic tool utilized.  


ϭϯ
Eating disorders are also not uncommon during pregnancy. However, since women with 
eating disorders tend to not disclose any eating disorder, either past or present, to their treating 
obstetricians, these conditions may be under-recognized in prenatal routine care.49 According 
to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV and DSM-5,50,51 
eating disorders are classified into anorexia nervosa (AN), bulimia nervosa (BN), binge-eating 
disorder (BED), and eating disorders not otherwise specified (EDNOS). A recent study among 
women attending their first routine ultrasound (mean gestational week: 11.5) found that the 
prevalence of AN, BN, BED and EDNOS were 0.5%, 0.1%, 1.8% and 5.0%, respectively.52 
Another study from the Norwegian Mother and Child Cohort (MoBa) found that the 
prevalence of BN, BED and EDNOS purging type (EDNOS-P) in early pregnancy were 0.2%, 
4.8% and 0.1%, respectively.53 In general, eating disorder symptoms have been shown to 
decrease during pregnancy. They do not disappear completely, and some women with a past 
eating disorder history can have a resurgence of symptoms in pregnancy.54 Improvement in 
symptoms may be limited to the pregnancy period and perhaps for a brief period of time 
postpartum, but a significant portion of women returns to eating disorders symptoms after 
giving birth. Eating disorders are characterized by a high rate of psychiatric comorbidity, most 
commonly depression and anxiety.55 Indeed, high levels of anxiety and depression in the 
postpartum period have been found to be associated with active eating disorder symptoms in 
pregnancy.56 Other psychiatric disorders such as bipolar disorders, schizophrenia, obsessive-
compulsive disorders, are not presented here since they are not within the scope of this work.  
1.3.2 Psychotropic medication use in pregnancy 
³,DPFRQFHUQHGDERXWWKHHIIHFWVRIVHUWUDOLQHRQP\FKLOG 
but when I tried to gradually reduce my dose before pregnancy  
and during the first trimester I relapsed into a terrible depression.  
,HYHQWKRXJKWDERXWVXLFLGH´ 
- A 33-year-old woman from  
Canada, 23 weeks pregnant - 
Psychiatric disorders frequently require pharmacological treatment, even in pregnancy.57 
Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) are recommended 
as first-line pharmacological treatments for depressive and anxiety disorders since they carry a 
low risk of toxicity in overdose.4 SSRIs seem to moderately reduce the symptoms of BN and 


ϭϰ
BED, but exert little effect on full recovery.58-60 To date, fluoxetine is the only antidepressant 
approved for treatment of BN,61 and in January 2015 the psychostimulant lisdexamfetamine 
was approved by the FDA for treatment of BED.62 No psychotropic medication is approved 
for treatment of AN; indeed, clinical trials investigating the effect of antidepressants and 
antipsychotics for treatment of AN have shown disappointing results. Psychotropic 
medications are however used by patients with AN, often for treatment of comorbid 
psychiatric disorders or symptoms.63,64 
In Norway, approximately 3,000 children (5%) a year are exposed to psychotropic drugs during 
fetal life, most frequently antidepressants.28 Recent research has suggested that there is a 
steadily increasing trend of antidepressant use during pregnancy. Mitchell et al.32 examined 
trends of antidepressant use from 1976 to 2008 in the USA and found that exposure to these 
medications increased from 1% in 1988-1990 to 7.5% in 2008. Similarly, a study in The 
Netherlands found that exposure to SSRIs from three months before conception to delivery 
increased from 1.2% in 1995/1996 to 2.9% in 2003/2004.65 Tables 1a-1d below provide an 
overview of drug utilization studies published in the last ten years (February 2005 ± February 
2015) that were conducted in Western countries (i.e. Europe, North America and Australia) and 
provided estimates of use of any psychotropic medication in pregnancy, specifically 
antidepressants, antipsychotics or anxiolytics/sedatives. Although antiepileptics can be used for 
treatment of psychiatric illnesses such as bipolar disorders, this medication group was not taken 
into account in this work. Studies are grouped according to the source of information utilized 
(i.eTXHVWLRQQDLUHV LQWHUYLHZVSUHVFULEHUV¶PHGLFDO UHFRUGVDXWRPDWHGGDWDEDVHVDQGVRUWHG
by country of origin. Although general practice databases fall within the classification of 
automated databases, they were presented as drug utilization studies usLQJSUHVFULEHUV¶PHGLFDO
records as source of information about medication exposures in pregnancy. Whenever studies 
evaluated trends of mediation use overtime, we present the most recent estimate.  
As shown in Tables 1a-1d, most studies published in the last decade utilized automated 
databases, including general practice medical records, as source of information about medication 
use. Overall, antidepressants represent the psychotropic drug group most widely used in 
pregnancy in Europe, North America and Australia. The prevalence of antidepressant use in 
USA and Canada (ranging from 1.4% to 13.4%) is higher than that observed in European studies 


ϭϱ
(ranging from 0.8% to 4.5%). Also, drug utilization estimates extracted from interviews and 
questionnaires were substantially lower than those obtained from studies using medical records 
or automated databases. Indeed, these latter studies have measured rates of prescriptions (either 
filled or not) and therefore suffer from the main limitation as to whether pregnant women 
actually administered the prescribed drug(s). However, medical records and automated database 
are population-based data sources, as opposed to questionnaire or interview-based studies, which 
generally are covering a smaller segment of the target population.   


ϭϲ

dĂ
ďů
Ğ
ϭĂ
͗K
ǀĞ
ƌǀ
ŝĞǁ
Ž
ĨĚ
ƌƵ
Ő
Ƶƚ
ŝůŝǌ
Ăƚ
ŝŽŶ
Ɛ
ƚƵ
ĚŝĞ
Ɛ
ŝŶ
Ɖƌ
ĞŐ
ŶĂ
ŶĐ
Ǉ
ƵƐ
ŝŶŐ
ŝŶ
ƚĞ
ƌǀ
ŝĞǁ
Ă
Ɛ
ƐŽ
Ƶƌ
ĐĞ
Ž
Ĩŝ
ŶĨ
Žƌ
ŵ
Ăƚ
ŝŽ
Ŷ
Ăď
ŽƵ
ƚĞ
ǆƉ
ŽƐ
Ƶƌ
Ğ
ƚŽ
Ɖ
ƐǇ
ĐŚ
Žƚ
ƌŽ
Ɖŝ
ĐƐ
ŝŶ

Ɖƌ
ĞŐ
ŶĂ
ŶĐ
Ǉ
St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
  
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i-
ps
yc
ho
tic
s 
 
 
 
 
 
%
  
%
  
%
  
%
  
EU
R
O
PE
 
x 
IR
EL
A
N
D
 
Cl
ea
ry
 
et
 a
l. 
66
 
 
20
10
 
61
,2
52
 
20
00
-2
00
7 
In
te
rv
ie
w
 
M
at
er
ni
ty
 
ho
sp
ita
l 
-
 
0.
9*
 
-
 
-
 
x 
SP
A
IN
 
Ch
ec
a 
et
 a
l. 
67
 
20
05
 
1,
10
3 
Ja
n
-D
ec
 
20
02
 
In
te
rv
ie
w
 
M
at
er
ni
ty
 
w
ar
d 
in
 
o
n
e 
ho
sp
ita
l 
0.
8 
-
 
-
 
-
 
D
e 
La
s 
Cu
ev
as
 
et
 a
l. 
68
 
20
07
 
1,
33
2 
M
ay
-J
u
ly
 
20
06
 
In
te
rv
ie
w
 
M
at
er
ni
ty
 
w
ar
ds
 in
 
tw
o
 
pu
bl
ic
 h
o
sp
ita
ls 
2.
5 
0.
8 
1.
9 
-
 
N
O
R
TH
 A
M
ER
IC
A
 
x 
U
SA
 
Th
o
rp
e 
et
 a
l. 
43
 
20
13
 
5,
38
1 
20
06
-2
00
9 
(B
D
S)
 
 20
04
-2
00
7 
(N
BD
PS
) 
Co
m
pu
te
r-a
ss
ist
ed
 
te
le
ph
o
n
e 
in
te
rv
ie
w
s 
B
D
S 
&
 N
BD
PS
 
-
 
Se
rtr
al
in
e:
 1
.5
§  
Pa
ro
x
et
in
e:
 0
.6
§  
Fl
uo
x
et
in
e:
 1
.
0§
 
Es
ci
ta
lo
pr
am
: 
0.
7§
 
A
lp
ra
zo
la
m
: 
0.
5§
 
-
 
M
itc
he
ll 
et
 a
l. 
32
 
20
11
 
25
,3
13
 
(B
D
S)
  
 5,
00
8 
(N
BD
PS
) 
 
19
76
-2
00
8 
(B
D
S)
 
 19
97
-2
00
3 
(N
BD
PS
) 
Co
m
pu
te
r-a
ss
ist
ed
 
te
le
ph
o
n
e 
in
te
rv
ie
w
s 
B
D
S 
&
 N
BD
PS
 
-
 
B
D
S 
es
tim
at
es
: 
Se
rtr
al
in
e:
 2
.2
§  
Fl
uo
x
et
in
e:
 1
.
4§
  
Es
ci
ta
lo
pr
am
: 
1.
0§
 
A
ny
: 
7.
5 
-
 
-
 
A
lw
an
 
et
 a
l. 
69
 
20
11
 
6,
58
2 
19
98
-2
00
5 
Co
m
pu
te
r-a
ss
ist
ed
 
te
le
ph
o
n
e 
in
te
rv
ie
w
s 
N
B
D
PS
 
-
 
4.
5¶
 
-
 
-
 


ϭϳ

ď
ďƌ
Ğǀ
ŝĂƚ
ŝŽ
ŶƐ
͗
^
с
^
ůŽ
ŶĞ

Ɖŝ
ĚĞ
ŵ
ŝŽ
ůŽ
ŐǇ
Đ
ĞŶ
ƚĞ
ƌ͛Ɛ

ŝƌƚ
Ś
Ğ
ĨĞ
Đƚ
^
ƚƵ
ĚǇ
͖E

W^
с


ͲĐŽ
Žƌ
Ěŝ
ŶĂ
ƚĞ
Ě
ŶĂ
ƚŝŽ
ŶĂ
ů
ŝƌƚ
Ś
Ğ
ĨĞ
Đƚ
Ɛ
Ɖƌ
Ğǀ
ĞŶ
ƚŝŽ
Ŷ
^ƚ
ƵĚ
Ǉ͘
Ύd
ŚĞ
Ğ
Ɛƚŝ
ŵ
Ăƚ
Ğ
ŝŶ
ĐůƵ
ĚĞ
Ɛ
ĂŶ
ƚŝĚ
ĞƉ
ƌĞ
ƐƐ
ĂŶ
ƚƐ
ĂŶ
Ě
ĂŶ
ƚŝƉ
ƐǇ
ĐŚ
Žƚ
ŝĐƐ
͘Α
/Ŷ
Ěŝ
ĐĂ
ƚĞ
Ɛŵ
ĞĚ
ŝĐĂ
ƚŝŽ
Ŷ
ƵƐ
Ğ
ƐƉ
ĞĐ
ŝĨŝ
ĐĂ
ůůǇ
Ě
Ƶƌ
ŝŶ
Őƚ
ŚĞ
Ĩŝ
ƌƐ
ƚƚ
ƌŝŵ
ĞƐ
ƚĞ
ƌŽ
ĨƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
͘Β
/Ŷ
Ěŝ
ĐĂ
ƚĞ
Ɛŵ
ĞĚ
ŝĐĂ
ƚŝŽ
Ŷ
ƵƐ
Ğ
ĨƌŽ
ŵ
ϯ
ŵ
ŽŶ
ƚŚ
ƐƉ
ƌĞ
ĐŽ
ŶĐ
ĞƉ
ƚŝŽ
Ŷ
ƚŽ
ƚŚ
ĞĞ
ŶĚ
Ž
ĨƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
͘

ϭϴ

dĂ
ďů
Ğϭ
ď͗
K
ǀĞ
ƌǀ
ŝĞǁ
ŽĨ
Ě
ƌƵ
ŐƵ
ƚŝů
ŝǌĂ
ƚŝŽ
Ŷ
ƐƚƵ
ĚŝĞ
Ɛŝ
Ŷ
Ɖƌ
ĞŐ
ŶĂ
ŶĐ
ǇƵ
ƐŝŶ
ŐƋ
ƵĞ
Ɛƚŝ
ŽŶ
ŶĂ
ŝƌĞ
ĂƐ
ƐŽ
Ƶƌ
ĐĞ
ŽĨ
ŝŶ
ĨŽ
ƌŵ
Ăƚ
ŝŽ
Ŷ
Ăď
ŽƵ
ƚĞ
ǆƉ
ŽƐ
Ƶƌ
Ğƚ
ŽƉ
ƐǇ
ĐŚ
Žƚ
ƌŽ
Ɖŝ
ĐƐ
ŝŶ

Ɖƌ
ĞŐ
ŶĂ
ŶĐ
Ǉ
St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
 
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i- 
ps
yc
ho
tic
s 
 
 
 
 
 
%
  
%
  
%
  
%
  
EU
R
O
PE
 
x 
IC
EL
A
N
D
 
A
xe
lsd
ot
tir
 
et
 
a
l. 
70
 
20
14
 
1,
11
1 
20
09
-2
01
0 
Qu
est
io
nn
ai
re
 
H
ea
lth
 
ca
re
 c
en
te
rs
 
6.
0 
3.
0 
1.
0-
2.
0 
-
 
x 
N
O
R
W
A
Y
 
N
or
de
ng
 
et
 a
l. 
36
 
20
12
 
1,
98
4 
20
08
-2
01
0 
Qu
est
io
nn
ai
re
 
M
at
er
ni
ty
 
w
ar
d 
1.
8 
-
 
-
 
-
 
Y
st
ro
m
 
et
 a
l. 
71
 
20
12
 
83
5 
Se
p-
O
ct
 
20
08
 
Qu
est
io
nn
ai
re
 
(el
ec
tro
nic
) 
-
 
1.
9 
1.
4 
-
 
N
O
R
TH
 A
M
ER
IC
A
 
x 
U
SA
 
R
o
be
rs
o
n
 
et
 
a
l. 
72
 
20
14
 
4,
73
5 
20
09
-2
01
1 
Qu
est
io
nn
ai
re
  
PR
A
M
S 
su
rv
ey
 
da
ta
 
 
 
1.
4 
-
 
-
 
-
 
A
U
ST
R
A
LI
A
 
Sa
w
ic
ki
 
et
 a
l. 
73
 
20
11
 
81
9 
Fe
b-
M
ay
 
20
09
 
Qu
est
io
nn
ai
re
 
M
at
er
ni
ty
 
ho
sp
ita
l 
-
 
1.
5 
-
 
-
 
ď
ďƌ
Ğǀ
ŝĂƚ
ŝŽ
ŶƐ
͗W
Z
D
^с
Wƌ
ĞŐ
ŶĂ
ŶĐ
ǇZ
ŝƐŬ

ƐƐ
ĞƐ
Ɛŵ
ĞŶ
ƚD
ŽŶ
ŝƚŽ
ƌŝŶ
Ő^
ǇƐ
ƚĞ
ŵ



ϭϵ

dĂ
ďů
Ğϭ
Đ͗
Kǀ
Ğƌ
ǀŝĞ
ǁ
ŽĨ
Ěƌ
ƵŐ
Ƶƚ
ŝůŝǌ
Ăƚ
ŝŽ
Ŷ
ƐƚƵ
ĚŝĞ
Ɛŝ
Ŷ
Ɖƌ
ĞŐ
ŶĂ
ŶĐ
ǇƵ
ƐŝŶ
ŐƉ
ƌĞ
ƐĐ
ƌŝď
Ğƌ
Ɛ͛
ŵ
ĞĚ
ŝĐĂ
ůƌ
ĞĐ
Žƌ
ĚƐ
ĂƐ
ƐŽ
Ƶƌ
ĐĞ
ŽĨ
ŝŶ
ĨŽ
ƌŵ
Ăƚ
ŝŽŶ
Ăď
ŽƵ
ƚĞ
ǆƉ
ŽƐ
Ƶƌ
Ğƚ
Ž
ƉƐ
ǇĐ
ŚŽ
ƚƌŽ
Ɖŝ
ĐƐ
ŝŶ
Ɖ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
 
St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
 
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i- 
ps
yc
ho
tic
s 
 
 
 
 
 
%
  
%
  
%
  
%
  
EU
R
O
PE
 
x 
U
N
IT
ED
 K
IN
G
D
O
M
 
Pe
te
rs
en
 
et
 a
l. 
74
 
20
14
 
49
5,
95
3 
19
95
-2
01
2 
TH
IN
 p
rim
ar
y 
ca
re
 
da
ta
ba
se
 
-
 
-
 
-
 
0.
2 
M
ar
gu
lis
 
et
 a
l. 
75
 
20
14
 
42
1,
64
5 
19
89
-2
01
0 
G
PR
D
 p
rim
ar
y 
ca
re
 
da
ta
ba
se
 / 
M
ot
he
r-
B
ab
y 
Li
n
k 
 
-
 
1.
3-
2.
8 
-
 
0.
3-
1.
3 
Ce
a-
So
ria
no
 
et
 
a
l. 
76
 
20
13
 
14
8,
54
4 
19
96
-2
01
0 
TH
IN
 p
rim
ar
y 
ca
re
 
da
ta
ba
se
 
-
 
3.
6*
 
0.
6-
1.
7*
 
-
 
Pe
te
rs
en
 
et
 a
l. 
77
 
20
11
 
11
4,
99
9 
19
92
-2
00
6 
TH
IN
 p
rim
ar
y 
ca
re
 
da
ta
ba
se
 
-
 
3.
0 
-
 
-
 
H
ar
dy
 
et
 a
l. 
78
 
20
06
 
81
,9
75
 
19
91
-1
99
9 
G
PR
D
 p
rim
ar
y 
ca
re
 
da
ta
ba
se
 
-
 
0.
2*
 
0.
3*
 
-
 
N
O
R
TH
 A
M
ER
IC
A
 
x 
U
SA
 
Y
am
am
o
to
 
et
 
a
l. 
79
 
20
14
 
37
.8
 
m
ill
io
n
s 
 
20
06
-2
01
0 
A
m
bu
la
to
ry
 
an
d 
ho
sp
ita
l 
o
u
tp
at
ie
nt
 re
co
rd
s 
N
A
M
CS
 &
 
N
H
A
M
CS
 
-
 
2.
2 
-
 
-
 
M
eu
n
ie
r e
t a
l. 
80
 
20
13
 
27
,3
28
 
20
02
-2
01
0 
A
m
bu
la
to
ry
 
an
d 
ho
sp
ita
l 
o
u
tp
at
ie
nt
 re
co
rd
s 
N
A
M
CS
 &
 
N
H
A
M
CS
 
-
 
2.
1 
-
 
-
 
x 
C
A
N
A
D
A
 
D
aw
 
et
 a
l. 
81
 
20
12
 
16
3,
08
2 
 
20
01
-2
00
6 
H
os
pi
ta
l r
ec
or
ds
 li
nk
ag
e 
to
 o
ut
pa
tie
nt
 
pr
es
cr
ip
tio
n-
dr
ug
 
cl
ai
m
s 
-
 
4.
5 
3.
3 
-
 
ď
ďƌ
Ğǀ
ŝĂƚ
ŝŽ
ŶƐ
͗d
,/
E
сd
ŚĞ
,
ĞĂ
ůƚŚ
/ŵ
Ɖƌ
Žǀ
Ğŵ
ĞŶ
ƚE
Ğƚ
ǁŽ
ƌŬ
͖'
WZ

сd
ŚĞ
'
ĞŶ
Ğƌ
Ăů
ZĞ
ƐĞ
Ăƌ
ĐŚ
Wƌ
ĂĐ
ƚŝĐ
Ğ
Ăƚ
Ăď
ĂƐ
Ğ͖
E
D
^
с
Ğ
Ŷƚ
Ğƌ
ƐĨ
Žƌ

ŝƐĞ
ĂƐ
Ğ
ŽŶ
ƚƌŽ
ůĂ
ŶĚ
Wƌ
Ğǀ
ĞŶ
ƚŝŽ
Ŷ͛
ƐE
Ăƚ
ŝŽ
ŶĂ
ů
ŵ
ďƵ
ůĂƚ
Žƌ
ǇD
ĞĚ
ŝĐĂ
ů
Ăƌ
Ğ^
Ƶƌ
ǀĞ
Ǉ͖
E,
D
^
с
EĂ
ƚŝŽ
ŶĂ
ů,
ŽƐ
Ɖŝ
ƚĂ
ůD
ĞĚ
ŝĐĂ
ů
Ăƌ
Ğ^
Ƶƌ
ǀĞ
Ǉ͘
Ύ/
ŶĚ
ŝĐĂ
ƚĞ
Ɛŵ
ĞĚ
ŝĐĂ
ƚŝŽ
Ŷ
ƵƐ
ĞƐ
ƉĞ
ĐŝĨ
ŝĐĂ
ůůǇ
Ě
Ƶƌ
ŝŶ
Ő
ƚŚ
ĞĨ
ŝƌƐ
ƚƚ
ƌŝŵ
ĞƐ
ƚĞ
ƌŽ
ĨƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
͘

ϮϬ

dĂ
ďů
Ğϭ
Ě͗
K
ǀĞ
ƌǀ
ŝĞǁ
ŽĨ
Ě
ƌƵ
ŐƵ
ƚŝů
ŝǌĂ
ƚŝŽ
Ŷ
ƐƚƵ
ĚŝĞ
Ɛŝ
Ŷ
Ɖƌ
ĞŐ
ŶĂ
ŶĐ
ǇƵ
ƐŝŶ
ŐĂ
Ƶƚ
Žŵ
Ăƚ
ĞĚ
ĚĂ
ƚĂ
ďĂ
ƐĞ
ƐĂ
ƐƐ
ŽƵ
ƌĐ
ĞŽ
Ĩŝ
ŶĨ
Žƌ
ŵ
Ăƚ
ŝŽ
Ŷ
Ăď
ŽƵ
ƚĞ
ǆƉ
ŽƐ
Ƶƌ
Ğƚ
Ž
ƉƐ
ǇĐ
ŚŽ
ƚƌŽ
Ɖŝ
ĐƐ
ŝŶ
Ɖ
ƌĞ
ŐŶ
ĂŶ
ĐǇ

St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
 
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i- 
ps
yc
ho
tic
s 
 
 
 
 
 
%
  
%
  
%
  
%
  
EU
R
O
PE
 
x 
D
EN
M
A
R
K
 
A
sk
aa
 
et
 a
l. 
82
 
20
14
 
91
1,
01
7 
19
97
-2
01
0 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
Re
gi
st
er
 o
f 
M
ed
ic
in
al
 P
ro
du
ct
 
St
at
ist
ic
s l
in
ka
ge
 
-
 
-
 
0.
2 
-
 
Jim
en
ez
-
So
le
m
 
et
 a
l. 
83
 
20
13
 
91
2,
32
2 
19
97
-2
01
0 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
Re
gi
st
er
 o
f 
M
ed
ic
in
al
 P
ro
du
ct
 
St
at
ist
ic
s l
in
ka
ge
 
-
 
3.
2 
-
 
-
 
M
un
k-
O
lse
n
 
et
 a
l. 
84
 
20
12
 
86
,2
16
 
19
96
-2
00
7 
Ci
vi
l R
eg
ist
ra
tio
n 
Sy
st
em
 
an
d 
Re
gi
st
er
 o
f 
M
ed
ic
in
al
 P
ro
du
ct
 
St
at
ist
ic
s l
in
ka
ge
 
-
 
0.
9-
1.
5 
-
 
-
 
B
jor
n
 
et
 a
l. 
85
 
20
11
 
85
,7
10
 
19
99
-2
00
9 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
A
ar
hu
s 
U
n
iv
er
sit
y 
Pr
es
cr
ip
tio
n 
D
at
ab
as
e 
lin
ka
ge
 
-
 
2.
2 
-
 
-
 
x 
FR
A
N
C
E 
La
cr
o
ix
 
et
 a
l. 
30
 
20
09
 
10
,0
08
  
20
04
-2
00
5 
H
ea
lth
 
In
su
ra
n
ce
 S
er
vi
ce
 
da
ta
ba
se
 a
n
d 
M
ot
he
r 
an
d 
Ch
ild
 P
ro
te
ct
io
n
 
Ce
nt
re
 D
at
ab
as
e 
 
an
d 
A
nt
en
at
al
 D
ia
gn
o
st
ic
 
Ce
nt
re
 D
at
ab
as
e 
lin
ka
ge
 
-
 
2.
0 
1.
0-
3.
0 
-
 
x 
FI
N
LA
N
D
 
A
rta
m
a 
et
 a
l. 
20
11
 
73
9,
92
4 
19
96
-2
00
6 
N
at
io
n
al
 h
ea
lth
 
re
gi
str
ie
s 
1.
1-
3.
8§
 
-
 
-
 
-
 


Ϯϭ

St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
 
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i- 
ps
yc
ho
tic
s 
86
 
lin
ka
ge
 
x 
IT
A
LY
 
G
ag
n
e 
et
 a
l. 
27
 
20
08
 
33
,3
43
  
Ja
n
-D
ec
 
20
04
 
Po
pu
la
tio
n-
ba
se
d 
lo
ng
itu
di
n
al
 h
ea
lth
 
ca
re
 d
at
ab
as
e 
-
 
Pa
ro
x
et
in
e:
  
0.
3 
-
 
-
 
x 
N
O
R
W
A
Y
 
R
isk
a 
et
 a
l. 
87
 
20
14
 
34
5,
70
3 
20
04
-2
01
1 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
Pr
es
cr
ip
tio
n 
D
at
ab
as
e 
lin
ka
ge
 
-
 
-
 
1.
5 
-
 
En
ge
la
n
d 
et
 
a
l. 
28
 
20
08
 
10
6,
32
9 
 
20
04
-2
00
7 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
Pr
es
cr
ip
tio
n 
D
at
ab
as
e 
lin
ka
ge
 
-
 
0.
4-
1.
1 
0.
5-
1.
0 
0.
2-
0.
9 
x 
TH
E 
N
ET
H
ER
LA
N
D
S 
B
ak
ke
r 
et
 a
l. 
65
 
20
08
 
14
,9
02
 
19
95
-2
00
4 
Pr
es
cr
ip
tio
n 
D
at
ab
as
e 
-
 
2.
1*
 
-
 
-
 
V
er
v
er
s 
et
 a
l. 
88
 
20
06
 
29
,0
05
 
20
00
-2
00
3 
H
ea
lth
 
in
su
ra
n
ce
 c
la
im
s 
-
 
1.
8-
2.
0 
-
 
-
 
B
ak
ke
r 
et
 a
l. 
29
 
20
06
 
5,
41
2 
19
94
-2
00
3 
Pr
es
cr
ip
tio
n 
dr
ug
 
di
sp
en
sin
g 
da
ta
 fr
o
m
 
co
m
m
u
n
ity
 
ph
ar
m
ac
ie
s 
0.
9-
1.
9¶
 
-
 
1.
2-
1.
5 
-
 
x 
SW
ED
EN
 
St
ep
ha
n
ss
o
n
 
et
 
a
l. 
89
 
20
11
 
10
2,
99
5 
Ja
n
-D
ec
 
20
07
 
M
ed
ic
al
 B
irt
h 
R
eg
ist
ry
 
an
d 
Pr
es
cr
ip
tio
n 
D
at
ab
as
e 
lin
ka
ge
 
-
 
1.
0-
2.
0 
0.
2-
0.
7 
0.
1-
0.
7 
x 
M
U
LT
IN
A
TI
O
N
A
L:
 D
EN
M
A
R
K
, 
U
N
IT
ED
 K
IN
G
D
O
M
, 
TH
E 
N
ET
H
ER
LA
N
D
S 
A
N
D
  I
TA
LY
 
Ch
ar
lto
n
 
et
 a
l. 
90
 
20
14
 
86
2,
94
3 
 
20
04
-2
01
0 
El
ec
tro
ni
c 
he
al
th
ca
re
 
da
ta
ba
se
s 
 
-
 
1.
5-
4.
5ί
 
-
 
-
 
N
O
R
TH
 A
M
ER
IC
A
 
x 
U
SA
 
H
an
le
y 
e
t a
l. 
91
 
20
14
 
34
3,
29
9 
20
06
-2
01
1 
In
su
ra
n
ce
 c
la
im
s 
 
Tr
u
v
en
 H
ea
lth
 
M
ar
ke
tS
ca
n
 
10
.6
 
6.
5 
4.
2 
1.
1 

ϮϮ

St
ud
y 
Sa
m
pl
e 
M
ed
ic
at
io
n
 u
se
 in
 p
re
gn
a
n
cy
 
A
ut
ho
rs
 
Pu
bl
ic
at
io
n 
ye
ar
 
N
 
Y
ea
r 
o
f 
de
liv
er
y 
D
at
a 
so
ur
ce
 
A
ny
 
ps
yc
ho
tr
op
ic
 
A
nt
i-
de
pr
es
sa
n
ts
 
A
nx
io
ly
tic
s 
a
n
d 
se
da
tiv
es
 
A
nt
i- 
ps
yc
ho
tic
s 
da
ta
ba
se
  
To
h 
et
 a
l. 
92
 
20
13
 
58
5,
61
5 
20
01
-2
00
7 
A
ut
om
at
ed
 
ad
m
in
ist
ra
tiv
e 
da
ta
ba
se
s 
H
ea
lth
 
pl
an
 c
ar
e 
cl
ai
m
s 
w
ith
in
 
n
in
e 
U
S 
st
at
es
 
-
 
-
 
-
 
0.
7 
Ep
ste
in
 
et
 a
l. 
93
 
 
20
13
 
29
6,
81
7 
 
19
85
-2
00
5 
In
su
ra
n
ce
 c
la
im
s 
 
Te
n
n
es
se
e 
M
ed
ic
ai
d 
da
ta
 li
nk
ed
 
to
 
bi
rth
 
ce
rt
ifi
ca
te
s 
-
 
-
 
-
 
0.
4 
H
uy
br
ec
ht
s 
et
 
a
l. 
94
 
20
13
 
1,
10
6,
75
7 
20
00
-2
00
7 
M
ed
ic
ai
d 
A
n
al
yt
ic
 
eX
tra
ct
 
-
 
8.
1 
-
 
-
 
H
ay
es
 
et
 a
l. 
95
 
20
12
 
22
8,
87
6 
19
95
-2
00
7 
In
su
ra
n
ce
 c
la
im
s 
 
Te
n
n
es
se
e 
M
ed
ic
ai
d 
-
 
2.
8-
7.
4 
6.
1 
1.
2 
A
nd
ra
de
 
et
 a
l. 
96
 
20
08
 
11
8,
93
5 
20
01
-2
00
5 
A
ut
om
at
ed
 
ad
m
in
ist
ra
tiv
e 
da
ta
ba
se
s 
fro
m
 
th
e 
he
al
th
 
pl
an
s 
H
ea
lth
 
pl
an
 c
ar
e 
cl
ai
m
s 
w
ith
in
 
se
v
en
 
U
S 
sta
te
s 
-
 
6.
6 
-
 
-
 
Co
o
pe
r e
t a
l. 
97
 
20
07
 
10
5,
33
5 
19
99
-2
00
3 
In
su
ra
n
ce
 c
la
im
s 
 
Te
n
n
es
se
e 
M
ed
ic
ai
d 
-
 
13
.4
 
-
 
-
 
x 
C
A
N
A
D
A
 
B
er
ar
d 
et
 a
l. 
98
 
20
14
 
28
9,
68
8 
 
19
98
-2
00
8 
A
dm
in
ist
ra
tiv
e 
da
ta
ba
se
s 
lin
ka
ge
  
-
 
4.
5 
4.
0 
-
 
A
U
ST
R
A
LI
A
 
Co
lv
in
 
et
 a
l. 
99
 
20
13
 
96
,6
98
 
20
02
-2
00
5 
A
dm
in
ist
ra
tiv
e 
da
ta
ba
se
s 
lin
ka
ge
 
-
 
4.
6 
-
 
-
 
Ύ/
ŶĚ
ŝĐĂ
ƚĞ
Ɛŵ
ĞĚ
ŝĐĂ
ƚŝŽ
Ŷ
ƵƐ
ĞƐ
ƉĞ
ĐŝĨ
ŝĐĂ
ůůǇ
Ě
Ƶƌ
ŝŶ
Őƚ
ŚĞ
Ĩŝ
ƌƐƚ
ƚƌ
ŝŵ
ĞƐ
ƚĞ
ƌŽ
ĨƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
͘Α
dŚ
ĞĞ
Ɛƚŝ
ŵ
Ăƚ
Ğŝ
ŶĐ
ůƵ
ĚĞ
ƐĂ
ůůŵ
ĞĚ
ŝĐĂ
ƚŝŽ
ŶƐ
Ƶ
ŶĚ
Ğƌ
ƚŚ
Ğ
d
Őƌ
ŽƵ
ƉƐ
E
Ϭϱ
ĂŶ
Ě
EϬ
ϲŝ
Ŷ
ƚŚ
ĞƉ
Ğƌ
ŝŽ
Ě
ŽŶ
Ğ
ŵ
ŽŶ
ƚŚ
Ɖ
ƌŝŽ
ƌƚ
Ž
Ɖƌ
ĞŐ
ŶĂ
ŶĐ
ǇĂ
ŶĚ
ͬŽ
ƌĚ
Ƶƌ
ŝŶ
ŐƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
͘Β
dŚ
ĞĞ
Ɛƚŝ
ŵ
Ăƚ
Ğŝ
ŶĐ
ůƵ
ĚĞ
ƐĂ
Ŷƚ
ŝĚ
ĞƉ
ƌĞ
ƐƐ
ĂŶ
ƚƐ
ĂŶ
Ě
ĂŶ
ƚŝƉ
ƐǇ
ĐŚ
Žƚ
ŝĐƐ
͘ί
dŚ
ĞĞ
Ɛƚŝ
ŵ
Ăƚ
ĞƐ
ƌĞ
ĨĞ
ƌƚ
Ž
^^
Z/
ĂŶ
ƚŝĚ
ĞƉ
ƌĞ
ƐƐ
ĂŶ
ƚƐ
ŽŶ
ůǇ͘

*
*
/Ŷ
Ěŝ
ĐĂ
ƚĞ
ƐƵ
ƐĞ
Ĩƌ
Žŵ
ϲϬ
Ě
ĂǇ
Ɛď
ĞĨ
Žƌ
ĞƉ
ƌĞ
ŐŶ
ĂŶ
ĐǇ
ƚŚ
ƌŽ
ƵŐ
Ś
ĚĞ
ůŝǀ
Ğƌ
Ǉ͘


Ϯϯ
1.3.3 The impact of maternal psychiatric disorders on maternal-fetal health 
x Depression and anxiety 
Depression and anxiety are per se physiologically important exposures in pregnancy; they 
can affect maternal homeostatic systems such as appetite and stress response as well as 
lifestyle factors such as substance use and engagement in prenatal care, thereby subsequently, 
either directly or indirectly, impact maternal-fetal health.4 From a biological perspective, 
depression is known to alter the hypothalamic-pituitary-adrenal (HPA) axis, which is the 
core endocrine stress system in humans, with a subsequent increase in the level of circulating 
glucocorticoids.100 Maternal increased level of circulating glucocorticoids implies a higher 
fetal exposure to these agents, with a subsequent HPA axis dysfunction in the fetus; as 
shown in animal studies, this scenario is responsible for smaller birth weight, HPA axis 
function, and anxiety-related behaviors.101  
Although anxiety and depressive disorders are highly comorbid, most studies have so far 
explored the impact of depression on perinatal outcomes, and very little is known about the 
sole effect of anxiety.102,103 Two recent meta-analyses have in fact attempted to pool results 
of various studies on the relationship between not medicated depression and perinatal 
outcomes such as low birth weight or prematurity.104,105 Grote et al.105 pooled results of 
studies published in the period 1980-2009, which reported data on prematurity (< 37 weeks 
gestation), low birth weight (< 2,500 g) and intrauterine growth restriction (<10th percentile 
for gestational age) using random-effects methods. The findings of this meta-analysis 
suggested that antenatal depression (when used as categorical variable) conferred a 
significantly increased risk for prematurity (pooled relative risk [RR]: 1.39; 95% Confidence 
Interval [CI]: 1.19-1.61), low birth weight (pooled RR: 1.49; 95% CI: 1.25-1.77), and 
intrauterine growth restriction (pooled RR: 1.45; 95% CI: 1.05-2.02). Using severity of 
depression as continuous variable attenuated these measures of associations (magnitude 
range of the pooled RR: 1.02-1.03). In a more recent meta-analysis, Grigoriadis et al.104 
pooled results of both retrospective and prospective studies published from inception to June 
2010. In the overall analysis it was found that maternal depression was significantly 
associated with premature delivery (pooled Odds Ratio [OR]: 1.37; 95% CI: 1.04-1.81) and 
diminished breastfeeding initiation (pooled OR: 0.68; 95% CI: 0.61-0.76); however no 
significant associations were found in relation to other outcomes such as birth weight, low 


Ϯϰ
birth weight, gestational age, Apgar scores at one and five minutes, neonatal intensive care 
unit admission, and preeclampsia.104 
Beyond having an impact on immediate pregnancy outcomes, antenatal depression and 
anxiety are important risk factors for maternal mental health postpartum.106 Sutter-Dallay 
et al.48 found that women with an anxiety disorder during pregnancy presented a 
significant 3-fold increased risk of developing intense postnatal depressive symptoms, 
independently from the presence or absence of concomitant depression during gestation. A 
meta-analysis by Beck107 evaluating predictors of postpartum depression found that 
antenatal depression, in any of the three trimesters, was one of the strongest predictors for 
postpartum depression. Another study108 of small sample size (n=201) investigated the risk 
of relapse of major depression during pregnancy among women with a history of major 
depression prior to pregnancy. It was found that women who discontinued their medication 
at conception relapsed more frequently (68%) compared to those women who maintained 
their medication throughout the pregnancy (26%) (Hazard ratio: 5.0; 95% CI: 2.8-9.1).  
x Eating disorders 
In the last decade there has been an increasing number of studies examining perinatal 
outcomes among women with eating disorders, often showing conflicting results.54 No 
study has however discerned the effect of medicated versus not medicated maternal eating 
disorder on perinatal outcomes. Bulik et al.109 explored birth outcomes among women with 
eating disorders before and/or during pregnancy in the MoBa study and found that only 
women with BED had higher risk for delivering higher birth weight babies and large for 
gestational age babies; women with AN did not present higher rates of premature or small 
for gestational age children. Similarly, findings from the Generation R study suggested that 
while AN was positively associated with suspected fetal distress neither AN nor BN 
women presented higher rates for babies with lower weight or prematurity compared to 
controls.110 In both studies, increased gestational weight gain during pregnancy was 
thought to have mitigated the association between AN and having low birth weight babies. 
A Finnish study111 has instead observed higher rates of low birth weight babies among 
mothers with AN or BN, compared to controls; maternal AN, in particular, was also 
associated with very premature birth (OR: 4.59; 95% CI: 1.25-16.87), being born small for 
gestational age (OR: 2.20; 95% CI: 1.23-3.93) and perinatal death (OR: 4.06; 95% CI: 
1.15-14.35). In a recent meta-analysis it was found that women with past or active AN 


Ϯϱ
were more likely than healthy controls to have babies with lower birth weight (-0.19 kg; 
95%: -0.25, -0.15).112  
Studies investigating the association between mood and eating disorders have found 
significantly higher rates of postnatal depression in this group compared to controls. In 
particular, studies on clinical samples of women with active or previous eating disorder 
found that about one-third or more of these had postnatal depression.113,114 A recent cohort 
study56 showed that high levels of anxiety and depression in the postpartum period are 
associated with active eating disorder symptoms in pregnancy.  
1.4 Adherence to pharmacotherapy with psychotropics 
during pregnancy     
    ³I stopped using antidepressants as soon as 
  I found out I was pregnant (5 weeks)´ 
- A 28-year-old woman from  
Italy, 29 weeks pregnant ± 
Adequate clinical management of maternal psychiatric disorder during pregnancy is 
essential to ensure maternal-fetal health.105,108 Pregnancy represents an important time 
window for recognition of potential psychiatric symptomatology, establishment of their 
treatment, and not least tailored interventions by healthcare professionals to ensure that 
QHHGHGPHGLFDWLRQVDUHWDNHQDVSUHVFULEHG0HGLFDWLRQDGKHUHQFHLVGHILQHGDV³WKHH[WHQW
to which patients take medications as prescribed by their health care pURYLGHUV´ DQG LV
based on a therapeutic alliance between the patient and the physician.115 Poor adherence to 
chronic therapies is a well-known public health concern. It is estimated that approximately 
50% of medications for chronic diseases are not taken as prescribed in the general 
population.116  
Several methods can be employed to measure medication adherence. Osterberg et al.115 
categorized these methods as either direct or indirect. Direct methods include directly 
observed therapy (e.g., measurement of the level of medicine or metabolite in blood) and 
are considered more robust than indirect methods; indeed, these are accurate and objective, 
however they are expensive and difficult to implement in daily clinical practice. Indirect 
methods are often based on patient self-report via questionnaires or diaries, pill counts, 
rates of prescription refill, or measurement of physiological markers. These are generally 


Ϯϲ
easy to perform, inexpensive, and can also be objective (e.g., pill counts and rates of 
prescription refill).115 However, indirect methods may suffer from drawbacks such as 
SDWLHQW¶V DWWLWXGH LQ UHSRUWLQJ DQG UHFDOO DQG SUHVcription refill, for instance, does not 
QHFHVVDULO\ UHIOHFW SDWLHQW¶V LQWDNH RI WKH PHGLFDWLRQ 'HVSLWH WKHLU OLPLWDWLRQV LQGLUHFW
methods can more easily be implemented in clinical settings and are therefore the preferred 
choice for assessment of medication adherence also in clinical research.115 
To date, little is known about patterns of medication adherence in pregnant subjects and 
factors associated with non-adherence.117 Two studies from the UK primary care database 
have shown that pregnancy is a major determinant for discontinuation of antidepressants 
and antipsychotics; specifically, of the women on treatment with antidepressants, atypical 
antipsychotics or typical antipsychotics before pregnancy, only 10%, 38% and 19%, 
respectively, were still taking these medications at the beginning of the third trimester.74,77 
However, no study has so far investigated the medication-taking behavior and the extent of 
adherence to psychotropic medications among those women who decide to maintain this 
pharmacotherapy in pregnancy. Although the literature pertaining to non-pregnant subjects 
is extensive, no study has attempted to understand and identify what maternal factors 
might have an impact on adherence to psychotropic medications in pregnancy.  
1.4.1 Factors associated with medication adherence 
Research in the general non-pregnant population has shown that non-adherence to 
medications is a complex and multifaceted behavior where unintentional causes (practical 
barriers, capacity, resources) as well as intentional causes (motivational beliefs, 
preferences, perceptual barriers) are in place.118 In the last decade several studies have 
explored the role of individual beliefs about medications on adherence.119-121 Horne et 
al.120 investigated the role of beliefs about prescribed medicines on adherence, which 
LQFOXGH WKH ³QHFHVVLW\ RI WKH SUHVFULEHG PHGLFDWLRQ´ IRU PDLQWDLQLQJ WKH LQGLYLGXDO¶V
KHDOWK DQG WKH ³FRQFHUQV DERXW WKH SUHVFULEHG PHGLFDWLRQV´ LH WKH SRWHQWLDO DGYHUVH
effects of taking them, such as becoming too dependent on the medication or that regular 
use would lead to long-term adverse effects). This study found that while factors such as 
gender, educational level, or the number of prescribed medication were not major 
predictors of medication adherence, indiviGXDOV¶ EHOLHIV VLJQLILFDQWO\ FRUUHODWHGZLWK WKH
level of medication adherence.120 


Ϯϳ
3UHJQDQWZRPHQ¶VEHOLHIVZLOOOLNHO\LPSDFWWKHLUGHFLVLRQZKHWKHUWRXVHDPHGLFDWLRQRU
not during pregnancy. In a previous study122 from our research group we found that 
pregnant women agreeing with the statement that it is better to abstain from using 
medication whilst pregnant despite being ill, presented a significant increased likelihood of 
low adherence (OR: 2.17; 95 % CI: 1.09±4.34) to chronic pharmacotherapy for treatment 
of somatic disorders, compared to those women who disagreed. Similarly, women agreeing 
with the statement that herbal remedies rather than conventional medications should be 
used during pregnancy, presented a significant increased likelihood of low adherence (OR: 
3.74; 95 % CI: 1.73±8.06) compared to those who disagreed. Hence, beliefs about 
medications act as an important determinant of poor medication adherence, even in 
pregnancy.  
Fear of teratogenic drug effects may possibly result in even lower adherence to prescribed 
treatments in pregnancy. A number of studies have been conducted to assess the perception 
of teratogenic risk and how this factor affects decision-making regarding whether or not to 
take a medication during pregnancy. One study examined the effects of information 
presentation (framing) on women's perception of fetal risk, and their intention to use a safe 
drug during pregnancy. Women who were given negatively framed information (e.g., a 1±
3% chance of having a malformed child) had a significantly higher perception of 
teratogenic risk when compared to women who were given positively framed information 
(a 97±99% chance of having a normal child).6 In another study,7 researchers evaluated the 
impact of negative information from various sources on women who had taken an 
antidepressant during pregnancy.7 More than half of the women who continued the 
medication throughout the pregnancy frequently considered discontinuing, despite 
reassurance of no harm to their children. Negative information was recalled far more often 
than reassuring information and information from friends, family, and health care 
providers had a negative impact on decision-making regarding treatment of depression 
with pharmacotherapy during pregnancy.  
Nevertheless, it is important to recognize that the heightened fear of teratogenicity among 
pregnant women and their negative attitudes towards psychotropic medications, especially 
antidepressants, can be ascribed, at least in part, to the discordant findings of the studies 
investigating fetal risks after exposure in utero to these medications.  


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1.5 Safety of antidepressants in pregnancy 
Antidepressants are the psychotropic medications most commonly used in pregnancy for 
treatment of various psychiatric disorders, as outlined in section 1.3.2 above. Therefore 
most of the literature in the last decade has been focusing on their safety profile in 
pregnancy. The following section will consequently focus on this medication group.  
1.5.1 Neonatal safety 
To date, several studies have investigated the risk of neonatal outcomes after exposure in 
utero to antidepressants, although producing conflicting results. With respect to congenital 
malformations, some studies have reported an increased risk123,124 while others have 
documented no increased risk for major malformations.125,126 Different studies have 
singled out specific SSRIs associated with increased risk of different malformations most 
notably various types of cardiovascular malformations, with paroxetine,127-129 sertraline123 
and citalopram123 as being more risky than others. Studies investigating other clinically 
relevant outcomes such as birth weight, prematurity and perinatal complications have also 
reported conflicting results. Some studies reported increased risk of these outcomes129-131 
whereas others did not.132 These inconsistencies strongly suggest that the various studies 
may suffer from uncontrolled and possibly unrecognized sources of bias.  
Given this scenario, meta-analyses and systematic reviews pooling data from studies 
having quality above a certain threshold, are therefore of value in order to synthesize the 
available data and increase study power. Table 2 outlines the most recent and thorough 
meta-analyses assessing the risk of perinatal outcomes after exposure in utero to 
antidepressants. As indicated by the pooled results, exposure to antidepressants in utero 
seem to increase the risk of prematurity (53-96% increased risk),133-135 low birth weight 
(44% increased risk),133 persistent pulmonary hypertension of the new-born (2.5 to 3.3-fold 
increased risk),136 neonatal adaptation (5.1-fold increased risk),137 and cardiac 
malformations (36% increased risk), especially paroxetine (43% increased risk).138  
Lately, a growing number of studies have investigated the long-term potential effects of in 
utero exposure to psychotropics, especially antidepressants. It has been hypothesized that 
prenatal exposure to these medications may affect the neurotransmitter systems in the brain 
and have long-lasting consequences on neurodevelopment in the offspring. Findings of a 
recent systematic review139 have pointed out that although some studies indicate a relation 


Ϯϵ
between prenatal exposure to antidepressants and adverse neurodevelopmental outcomes 
such as delayed motor development/motor control, social difficulties, internalizing 
problems and autism, confounding by indication is still a major drawback, and a causal 
association has by no means been established. Also, as pointed out by Hermansen et al.,140 
most of the published studies investigating the association between prenatal exposure to 
antidepressants and adverse neurodevelopmental outcomes presented an insufficient 
statistical power (range: 40-60%).  
The task of assessing the risks and benefits of antidepressant use for the treatment of 
depression during pregnancy is complicated. The magnitude of the impact, in absolute 
terms, of the observed associations between antidepressant exposure in utero and various 
perinatal and long-term outcomes, is of utmost importance to guide such assessment (cf. 
section 1.6.3). Further, since two meta-analyses have shown that non-medicated maternal 
depression as such may confer an increased risk of prematurity and low birth weight,104,105 
this raises the concern about potential confounding by indication in most studies and 
whether these perinatal outcomes are more likely to be secondary to the underlying 
maternal psychiatric disorder rather than to the medication.  
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1.5.2 Maternal safety 
The literature about the risk of obstetric complications or maternal health after use of 
antidepressants in pregnancy is not extensive. It has been hypothesized that maternal stress, 
anxiety and depression may trigger pathogenic vascular processes through the altered 
release of vasoactive hormones or other neuroendocrine transmitters, and thereby damage 
the vascular endothelium of the developing placenta.141,142 Serotonin plays a critical role in 
hemostasis and SSRIs are able to affect the circulating serotonin level;143,144 hence, 
exploring the association between SSRIs and preeclampsia by distinguishing the effect of 
the medications from that of maternal depression, became an important research question. 
Two studies have suggested that use of SSRIs in pregnancy may increase the risk of 
preeclampsia and gestational hypertension.145,146 However such findings could not be 
replicated in a more recent study. Palmsten et al.147 in fact found no association between 
SSRIs and preeclampsia (RR: 1.00; 95% CI: 0.93-1.07) compared to women with 
depression and taking no antidepressants; on the contrary, exposure to serotonin-
noradrenalin reuptake inhibitors (SNRIs) or tricyclic antidepressants (TCAs) conferred a 
significantly increased risk of preeclampsia (SNRIs, RR: 1.52; 95% CI: 1.26-1.83); (TCAs, 
RR: 1.62; 95% CI: 1.23-2.12).147 In an additional study, Palmsten et al.148 observed an 
increased risk for preeclampsia among women exposed to SNRIs and TCAs, but not 
SSRIs, raising the question whether these associations may reflect drug effects, more 
severe depression, or other unmeasured maternal factors.  
A study from the Swedish Medical Birth Registry149 examined several obstetric outcomes 
and found that use of any antidepressant in early and/or late pregnancy was significantly 
associated with gestational diabetes (37% increased risk), preeclampsia (28-50% increased 
risk), placenta previa (21-38% increased risk), and bleeding during partum (45-58% 
increased risk). However, because of the multiple testing, we cannot exclude that some of 
the significant results were in fact caused by chance. Indeed a recent meta-analysis150 did 
not find evidence of an increased risk of gestational diabetes in women with psychiatric 
illness who took psychiatric medications compared to non-medicated women with 
psychiatric illness.  
SSRIs can hinder the reuptake of serotonin from plasma into the platelets, with consequent 
inhibition of platelet aggregation and clot formation, resulting in bleeding events.143,144 
Studies among non-pregnant subjects have shown that SSRIs or antidepressants with high 
ϯϰ

affinity to the serotonin transporter might be implicated in bleeding-related outcomes from 
the gastrointestinal tract.151-153 Not surprisingly, bleeding events have also been reported in 
patients treated with antidepressants exhibiting non-selective serotonin reuptake inhibitor 
activity such as venlafaxine.154 Reis et al.149 found that exposure to antidepressants in early 
pregnancy, but not in late pregnancy, conferred an increased risk (11%) to experience 
bleeding after partum. Four additional studies155-158 have investigated the relationship 
between use of antidepressants and postpartum hemorrhage and found conflicting results. 
In a nested case-control study, Salked et al.155 found that exposure to SSRIs within 90 days 
before delivery (based upon prescription claims) did not increase the risk of postpartum 
hemorrhage (OR: 1.30; 95% CI: 0.98-1.72), and similar results were found when the 
exposure window was restricted to 30 days before delivery (OR: 1.33; 95% CI: 0.94-1.89). 
On the contrary, in a sub-cohort of Medicaid women diagnosed with mood or anxiety 
disorders, Palmsten et al.156 found that women with a monotherapy supply of an SSRI, an 
SNRI or a TCA that overlapped with the delivery date, had a 1.42-, 1.90- and 1.77-fold 
increased risk to experience postpartum hemorrhage respectively, compared to controls. 
The sensitivity analyses and adjustment for high dimension propensity score did not confer 
major changes to these findings. A recent hospital-based study found that compared to 
non-exposed, women taking SSRIs during pregnancy presented a significant 2.6-fold 
increased risk of postpartum hemorrhage as well as for anemia following a vaginal 
delivery.157 Another recent case-control study158 using data from the linked administrative 
and hospital database of the Québec Pregnancy Cohort found that exposure to any 
antidepressant, measured by filling a prescription in the six months prior to index date (i.e., 
delivery date), conferred a significant 48% and 40% increased risk for any and atonic 
postpartum hemorrhage, respectively. However the latter two studies suffers from 
important drawbacks, primarily lack of an active comparator group including women with 
not medicated depression during pregnancy, proof of timely exposure to SSRIs near 
delivery and lack of distinction between antidepressants showing different affinity to the 
serotonin transporter.  
1.6 Pharmacoepidemiology 
The majority of studies described in the previous sections are of observational nature. 
Ethical reasons preclude inclusion of pregnant women in the vast majority of pre-
marketing clinical trials,159 and therefore pregnancy research is mainly based on 
ϯϱ

REVHUYDWLRQDOVWXGLHV3KDUPDFRHSLGHPLRORJ\GHILQHGDV³WKHVWXG\RIWKHHIIHFWVRIGUXJV
LQ ODUJH QXPEHUV RI SHRSOH´ LV D GLVFLSOLQH EULGJLQJ Hpidemiology and clinical 
pharmacology. It applies epidemiological methods to studies of the use of drugs at a 
population level. Pharmacoepidemiology is the best discipline enabling us to explore the 
prevalence and safety of medication exposure in pregnancy.160 These two elements, 
prevalence and safety, are interdependent and complementary within each other. Indeed, 
drug utilization research set the basis and priorities for analytic pharmacoepidemiological 
studies. 
1.6.1 Drug utilization research  
Drug utilization UHVHDUFKZDVGHILQHGE\ WKH:RUOG+HDOWK2UJDQL]DWLRQ :+2DV³WKH
marketing, distribution, prescription, and use of drugs in a society, with special emphasis 
RQWKHUHVXOWLQJPHGLFDOVRFLDODQGHFRQRPLFFRQVHTXHQFHV´161 The scope of this research 
is to provide information about the prevalence of drug use in a defined population, trends 
of use over-time, and also non-pharmacological factors influencing such use (e.g. 
sociodemographics). Ideally, quantitative drug utilization studies should also include 
information about the diagnosis or indication for use of the medication of interest, the 
dosage used, the timing of use, and should provide information on the specific substance-
level.162  
Every year new medications are placed into the market while others are withdrawn, 
prescription medications may become available as OTC drugs, clinical protocols for 
treatment of specific disorders can change, and hence there is the potential of a constant 
shift in type and extent of exposure to medications during pregnancy. The need of drug 
utilization research in pregnancy is thus warranted.163  
To date, several sources of information about medication use in pregnancy are available to 
researchers, and these can be grouped under three main domains: patients, prescribers, and 
automated databases. An overview of the various data sources of information, each with its 
inherent most common advantages and disadvantages, is outlined in Table 3.   
1.6.2 Observational, analytic pharmacoepidemiology  
Observational, analytic pharmacoepidemiology is a discipline providing information about 
the magnitude of the association between specific exposures during pregnancy and 
ϯϲ

determined immediate or long-WHUP SUHJQDQF\ RXWFRPHV 7KH WHUPLQRORJ\ ³DQDO\WLF´ LV
used in order to emphasize the ability to determine measures of associations. Studies 
addressing the safety of those medications most commonly used by women in pregnancy 
(since a moderate increase in the relative risk for a specific outcome may have a significant 
impact in terms of absolute risk), as well as those medications for treatment of disorders 
that, if sub-optimally treated, may jeopardize maternal-fetal health, are usually a central 
part of analytic pharmacoepidemiology research.  
Analytic observational pharmacoepidemiological studies can be retrospective or 
prospective in nature. In retrospective case-control studies, cases with a specific pregnancy 
outcome are compared to controls without that outcome, looking whether there are 
differences in antecedent exposures during gestation. In prospective cohort studies a 
specific maternal exposure is ascertained during pregnancy and the pregnancy outcome is 
evaluated and compared to a control group.164 The main characteristics of prospective and 
retrospective study designs, along with most common advantages and disadvantages, are 
outlined in Table 4. 
Data for such studies, i.e., information about exposure, outcome and covariates, may stem 
from one or more sources combined. The sources of information about exposure to 
medication in pregnancy are various, as outlined in Table 3, and can be self-reported by the 
ZRPHQ RU DEVWUDFWHG IURP DXWRPDWHG GDWDEDVHV DQG SUHVFULEHUV¶ UHFRUGV ,GHDOO\ KHDOWK
outcomes should be clinically ascertained (e.g., via medical diagnosis) or extrapolated 
from validated psychometric instruments rather than self-reported by the women.  
x Follow-up of women exposed to medication in pregnancy 
In pregnancy research, women exposed to specific medications can be identified in various 
ways. For instance, physicians can enroll their pregnant patients using medications into 
relevant pregnancy registries. Pregnant women can also enroll themselves into pregnancy 
registries upon calling teratology information services or when visiting the service 
webpage.165 Pregnancy registries are often used as a source population for cohort studies or 
case±control studies.166 Pregnancy registries are observational studies collecting uniform 
data to evaluate outcomes for a particular population defined by a particular exposure, of 
pregnant women which can be based on a common exposure to a medication, or on a 
common outcome of the pregnancy (e.g., congenital anomalies). These registries are most 
ϯϳ

useful when they strive to include all exposed women, rather than relying on passive or 
spontaneous reporting.  
An important advantage of this way of enrollment is that women exposed to specific 
medications are identified early in pregnancy and before knowing the outcome of the 
pregnancy. On the other hand, this type of studies suffers from important drawbacks such 
as loss to follow-up, self-referral bias, and appropriate selection of a control group.    
To date there are several ongoing pregnancy registries run by pharmaceutical industries 
(e.g., the Seasonal Influenza Vaccine Pregnancy Registry by GlaxoSmithKline), general 
hospitals (e.g., the National Pregnancy Registry for Atypical Antipsychotics by the Center 
IRU :RPHQ¶V 0HQWDO +HDOWK DW 0DVVDFKXVHWWV *HQHUDO +RVSLWDO RU QRQ-profit 
organizations (e.g., the OTIS AutoImmune Diseases Study by the Organization of 
Teratology Information Specialists [OTIS]; the prospective multicenter observational study 
on safety of TNF-alpha inhibitors in pregnancy by the European Network of Teratology 
Information Services [ENTIS]).167  
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1.6.3 Critical appraisal of observed associations in pregnancy studies 
x Addressing causation in pregnancy studies: the importance of the 
temporality and plausibility criteria 
Analytic observational pharmacoepidemiology provides information about measures of 
associations and generally, association does not imply causation. In the latest years though, 
there has been a growing interest and discussion in the field of epidemiology research 
about the need of a conceptual model of causation.175 $OUHDG\LQWKHPLG¶V'U$XVWLQ
Bradford Hill proposed a set of viewpoints that could be of use in addressing causation in 
epidemiology.176 +RZHYHU WKH+LOOV¶ YLHZSRLQWV DUH QRW D ³KDUG-and-IDVW UXOH´ WR MXGJH
causation.175 7KH+LOOV¶YLHZSRLQWVXQGHUZHQWYDULRXV LQWHUSUHWDWLRQV DQGDSSOLFDWLRQV LQ
various fields, including teratology. Drs. Shepard and Brent in fact adapted some of the 
+LOOV¶VYLHZSRLQWVDVFULWHULDRISURRIRI WHUDWRJHQLFLW\7KHOLVWRI+LOO¶VYLHZSRLQWVDQG
WKHLUWUDQVODWLRQLQWRWKH6KHSDUG¶VFULWHULDRISURRIRIWHUDWRJHQLFLW\DUe outlined in Figure 
1.  
&ŝŐƵƌĞϭ͗,ŝůůǲƐǀŝĞǁƉŽŝŶƚƐĂŶĚ^ŚĞƉĂƌĚǲƐĐƌŝƚĞƌŝĂŽĨƉƌŽŽĨŽĨƚĞƌĂƚŽŐĞŶŝĐŝƚǇ
 
&ŝŐƵƌĞĂĚĂƉƚĞĚĨƌŽŵ,ŝůů͕^ŚĞƉĂƌĚĂŶĚ^ĐŝĂůůŝ͘ϭϳϲͲϭϳϴ
ΎdŚĞĂƵƚŚŽƌŽĨƚŚŝƐƚŚĞƐŝƐƉĞƌĨŽƌŵĞĚĂĚĂƉƚĂƚŝŽŶŽĨƚŚĞǆƉĞƌŝŵĞŶƚĂŶĚŽŚĞƌĞŶĐĞǀŝĞǁƉŽŝŶƚƐ͘

 
ϰϮ
Several considerations should then be addressed in the appraisal of study results presenting 
associations between medication exposures in pregnancy and pregnancy outcomes 
(concerning the health of either mother or child or both). Temporality is the only necessary 
and sufficient criterion for determining whether an observed association is causal.175 
Indeed, exposure should occur at critical time of fetus (for studies investigating the risk of 
congenital malformations and other perinatal outcomes), or pregnancy development (for 
studies investigating maternal obstetric outcomes). Figure 2 outlines the timing of fetal 
development and the critical windows of vulnerability to medication exposure for 
determined perinatal outcomes.  
&ŝŐƵƌĞϮ͗&ĞƚĂůĚĞǀĞůŽƉŵĞŶƚĂŶĚƚŝŵĞǁŝŶĚŽǁƐŽĨƐƵƐĐĞƉƚŝďŝůŝƚǇƚŽŵĞĚŝĐĂƚŝŽŶĞǆƉŽƐƵƌĞ
 
&ŝŐƵƌĞĂĚĂƉƚĞĚĨƌŽŵDŽŽƌĞ͕ϮϬϭϯ͘ϭϳϵ
Biological plausibility is another important factor to address in causal inference. In the 
field of teratology though, the underlying mechanisms of teratogenicity are often 
completely unknown, which makes adoption of this criterion difficult. However, this 
criterion can be of higher relevance when assessing causal relationship between medication 
exposures in pregnancy and maternal obstetric outcomes. For instance, when assessing the 

 
ϰϯ
relationship between use of SSRIs in pregnancy and postpartum hemorrhage, it is crucial 
to ensure that the exposure occurred during plausible time windows in order for the 
medication to exert its pharmacological properties and evoke bleeding complications. 
Specifically, it is known that the antiplatelet effect of SSRIs is completely over two weeks 
DIWHU LWV ZLWKGUDZDO LQFOXGLQJ WKH GUXJ¶V HOLPLQDWLRQ KDOI-life plus platelet half-life).144 
Hence, evaluation of exposure windows in relation to postpartum hemorrhage outside this 
specific time window would not have any biological plausibility.  
The dose-response relationship, comprising the concepts of dose, duration and cumulative 
dose of exposure, is indeed another important criterion to account for. Roca et al.,180 for 
instance, evaluated the effects of prenatal exposure to SSRIs on obstetrical and neonatal 
outcomes and found that upon stratification on SSRI dose, women treated with a high dose 
were those mainly more likely to have premature babies. Wisner et al.181 explored the 
concept of duration of exposure and found that infants exposed to SSRIs continuously 
during pregnancy were more likely to be born preterm than infants with partial or no 
exposure. However, in this latter study analogue findings were observed for infants 
continuously exposed to maternal not medicated depression. Similarly, Oberlander et al.182 
examined in a population-based setting whether late gestational exposure to SSRIs was 
associated with an increased risk of perinatal outcomes compared to early exposure. This 
study found that length of gestational exposure to SSRIs, rather than timing, conferred an 
increased risk for outcomes such as neonatal respiratory distress, lower birth weight and 
reduced gestational age, even after accounting for maternal illness and medication dose.182  
Since pregnancy research is mainly based on observational studies, replication of study 
findings (i.e., the Consistency criterion) is of relevance when attempting to infer causality. 
In this context, it is worth mentioning the value of meta-analyses in pregnancy research. 
This study type can be used to examine the reasons/sources of discrepancy among study 
findings, combine small comparable studies and provide pooled effect measures.183 
Although meta-analyses can provide pooled association measures and potentially detect 
safety signals earlier, it is important to critically appraise the clinical and methodological 
quality and homogeneity of the included studies.  

 
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1.6.4 Proof of exposure in pregnancy 
Proof of exposure in pregnancy is fundamental in pharmacoepidemiological studies. In the 
latest years most studies assessing the safety of antidepressants in pregnancy stem from 
automated databases where information about exposure derives from insurance claims or 
filled prescriptions, thus questioning whether these medications were actually taken. 
Several studies have recently been carried out with the aim to validate information about 
medication exposure in pregnancy in automated databases. Skurtveit et al.184 examined the 
impact of exposure misclassification on risk associations when using the Norwegian 
Prescription Database as the source for SSRI exposure in pregnancy. The validity of the 
Norwegian Prescription Database data was estimated using self-reported use in the MoBa 
study as the reference standard. It was found that expanding the exposure time window 
regarding the filling of a prescription to periods before pregnancy could lead to lower 
specificity and underestimation of risk associations. Results from another validation study 
indicated that there is a high concordance between self-report and prescription data for 
long-term/chronic medication groups used in pregnancy; contrarily, the concordance is 
poor for those medications used intermittently or in short courses.185 In a validation study 
embedded in Eurocat Northern Netherlands, Van Gelder et al.186 compared pregnancy 
exposure to medication from a self-administered questionnaire completed by mothers of 
children with major birth defects, with pharmacy prescription data that have been 
previously checked against maternal interview. The observed sensitivity for any 
prescription medication was 0.57, whereas specificity was high (0.93-1.00). According to 
this study, the validity of the self-administered questionnaire for prescription medication 
use during pregnancy was moderate to poor. Hence, combination of information about 
exposure from two or more sources, e.g. self-reported data, electronic medical records, and 
prescription or claims records, along with data about maternal adherence to such 
medication during pregnancy, would probably represent a better option in the 
ascertainment of medication exposure during pregnancy. Yet, the golden standard of proof 
of exposure to medications during pregnancy would obviously be represented by the 
plasma concentration of medications during gestation.187   
1.6.5 Extrapolation of relative measures into absolute terms 
Most studies exploring associations between a determined medication exposure in 
pregnancy and a perinatal/obstetric outcomes present relative measures of association, and 

 
ϰϱ
only a few extrapolate these relative measures into absolute terms. This often represents an 
important drawback for many studies, which fail to address the impact of their findings in 
terms of absolute risk, number needed to harm, or population attributable risk. In the field 
of teratology, for instance, the absolute impact of a relative measure (OR) of 2.5 for the 
association between exposure to antidepressants during late gestation and risk of persistent 
pulmonary hypertension in the newborn would imply one additional case for every 286-
351 women treated with an SSRI in late gestation.136 Similarly, in the assessment of the 
association between SSRI use near delivery and postpartum hemorrhage, Palmsten et al. 
described an adjusted excess risk of 1.26% (95% CI: 0.90% to 1.62%), with a number 
needed to harm of 80. Such information is crucial in the assessment of medication safety in 
pregnancy, and it provides clinically relevant guidance to healthcare professionals when 
evaluating the benefit-risk ratio of medication exposure in pregnancy and providing 
evidence-based teratogenic counseling to expectant women.  

 
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2. Objectives 
The overall objective of this work was to increase knowledge about the extent of use, 
adherence and safety of medication during pregnancy, with special focus on psychotropics, 
through a series of studies that addressed the following specific objectives:  
Study I: 
x To explore from a multinational perspective patterns of medication use in pregnancy 
according to type of medication and self-reported indications for use, with particular 
focus on psychotropics  
x To identify maternal background factors associated with medication use for 
acute/short-term illnesses, medication use for chronic/long-term disorders and OTC 
medication use during pregnancy, and also with chronic use of psychotropics for 
treatment of depression and anxiety 
Study II: 
x To investigate patterns of use of psychotropics and other relevant medication groups 
(i.e., analgesic and gastrointestinal medications) before, during, and after pregnancy 
among women with eating disorders 
x To explore the relationship between eating disorders and use of these specific 
medications during pregnancy and the postpartum, including whether there was a 
direct association between eating disorders and medication use or whether the 
association was indirect 
Study III: 
x To estimate the level of adherence to psychotropic medication during pregnancy for 
treatment of depression, anxiety and other psychiatric disorders 
x To explore whether maternal socio-demographics, maternal depressive symptoms, 
ZRPHQ¶VEHOLHIVDQGDQWLGHSUHVVDQWULVNSHUFHSWLRQZHUHDVVRFLDWHGZLWKPHGLFDWLRQ
adherence during pregnancy 
Study IV: 

 
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x To examine whether women exposed to antidepressants during gestation were more 
likely than non-exposed to experience vaginal bleeding in early and midpregnancy, 
and postpartum hemorrhage  
 

 
ϰϴ
3. Materials and Methods 
The Multinational Medication Use in Pregnancy Study provided the data for studies I and 
III, whereas studies II and IV were based on the MoBa study and the Medical Birth 
Registry of Norway (MBRN). Figures 3 and 4 provide a short methodological overview of 
the studies included in this work according to the main study source.  
&ŝŐƵƌĞϯ͗DĞƚŚŽĚŽůŽŐŝĐĂůƐƵŵŵĂƌǇŽĨƐƚƵĚŝĞƐ/ĂŶĚ///
 
&ŝŐƵƌĞϰ͗DĞƚŚŽĚŽůŽŐŝĐĂůƐƵŵŵĂƌǇŽĨƐƚƵĚŝĞƐ//ĂŶĚ/s
 
ďďƌĞǀŝĂƚŝŽŶƐ͗dŚĞEŽƌǁĞŐŝĂŶDŽƚŚĞƌĂŶĚŚŝůĚŽŚŽƌƚ^ƚƵĚǇсDŽĂ͖DĞĚŝĐĂůŝƌƚŚZĞŐŝƐƚƌǇŽĨEŽƌǁĂǇс
DZE͖YƵĞƐƚŝŽŶŶĂŝƌĞ ϭ сYϭ͖YƵĞƐƚŝŽŶŶĂŝƌĞ ϯ сYϯ͖YƵĞƐƚŝŽŶŶĂŝƌĞ ϰ сYϰ͘ ΎƐƚŝŵĂƚĞƐ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ
ůĂƚĞƐƚĨŝůĞƐƌĞůĞĂƐĞĚĨŽƌƌĞƐĞĂƌĐŚŝŶĐůƵĚŝŶŐǁŽŵĞŶǁŚŽĚĞůŝǀĞƌĞĚďĞƚǁĞĞŶϭϵϵϵĂŶĚϮϬϬϵ͘

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3.1 Study design and data collection 
3.1.1 The Multinational Medication Use in Pregnancy Study  
The Multinational Medication Use in Pregnancy Study is a cross-sectional, multinational, 
web-based study carried out within the period 1-Oct-2011 to 29-Feb-2012. Pregnant 
women at any gestational week and mothers of children less than one year of age were 
eligible to participate. Member countries of the ENTIS, OTIS in North America, 
MotherSafe in Australia and European institutions conducting public health research were 
invited to take part in the project. Of these, centers from 18 countries participated 
(Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, 
Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Via 
OTIS we also collected data originating from some South and Central American countries. 
The study was conducted in accordance to the CHERRIES statement.188 
An electronic anonymous questionnaire administered by Quest Back 
(http://www.questback.com) was utilized to collect relevant data. The questionnaire was 
available and accessible on-line for a period of two months in each participating country 
within the main study period stated above. The study was an open survey; the 
questionnaire was open to the public via utilization of banners (invitations to participate in 
the study) on 2-3 national websites and/or social networks and/or pregnancy forums 
commonly visited and consulted by pregnant women and/or new mothers. The 
questionnaire was carefully designed to suit the internet administration approach. To 
improve the questionnaire completion rate we applied specific technical features such as 
multiple page design, routing of questions and progress indicator of completion. National 
websites were selected by the study coordinators in the country according to the number of 
daily users. Detailed information about recruitment tools utilized and internet penetration 
rates in each participating country is summarized in the Appendix 2 of paper I.  
The questionnaire was first developed in Norwegian and English and then translated into 
the other relevant languages. The study coordinator in each participating country ensured 
quality, comprehension, and adaptation of the translated questionnaire to the relevant 
national context; for instance, the question about use of OTC medications during 
pregnancy was aided with examples of brand names of OTC drugs marketed in the specific 

 
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country. Information about translated versions of the psychometric instruments used in the 
questionnaire is provided in section 3.5. 
A pilot study was carried out in September 2011 in four countries (Finland, Italy, Norway 
and Sweden) (n=47) to ensure comprehension of the questionnaire, its suitability to the 
national context, and functionality of the electronic questionnaires. The pilot study elicited 
no major change to the questionnaire. Data from the pilot were not included in the study 
dataset. 
Collected data were scrutinized for the presence of potential duplicates (based on reported 
country of residency, socio-demographic characteristics, date and exact time of 
questionnaire completion) but none were identified. Since the study was anonymous, no 
information about IP addresses was collected. The complete questionnaire is presented in 
Appendix 1 of paper I. 
Studies I and III are based on the unique original version of the Multinational Medication 
Use in Pregnancy Study dataset. 
3.1.2 The Norwegian Mother and Child Cohort Study  
MoBa is a prospective population-based pregnancy cohort study conducted by the 
Norwegian Institute of Public Health.189 The aim of the MoBa is to identify causes of 
serious diseases in mothers and children. The cohort is dynamic and comprises more than 
100,000 pregnancies from all over Norway recruited from 1999 to 2008.190 The 
recruitment began in Western Norway in 1999 and by the end of January 2006, a total of 
50 out of 52 hospital and maternity units in Norway with more than 100 births annually, 
participated in the study. The women consented to participation in 40.6% of all 
pregnancies.189 The cohort now includes 114,500 children, 95,200 mothers and 75,200 
fathers. Participants were recruited through a postal invitation in connection with a routine 
ultrasound examination offered to all pregnant women in Norway at 17-18 weeks of 
gestation. The invitation included an informed consent form, the first of six self±
administered questionnaires and an information brochure. There were no exclusion criteria.  
The study is based on self-administered questionnaires. Participants completed three 
questionnaires during pregnancy: The first questionnaire (Q1) was completed around 
gestational weeks 13 to 17 (covering the period between six months prior to pregnancy and 
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gestational week 18); the second questionnaire (Q2) was completed at gestational week 22 
and covered information about dietary habits in pregnancy; the third questionnaire (Q3) 
(covering the second and part of the third trimester of pregnancy [until gestational week 
29+]) was completed at gestational week 30. The fourth questionnaire (Q4) was distributed 
when the infant was six months old and comprised information on the last period of 
pregnancy (from the 30th gestational week until childbirth). Q1, Q3 and Q4 collected a 
wide range of information on socio-demographic characteristics, outcomes of previous 
pregnancies, medical history, maternal health, lifestyle habits, and medication exposures as 
well as other exposures during pregnancy.189 The questionnaires Q1, Q3 and Q4 are 
outlined in Appendix 1. The study participants also received, and are still receiving, 
additional questionnaires at 18 months, three years, five years, seven years, and by 2012, 
eight years postpartum. Among those who agreed to participate in the MoBa, the response 
rate was 95% for Q1, 92% for Q3, and 87% for Q4.189  Biological specimens have also 
been collected from both parents during pregnancy and postpartum and from the 
offspring.190,191  
Updated versions of the original MoBa dataset are released for research purposes each year. 
Study II is based on version 7 of the quality-assured data file including women who 
delivered between 1999 and 2009. Study IV is based on version 4 including women who 
delivered between 1999 and 2006. 
3.1.3 The Medical Birth Registry of Norway  
The MBRN was established in 1967 and encompasses all births in Norway. The registry is 
based on compulsory notification of all live births, stillbirths and induced abortions after 
gestational week 12 (after week 16 up to 2002).192,193 Information on maternal health prior 
to and during pregnancy, the course of pregnancy and pregnancy complications, delivery 
and postpartum complications and interventions, and the health of the neonate is available 
from standardized forms, as outlined in Appendix 2. These forms were filled in by 
midwives and obstetricians and/or gynecologists at each delivery and also include 
antepartum obstetric records that are completed by general practitioners, gynecologists, or 
midwives throughout the pregnancy. Medical conditions within the mother and/or child are 
coded according to the International Classification of Disease (ICD) and related health 
problems and using unique codes created by the MBRN.194   
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3.2 Study population 
The selection of the study population in studies I-IV reflected the individual research 
questions investigated. Studies I and III were based on the Multinational Medication Use 
in Pregnancy Study dataset and included responses from women residing in one of the 18 
eligible countries (cf. section 3.1.1 above) and from South American countries (the various 
countries in South America were aggregated into one region) (the South American region 
was only included in study I). Responders from Central American countries were excluded 
(isolated responses). In both studies, participating women were categorized according to 
the reported country of residency and grouped into six regions: Western Europe, Northern 
Europe, Eastern Europe, North America, South America and Australia.  
As depicted in Figure 3, study I included women who were pregnant (at any gestational 
week) or mothers of a child younger than one year of age. The final study population 
comprised 9,459 women. 
In study III we only included pregnant women who reported to suffer from a psychiatric 
disorder, namely depression, anxiety, or other psychiatric disorders (i.e., bipolar, panic or 
personality disorGHUVDQGFRPSOHWHGDWOHDVWVL[RIWKHHLJKWLWHPVFRPSOHWLRQRQ
the Morisky Medication Adherence Scale (MMAS-8).195 The final study population 
comprised 259 pregnant women. 
As depicted in Figure 4, studies II and IV were based on the MoBa and MBRN datasets. 
'DWDIURP0R%DZDVOLQNHGWRWKH0%51YLDWKHZRPHQ¶VSHUVRQDOLGHQWLILFDWLRQQXPEHU
which is assigned to every subject registered in the National Population Register as being a 
resident of Norway. In both studies we included pregnant women with a singleton 
pregnancy and a record in the MBRN, and who had completed the MoBa Q1, Q3 and Q4. 
Completion of Q4 by default implies delivery of a live-born child. 
In study II, we excluded women with missing age, implausible weight before and/or during 
pregnancy, implausible height, those with pregnancies ending in stillbirth, those who 
returned the survey after birth, those participating in the pilot version of the survey, those 
women participating in the MoBa with more than one pregnancy, and women who did not 
answer to the eating disorder items in Q1. The final study population comprised 62,019 
women.  
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In study IV we excluded women reporting use of unspecified medication for depression 
and those using SSRIs/SNRIs concomitantly with TCAs/other antidepressants (OADs). 
Women could participate with more than one pregnancy in this study. The final study 
population included 57,279 women.  
3.3 Ethics 
The Multinational Medication Use in Pregnancy Study was approved by the Regional 
Ethics Committee, Region South-East in Norway. Ethical approval or study notification to 
the relevant national Ethics Boards was achieved in specific countries as required by 
QDWLRQDO OHJLVODWLRQ $OO SDUWLFLSDQWV JDYH LQIRUPHG FRQVHQW E\ DQVZHULQJ ³<HV´ WR WKH
TXHVWLRQ³$UH\RXZLOOLQJ WRSDUWLFLSDWH LQ WKHVWXG\"´$OOGDWDZHUHKDQGOHGDQGVWRUHG
anonymously. 
The MoBa study was approved by The Regional Committee for Ethics in Medical 
Research, Region South, and the Norwegian Data Inspectorate. Informed written consent 
was obtained from each participant. 
3.4 Measures 
In Studies I and III, information about outcome and explanatory variables and covariates 
originated from the electronic questionnaire within the Multinational Medication Use in 
Pregnancy Study. In studies II and IV, which are based on the MoBa and MBRN datasets, 
such information stemmed from the three MoBa questionnaires and the MBRN. An 
overview of how this information was retrieved in the latter instance is outlined in Figure 5.  
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&ŝŐƵƌĞϱ͗KǀĞƌǀŝĞǁŽĨĚĂƚĂĐŽůůĞĐƚŝŽŶŝŶƚŚĞDŽĂƐƚƵĚǇĂŶĚDZE

ďďƌĞǀŝĂƚŝŽŶƐ͗'t͗ŐĞƐƚĂƚŝŽŶĂůǁĞĞŬ͖DZE͗DĞĚŝĐĂůŝƌƚŚZĞŐŝƐƚƌǇŽĨEŽƌǁĂǇ͖^>Ͳϱ͗^ŚŽƌƚǀĞƌƐŝŽŶŽĨƚŚĞ
,ŽƉŬŝŶƐ^ǇŵƉƚŽŵƐŚĞĐŬůŝƐƚ ;ϱ ŝƚĞŵƐͿ͖^>Ͳϴ͗^ŚŽƌƚǀĞƌƐŝŽŶŽĨ ƚŚĞ,ŽƉŬŝŶƐ^ǇŵƉƚŽŵƐĐŚĞĐŬůŝƐƚ ;ϴ ŝƚĞŵƐͿ͖
^DͲ/s͗ŝĂŐŶŽƐƚŝĐĂŶĚ^ƚĂƚŝƐƚŝĐĂůDĂŶƵĂůŽĨDĞŶƚĂůŝƐŽƌĚĞƌƐ͕ǀĞƌƐŝŽŶ/s͘
3.4.1 Outcome variables 
x Use of medication during pregnancy and postpartum (studies I and II) 
7KH RXWFRPH PHDVXUHV ³0HGLFDWLRQ XVH GXULQJ SUHJQDQF\´ VWXGLHV , DQG ,, DQG
³SRVWSDUWXP´VWXG\ ,,ZHUHGLFKRWRPRXs (yes/no). In both studies, this information was 
self-reported by the respondents and was retrieved from the unique electronic 
questionnaire within the Multinational Medication Use in Pregnancy Study, and the MoBa 
Q1, Q3 and Q4, respectively.  
Respondents were asked to report medication use for numerous chronic, short-term, and 
pregnancy-related conditions as free entry text, along with the timing of use, as described 
in detail in studies I and II. In both studies, we measured medication use for any disorder 
listed in the relevant questionnaire.  
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A medicine was defined as a single product containing one or more active ingredients. All 
recorded medications were coded into the corresponding Anatomical Therapeutic 
Chemical (ATC) codes at the ATC 5th level (i.e. the substance level) whenever possible, 
otherwise into higher ATC levels, in accordance with the WHO ATC index.196 Iron, 
mineral supplements, vitamins, herbal remedies and any type of alternative medicine were 
recorded separately and excluded from the estimation of medication use. In study I, each 
national coordinator was responsible for the accuracy of medication coding into their 
corresponding ATC codes. A different person reviewed all coded data and any 
disagreement was settled.  
In study I, we explored use of any medication during pregnancy as well as medication use 
by indication, i.e., for treatment of acute/short-term illnesses and chronic/long-term 
disorders, as well as OTC medication use. Details about the disorders and OTC types 
included in these groups are presented in detail in study I. For the purpose of this thesis, we 
DGGLWLRQDOO\ H[SORUHG WKH RXWFRPH YDULDEOH ³XVH RI SV\FKRWURSLF PHGLFDWLRQV GXULQJ
SUHJQDQF\´ referring to use of any psychotropic medication during pregnancy for 
treatment of chronic/long-term psychiatric disorders, namely depression and anxiety.  
In study II, our outcome measures were use and incident use of psychotropic, 
gastrointestinal, and analgesic medications during pregnancy and postpartum. Incident use 
of medication ³GXULQJ SUHJQDQF\ RQO\´ UHIHUUHG WR ZRPHQ ZKR VWDUWHG WDNLQJ WKH
medication in pregnancy and were not using that medication neither before nor after 
pregnancy. Incident use of medication ³SRVWSDUWXPRQO\´UHIHUUHG WRZRPHQZKRVWDUWHG
taking the medication postpartum and were not using that medication neither before nor 
during pregnancy. Details about the medication types included in these groups are 
presented in detail in study II. 
x Adherence to psychotropic medication in pregnancy (study III) 
This outcome measure was derived from a validated psychometric instrument, the MMAS-
8,195 and used as both a continuous variable and a dichotomous variable (categorized as 
low versus medium/high adherence) in the analysis. The MMAS-8 has been described in 
detail in study III. In brief, the MMAS-8 is a structured, self-reported medication 
adherence measure consisting of seven yes/no items and one 5-point Likert scale. Each 
item measures specific medication-taking behaviors.195 The seven yes/no items are 
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assigned values 0 or 1 (1=higher adherence), whereas the value of the Likert scale item is 
standardized from 0-4 into 0-1 (this item is divided by 4 when calculating the summated 
score). The total scale has a range from 0 to 8. Categorization of the adherence level is as 
follows: low (sum score<6), medium (sum score 6 to <8) and high (sum score=8). The 
predictive validity of the MMAS-8 has been examined through associations with blood 
pressure control among patients treated with antihypertensive drugs, where correct 
classification for high/medium adherence was 80.3%.195  
x Bleeding complications during pregnancy and postpartum (study IV) 
Our outcome variables were: Vaginal bleeding in early pregnancy (any type of bleeding, 
bleeding as trace of blood, medium blood loss or clots, multiple bleeding episodes); 
vaginal bleeding in midpregnancy (any type of bleeding, bleeding as trace of blood, 
medium or large blood loss, multiple bleeding episodes); postpartum hemorrhage (> 500 
ml blood loss at delivery). The outcome variables concerning maternal vaginal bleeding 
during pregnancy were self-reported by the responders and retrieved from the MoBa Q1 
and Q3. They were all used as dichotomous variables (yes/no). In both Q1 and Q3, women 
could report details about two bleeding episodes: the first and last episode in Q1, and the 
second last and last episode in Q3. Information about type of bleeding and duration (in 
days) could be reported for each individual episode. If such episodes differed in typology 
(trace versus large/medium amRXQWRIEORRGORVVZHEDVHGRXUDQDO\VLVRQZRPDQ¶VPRVW
VHYHUH EOHHGLQJ H[SHULHQFH 7KH RXWFRPH ³EOHHGLQJ LQ HDUO\ SUHJQDQF\´ZDV GHILQHG DV
DQ\RFFXUUHQFHRIYDJLQDO EOHHGLQJGXULQJ WKH ILUVW WULPHVWHURISUHJQDQF\ ´%OHHGLQJ LQ
PLGSUHJQDQF\´ ZDV GHILQed as any occurrence of vaginal bleeding during the second 
trimester of pregnancy. Bleeding type in early and midpregnancy was subdivided into trace 
of blood or spotting, moderate/large amount of blood loss or clots, or multiple episodes 
irrespective of amRXQWRIEORRGORVV7KHRXWFRPH³SRVWSDUWXPKHPRUUKDJH´ZDVDYDLODEOH
from MBRN records and is medically confirmed information. The MBRN does not 
classify postpartum hemorrhage according to mode of delivery, i.e. as an estimated blood 
loss >500 ml after vaginal birth or >1,000 ml after cesarean delivery. Postpartum 
hemorrhage was defined as blood loss >500 ml regardless of delivery mode. 
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3.4.2 Explanatory variables 
x Maternal sociodemographics and life-style factors (studies I and III) 
In studies I and III, these explanatory variables were all self-reported by the respondents 
DQG FRPSULVHG PDWHUQDO DJH LQ \HDUV  -30; 31-  RU  - 
educational level (less than high school; high school; more than high school; 
others/unspecified), first language different from the official main language in the country 
of residency (yes; no), working status at time of conception (employed, but not as 
healthcare provider; healthcare provider; student; housewife; job seeker; others), previous 
children (yes; no), marital status (married/cohabiting; single/divorced/others), unplanned 
pregnancy (yes; no), smoking status during pregnancy (no; yes, but less than before 
pregnancy; yes, the same or more than before pregnancy or yes; no), alcohol consumption 
after awareness of pregnancy (yes; no). Study I additionally comprised region of residency 
(Western Europe; Northern Europe; Eastern Europe; North America; South America; 
Australia) as explanatory variable, whereas gestational age (continuous variable ranging 
from 1 to 42), folic acid use before and/or during pregnancy (yes; no), and number of 
psychotropics (=1; >1) were so in study III.  
x Maternal psychiatric disorders and mental health (studies II, III) 
Eating disorder (i.e., AN, BN, EDNOS-P or BED) before and/or during pregnancy was the 
main explanatory variable in study II and was retrieved from items in MoBa Q1. These 
items on eating disorder symptoms and behaviors were designed in accordance with the 
criteria for eating disorders in the DSM±IV.50 These criteria have previously been used for 
studies on eating disorders in the MoBa sample53,109 and in the Norwegian Institute of 
Public Health Twin Panel.197 Diagnostic algorithms and hierarchies were constructed to 
define the presence of eating disorders in the six months prior to pregnancy (retrospective 
assessment) and during pregnancy. Detailed information about definition and hierarchy 
classification of the eating disorder subtypes is described in study II.  
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In study III, underlying maternal mental health during pregnancy was measured via The 
Edinburgh Postnatal Depression Scale (EPDS). The EPDS is a screening self-rating 
questionnaire for symptoms of depression during pregnancy and postpartum, comprising 
10 items. The scale is validated for major and minor depression in clinical settings and 
ZLWK VDWLVIDFWRULO\ &URQEDFK¶V DOSKD UHOLDELOLW\ 198 Each question was scored 0-3, 
producing a total score of 0-30. The cut-off for probable depression was set to 13.198 This 
variable was used as dichotomous (yes; no) in the multivariate analysis of study III.  
x Risk perception and beliefs about medication (study III) 
The perceived risk of antidepressant exposure during pregnancy was measured via a 
numeric scale ranging from 0 µQRWKDUPIXOWRWKHIHWXV¶WRµYHU\KDUPIXOWRWKHIHWXV¶
:RPHQFRXOGDOVRVHOHFWWKHRSWLRQ³XQNQRZQVXEVWDQFH´LIDSSOLFDEOHThis variable was 
initially utilized as continuous, but it was then categorized in three groups (risk 0-3; 4-5; 
EHFause of non-linearity in the logit link function.  
:RPHQ¶V EHOLHIV DERXW PHGLFLQHV ZHUH H[SORUHG YLD WKH %HOLHIV $ERXW 3UHVFULEHG
Medicines Questionnaire (BMQ-specific), which comprises two subscales: the BMQ-
Necessity (5 items) and BMQ-Concerns (5 items).120,199 Respondents indicated their degree 
of agreement with each statement on a 5-point Likert scale (1=strongly disagree, 
2=disagree, 3=uncertain, 4=agree, 5=strongly agree). Individual item scores were added, 
giving a total score of 5-25. Higher scores indicate stronger beliefs in the concepts 
represented by the subscale. The belief variables were used as continuous in the analysis. 
The Necessity-Concerns differential was also calculated. The Necessity-Concerns 
differential is the difference between the BMQ-Necessity and BMQ-Concerns scores 
(positive scores indicate that the patient perception of the benefits of medication outweigh 
the risks whereas a negative score indicates the converse).  
7KUHHVWDWHPHQWVZHUHDGGLWLRQDOO\XVHGWRH[SORUHZRPHQ¶VEHOLHfs about medication use 
GXULQJSUHJQDQF\ L³,KDYHDKLJKHU WKUHVKROG IRUXVLQJPHGLFLQHVZKHQ ,DPSUHJQDQW
WKDQZKHQ,DPQRWSUHJQDQW´LL³(YHQWKRXJK,DPLOODQGFRXOGKDYHWDNHQPHGLFLQHVLW
is better for the fetus that I refrain from using them´ LLL ³3UHJQDQW ZRPHQ VKRXOG
SUHIHUDEO\XVHKHUEDOUHPHGLHVWKDQFRQYHQWLRQDOPHGLFLQHV´5HVSRQGHQWVFRXOGLQGLFDWH
their degree of agreement with each statement on a 5-point Likert scale (0=strongly 

 
ϱϵ
disagree, 1=disagree, 2=uncertain, 3=agree, 4=strongly agree). The belief variables were 
used as continuous (score range 0-4) in the analysis.  
x Antidepressant exposure (study IV) 
Information about type and timing (by trimester) of antidepressant exposure in pregnancy 
was retrieved from MoBa Q1, Q3 and Q4. We explored exposure to antidepressant in first 
trimester, second trimester, and last part of the pregnancy (from gestational week 30 to 
childbirth), according to the outcome investigated. Antidepressants were subdivided into 
two main groups: 1) SSRIs (ATC code N06AB) and SNRIs (ATC codes N06AX16 and 
N06AX21); 2) TCAs (ATC code N06AA) and other antidepressants (OADs) (ATC codes 
N06AX03, N06AX06, N06AX11, N06AX12 and N06AX18). SSRIs and SNRIs were 
grouped together since both drug groups significantly inhibit serotonin reuptake.144 Even 
though clomipramine, belonging to the TCA group, is known to have high affinity to 
serotonin transporters, its active metabolite desmethylclomipramine is not particularly 
serotonin-selective, and it was therefore kept under the TCA group. TCAs and OADs were 
grouped together in order to increase power secondary to the low number of women 
reporting use of these drug groups. A disease comparison group, defined as no exposure to 
antidepressants but presence of depressive symptoms at both gestational week 17 and 30, 
was also created. 
In each questionnaire several indications for antidepressant drug treatment were 
specifically named: unusual tiredness/sleepiness, sleeping problems, 
anorexia/bulimia/other eating disorders, depression, anxiety and other long-term illnesses 
or mental health problems. For each indication, women could specify use of several 
medicinal products and the corresponding periods of exposure. Details about the available 
exposure windows in the MoBa questionnaire and its classification are provided in study 
IV.  
3.4.3 Other variables 
In studies I and III, we sought to build predictor models of factors associated with the 
specific outcomes; hence, all variables analyzed in these two studies have been dealt with 
in the section DERYHµ([SODQDWRU\YDULDEOHV¶7KLVVHFWLRQRQO\DSSOLHV WRVWXGLHV ,,
and IV. 
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x Socio-demographic, life-style and health characteristics 
Information about maternal age stemmed from the MBRN and was used as both 
continuous (study II) and categorical variable (<20; 20-29; 30-\HDUVVWXG\,9
Additional covariates originating from the MBRN were used in study IV and were: parity 
(previous pregnancies after gestational week 12; no previous pregnancies after gestational 
week 12), placenta previa (yes; no), placental abruption (yes; no), coagulation defects 
before and/or during pregnancy (yes; no), instrumental delivery (i.e., use of vacuum or 
forceps) (yes; no), and type of delivery (vaginal; cesarean section).  
The following covariates stemmed from the MoBa Q1, Q3 and Q4 and were: body mass 
index (BMI) at conception, used as both continuous (study II) and categorical variable 
(<18.5; 18.5-24.9; 25.0- VWXG\ ,9ZHLJKW JDLQ GXULQJ SUHJQDQF\ DQGZHLJKW
decrease six months after delivery (both as continuous variable)(study IV), educational 
level (primary; secondary; tertiary short; tertiary long or primary/secondary; 
university/higher degree) (studies II and IV), socioeconomic status as household minimum 
yearly income (0-499,999 NOK; 500,000-999,999 NOK; >1 million NOK; 
unknown)(study II), comedication during pregnancy with nonsteroidal anti-inflammatory 
drugs (NSAIDs) and/or antithrombotic agents (yes; no)(study IV), smoking status during 
pregnancy (yes; no) (studies II and IV), history of abortions/miscarriages (yes; no)(study 
IV), marital status (married or cohabiting; others) (studies II and IV), and breastfeeding 
status in the 0-6 months period after childbirth (yes; no) (study II).  
x Maternal mental health 
The severity of maternal underlying depressive and anxiety symptoms during pregnancy 
and postpartum was measured via the short versions of The Hopkins Symptom Checklist-
25 (SCL-25) that is, the Symptom Checklist-5 (SCL- 5) in Q1, and the Symptom 
Checklist-8 (SCL-8) in Q3 and Q4.200,201 The scale is considered a reliable screening 
instrument for depression and anxiety as defined by the ICD-10.202 Both SCL-5 and SCL-8 
are highly correlated to the SCL-25.201,203 For each item of the scales, a score from 1 to 4 
can be assigned. For all three instruments, the mean score was separately computed.  
When used as covariates, these variables were all used as continuous in studies II and IV. 
In study II, we summed the mean scores for the SCL-5 in Q1 and the SCL-8 in Q3 in order 
to measure symptoms of depression and anxiety throughout the pregnancy. In study IV, we 
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additionally utilized a cutoff score greater than 2.0 in the SCL-5 in Q1 and greater than 
1.85 in the SCL-8 in Q3 to define the disease comparison group, i.e. women with 
depressive and anxiety symptoms throughout the pregnancy but not exposed to 
antidepressants.200 
3.5 Use and translation of psychometric instruments 
In the Multinational Medication Use in Pregnancy Study we used translated versions of the 
following psychometric instruments: the MMAS-8, the EPDS, and the BMQ-Specific. 
Copyright agreements were signed with Prof. DE. Morisky and Prof. R. Horne in order to 
utilize the MMAS-8 and BMQ-Specific, respectively. Use of the EPDS for research 
purposes could be done without seeking permissions from Prof. J. Cox.204 Information 
about validation properties and translation process has been described in study III.    
3.6 Statistical analysis 
The statistical analyses were performed using the Statistical Package for Social Sciences 
SPSS (IBM® SPSS® Statistics) version 20.0 (studies I, III, IV) and 22.0 (study II).  
Descriptive analyses were performed in all studies. The Pearson chi-square or Fisher exact 
tests, and the Student's t-test or one-way analysis of variance (ANOVA) were utilized to 
compare proportions and mean scores between independent groups, respectively. In all 
analyses, missing values were less than 5% of the total. In studies I, III and IV, a two-tailed 
p-value of < 0.05 was considered statistically significant. Because of the numerous 
analyses conducted in study II, we undertook a conservative approach and considered two-
tailed p-YDOXHVRIVWDWLVWLFDOO\VLJQLILFDQW 
3.6.1 Associations between explanatory and outcome variables  
x Logistic regression  
Logistic regression analyses were utilized to determine any association between the 
explanatory and outcome variables (studies I, IV). In study I, we first fit the univariate 
logistic regression model for all explanatory variables. The multivariate model was then 
built and adjusted for all remaining covariates.  
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In study IV, we first fit the univariate logistic regression model for the exposure and 
candidate confounding variables. Candidate variables were selected based on a univariate 
p-value of <0.15 and added into the multivariate model. Variables having no role (p-
value >0.05) or yielding a change smaller than 15% in the beta coefficients of the retained 
variables were removed.  
In both studies, the main effect model was checked for the presence of clinically relevant 
interactions. The final multivariate model included statistically significant independent 
variables and clinically significant variables. Goodness of fit of the final multivariate 
model was assessed by using the Hosmer and Lemeshow test.205  
x Generalized Estimating Equation 
Generalized Estimating Equation (GEE) with a Poisson distribution was utilized in study II. 
A Poisson regression provides direct estimates of relative risks and was therefore 
considered the preferable choice compared to logistic regression. However, a Poisson 
regression applied to binary data (without adjustments) provides conservative results by 
overestimating the standard error for the risk estimates. To remove this bias, a robust 
variance estimator was used. We carried out two sets of analyses: in Model 1, we 
computed the total association between eating disorders and the outcomes of interest by 
adjusting for the the minimal sufficient set of variables; these variables were identified via 
utilization of Directed Acyclic Graphs (DAGs) using DAGitty version 2.2 (one DAG for 
each medication-outcome pair).206 In Model 2 we entered the set of confounders from 
Model 1 plus additional covariates (as directed by the DAGs) in order to estimate the direct 
association between eating disorders and the outcomes of interest. 
In study III, a GEE analysis with a binomial distribution was performed to take into 
account clustering on region of residency. The multivariate GEE model was built as 
follows: candidate variables were selected based on a univariate p-value<0.15; variables 
having no role (p-value>0.05) or yielding a change smaller than 15% in the beta 
coefficients of the retained variables were removed; continuous variables were checked for 
linearity in the logit link. Because of non-linearity, the variable antidepressant risk 
perception was categorized according to the non-linearity midpoints (risk 0-3; 4- 
The final multivariate model included statistically significant independent variables and 
potential confounders.  
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x Directed Acyclic Graphs 
DAGs were employed in study II with the aid of DAGitty version 2.2206 in order to identify 
potential confounding and mediating factors of the association between eating disorder 
subtypes before and/or during pregnancy and medication use during pregnancy or 
postpartum.  
DAGs graphically encode relationships between variables, and they enable us: 1) to 
identify whether there is confounding; 2) to identify which variables need to be controlled 
for; 3) identify which variables should not be controlled for. Employing DAGs require to 
clearly setting down assumptions about causal relationship and direction of the association 
between variables.175,207 A description of our assumptions about the direction of the 
association between variables is provided in study II. The six individual DAGs utilized in 
study II are outlined in Appendix 3.  
x Correlation analyses 
,QVWXG\,,,ZHXVHGWKH6SHDUPDQ¶VUDQNFRUUHODWLRQFRHIIicient to explore the correlation 
between the medication adherence sum scores and beliefs about medications. 
3.6.2 Sensitivity analysis 
In study I, we built multivariate models of factors associated with the outcomes of interest 
separately for each region. In these instances, region of residency was not included in the 
model. We also carried out GEE analyses with a binomial distribution taking into account 
clustering on region of residency, in order to evaluate whether the measure of association 
between the other explanatory variables and the outcomes of interest differed substantially 
from those obtained in the logistic regression analyses.   
In study II, we included BMI at conception as additional covariate in Model 1 because of 
the uncertainty in the direction of the association between BMI and eating disorders. In this 
study we excluded from the sample those pregnancies ending in a stillbirth, and therefore 
we could not evaluate patterns and factors associated with medication use among these 
women.   
In study III, we explored the role of the explanatory variables, namely smoking during 
pregnancy, depressive symptoms or risk perception of antidepressant exposure, for which a 
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clustering effect on individual country of residency could not be ruled out. Hence, we 
performed sensitivity analyses taking into account clustering on country of residency, even 
though this led to lower statistical power.  
In study IV, we explored whether there was a difference in the mean duration (in days) of 
vaginal bleeding episodes between the exposed and non-exposed women. Additional 
analyses on individual antidepressant level were also performed when statistical power 
allowed doing so. Antidepressants were also regrouped according to the level of affinity to 
the serotonin transporter. We also explored the association between antidepressant 
exposure and postpartum hemorrhage among women who delivered vaginally with or 
without instrumental intervention (i.e. forceps and/or vacuum). Since we included women 
with multiple participations in the MoBa study, we performed sensitivity analyses 
restricted to women who participated only one time in the study, leading to the exclusion 
of 18.5% of the MoBa population. We additionally carried out sensitivity analyses 
including only the first pregnancy of those women participating more than once in the 
MoBa study, leading to the exclusion of 9.3% of the MoBa population. We also carried out 
GEE analyses taking into account such dependency within the data, with the maternal id 
being the repeated measure.  
3.6.3 Power calculation 
Information about sample size calculation (using 5% precision with 95% confidence 
interval) for the prevalence of medication use in pregnancy on country and region level has 
been described in Appendix 4 of study I. Sample size calculations were performed in Epi 
Info TM 7.208 
In study II, no power calculation was carried out due to the lack of previous studies about 
medication use in pregnancy among women with eating disorders.  
In study III, the overall prevalence of low adherence to psychotropics could be calculated 
with a precision of ±8%. No power calculation about the minimal detectable magnitude of 
the association between the various maternal factors and low medication adherence was 
performed due to lack of previous similar studies. Sample size calculations were performed 
in Epi Info TM 7.208 
In study IV, post hoc sample power analysis for the exposure group SSRIs/SNRIs revealed 
that we could detect a 25% and 50% increase in the odds of vaginal bleeding in early 
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pregnancy and midpregnancy, respectively, with an 80% power. With respect to the 
outcome of postpartum hemorrhage, we had power to detect a 60% increase in the odds. 
The sample size calculator developed by Dr. Stigum was utilized.209  
3.6.4 Imputation 
In studies II, III and IV we imputed missing values on scale variables, namely the SCL-5, 
SCL-8, MMAS-8, and BMQ-Specific, using the estimation-maximization algorithm.210 
Information about the percentage of imputed values and the criteria applied for each 
imputation is provided in each individual study.  
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4. Main findings 
4.1 Study I: Medication use in pregnancy: a cross-
sectional, multinational web-based study 
Of the 9,459 women in the study, 7,678 (81.2%) reported use of at least one medication, 
either prescribed or OTC, during the course of the pregnancy. The prevalence estimates of 
any medication use ranged from 75.7% in Eastern Europe to 86.2% in Australia. There 
were inter-region variations in the estimates of the self-reported disorders and related 
medication use, for all medication sub-types explored.  
Medications for the nervous system (ATC class N) were the most commonly used during 
pregnancy (57.5%), mostly due to paracetamol and its combinations, followed by 
medications for the alimentary tract and metabolism (ATC class A) (45.2%), mostly 
comprising antacids and laxatives, medications for the respiratory system (ATC class R) 
(27.6%) and anti-infectives for systemic use (ATC class J) (14.6%). During the first 
trimester of pregnancy, about 50% of the sample reported to be exposed to at least one 
medication. The most frequently used medication groups during this time window were 
analgesics (38%), antacids (22%), nasal preparations (11%), systemic antibiotics (9%), 
antihistamines (8%), thyroid medication (4%), NSAIDs (4%), drugs for obstructive airway 
diseases (3%), antidepressants (2%) and anxiolytics/sedatives (2%).  
Use of OTC medication during pregnancy was reported by 66.9% of the women, with 
analgesics (mostly paracetamol), antacids, sympathomimetic nasal decongestants, laxatives 
and antinauseants being the most common. Maternal factors positively associated with use 
of OTC medication were: having previous children, education lower than high school, 
working as a healthcare provider and consumption of alcohol after awareness of pregnancy. 
Women residing in Northern Europe (1.5-fold magnitude) and Australia (1.6-fold 
magnitude) were more likely than those in Western Europe to use OTC drugs during 
pregnancy. Women residing in the remaining regions (Eastern Europe, North America and 
South America) were less likely than Western Europeans to report use of OTC medication 
during pregnancy.  
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Overall, 68.4% of the sample reported use of medications during pregnancy for treatment 
of acute/short-term illnesses, mainly headache, heartburn, pain, nausea and UTIs. The most 
commonly used medications for these illnesses were paracetamol, antacids (mainly 
aluminum, salt combinations, antiflatulents, alginic acid complex/sucralfate/bismuth), first 
generation antihistamines, metoclopramide and penicillins.  
Use of medication for treatment of chronic/long-term disorders during pregnancy was 
reported by 17.0% of the sample, with hypothyroidism, asthma, allergy and depression 
being the leading indications for such use. Compared to Western European women, those 
residing in Northern Europe, North America and Australia were more likely to use chronic 
medications during pregnancy (1.7-2.8 fold increased likelihood). Older women, those 
working as housewives, with education lower than high school, or with an unplanned 
pregnancy, were more likely to use chronic medications in pregnancy. Immigrant women 
in Western (adjusted OR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (adjusted OR: 
0.50, 95% CI: 0.31-0.83) were less likely to report use of medication for chronic/long-term 
disorders during pregnancy than non-immigrants.  
With respect to the psychiatric disorders investigated in this study, namely depression and 
anxiety, 464 women (4.9%) reported to suffer from either condition during pregnancy, and 
281 (3.0%) reported to be medicated. In general, SSRIs were the most common 
psychotropic medications used for treatment of depression and anxiety, followed by SNRIs 
and benzodiazepines, as outlined in Appendix 4a. There was a substantial inter-region 
variability in the extent of self-reported disorders and related psychotropic medication use. 
The results of the analysis of factors associated with psychotropic medication use during 
pregnancy for treatment of depression and/or anxiety are outlined in Appendix 4b. The 
obtained measures of associations did not substantially differ from the main analysis on 
chronic medication use in general, although stronger measures of association were detected. 
Specifically, women residing in Northern Europe (2.1-fold magnitude), North America 
(3.0-fold magnitude) and Australia (4.4-fold magnitude) were more likely than those in 
Western Europe to use psychotropic medications. Other factors significantly associated 
ZLWKVXFKXVHZHUHROGHUPDWHUQDODJHEHLQJVLQJOHRUGLYRUFHGEHLQJDVWXdent or 
housewife, having lower education than high school, an unplanned pregnancy, smoking 
during pregnancy and alcohol consumption after awareness of pregnancy.  
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4.2 Study II: Medication use before, during, and after 
pregnancy among women with eating disorders: a 
study from the Norwegian Mother and Child Cohort 
Study 
This study included 62,019 women. The prevalence of eating disorder subtypes before 
and/or during pregnancy was: 0.09% for AN (n=54), 0.94% for BN (n=585), 0.10% for 
EDNOS-P (n=61) and 5.00% for BED (n=3,104). The remaining 93.87% did not have any 
eating disorder (reference group). Women within the AN, BN, EDNOS-P, and BED 
groups more frequently had less education and lower socio-economic status than the 
reference group, and showed significantly higher rates of depressive and anxiety symptoms 
throughout the pregnancy. 
Women with AN or EDNOS-P reported the highest rate of psychotropic medication use 
prior to pregnancy (AN: 22.2%; EDNOS-P: 9.8%), during (AN: 11.1% in first trimester to 
3.7% in third trimester; EDNOS-P: 8.2% in first trimester to 4.9% in third trimester), and 
after pregnancy (AN: 9.3% at 4-6 months postpartum; EDNOS-P: 8.2% at 4-6 months 
postpartum). Use of psychotropics decreased during pregnancy across all eating disorders 
compared to the period before conception. The discontinuation rate of psychotropics from 
the six months period prior to conception to first trimester was about 50% in women with 
AN or BED or no eating disorder, and lower among women with BN (about 35%) or 
EDNOS-P (about 16%). However, at 4-6 months postpartum the AN and EDNOS-P 
groups were characterized by a significant increase in such use (mainly anxiolytics and 
sedatives). Antidepressants comprised the medication class most widely used before, 
during, and after pregnancy. Continuous use of antidepressants before, as well as during 
and after pregnancy was more common among women with AN (1.9%), BN (1.2%), 
EDNOS-P (1.6%) or BED (0.5%) than the reference group (0.3%). 
After adjusting for the minimum sufficient set of confounders, all eating disorder subtypes 
were totally significantly associated with use of psychotropics during pregnancy 
(magnitude of the associations ranging from 1.7-fold for BED to 5.6-fold for AN). Having 
BN was significantly directly associated with use (1.8-fold magnitude) and incident use of 
psychotropics during pregnancy (2.3-fold magnitude). In the analysis on specific 
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psychotropics, BN was found to be directly associated with use of anxiolytics/sedatives 
during pregnancy (adjusted RR: 2.36; 99% CI: 1.26-4.41), whereas BED (adjusted RR: 
1.45; 99% CI: 1.01-2.08) was so in relation to use of antidepressants during this time 
window, compared to women with no eating disorders. AN and EDNOS-P were directly 
associated with an increased likelihood of using anxiolytics/sedatives in the postpartum 
period (adjusted RR: 5.11; 99% CI: 1.53-17.01; adjusted RR: 6.77; 99% CI: 1.41-32.53, 
respectively). 
Women with any eating disorder were characterized by a high use of gastrointestinal drugs 
during pregnancy (especially in the second and third trimester) and postpartum. Compared 
to the reference group, all eating disorder subtypes were characterized by a higher rate of 
laxative use at some point before, during, or after pregnancy. Only the EDNOS-P subtype 
(1.7-fold magnitude) was significantly directly associated with gastrointestinal drug use 
during pregnancy (specifically for antacids and laxatives). BN was significantly directly 
associated (1.6-fold magnitude) with use of gastrointestinal drugs postpartum compared to 
the reference group.  
Even though not always significantly different, use of analgesics was at almost all time 
points higher among women with AN than the reference counterpart. Women with BED 
were characterized by a significantly higher use of any type of analgesics before, as well as 
during and after pregnancy. However, none of the eating disorder subtypes was directly 
associated with use of analgesics during pregnancy or postpartum.  
4.3 Study III: Patterns and factors associated with low 
adherence to psychotropic medications during 
pregnancy - a cross-sectional, multinational web-
based study 
Of the 4,938 eligible pregnant women, 259 (5.2%) reported to suffer from at least one 
psychiatric disorder and filled in the MMAS-8, and were therefore included in the analysis. 
This sample included 160 (61.8%) and 99 (38.2%) women who reported use and non-use, 
respectively, of psychotropic medications during pregnancy. Women who did not use 
psychotropic medications most strongly believed that the necessity of medications did not 
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outweigh their concerns and that despite being ill, it was better for the fetus to refrain from 
taking medications. Compared to non-users, women using psychotropics during pregnancy 
were more often older, with previous children, with an unplanned pregnancy, or consumed 
alcohol after awareness of pregnancy. The presence of depressive symptomatology (as 
PHDVXUHGE\WKH(3'6VFRUHZDVFRPSDUDEOHEHWZHHQWKHWZRJURXSVDPRQJ
psychotropic users vs. 52% among non-users).  
Among the women using psychotropics during pregnancy, antidepressants (mainly SSRIs) 
were the medication group most commonly used and most women (75%) were on 
monotherapy. According to the MMAS-8, 48.8% of the women (95% CI: 41.1-56.4%) 
demonstrated low adherence to psychotropics during pregnancy. The rates of low 
adherence were 51.3% for anxiety, 47.2% for depression and 42.9% for other psychiatric 
disorders.  
In the multivariate analysis, smoking during pregnancy, psychotropic monotherapy, 
elevated risk perception of antidepressants and depressive symptoms during pregnancy 
were significantly associated with low adherence. Specifically, women smoking during 
pregnancy had a 3.9-fold increased odds to show low adherence compared to non-smokers; 
women on polytherapy presented a 68% reduced odds to be low adherers compared to 
ZRPHQ RQPRQRWKHUDS\ZRPHQZLWK GHSUHVVLYH V\PSWRPV GXULQJ SUHJQDQF\ (3'6
13) had a 2.5-fold increased odds to demonstrate low adherence compared to absence of 
depressive symptoms; women with a moderately high (4-5) and elevated risk perception 
RIDQWLGHSUHVVDQWH[SRVXUHGXULQJSUHJQDQF\SUHVHQWHGDVLJQLILFDQW- and 2.3-fold 
increased odds, respectively, to be low adherers.  
$Q LQGLYLGXDO¶V EHOLHI DERXWPHGLFDWLRQV ZDV VLJQLILFDQWO\ FRUUHODWHGZLWK DGKHUHQFH WR 
psychotropics in pregnancy. There was a positive correlation between the perception that 
the benefit of pharmacotherapy outweighed the risks and increasing level of adherence to 
psychotropic medication (r=0.282; p<0.001). There was a negative correlation between 
agreement with the statement that it is better to use herbal remedies than conventional 
medication during pregnancy and increasing level of adherence to psychotropic medication 
and (r= - 0.243; p<0.01). 
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4.4 Study IV: Risk of vaginal bleeding and postpartum 
hemorrhage after use of antidepressants in pregnancy: 
a study from the Norwegian Mother and Child Cohort 
Study 
Of the 57,279 women included in the study, 587 (1.02%) reported use of antidepressants 
during pregnancy. The most frequently used antidepressants were SSRIs/SNRIs (0.92%), 
in particular citalopram (0.31%), sertraline (0.16%) and escitalopram (0.15%). A total of 
123 women (0.2%) reported continuous use of any antidepressant at all trimesters. Overall, 
5.9% and 6.3% of the sample presented depressive symptoms at week 17 and 30, 
respectively, whereas 32.5% had lifetime history of depression. Maternal underlying 
depression in pregnancy was more severe among women in the disease comparison group 
than the medicated counterparts. 
Compared to non-exposed, women using either SSRIs/SNRIs (adjusted OR: 0.91; 95% CI: 
0.72-1.16) or TCAs/OADs (adjusted OR: 0.83; 95% CI: 0.36-1.92) during the first 
trimester did not show any increased risk of vaginal bleeding of any kind during early 
pregnancy. Compared with non-exposed women, those in the disease comparison group 
had a significant 1.2-fold increased risk of bleeding of any kind during early pregnancy 
(adjusted OR: 1.22; 95% CI: 1.06-1.39).  
Compared to non-exposed women, those using SSRIs/SNRIs (adjusted OR: 0.81; 95% CI: 
0.50-1.31) or TCAs/OADs (adjusted OR: 0.96; 95% CI: 0.26-3.53) during the second 
trimester did not present any increased risk of vaginal bleeding of any kind during 
midpregnancy. Compared to non-exposed women, those in the disease comparison group 
had a significant 1.3-fold increased risk of bleeding of any kind during midpregnancy 
(adjusted OR: 1.28; 95% CI: 1.07-1.55).  
Exposure to SSRIs/SNRIs between gestational week 30 and childbirth did not confer any 
increased risk for postpartum hemorrhage overall (adjusted OR: 0.97; 95% CI: 0.57-1.65) 
and upon stratification by mode of delivery, compared to non-exposure. Compared to non-
exposed women, exposure to TCAs/OADs between gestational week 30 and childbirth was 
associated with a 3.75-fold increased risk of postpartum hemorrhage (adjusted OR: 3.75; 
95% CI: 1.09-12.94). Due to low statistical power, no stratification by mode of delivery 
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could be carried out and therefore such association cannot be further examined. Compared 
to non-exposed, the adjusted OR for women in the disease comparison group was 1.14 (95% 
CI: 0.97-1.34) for postpartum hemorrhage. Stratification by type of delivery did not confer 
any change to such a scenario.   
4.5 Sensitivity analyses 
In study I, the results of the sensitivity analyses taking into account clustering on region of 
residency showed that the direction and magnitude of the association between the various 
maternal factors and medication use outcomes (for acute/short-term illnesses; 
chronic/long-term disorders; OTC) were generally similar to those obtained in the main 
analyses, except for educational level (which was no longer associated with use of chronic 
medication or OTC medication during pregnancy), working as a healthcare provider and 
smoking during pregnancy (which both became significantly associated with medication 
use for chronic/long-term disorders). The directions and magnitudes of the associations 
between the explanatory variables and psychotropic medication use for treatment of 
depression and/or anxiety were overall similar to those observed in the main logistic 
regression analysis (cf. Appendix 4b). However, in the GEE analysis we found that women 
working as a healthcare provider (32% magnitude) or seeking for job (66% magnitude) 
were significantly more likely than the reference group to use psychotropic medications in 
pregnancy. 
In study II we included BMI at conception as additional covariate in Model 1 because of 
the uncertainty in the direction of the association between BMI prior to conception and 
eating disorders before and/or during pregnancy. The observed results were principally 
similar to those observed in the main analyses. 
In study III we performed a GEE analysis taking into account clustering on individual 
country of residency, and not region of residency. The magnitude of the measure of 
association observed in the GEE analysis adjusted on clustering for country of residency 
did not differ from those obtained in the GEE adjusted on clustering on region of residency; 
in the former analysis the 95% CI were wider than those observed in the latter analysis, 
and the association between antidepressant risk perception and non-adherence lost 
statistical significance for score category 4-5.  
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In study IV, the analyses restricted to women with a single participation in the MoBa study 
(cf. Appendices 5a and 5b) revealed slightly different results than those observed in the 
main analyses for the disease-comparison group, but not for the two exposure groups. 
Specifically, women in the disease-comparison group presented a significant 35% 
increased odds of vaginal bleeding in medium/large amount during midpregnancy, an 
association which was not reflected in the main analysis. Similarly, these women presented 
a significant 18% increased odds of postpartum hemorrhage regardless of delivery type, an 
association which was borderline significant in the main analysis. However, there were no 
differences in the results in the stratified analyses by mode of delivery.  
The results of the analyses including only the first pregnancy for those women 
participating more than once in the MoBa study were principally similar to those observed 
in the main analyses for bleeding complications in early and midpregnancy, as well as 
postpartum (cf. Appendices 6a and 6b). 
Similarly, the results of the GEE analyses taking into account the dependency within the 
data because of multiple participation in the study (with the maternal id being the repeated 
measure) were also similar to those observed in the main analyses (cf. Appendices 7a and 
7b).  
The analyses on individual antidepressants for all bleeding outcomes did not reveal 
different patterns than those observed for the two antidepressant groups (i.e., SSRIs/SNRIs 
and TCAs/OADs). The analysis of antidepressants regrouped according to their level of 
affinity to serotonin transporter (high, intermediate or low affinity) did not identify any 
significant association between antidepressants and bleeding complications during 
pregnancy and postpartum. With respect to the postpartum hemorrhage outcome, a 
sensitivity analysis restricted to women who delivered vaginally without any instrumental 
intervention (i.e. forceps and/or vacuum) showed no statistically significant association 
between exposure to SSRIs/SNRIs between gestational week 30 and childbirth and 
postpartum hemorrhage (adjusted OR: 0.98; 95% CI: 0.49-1.95). 
The sensitivity analyses examining the duration (mean number of days) of bleeding in 
early and midpregnancy was restricted to women reporting plausible time extents, i.e. not 
more than 90 days, and exposed to antidepressants in first or second trimester. Women 
exposed to SSRIs/SNRIs (mean: 4.4 days; ANOVA test, p=0.96) or TCAs/OADs (mean: 
3.2 days; ANOVA test, p=0.67) did not bleed significantly longer than non-exposed (mean: 
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4.3 days) during early pregnancy; however women in the disease comparison bled 
significantly longer than non-exposed women (mean: 5.9 days; ANOVA test, p < 0.001). 
There were no differences in terms of bleeding duration during midpregnancy across the 
groups (mean non-exposed: 3.1 days; mean SSRIs/SNRIs: 2.1 days; mean TCAs/OADs: 
1.6 days; mean disease comparison group: 3.1 days).   
 

 
ϳϱ
5. Discussion 
5.1 Summary of the most relevant findings 
The summary of the most relevant findings of this work are presented below and discussed 
in this section of the thesis. The selection of the most relevant findings was based on their 
clinical relevance or novelty, and their relation to maternal mental health and psychotropic 
medication use during pregnancy and postpartum.  
x Study I: Use of medication at any time during pregnancy (about 80%) and during the 
first trimester (about 50%) is common. Similarly, about 67% of women used at least 
one OTC medication during pregnancy. A number of socio-demographic and life-style 
factors, including region of residency, were significantly associated with use during 
pregnancy of the different types of medications. The observed estimate of psychotropic 
medication use during pregnancy was approximately 3%, with SSRIs being the 
preferred therapeutic choice. Disadvantaged women (e.g. single or divorced, older, 
with low education, smokers and alcohol consumers during pregnancy) or with an 
unplanned pregnancy were more likely to use psychotropics during pregnancy. 
x Study II: The prevalence of eating disorders before and/or during pregnancy was 
0.09% for AN, 0.94% for BN, 0.10% for EDNOS-P, 5.00% for BED; 93.87% of the 
sample did not present any eating disorder. The crude estimates of psychotropic 
medication use were highest among women with AN or EDNOS-P before, during and 
after pregnancy, as well as continuous use throughout these time periods. 
Antidepressants were the most commonly used medication group within the 
psychotropics. In the multivariate analysis, having BN was found to be significantly 
directly associated with use (1.8-fold magnitude) and incident use (2.3-fold magnitude) 
of psychotropics during pregnancy. Having AN or EDNOS-P was significantly directly 
associated with use of anxiolytics/sedatives postpartum (5.1- and 6.8-fold risk 
magnitude, respectively).  
x Study III: About 5% of the sample reported having a psychiatric disorder during 
pregnancy, mainly depression and/or anxiety, and within this group about 50% 
presented symptoms of depression as measured by the EPDS. Of the women reported 
having a psychiatric disorder during pregnancy, 62% were medicated with 
psychotropics, mostly SSRIs. The group of not medicated women more strongly 
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believed in refraining from using medicines during pregnancy than the medicated 
counterpart. According to the MMAS-8, about 49% of the medicated women 
demonstrated low adherence to psychotropics during pregnancy. Factors positively 
associated with low adherence were smoking in pregnancy (3.9-fold magnitude), 
presenting symptoms of depression (2.5-fold magnitude), and elevated antidepressant 
risk perception (range 1.3- IROG PDJQLWXGH :RPHQ¶V EHOLHI WKDW WKH EHQHILW RI
pharmacotherapy outweighed the risks positively correlated (r=0.282; p<0.001) with 
medication adherence, while preference for herbal remedy use over conventional 
medicines during pregnancy negatively correlated with medication adherence (r=-
0.243; p<0.001). 
x Study IV: Antidepressant use during pregnancy, mostly SSRIs, was reported by 1.02% 
of the sample. Compared to non-exposed, women exposed to either SSRIs/SNRIs or 
TCAs/OADs during the first or second trimester were not more likely to experience 
vaginal bleeding in early or midpregnancy, respectively. Compared to non-exposed, 
women exposed to SSRIs/SNRIs between gestational week 30 and childbirth did not 
present any increased odds for postpartum hemorrhage, overall and by mode of 
delivery. Exposure to TCAs/OADs during this time window conferred a significant 
3.8-fold increased odds of postpartum hemorrhage overall, but low statistical power 
impeded the analysis by mode of delivery. Compared to non-exposed, women in the 
disease-comparison group had a significant increased likelihood to experience vaginal 
bleeding episodes in both early (1.2-fold magnitude) and midpregnancy (1.3-fold 
magnitude), but not postpartum hemorrhage. 
5.2 Interpretation and comparison with other studies 
The discussion section of this thesis will mainly focus on the most relevant findings (as 
summarized above). Other specific results of studies I-IV are discussed and compared with 
other studies in the discussion section of each paper and will not be fully repeated here. 
5.2.1 Overall medication use in pregnancy 
No previous study has examined medication use in pregnancy on a multinational level and 
via utilization of a web-based data collection approach. The latest intercontinental study 
was performed in 1987 and included about 15,000 women delivering at 148 selected 
hospitals in 22 countries; however, this study was hospital-based and examined the extent 
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of prescription drug use only.25 Because of the over-time change in therapeutic strategies 
and shift in drug availability, conversion of prescription drugs into OTC and changes in 
prescribing attitudes, updated estimates of medication use in pregnancy allowing for inter-
country comparability were warranted.24,163  
In study I we found that overall eight out of ten women reported use of at least one 
medication, either prescribed or OTC, during the course of the pregnancy, which is in line 
ZLWKILQGLQJVRISUHYLRXVUHVHDUFKXWLOL]LQJSDWLHQWV¶LQWHUYLHZVDVVRXUFHVRILQIRUPDWLRQ
about drug utilization.32 Our observed estimates of medication use differed across the 
individual participating countries. Specifically, women residing in countries such as 
Croatia, Serbia, Slovenia or Italy were those reporting the least use of any medication 
(range 62-71%) during pregnancy, as opposed to women residing in Finland, Iceland, or 
The Netherlands who reported the highest use (range 92-95%). This approximate 30% 
difference in the extent of any medication use across specific countries could be explained 
by several factors, primarily dissimilarities in culture, prenatal care, access to medicine and 
KHDOWKFDUH FRVWV EXW DOVR E\ GLIIHUHQFHV LQ ZRPHQ¶V VHOI-perception of illness and 
reporting attitudes. Since most of the country-specific drug utilization studies published in 
the last ten years used prescription claim databases as source of information,28-30,65,82,85,86,91-
93,98
 comparison between our finding and those of these latter studies is difficult; in our 
study women were not specifically enquired about use of medication prescribed by their 
treating physicians, but rather on any medication use according to indication and 
additionally about OTC medication use. The current literature however indicates that use 
of prescribed medication during pregnancy is higher in countries such as Canada, USA, 
The Netherlands or France (range 59-93%) compared to countries such as Serbia (26%).26-
31,33,98
 Thus, since knowledge about the extent of prescribed medication use may, at least to 
some extent, be an indicator of the degree of total medication use in pregnancy, our results 
can be deemed to be in line with previous research.  
Notably, about 50% of our sample was exposed to a medication during the first trimester. 
In accordance with previous studies,43,78,211 the most common exposures were represented 
by analgesics, antacids, nasal preparations, systemic antibiotics, antihistamines, thyroid 
medication, NSAIDs, drugs for obstructive airway diseases, antidepressants and 
anxiolytics/sedatives. While the effectiveness, safety and benefit-risk ratio of 
pharmacotherapy versus untreated illness is established for some of these exposures (e.g., 
thyroid medication), there is still controversy and disagreement in the literature pertaining 
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to other exposures (e.g., antidepressants, NSAIDs), and for many medications the risk of 
teratogenicity and for other subtle outcomes remain undetermined.13,212 Awareness that one 
out of two pregnant women may inadvertently or not be exposed to medication during the 
most sensitive period for fetal organogenesis has important clinical implications. Indeed, 
this finding urges the need to increase awareness among healthcare providers that a large 
proportion of pregnant women will be in need of tailored evidence-based information 
about the fetal risk of medication exposures during pregnancy.  
The specific analysis on OTC medication use showed that overall, 67% of the sample 
reported use of at least one OTC drug during the course of the pregnancy, indicating a high 
degree of self-medication during pregnancy. This may be cause for concern, especially in 
certain countries such as Finland, Iceland, United Kingdom or The Netherlands which 
presented the highest estimates of OTC use (range 82-85%). The available literature about 
the extent and typology of OTC medication used in pregnancy is not extensive.213 In our 
study the most common OTC medications utilized were analgesics, antacids and nasal 
decongestants, as also observed in previous studies.37,39 Paracetamol was the most common 
medication among the analgesics (ranging from 25-27% in South America and Eastern 
Europe to 62-67% in Northern Europe and Australia), however a surprisingly high 
proportion of women also reported use of OTC NSAIDs during pregnancy, ranging from 
17.1% in South America to 7.5% in North America, 6.5% in Northern Europe and about 3% 
in the remaining regions. To date, there is not enough evidence to recommend use of 
NSAIDs during the first trimester. Several studies have suggested an increased risk of 
congenital malformations such as for heart defects or gastroschisis, as well as spontaneous 
abortion/preimplantation loss associated with this exposure.13 Nevertheless, women should 
be advised against use of NSAIDs in the third trimester since it may increase the risk of 
premature closure of the ductus arteriosus, oligohydramnios, and inhibition of labor.13  
The observed estimate of use of OTC aspirin (in a high dose) and metamizole (dipyrone) 
were surprisingly high in Eastern Europe (about 1.4%) compared to the other regions 
(range 0.2-0.6%). Use of OTC metamizole was also high in South America (3.5%). 
Although differences in medical practices and access to medications might explain this 
finding, use of high dose aspirin should be avoided in pregnancy since it may increase the 
risk of hemorrhage, premature closure of the ductus arteriosus, and other important 
perinatal complications, including specific birth defects.13 Similarly, very little is known 
about the fetal risk associated with gestational exposure to metamizole,214,215 and more 
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intensively studied analgesics, e.g., paracetamol, should be considered the first choice in 
pregnancy for treatment of fever and pain.13 Given this scenario and in light of recent 
findings showing an association between prolonged use of paracetamol during gestation 
and adverse neurodevelopmental outcomes in the offspring,216 it is of utmost importance 
that healthcare providers enquire their pregnant patients during the routine prenatal check-
ups about the types of OTC medications used, if any, and duration of such use. Subsequent 
tailored counseling about safety of these medications is essential to ensure maternal-fetal 
health.  
Having previous children, an educational level lower than high school, working as a 
healthcare provider and using alcohol after awareness of pregnancy were factors positively 
associated with use of OTC medication during pregnancy, SRVVLEO\ UHIOHFWLQJ ZRPHQ¶V
higher confidence in self-treatment and/or less anxiety for the pregnancy outcome. 
Contrary to previous studies indicating an association between higher maternal education 
and more prevalent use of medication during pregnancy,39,217,218 we found that lower 
education was associated with a higher use of OTC medications as well as medication for 
chronic/long-term disorders (30-50% increased risk). Results of similar magnitude (30% 
increased risk) were also observed by Olesen et al.,219 whereas Stokholm et al.220 identified 
a stronger association (2.3-fold increased risk) between low maternal education and use of 
antibiotic for respiratory tract infections during pregnancy. However, in the sensitivity 
analysis taking into account clustering on region of residency, we no longer observed a 
significant association between educational level and OTC medication use, probably 
secondary to an underlying difference in educational level across the regional clusters. 
Given the high degree of self-medication with OTC drugs during pregnancy, it is important 
for health care personnel in care of pregnant women to remember to ask for and discuss 
OTC-medications at maternity check-ups. 
5.2.2 Psychotropic medication use in pregnancy 
x Women with depression and/or anxiety 
In The Multinational Medication Use in Pregnancy Study the total prevalence of 
depression or anxiety during pregnancy as self-reported by the participating women was 
approximately 5% in the analysis on the entire study population comprising pregnant 
women and new mothers (study I), as well as in the analysis restricted to pregnant women 
only (study III). This estimate is similar to finding of previous studies evaluating the extent 
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of depression in pregnancy as diagnosed by clinicians during prenatal ambulatory care 
visits.79,80 However, studies conducted in more disadvantages populations94 or using 
psychometric instruments as screening tools for depressive symptoms46,221 have shown 
higher estimates of depression and/or anxiety during pregnancy. Indeed, womHQ¶V VHOI-
report of depression and/or anxiety during pregnancy is most likely based on a previous 
medical diagnosis and/or received treatment (either pharmacological or cognitive 
behavioral). Also, in our electronic questionnaires, women were specifically asked to 
report chronic or long-term depression or anxiety, which might have caused a missed 
detection of women with less severe or transitory illnesses and other types of psychiatric 
disorders; however, on the other hand, it cannot be excluded that women with more severe 
psychiatric disorders might have been less likely than healthy women to engage in a 
research study. As addressed by Gavin et al.222 in a systematic review, the prevalence 
estimates for perinatal depression may vary according to trimester of pregnancy and 
diagnostic tool utilized, however it can be estimated that approximately up to 5% and 11% 
of pregnant women suffer from major depression, or major and minor depression, 
respectively, during pregnancy.  
The overall self-reported use of psychotropic medications for treatment of depression 
and/or anxiety was approximately 3% in both studies I and III. The variability in the self-
reported use of psychotropic medications during pregnancy across the various regions in 
study I can probably be ascribed to differences in medical practice, maternity care, access 
WRPHGLFDWLRQV DQG VSHFLDOLVW KHDOWKFDUH DQGQRW OHDVWZRPHQ¶V VRFLRGHPRJUDSKLFV2XU
observed estimates of use of psychotropic medications for treatment of depression are 
generally similar to those observed in previous studies carried out in North American (5.4% 
versus 4-8%),32,81,91,95,98,223 Western European (1.9% versus 1.3-3.0%),29,30,65,75,77,90 and 
Northern European (3.5% versus 1.0-3.0%),28,70,71,86,89 countries, although higher in the 
Australian sample (8.2% versus 1.5-4.6%).73,99 In the latter instance, different recruitment 
strategies, i.e., web-based questionnaire in study I versus hospital outpatient clinics and 
dispensing records, may explain such a discrepancy. Indeed, it cannot be excluded that 
women with chronic disorders and/or taking medications during pregnancy might have 
sought the internet for information and thus being more likely to fill out the online 
questionnaire. The self-reported prevalence of depression and/or anxiety and related 
medication use in the South American and Eastern European regions was substantially 
lower than that reported in the other regions. Ethnical differences pertaining to the risk of 
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psychiatric disorders, but also differences in perception of illness and negative attitudes 
towards pharmacotherapy and psychological help-seeking, may, at least to some degree, 
explain this finding.224 Qualitative studies in the non-pregnant population have in fact 
shown that there are differences in symptom interpretation and definitions of illness among 
persons with different ethno-racial backgrounds, and that stigma and concerns about 
dependence on medication represent barriers to treatment.225,226  However, knowledge 
about mental health and related medication use during pregnancy in South American and 
Eastern European countries is to date scarce and further research is needed in these regions.  
Overall, SSRIs were the most common psychotropic medications reported for treatment of 
depression and anxiety, followed by SNRIs and benzodiazepines. Indeed, SSRIs are 
considered the preferred therapeutic choice in pregnancy for treatment of both depression 
and anxiety.4 In study I, women using psychotropics were more likely to be older, single or 
divorced, smokers, to have lower education than high school, an occupation as student or 
housewife at conception, an unplanned pregnancy, or to consume alcohol after awareness 
of pregnancy, as also shown by previous research.70 However, marital status, occupation at 
conception, and smoking during pregnancy did not significantly differ in the crude 
comparison between users and non-users of psychotropic medication during pregnancy 
performed in study III, which was restricted to women suffering from depression or 
anxiety; these maternal factors may in fact represent risk factors of the psychiatric disorder 
itself rather than of the pharmacotherapy.227,228  
Disentangling maternal determinants of psychiatric illness from those of psychotropic 
medication use in pregnancy is surely challenging. Furthermore, the maternal decision 
whether to use or not a psychotropic medication during pregnancy is multifaceted and 
driven by additional components such as severity of the underlying illness, risk perception, 
attitudes, personality traits and not least fear to harm the fetus.71,229 This scenario became 
clearer in study III where it was found that women suffering from depression or anxiety 
but not using psychotropics had significantly different perceptions from women using 
psychotropics, specifically that their necessity of the psychotropic therapy did not 
outweigh their concerns, and that it was better to refrain from using medications during 
pregnancy for the sake of the fetus. 
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x Women with eating disorders 
Research about perinatal mental disorders and related medication use has so far largely 
focused on depression, whereas other important psychiatric conditions such as eating 
disorders have not been extensively explored, especially in a population-based setting. 
Study II was the first to address the extent of psychotropic medication use in relation to 
pregnancy among women with eating disorders. Several of the findings in study II are 
novel and relevant for clinical practice. First, use of psychotropic medication, especially 
antidepressants, was found to be common among women with any eating disorder in the 
preconception period as well as during pregnancy and postpartum. Our observed rates of 
use of psychotropics in the preconception period were lower than those found in three 
previous studies among women with AN (53%), BED (18%), or all eating disorders 
(97%).63,230,231 These discrepancies could probably be explained by different recruitment 
strategies, that is, population-based recruitment in the present study versus clinical research 
recruitment in others, country-specific therapeutic traditions and access to special care in 
different countries. Factors such as pregnancy planning might have also deflated our 
estimates; because of fear to harm the unborn child and elevated risk perception of 
medication exposure, many women may discontinue their needed pharmacotherapy during 
pregnancy or when attempting to conceive.6,77  
Second, in this study it was also found that about 50% of women with AN or BED 
discontinued their pharmacotherapy with psychotropics in the first trimester of pregnancy, 
though lower rates were observed for the BN (about 35%) and EDNOS-P (about 16%) 
groups. However the lack of information about the presence of alternative non-
pharmacological therapies among these women impedes any further evaluation of this 
finding, and it cannot be corroborated whether the decision to discontinue the 
pharmacotherapy was woman or physician driven.  
The lack of drug utilization studies among women with eating disorders during pregnancy 
unfortunately impedes any comparison of our observed estimates of use during pregnancy 
of antidepressants (highest for AN: 13.0%), anxiolytics and sedatives (highest for EDNOS-
P and BN: 3.9% and 3.3%, respectively) and antipsychotics (highest for AN: 3.7%) with 
the existing literature. Not surprisingly, our estimates for use of psychotropic drugs in the 
AN, BN and EDNOS-P groups, but not BED, were substantially higher than those 
observed by Engeland et al.28 in a population-based study from the Norwegian Prescription 
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Database in the period from three months before to three months after pregnancy. Clinical 
trials have in fact shown that antidepressants, especially SSRIs, can moderately reduce the 
symptoms of BN and BED and fluoxetine is the only medication approved for treatment of 
BN;61 however the effect of these medications on full recovery is small.58-60 Although there 
is no evidence supporting general use of antidepressants or antipsychotics for the treatment 
of AN, Kaye et al.232 showed in a double-blind placebo-controlled trial that use of 
fluoxetine may be useful in improving outcome and preventing relapse of patients with AN 
after weight restoration; since most women with AN are weight restored during the course 
of the pregnancy, SSRI antidepressants, and in particular fluoxetine, may actually be more 
beneficial in this setting than before conception.  
In study II the relationship between eating disorders and use of psychotropics during 
pregnancy was also addressed, including whether the association was direct or indirect, e.g. 
via an underlying maternal depression and anxiety. In the adjusted analysis, all eating 
disorder subtypes were significantly associated with use of psychotropics during 
pregnancy, with a magnitude for the total association ranging from 1.7-fold for BED to 
5.6-fold for AN. However, in the analyses of direct associations on overall and specific 
psychotropic groups, only BN was found to be directly associated with use of 
psychotropics during pregnancy (1.8-fold magnitude), in particular with use of 
anxiolytics/sedatives (2.4-fold magnitude), compared to women with no eating disorders. 
The direct associations between BN and use of anxiolytics/sedatives during pregnancy 
could be secondary to an important anxiety symptomatology among these women. One 
study carried out in a clinical setting found that women with BN using laxatives as purging 
method experienced very high level of anxiety when laxatives were acutely discontinued 
for treatment purposes.233 In study II, the self-reported use of laxatives among women with 
BN was actually higher during pregnancy than in the period prior to pregnancy, however it 
cannot be excluded that these women attempted to reduce other purging symptoms, for 
instance vomiting, or their bingeing behaviors during gestation, which might as well have 
affected the anxiety symptomatology with subsequent requirement of pharmacotherapy.  
Previous research has in fact shown that, in general, there is an improvement of eating 
disorder symptoms during pregnancy and perhaps for a brief period of time postpartum, 
however a significant portion of women return to eating disorder symptoms after giving 
birth.54 A previous study53 using MoBa data found that the most common pattern for BN 
was remission or partial remission of symptoms from the pre-pregnancy period to early 
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pregnancy, and incident cases were rare. However in study II it was found that BN was the 
only eating disorder subtype directly associated with incident use (2.3-fold magnitude) of 
psychotropics during pregnancy. Given this scenario, we cannot exclude the possibility 
that pharmacotherapy with psychotropics might have contributed, at least to some extent, 
to remission of symptoms among women with BN. Also, women with BN might have 
sought specialist care and treatment once pregnant for the well-being of the fetus. Two 
previous studies have for example shown that use of dietary supplements and nutritional 
intake during pregnancy were similar among women with and without eating 
disorders,234,235 underscoring how these women do their utmost to ensure the well-being of 
the developing fetus. The lack of significant direct associations between AN or EDNOS-P 
and psychotropic use during pregnancy could be ascribed to the small sample size and/or 
to the role of other factors, namely severity of depressive and anxiety symptoms, BMI at 
conception and weight gain throughout the pregnancy, in the path from eating disorder to 
the outcome of interest.   
In the 4-6 months postpartum period, women with AN or EDNOS-P were characterized by 
a substantial increase in the use of psychotropics (estimate range 8-9%), mainly anxiolytics 
and sedatives, compared to women with no or other eating disorders (estimate range 1-3%). 
In the multivariate model, all eating disorder subtypes were significantly associated with 
use of psychotropics in the 0-6 months period postpartum, with a magnitude of the total 
association ranging from 1.5-fold for BED to 9.6-fold for AN. The general analysis on all 
psychotropics showed that only EDNOS-P was directly associated with such use 
postpartum (4.5-fold magnitude) compared to women with no eating disorders; however, 
in the specific analyses by psychotropic group, it was found that both AN (5.1-fold 
magnitude) and EDNOS-P (6.8-fold magnitude) were directly associated with use of 
anxiolytics/sedatives postpartum, even after cancelling out the effect of factors such as 
weight decrease postpartum or depressive and anxiety symptoms. The substantial physical 
changes accompanying motherhood may represent a special challenge for women with AN, 
being characterized by a profound fear of gaining weight and by a distorted perception of 
body shape. Although about 50% of women with AN or EDNOS-P have been shown to 
remit at 18 months postpartum,236 little is known about the course of these disorders in the 
earlier postpartum period. Women with AN or EDNOS-P were found to lose the 
gestational weight more quickly than controls over the first six months postpartum,237 thus 
for these women a return to restrictive weight control behaviors and a worsening of the 
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anxiety symptomatology in the early postpartum period, requiring use of 
sedatives/anxiolytics, cannot be excluded.  
5.2.3 Adherence to psychotropics in pregnancy 
Study III was the first to examine how closely pregnant women follow their 
pharmacotherapy with psychotropics in the context of ongoing use. It is well established 
that pregnancy constitutes a major determinant of discontinuation of antidepressants and 
other psychotropics,74,77,224 however to date there is no knowledge about the medication-
taking behavior of those women who continue their therapy with psychotropic medication 
upon awareness of pregnancy. This group of women may in fact still cut or reduce the 
medication dosage because they fear to harm the unborn child, or being non-adherent 
because of unintentional causes such as forgetfulness. Thus, understanding the extent of 
and maternal risk factors for low adherence to psychotropics during pregnancy represents 
an important clinical question: indeed, suboptimal drug therapy of the underlying 
psychiatric disorder, and not only drug discontinuation, may lead to a relapse of the 
disorder over the course of the pregnancy and to adverse pregnancy outcomes.102,105,108  
In study III, the self-reported prevalence of depression and/or anxiety was equal to 5.3%, 
which although lower than estimates detected in more disadvantaged population, it does 
align with the estimates of previous studies using medical diagnosis of depression (as 
described in detail in section 5.2.2 above). The validity of the self-report of depression 
and/or anxiety may, at least in part, be corroborated by the level of underlying depressive 
symptomatology as measured by the EPDS. Indeed, in the total sample, about one of two 
ZRPHQKDGD VFRUHRQ WKH(3'6ZKLFK LV D FXW-off score widely used to indicate 
probable depressive symptoms.198 Although women not using psychotropics during 
pregnancy presented a slightly higher mean score on the EPDS (13.3) than the medicated 
counterpart (12.5), this difference did not reach statistical significance. The lack of 
information about ongoing treatments other than pharmacotherapy (e.g., cognitive 
behavioral therapy) impeded us to infer whether the similarity in severity of depressive 
symptomatology could be ascribed, at least in part, to ongoing non-pharmacological 
therapies.  
The prevalence of low adherence to psychotropic medication as measured by the MMAS-8 
was notably high during pregnancy. Indeed, almost one out of two women taking 
psychotropics for treatment of depression or anxiety or other psychiatric disorders during 
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pregnancy, demonstrated low adherence (48.8%). There was no substantial difference in 
the level of low medication adherence across the various disorders (51.3% for anxiety, 
47.2% for depression, and 42.9% for other psychiatric disorders), indicating that low-
adherence is an important widespread clinical problem in psychiatry. A recent study238 
among a low-income insured Medicaid population explored the extent of treatment 
persistence among women diagnosed with major depression. The authors found that about 
45% of the women who commenced therapy with antidepressants during pregnancy, 
showed a gaSGD\VEHWZHHQ WZRSUHVFULSWLRQV'HVSLWH WKHFRQFHSWXDOGLIIHUHQFHRI
medication persistence from medication adherence (i.e., medication persistence may be 
GHILQHG DV ³WKH GXUDWLRQ RI WLPH IURP LQLWLDWLRQ WR GLVFRQWLQXDWLRQ RI WKHUDS\´ZKHUHDV
medicDWLRQ DGKHUHQFH LV GHILQHG DV ³WKH H[WHQW WR ZKLFK SDWLHQWV WDNH PHGLFDWLRQV DV
SUHVFULEHGE\WKHLUKHDOWKFDUHSURYLGHUV´DQGLVEDVHGRQDWKHUDSHXWLFDOOLDQFHEHWZHHQ
the patient and the physician)115,239 and the different study methodologies, both constructs 
underline the concern that about one out of two women with a psychiatric disorder may be 
at risk of suboptimal control of the underlying maternal illness during pregnancy.  
The estimates of low medication adherence observed in study III were found to be similar 
to those detected in the general non-pregnant population with psychiatric disorders (40-
53%),240,241 but higher than what was previously found among women with somatic illness 
during pregnancy (36%).122 Several factors might explain the reason as to why women 
with psychiatric disorders have poorer medication adherence than women with somatic 
GLVRUGHUVGXULQJSUHJQDQF\ZRPHQ¶VSHUFHSWLRQ WKDW WKHPHQWDO GLVRUGHUPD\JHW EHWWHU
during pregnancy, preference of non-pharmacological therapeutic methods, decisional 
conflicts about the necessity of their medication during a sensitive time period such as 
pregnancy, but also uncertainty about how to treat the illness given the battery of 
contradictory findings about the safety of e.g. antidepressants during pregnancy.242 The 
controversies between study findings have indeed posed important challenges on 
practicing clinicians when assessing the risk of untreated depression versus the risk of 
pharmacotherapy, but also on the pregnant patient when weighing the fear of teratogenicity 
versus the necessity of the medication.243 
Study III was also novel in providing insights into the role played by ZRPHQ¶VEHOLHIVRQ
adherence to psychotropic medications during pregnancy. Overall, both the BMQ-
Necessity (r=0.208; p-value<0.01) and BMQ-Concern (r=-0.213; p-value<0.01) subscales 
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were significantly associated with adherence to psychotropics during pregnancy. Also, the 
perception that the benefit of pharmacotherapy outweighed the risks (r=0.282; p-
value<0.001) and that herbal remedies should be preferred to conventional medications 
during pregnancy (r=- 0.243; p-value<0.01) were positively and negatively associated, 
respectively, with an increasing level of medication adherence during pregnancy. 
Analogue results were obtained in the analysis of medication adherence specifically for 
treatment of depression, but not for the remaining disorders. However, in the latter 
instances, the small sample sizes might explain such a discrepancy. The magnitude of the 
observed correlation coefficients was not large, but it was however similar to those 
observed in a previous study among non-pregnant subjects treated for disorders such as 
asthma or cardiac disease (r=0.21-0.28 for the necessity-adherence association).120 
Nonetheless, factors weakly correlating with medication adherence can still be deemed 
noteworthy and of importance in clinical settings. Indeed, medication adherence is a 
composite and multifaceted medication-taking behavior affected by several practical and 
perceptual factors, and therefore even factors with weak influence could be considered 
relevant for its overall improvement. Yet, the significant correlation between increasing 
agreement with the concept that herbal remedies should be preferred to conventional 
medications during pregnancy and decreasing medication adherence underscores the need 
to promote evidence-based counseling about exposure to medication and other agents 
during gestation. If the current knowledge on the immediate and long-term effects of 
gestational exposure to medications is limited, even less is known about the risk associated 
with exposure to the vast array of herbal remedies. Furthermore, the proof of efficacy of 
herbal remedies in the treatment of important disorders is questionable also during 
pregnancy, which raises the additional concern about suboptimal treatment of important 
disorders which may jeopardize maternal-fetal health.244  
In the multivariate analysis, smoking during pregnancy, psychotropic monotherapy, 
elevated risk perception of antidepressants and depressive symptoms during pregnancy 
were the only maternal factors significantly associated with an increased likelihood of low 
medication adherence in women with depression and/or anxiety. The effect estimates were 
largest for smoking during pregnancy (3.9-fold increase) and having symptoms of 
depression (2.5-fold increase) indicating that these women should be especially targeted 
for discussions on medication adherence. In relation to the latter association, the study 
design impeded any corroboration as to whether low medication adherence led to poorer 

 
ϴϴ
mental health or the converse. Women on monotherapy were also found to demonstrate 
poorer adherence than those on polytherapy. A previous study by Horne et al.120 showed 
WKDWSDWLHQWV¶VRFLRGHPRJUDSKLFDQGFOLQLFDOIDFWRUVLQFOXGLQJWKHQXPEHURIPHGLFDWLRQV
did not significantly predict adherence to pharmacotherapy for treatment of asthma or 
cardiac diseases. However, another study245 conducted specifically among patients with 
depression found that patients receiving polytherapy presented better compliance than 
those on monotherapy. In the pregnancy scenario, it can be assumed that women on 
polytherapy with psychotropics are most likely those with a more severe or longer history 
of psychiatric disorders, which may lead to better knowledge of the medications that are 
regularly taken, and not least higher awareness of the correct administration schedule. 
However, in study III we could not verify this assumption because of lack of information 
about maternal history of psychiatric disorders before conception, and whether the onset of 
maternal depression or anxiety took place before or during pregnancy.  
The odds of demonstrating low adherence to psychotropic during pregnancy was 
increasingly higher among women assessing the risk of antidepressant exposure in the 
range 4-5 (1.3-fold magnitude) or -fold magnitude), compared to baseline (score 0-
3). TKLV ILQGLQJ KLJKOLJKWV WKH UHOHYDQFH RI ZRPHQ¶V ULVN SHUFHSWLRQ LQ VKDSLQJ WKHLU
medication-taking behavior, even in relation to pharmacotherapy for important psychiatric 
illnesses.  
5.2.4 Maternal safety after use of antidepressants in pregnancy 
Study IV was the first to address the risk of vaginal bleeding during early and 
midpregnancy following gestational exposure to antidepressants using a large cohort 
followed prospectively and with inclusion of a disease comparison group including not 
medicated women with persistent depressive symptoms in pregnancy. About 20% and 9% 
of the cohort reported vaginal bleeding episodes during early and midpregnancy, 
respectively. These estimates are supported by previous epidemiological data addressing 
the burden of vaginal bleeding in pregnancy; indeed, up to 21% of pregnant women are 
expected to experience this symptom, especially during the first trimester.246 Vaginal 
bleeding during the first half of pregnancy is often a sign of abortion (threatened, 
spontaneous, missed), while bleeding in the second half of pregnancy is a risk factor for 
perinatal mortality and other adverse outcomes such as disorders of the amniotic fluid, low 
birth weight and a low Apgar score.247 Studies suggest that bleeding in either first or 
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second trimester of pregnancy is also associated with a 30-60% increased risk of premature 
delivery.248,249 Because the exact etiology of vaginal bleeding often cannot be 
determined,250 it is clinically relevant to ascertain the role of antidepressants with serotonin 
activity in the development and/or prolongation of this obstetric complication. Study IV 
showed that women exposed to either SSRIs/SNRIs (adjusted OR: 0.91; 95% CI: 0.72-1.16) 
or TCAs/OADs (adjusted OR: 0.83; 95% CI: 0.36-1.92) during the first trimester did not 
present a higher likelihood of vaginal bleeding complications in early pregnancy compared 
to non-exposed women. Similarly, exposure to either SSRIs/SNRIs (adjusted OR: 0.81; 95% 
CI: 0.50-1.31) or TCAs/OADs (adjusted OR: 0.96; 95% CI: 0.26-3.53) during the second 
trimester did not confer any increased odds of vaginal bleeding complications in 
midpregnancy. Since pregnancy in itself represents a status of hypercoagulability,251 such 
scenario may counteract the inhibiting effects of platelet function by SSRIs and other 
serotonergic antidepressants. The etiology of vaginal bleeding during pregnancy is often 
undetermined or thought to occur from local lesions, thus in this last instance, it would be 
assumed that exposure to antidepressants with serotonin activity might at least prolong the 
bleeding time. However, this hypothesis was also refuted in study IV where the mean 
duration of bleeding (in days) in both early and midpregnancy did not differ between non-
exposed and antidepressant exposed women. 
Study IV also provided relevant insights into the role of non-medicated depressive 
symptomatology in pregnancy. Women presenting depressive symptoms throughout the 
pregnancy, precisely at both gestational week 17 and 30, but not medicated with any 
antidepressants during this time window, presented a significant increased likelihood to 
experience vaginal blood loss in early (adjusted OR: 1.22, 95% CI: 1.06-1.39) and 
midpregnancy (adjusted OR: 1.28; 95% CI: 1.07-1.55), as well as recurrent bleeding 
episodes in early pregnancy (adjusted OR: 1.33; 95% CI: 1.10-1.61). These women were 
more likely to experience blood loss in medium amount or clots during early pregnancy, or 
as trace in midpregnancy. The sensitivity analysis on bleeding duration also confirmed that 
women in the disease-comparison group were more likely to bleed one-two days longer 
than non-exposed women during early pregnancy. The sensitivity analyses restricted to 
women with a single participation in the MoBa study showed a significant association 
between belonging to the disease-comparison group and having a vaginal bleeding with 
medium/large amounts of blood during midpregnancy (35% increased odds) which was not 
reflected in the main analysis; however given the similarity in magnitude between the latter 
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association and that observed for the outcome about any vaginal bleeding, such a 
discrepancy could simply be ascribed to a heighten accuracy in reporting among women 
participating only once in the MoBa study. 
Several factors could be implicated in the significant association between not medicated 
depressive symptomatology and vaginal bleeding during gestation: first, women with not 
medicated depressive symptoms may present higher level of anxiety and stress, potentially 
leading to different health behaviors and different accuracy and attitudes in reporting. 
Indeed, the number of ultrasound examinations undertaken during pregnancy by this group 
of women was significantly higher than that observed in the non-exposed or SSRI/SNRI-
exposed groups, possibly reflecting a higher level of apprehension and anxiety for the 
wellbeing of the unborn child. Second, the higher likelihood of vaginal bleeding among 
depressed not medicated women might be a sign of threatened abortion; Ross et al.135 
pooled results of three studies examining the association between antidepressant exposure 
and spontaneous abortion yielding an overall borderline significant OR of 1.47 (95% CI: 
0.99-2.17); however, the lack of a depressed control group in all three studies made it 
difficult to disentangle the effect of the medication from that of the underlying maternal 
illness. Third, since both vaginal bleeding during pregnancy and antenatal depression are 
considered risk factors for prematurity,104,105,248 it cannot be excluded that vaginal bleeding 
during gestation might be an intermediate on the path from depression to prematurity.  
However, the latter assumption could only be tested in a mediation analysis model. Last, a 
damaging process of the vascular endothelium triggered by maternal stress, anxiety and 
depression cannot be ruled out.252 
Study IV also added to the discordant literature about the association between exposure to 
antidepressants during gestation and postpartum hemorrhage. Since postpartum 
hemorrhage is not uncommon and it is a leading cause of maternal morbidity and 
mortality,253 identification of risk factors of even moderate magnitude would be of benefit 
in terms of public health. Recent studies have shown that the overtime changes in maternal 
characteristics and obstetric practice do not seem to explain the recent increase in 
postpartum hemorrhage in many developed countries.254,255 Given this scenario, it is of 
importance to determine whether exposure to antidepressants near delivery might increase 
the risk of this outcome. In study IV it was found that women exposed to SSRIs/SNRIs 
between gestational week 30 and childbirth were not more likely than non-exposed to 
experience postpartum hemorrhage (adjusted OR: 0.97; 95% CI: 0.57-1.65) overall as well 
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as in the two delivery mode strata (cesarean delivery / vaginal delivery). These findings 
were corroborated by additional sensitivity analyses accounting for instrumental 
intervention (i.e. forceps and/or vacuum), analysis on individual SSRI/SNRI, and 
classification of antidepressants according to their level of affinity to serotonin transporter. 
In the postpartum setting, contractions and retractions of the uterine muscle play an 
important role in securing blood loss,256 and this process is by far more important than 
blood clotting. Moreover, SSRI can elicit a contractile effect on the pregnant human 
myometrium,257 and therefore working in the opposite direction of postpartum hemorrhage. 
Nonetheless, tapering or stopping SSRI and SNRI treatment towards the end of pregnancy 
is often considered as a way to avoid neonatal withdrawal symptoms,258 and this may 
prevent identification of any increased risk of postpartum hemorrhage, if existing. Given 
such a pharmacological scenario, it is not surprising that exposure to SSRIs/SNRIs in the 
end of pregnancy did not confer any increased risk for postpartum hemorrhage. Although 
women reporting use of TCAs/OADs between gestational week 30 and childbirth were 
found to have a significant 3.8-fold increased odds to experience postpartum hemorrhage 
compared to non-exposed, this measure of association suffered from a very wide 
confidence interval and the small sample size impeded any further evaluation by mode of 
delivery. Nonetheless, TCAs are also alpha-1 receptor antagonists, and are thereby able to 
cause vasodilatation.144 This proposed mechanism of action can plausibly explain the 
association between exposure to TCAs and postpartum hemorrhage.  
To date, the literature about the association between exposure to SSRIs during gestation 
and postpartum hemorrhage is still inconclusive: although four studies149,156-158 have 
observed positive findings, two,155 including study IV, have not. In three149,156,158 out of the 
four positive studies, exposure was based on prescription claims and prescriptions issued 
during prenatal care. Beyond the question as to whether receiving or filling a prescription 
coincides with drug intake, the exposure windows examined in two of these studies,149,158 
specifically early pregnancy and 30 days or six months prior to delivery, may not entirely 
reflect a pharmacological plausibility. Based upon the elimination half-lives of 
antidepressants and turn-over time for the platelet population, the antiplatelet effect of 
SSRIs can be expected to be completely over two weeks after its withdrawal, except for 
fluoxetine which has an active metabolite (norfluoxetine) with  an elimination half-life of 
weeks.144 On the basis of these pharmacological properties, study IV employed gestational 
week 30 ± childbirth as exposure window, which is the closest exposure window to 
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delivery available in the MoBa study, and for which the impact of misclassification has 
been assessed as minimal.184 
In the study by Palmsten et al.,156 various exposure windows were examined, most 
importantly a supply of antidepressants that overlapped with the delivery date; women 
with a supply of an SSRI, an SNRI or a TCA that overlapped with the delivery date were 
found to have a significant 1.42-, 1.90- and 1.77-fold increased risk to experience 
postpartum hemorrhage respectively, compared to non-exposed women with a diagnosis of 
mood disorder. The larger risk associated with exposure to TCA or SNRI seem to 
contradict the platelet-serotonin theory, according to which a higher risk estimate would be 
expected for the SSRI group. However in study IV it was also found that women using 
TCA/OAD in the end of the pregnancy presented a significant increased likelihood (3.8-
fold magnitude) to experience postpartum hemorrhage, even though this result suffered of 
insufficient statistical power. It could also be assumed that women using TCAs/OADs 
might be those with more severe depression who probably did not benefit from the first-
line therapy with SSRIs, and the association between this drug group and postpartum 
hemorrhage could be secondary to maternal illness rather than to the drug. However in 
study IV the rates of history of life-time depression and depressive symptomatology during 
pregnancy (at two time points) were comparable between the TCA/OAD and the 
SSRI/SNRI exposed groups, thus refuting the first theory. Since previous studies have 
found stronger associations between SNRIs or TCAs and preeclampsia than those observed 
for SSRIs,147,148 and preeclampsia per se is an important risk factor for postpartum 
hemorrhage,259 it cannot be excluded that preeclampsia constitute a possible intermediate 
on the path between antidepressant exposure and postpartum hemorrhage.  
Study IV had the advantage to measure the severity of maternal underlying depressive 
symptomatology throughout the pregnancy and therefore adjust the multivariate analysis 
for this important factor which is often lacking in most studies. In fact, in the other studies 
examining the association antidepressants-postpartum hemorrhage, maternal depressive 
symptomatology was either not addressed149,157,158 or based on medical diagnosis,156 which 
beyond leading to a potential underascertainment of the disorder, it is certainly not an 
indicator of severity. Study IV had also the advantage of a unique disease comparison 
group including women with depressive symptomatology at two time points in pregnancy 
but not medicated with any antidepressants, which allowed separating the effect 
attributable to antidepressants from that of the underlying maternal depression. Women in 
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the disease-comparison group did not have higher odds than non-exposed to experience 
postpartum hemorrhage in the overall analysis (adjusted OR: 1.14; 95% CI: 0.97-1.34) and 
in the strata by mode of delivery. The association became instead significant (1.8-fold 
magnitude) in the sensitivity analysis restricted to women with a single participation in the 
MoBa regardless of delivery type, although it was not in the stratified analyses by mode of 
delivery.  
5.3 Methodological considerations 
The interpretation of the findings discussed in the section above should be made in the 
context of the following methodological strengths and limitations. The limitation section 
has been subdivided in sub-sections to facilitate readability; however several of the 
limitations addressed below pertain to multiple sub-sections and their placement must not 
be interpreted in strict terms (for instance, many considerations addressed in the sub-
VHFWLRQ ³,QIRUPDWLRQ ELDV´ DUH DOVR RI UHOHYDQFH IRU WKH VXE-VHFWLRQ ³Reliability and 
YDOLGLW\RIFROOHFWHGGDWD´  
5.3.1 The Multinational Medication Use in Pregnancy Study (studies I, III) 
The Multinational Medication Use in Pregnancy Study was unique in uniformly collecting 
information about medication use and related factors from over 9,000 pregnant women and 
new mothers. The anonymous web-based approach has indeed facilitated the reach of a 
large proportion of the birthing population in several countries worldwide. Recent 
epidemiological studies have indicated reasonable validity of web-based recruitment 
methods.260,261 It has been shown in several areas of research that the information provided 
in a web-based questionnaire is equivalent, of quality, and as reliable as that collected via 
traditional modes.262-264 Also, missing answers seemed to be lower in web-based than in 
paper-based questionnaires and sensitive questions can be answered more truthfully in a 
web-based questionnaire than in a face-to-face interview.265 Since data are entered 
electronically, errors in the process of data entry are also expected to be minimal. The 
growing body of evidence about the widespread utilization of the internet by pregnant 
women, supported by epidemiological studies indicating a reasonable validity of web-
based recruitment methods,260,261 may enhance utilization of e-epidemiology in pregnancy-
related research.  
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x Selection bias 
In the Multinational Medication Use in Pregnancy Study women were invited to 
participate via banners posted on pregnancy-related websites. The study design implied no 
probability sampling of the target population; respondents were those women who 
happened to have internet access, visited the website(s) where the invitation was posted, 
and decided to participate in the survey. Hence, the possibility of a self-selection bias 
cannot be excluded. In order to reduce this risk and reach the widest possible segment of 
the target population, the invitation to participate in the study was posted on 2-3 websites 
in each participating country, which were selected according to the number of daily users, 
and on social networks and/or pregnancy forums. Use of social networks and pregnancy 
forums was endorsed given their widespread use among the pregnant population. A recent 
study performed in Ireland has in fact shown that 95% of pregnant women attending a 
large maternity hospital reported to use the internet for pregnancy information, and the 
type of internet usage mostly included discussion forums (70%) and social networks 
(67%).266 Similar findings were observed in another study carried out in Italy.267 Another 
qualitative study found that pregnant women turned to the internet and smartphones to fill 
those knowledge gaps not dealt with during prenatal care visits.268  
Although the internet penetration rate in households or at work is relatively high among 
women of childbearing age in Europe, North America and Australia,269-273 a selection of 
more educated women and/or women with easier access to the internet cannot be ruled out. 
However, a recent study266 has found that even socially disadvantaged women reported 
high levels of digital media usage during pregnancy, and selection of more educated 
subjects is not limited to web-based studies but it applies to most epidemiological studies 
using patients or individuals as source of information.274 Although the analyses in study I 
and III were adjusted for educational level, a factor thought to be associated with selection 
of participants, this may not necessarily translate into adjustment for selection bias.275 
Furthermore, no variable reflecting internet coverage and/or usage across the participating 
countries was created in the analyses in studies I and III. Women with specific disorders or 
in need of information about medication use during pregnancy might have been more 
likely to consult internet websites and therefore participate in this study. However, the 
majority of websites used for recruiting purposes were general pregnancy-related and not 
medication-oriented websites. The possibility that the women who decided to participate in 
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the study differed from the general birthing population in other ways that our analysis 
could not control for cannot be excluded.  
x Response rate and representativeness 
The questionnaire was available through various internet websites, social networks and 
pregnancy forums; by using this kind of approach a conventional response rate cannot be 
calculated. Since the study was completely anonymous, no information about how many 
users clicked on the study invitation (for example via the computer IP address) could be 
retrieved. The recruitment took place via several platforms including websites, social 
networks and pregnancy forums, and therefore an overlap in website access is plausible; 
because of this, the click rate could not be calculated. In studies I and III we could however 
calculate how many women accepted to participate in the study among those who read the 
VWXG\ GHVFULSWLRQ DQG DQVZHUHG HLWKHU µ\HV¶ RU µQR¶ WR WKH TXHVWLRQ µ$UH \RXZLOOLQJ WR
participate in the stud\"¶ZKLFKZDVHTXDOWR 
Studies performed in 2004-2005 showed that the response rate for web-based 
questionnaires was lower than that for postal questionnaires.276,277 However, such scenario 
has probably improved in the recent years given the constantly increasing coverage of 
internet in household, work, smartphones; indeed, internet use is relatively high among 
individuals aged 25±34 years in Europe, ranging from 48% in Russia to 100% in Iceland. 
The internet penetration rates in other parts of the world vary, being highest in the USA, 
Australia, and Canada (80±94%) and lowest in South America (48%).269-273 A recent study 
has shown that web-based questionnaires are by far preferred over paper-based 
questionnaire by responders.264 The response rate to web-based questionnaires is also 
thought to very much depend on the context or population as well as on the design used for 
conducting the web-based study.278 Since women have been shown to use the internet in a 
very high extent during pregnancy to seek for pregnancy-related information,266,279 this 
population is probably a suitable target group in e-epidemiology. This assumption was 
certainly corroborated by a recent prospective cohort pilot study168 targeting women 
planning a pregnancy in Denmark and following them up; indeed, the questionnaire cycle-
specific response rates ranged from 87 to 90% and at 6 months 87% were still under 
follow-up. 
Studies have also attempted to compare the characteristics of the responders to web-based 
questionnaires versus those of responders to traditional mode of data collection; it has been 
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shown that factors such as gender, health status, income, age, or education are comparable 
between the two sets of responders, although responders to web-based questionnaires are 
more likely to be obese.280-282 However to date no such validation study has been 
conducted in the female birthing population, which makes it difficult to corroborate 
whether the characteristics of women responding to web-based surveys are equivalent to 
those responding to conventional questionnaires.  
The questionnaire in the Multinational Medication Use in Pregnancy Study was also 
carefully designed to suit the internet administration approach and for improving the 
completion rate: specific technical features such as multiple page design, routing of 
questions and progress indicator of completion were applied. A non-monetary incentive 
(participation in a lottery where the winner would get a gift card) was also used to promote 
the response rate.  
In order to appraise the representativeness of the sample in each participating country, the 
socio-demographic and life-style characteristics of sample on an individual country level 
were compared to those of the general birthing population in the same country. This latter 
battery of information was retrieved from reports of National Statistics Bureaus, Medical 
Birth Registry Statistics, or previous studies. On average, the women in the study had 
higher education and were slightly more often primiparous than the general birthing 
populations in the various countries. The ratio between the number of respondents and the 
estimated number of live births in the 2-months period was also examined for each 
country. In specific countries (Australia, Canada, France, Russia, The Netherlands, and the 
USA) the study sample was a small proportion of the general birthing population; hence 
the generalizability of our findings for these specific countries should be interpreted with 
caution.  
x Information bias 
Information about background sociodemographic and life-style characteristics, pregnancy 
details and medication use during pregnancy was dependent on the accuracy of the 
ZRPHQ¶VUHSRUWLQJDQGUHFDOO6WXG\,LQFOXGHGSUHJQDQWZRPHQDQGQHZPRWKHUVDQGLQ
the latter instance data were registered retrospectively; hence a risk of recall bias cannot be 
ruled out. In both studies I and III pregnant women were included in the analysis 
regardless of time of gestation. Since many ailments requiring pharmacotherapy occur in 
mid or late pregnancy, inclusion of pregnant women at early gestation in the total material 
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has somewhat inflated the prevalence of non-users of any medication and OTCs during 
pregnancy. However, this was tested to be not relevant in relation to the estimates of 
medication use for chronic disorders (study I). 
In order to enhance recall, all questions pertaining to medication use in pregnancy were 
indication-oriented. As shown in a previous study,283 adopting prompts and indication-
oriented questions over open-ended questions has the benefit to improve recall and 
accuracy in reporting use of medication during pregnancy. 
Recall of OTC medications was aided with a list of five OTC medication categories, along 
with examples of brand name products of relevance in each country. However it cannot be 
excluded that information about OTC use might be less accurate than information 
pertaining to medications used for chronic or long-term disorders. 
x Reliability and validity of collected data  
The Multinational Medication Use in Pregnancy Study suffered from lack of validity of the 
self-reported diagnoses. Both short-term illness and chronic disorders were self-reported 
by the respondents and therefore dependent on WKH ZRPHQ¶V SHUFHSWLRQ RI LOOQHVV DQG
accuracy in reporting. This limitation might have biased the observed prevalence estimates 
in two possible directions: 1) an overestimation of short-term illness such as UTIs is 
plausible since women may perceive dysuria without ascertainment of bacteriuria in the 
urine as UTI; women were not specifically enquired whether the UTI was confirmed by a 
urine test; 2) an underestimation of chronic/long-term disorders such as depression and 
anxiety for which underreporting is most often seen among individuals who have less 
severe illness or who have not received treatment.284 Also, women may ascribe symptoms 
of depression or anxiety to the pregnancy itself rather than to a probable disorder, and 
women with severe psychiatric disorders might be less likely to engage in research studies. 
However, the lack of validity of self-reported diagnosis is not considered to affect the 
prevalence estimates of medication use, which was in fact the main aim of the 
Multinational Medication Use in Pregnancy Study. 
Multiple psychometric instruments were used in the Multinational Medication Use in 
Pregnancy Study to measure medication adherence (MMAS-8), maternal symptoms of 
depression (EPDS), and beliefs about medicines (BMQ-Specific). In study III, the internal 
consistency of the MMAS-8 was satisfactory among women treated for depression and 
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for anxiety. With respect to the EPDS, we used a cut-off score with high sensitivity and 
specificity in predicting probable depression.198 In the Multinational Medication Use in 
Pregnancy Study, pregnant women were asked to complete the EPDS only once; although 
it has been shown that a single administration of the EPDS in early pregnancy is likely to 
detect transient distress for predictable reasons rather than depressive symptomatology, 
and administration at two time points in pregnancy is indeed considered to be 
preferable,204,285 another study found that use of the EPDS early in the second trimester 
identifies a substantial number of women with potential mental disorders.286 Since the 
mean gestational week of the sample in study III was about 21 weeks, and we additionally 
utilized an adequate cut-off score for probable depression, the measurement of maternal 
mental health in study III is deemed to be valid. The BMQ-Specific has been shown to 
have satisfactory psychometric properties in the setting of mental disorders; specifically, 
the Necessity and Concerns subscales were found to measure independent dimensions, 
with subsequent reliability of the Necessity-Concerns differential.121  
The EPDS, BMQ-Specific and MMAS-8 are valid psychometric instruments with good 
psychometric properties when used in paper-based questionnaires.120,195,198 However, their 
validity when administered over the internet has only been tested for the EPDS. Spek et 
al.287 showed that an internet-administered EPDS has good psychometric properties 
(Cronbach's alpha = 0.87) comparable to those observed in paper-and-pencil 
questionnaires;198 however the equivalency of the cut-off scores employed in paper-based 
versus web-questionnaires has to be verified. Further, the BMQ-Specific and MMAS-8 
have not been validated in the pregnant population. 
x Sample size and statistical considerations 
In paper I, the study sample obtained in most participating countries was large enough to 
warrant calculation of prevalence estimates with a precision of 5%. However, less precise 
estimates were permitted by the study sample in Austria, Iceland and The Netherlands 
(precision of 9-11%), as well as in Australia, Canada, Croatia, Serbia, Slovenia, and USA 
(precision of 6-7%). Individual countries were grouped into region in most analyses in 
order to facilitate readability and presentation of the results. For the very same reason, 
medications were not presented on individual substance level, but rather on clinically 
relevant groups. 
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In paper III, the overall prevalence of low adherence was uncertain due to the small total 
study sample, but could nevertheless be estimated with a precision of ±8%. The study 
sample was also small for the individual psychiatric disorders, thus limiting the statistical 
power of specific sub-analyses. Also, the country-specific samples had to be combined into 
regions because of low statistical power, thus restraining us from doing country-specific 
analyses on the relationship between beliefs and adherence. However, a recent meta-
analysis119 in a non-SUHJQDQW VDPSOH KDV VKRZQ WKDW WKH DVVRFLDWLRQ EHWZHHQ SDWLHQW¶V
beliefs and adherence seems to exist across different countries, languages and cultures. 
In both studies I and III, several statistical tests were performed with a 95% CI; hence, in 
one out of 20 tests the statistical significance may have been caused by chance rather than 
being a true association. The presence of unmeasured factors confounding the associations 
investigated in studies I and III cannot be ruled out. 
5.3.2 The Norwegian Mother and Child Cohort Study and Medical Birth Registry of 
Norway (studies II and IV) 
Several characteristics make the MoBa study unique for pregnancy-related research. The 
study includes more than 90,000 mother-child pairs recruited between 1999 and 2008 
which were prospectively followed-up throughout the pregnancy, and will be followed-up 
until the children reach the age of eight years. Data collection was carried out 
prospectively, hence avoiding the risk of recall bias. The prospective design diminishes the 
risk of differential misclassification of the exposure with subsequent limited risk of biased 
measures of associations.  
The collection of a vast array of health related information, sociodemographic and life-
style factors permitted to adjust the multivariate models for several important confounders. 
Information about the severity of maternal depressive symptomatology during pregnancy 
and postpartum, as measured via validated psychometric instruments,200-203 allowed to 
account for this factor in the multivariate analyses (studies II and IV), and not least to 
include a properly chosen disease comparison group (study IV) enabling to disentangle the 
effect attributable to pharmacotherapy from that of the underlying maternal psychiatric 
illness.  
The MBRN is a population-based registry where all information is prospectively collected 
by healthcare professional during prenatal care and at birth. Beyond providing medically 
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confirmed records, the MBRN is also unlikely to suffer from selection bias given its 
population-based characteristic.  
x Selection bias 
In the MoBa study all pregnant women in Norway were invited to participate in the study 
through a postal invitation in connection with a routine ultrasound examination offered to 
all women. Although the study was population-based, the risk of self-selection cannot be 
ruled out. Nilsen et al.274 have thoroughly examined self-selection in the MoBa and its 
potential for bias by comparing the MoBa study population with the total Norwegian 
birthing population. The findings of this study indicate that the youngest women (<25 
years), those living alone, mothers with >2 previous births and with previous stillbirth, and 
women smoking during pregnancy were strongly under-represented in MoBa. On the other 
hand, women using multivitamins and folic acid supplements were over-represented.274 
Given this scenario, it can be corroborated that the MoBa suffers from a possible self-
selection of the healthiest women to the study. Although the prevalence estimates for 
various exposures, outcomes or maternal characteristics in MoBa could not necessarily be 
generalized to the target population, Nielsen et al. also concluded that the estimates of 
exposure-outcome associations are not biased due to self-selection.274 Indeed, the MoBa 
was not a prevalence study but a prospective cohort study. Nilsen et al.274 compared 23 
well-known exposure variables (e.g., maternal smoking, maternal diabetes) and outcome 
variables (e.g., low birth weight, prematurity) in the MoBa and in the population of all 
other women giving birth in Norway during the same time period (using data from the 
MBRN). The researchers found that the magnitude of the association between maternal 
smoking and low birth weight in the MoBa study, for instance, was similar to that observed 
for all other women not participating in the MoBa. 
The findings of study II pertaining to the prevalence of eating disorders or psychotropic 
use among women with eating disorders in the time around pregnancy could therefore not 
necessarily be generalized to the target population. Prevalence estimates of eating 
disorders in the six months prior and during pregnancy were somewhat lower than point 
prevalence estimates reported in other population-based studies among young women for 
AN and BN (AN: 0.09% in the MoBa vs. 2.0%; BN: 0.94% in MoBa vs. 4.6%),53 but 
higher for BED (5.0% in MoBa vs. 1.8%).52,288 However, when the same eating disorder 
questions were used in studies of the Norwegian Twin panel, they yielded prevalence 
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estimates and comorbidity profiles similar to those seen in other large population-based 
samples.197 However the discrepancy in the prevalence of the eating disorder was most 
likely secondary to factors other than self-selection, primarily use of different instruments 
to measure eating disorders and different thresholds to define eating disorders and related 
behaviors; indeed, in study II the eating disorders subtypes were assessed as broadly 
defined AN, BN, EDNOS-P and BED. Additional factors such as under-detection of 
women with eating disorders in pregnancy because of their reluctance to disclose their 
illness during prenatal care or because of severity of illness or unlikelihood to become 
pregnant (particularly for women with AN), could also contribute to the above-mentioned 
discrepancies in prevalence estimates of eating disorders. On the other hand, the magnitude 
of the associations found between the exposure and outcome variables in studies II and IV 
can be deemed valid. We cannot, however, rule out that some of these associations could 
be influenced by selection bias.
x Response rate and representativeness 
The MoBa study has a low response rate (40.6% of all women invited),189 and therefore it 
cannot be ruled out that women participating in the MoBa possess specific characteristics 
that separate them from the population they are meant to represent. However, the response 
rate was high among those who agreed to participate: 95% for Q1, 92% for Q3, and 87% 
for Q4.189 It has been shown that women included in the MoBa are less often single or 
smokers than the non-included counterpart, and therefore represent the healthiest segment 
of Norwegian birthing population. However this potential for self-selection seems to have 
little impact on the magnitude of exposure-outcome associations (as described in detail 
earlier in this section).274  
The external validity of the results from study II is worth to be addressed. It is plausible 
that women with eating disorders who participated in MoBa may represent the healthier 
end of the eating disorder severity spectrum because they had to be well enough to 
conceive and participate. This especially applies to the AN group; indeed, engagement to 
participate in the MoBa study among women with severe AN was probably impeded by 
unfortunate physical conditions and difficulties with fertility and reproduction.289 In fact, in 
study II the mean BMI at conception among women with AN was equal to 18.2, indicating 
cases of mild anorexia. Also, women excluded from the analysis because of missing items 
for the eating disorder assessment had a more unfavorable profile in terms of age, 

 
ϭϬϮ
education, socioeconomic status and BMI than the included counterpart, implying a 
plausible exclusion of women with more severe eating disorder symptoms. 
In this regard, the risk of attrition bias merits to be addressed. In study II, women 
completing Q1 but being lost to follow-up at gestational week 30 (i.e., they did not 
complete Q3) were more likely than women completing both Q1 and Q3 to have 
symptoms of depression and anxiety around gestational week 17 (SCL-5 cut-off point: 
11.5% vs. 6.9%, respectively; p<0.001). Similarly, the prevalence of eating disorders was 
significantly higher (p<0.001) among women lost to follow-up than the non-lost 
counterpart (AN: 0.2% vs. 0.1%), BN (1.5% vs. 1.0%), EDNOS-P (0.3% vs. 0.1%), and 
BED (6.4% vs. 5.1%). Use of psychotropics before or during the first trimester was higher 
among the lost to follow-up women than the non-lost counterpart (before pregnancy: 4.6% 
vs. 3.9%; p=0.008; during the first trimester: 2.7% vs. 2.0%; p<0.001), but not during the 
second trimester. The analysis of attrition bias in relation to women lost to follow-up at six 
months postpartum showed that women completing Q1 and Q3 but not Q4 had a 
significantly higher burden of depressive symptoms around gestational week 30 compared 
to women who did complete Q4 (SCL-8 cut-off point: 10.8% vs. 6.8%, respectively; 
p<0.001), however these groups did not differ in terms of use of psychotropics during the 
third trimester. Overall, it can be substantiated that study II included the healthier end of 
the eating disorder and mental health severity spectrum; women who completed Q1, Q3 
and Q4 had to be well enough to conceive, participate throughout the pregnancy and even 
after childbirth.  
x Information bias 
In studies II and IV information about background sociodemographic and life-style 
characteristics and pregnancy details could originate from the MBRN or the MoBa study. 
In the former instance, all information is based on medically confirmed records 
prospectively collected during prenatal care and at birth, and therefore unlikely to suffer 
from recall or information bias. On the other hand, information retrieved from the MoBa 
VWXG\ZDVGHSHQGHQWRQWKHDFFXUDF\RIWKHZRPHQ¶VUHSRUWLQJDQGUHFDOO,QVWXGLHV,,DQG
IV, use of medication during pregnancy (as well as prior to and after pregnancy in study II) 
and life-style characteristics (i.e., smoking during pregnancy, alcohol consumption) was 
reported by the study participants and therefore susceptible to recall bias. However, a 
recent study has validated self-reported tobacco use against nicotine exposure assessed by 
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plasma cotinine in the MoBa and found that the sensitivity and specificity for self-reported 
daily smoking (using 30 nmol/l as the cut-off concentration) were 82 and 99%, 
respectively.290 Although the validity of maternal reporting of medication use during 
pregnancy has been shown to be satisfactory for medication used for chronic disorders,185 
or for vitamin supplements specifically in the MoBa study,291,292  a combination of 
maternal report with pharmacy records or prescription claims, can be considered a better 
method to ascertain exposure to medication during pregnancy.186 In most MoBa 
questionnaires (Q1 and Q3) information about medication use was collected prospectively. 
Use of medications in the period between gestational week 30 and childbirth was the only 
information collected retrospectively (in Q4), and may therefore be more susceptible to 
recall bias. However, a recent validation study between the MoBa and the Norwegian 
Prescription Database has shown that the impact of non-differential misclassification of the 
exposure (study IV) on risk associations is minimal for SSRIs.184 Hence, since in both 
studies II and IV the main focus was on antidepressants and other psychotropics, the 
impact of recall bias for these groups of medications can assumed to be low.   
In order to enhance recall, all questions pertaining to medication use in MoBa Q1-Q4 were 
indication-oriented. As shown in a previous study,283 adopting prompts and indication-
oriented questions over open-ended questions has the benefit to improve recall and 
accuracy in reporting use of medication during pregnancy. Yet, given the limited space 
provided in the MoBa questionnaires for answering questions pertaining to medication use, 
a potential under-reporting cannot be excluded. Also, in the MoBa questionnaires it was 
not possible to ascertain the timing of use of each specific medication when multiple drugs 
were used for the same indication. In this instance, that is when multiple drugs were used 
and multiple timings checked, we considered the drugs to be used in all time periods. 
Information about dosage and duration of pharmacotherapy is not completely accurate in 
the MoBa.  
In study IV, information about two outcome measures, vaginal bleeding episodes during 
early and midpregnancy, were self-reported by the study participants and therefore reliant 
RQ ZRPHQ¶V DWWLWXGH DQG DFFXUDF\ LQ UHSRUWLng, recall and not least perception of the 
bleeding event. This latter factor might have been particularly relevant in the assessment of 
the amount of blood loss (i.e., trace versus medium or large blood loss). Information about 
the outcome measure postpartum hemorrhage originated from the MBRN records; 
although this was medically confirmed information, a correct estimation of blood loss at 

 
ϭϬϰ
birth is difficult to achieve, and this might have led to a non-differential misclassification 
of the outcome in study IV. Although records in the MBRN have been shown to be valid 
for some specific maternal chronic disorders, other conditions or diagnosis at birth seem to 
be not optimally reported.293,294 
x Reliability and validity of collected data  
Validated psychometric instruments were utilized to measure symptoms of depression and 
anxiety during pregnancy (studies II and IV) and postpartum (study II), namely the short 
versions of the SCL-25: SCL-5 and SCL-8.200,201 These scales significantly correlated with 
the SCL-25, which is considered a reliable screening instrument for depression and anxiety 
as defined by the ICD-10.202 The SCL-5 was estimated to correlate at r=0.92 with the total 
score from the original instrument, whereas the SCL-8 correlated at r=0.94 with the 
original total score. The alpha reliability was estimated at 0.85 for the SCL-5 and 0.88 for 
the SCL-8.201,203 Strand et al.200 reported sensitivity and specificity for SCL-5 at 82% and 
96% with a cut-off of 2.00. The SCL-8 does not include somatic questions from the 
original scale, due to the special situation of pregnant woman and mothers of infants with 
regard to lack of sleep and fatigue.  
x Sample size and statistical considerations 
In study II, the AN and EDNOS-P groups were small, thus limiting the statistical power of 
several analyses. In study IV there was enough power (80%) for the SSRI/SNRI group to 
detect a moderately increased risk of bleeding complications during pregnancy and 
postpartum, however the study was underpowered for the TCA/OAD group and for the 
individual antidepressants. Also, low power impeded specific analyses based on severity of 
postpartum hemorrhage. Since bleeding complications are common in pregnancy, an 
alternative statistical method could have been applied in order to determine RR estimates 
rather than OR estimates.295  
In study IV, several statistical tests were performed with a 95% CI; hence, it cannot be 
excluded that in one out of 20 tests the statistical significance was due to chance rather 
than to a true association. In order to limit this risk, a more conservative approach was 
undertaken in study II by adopting a 99% CI.  

 
ϭϬϱ
In study II, utilization of DAGs permitted a proper selection of confounding factors for the 
multivariate models, thus diminishing the risk of over-adjustment. In paper IV, adjustment 
for confounding factors was made according to the statistical or clinical relevance of the 
candidate confounding variables. The variables measuring maternal underlying depressive 
symptomatology (SCL-5 and SCL-8) were used as continuous variables in the adjusted 
analyses in both studies II and IV since they are indicators of severity. Other variables such 
as maternal age and BMI at conception were used as continuous variables in study II, but 
as categorical variables in study IV. It cannot be excluded this categorization of variables 
might have caused residual confounding. In both studies, the presence of unmeasured 
factors confounding the associations investigated cannot be ruled out. 
6. Clinical implications and future research 
Several of the findings of this thesis have important clinical implications in the setting of 
obstetrics, psychiatry, primary care and pharmacy care, but they also address knowledge 
gaps that limit informed clinical decisions on medication use in pregnancy. Awareness that 
eight out ten women are exposed to at least one medication during pregnancy, and that five 
out of ten women may inadvertently or not be exposed to medication during the most 
sensitive period for fetal organogenesis has important clinical implications. Indeed, a large 
proportion of pregnant women will be in need of tailored evidence-based information 
about the fetal risk of medication exposures during pregnancy. Efforts should be made to 
disseminate the available evidence-based information among healthcare providers and 
make it easily accessible. Strategies should also be put in place in order to promptly 
translate repeated findings of well-designed studies into prescribing and clinical guidelines. 
For several disorders, there are no guidelines about pharmacotherapy in pregnancy, and in 
some instances, they are not conclusive, leaving clinicians with the dilemma as to whether 
medicate or not women with important illnesses during pregnancy, and balance on their 
own experience the benefit-risk ratio of pharmacotherapy versus maternal untreated 
disorder.   
An important step forward is the newly published amendment by the FDA entitled 
µPregnancy and Lactation Labelling Final Rule¶ ZKLFK RYHUFRPHV WKH REVROHWH DQG
simplistic pregnancy risk category letter system (i.e., A, B, C, D and X).296 The new 
labeling scheme will go into effect in June 2015 and will only affect prescription and 

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biological drugs, not OTCs. The pregnancy risk categories in letter format will be removed 
from the Physician Labeling Rule and substituted by information stemming from 
pregnancy exposure registries about dosing and fetal risks, whenever such information 
does exist for the medication in question.296 The purpose of the labeling revision is to 
provide physicians with updated and technical information about medications in pregnancy 
in order to identify the safest treatment options, and thereby tailor adequate counselling to 
pregnant women needing pharmacotherapy in pregnancy. Future studies should definitely 
evaluate the impact of the FDA labeling revision in the clinical and prescribing practice. It 
would be interesting to explore whether the new labeling will be able to attenuate the 
elevated perceived risk of medication exposure among healthcare professionals and 
WKHUHDIWHUDPRQJSUHJQDQWZRPHQ¶VDQGZKHWKHULWZLOl positively contribute to informed 
clinical decisions on medication use in pregnancy. 
Our findings about the maternal characteristics positively associated with use of the 
various types of medication in pregnancy, including OTC drugs, may facilitate 
identification in clinical settings of those women more likely to need information about 
medication use during pregnancy. In this specific context, the role of community 
pharmacists is indeed of value. Pharmacists are accessible healthcare providers who have 
the unique opportunity to counsel pregnant women about preconception care,297 but also 
about the teratogenic risk of exposure to OTC medications and optimal management of 
chronic disorders during pregnancy. Results of a systematic review298 has unfortunately 
shown that to date, pharmacists do not actively engage in dispensing teratology 
information to pregnant women, but they rather refer this population group to their 
physicians. Hence, adequate professional training and dissemination of more evidence-
based LQIRUPDWLRQLQWKLVILHOGLVQHHGHGLQRUGHUWRHPSRZHUWKHSKDUPDFLVW¶VUROHLQWKH
setting of obstetrics.   
Yet, evidence about the fetal risk of medication exposures during pregnancy is not always 
available. To date, few medications have been shown to be major teratogens in human 
pregnancies, however the risk of minor teratogenicity or of more subtle effects on fetal 
development still have to be determined for most medication.13 Thus, in many cases 
clinicians cannot provide their pregnant patients with clear-cut answers regarding 
teratogenicity and other adverse pregnancy outcomes, but the decision whether to medicate 
or not pregnant women is rather based on the severity of the disease in question and on 
individual risk-benefit evaluations.  Well-designed studies with adequate statistical power 

 
ϭϬϳ
are needed to determine the effects of medications on major and minor teratogenicity, but 
also in relation to other perinatal outcomes (e.g., stillbirth, prematurity, low birth weight) 
and long-term neurodevelopmental outcomes (e.g., psychomotor, behavioral, cognitive, 
and language development). Given the vast array of medications used by pregnant women 
in the different countries and the different burden of the various disorders in pregnant as 
well as childbearing women, setting research priorities in medication safety in pregnancy is 
surely challenging; however, the role of severity of the maternal disorders and the potential 
consequence of no pharmacotherapy for maternal-fetal health may indeed facilitate this 
decisional process.299  
Pregnancy may represent an important time window for recognition of potential 
psychiatric symptomatology such as depression and eating disorders, establishment of their 
treatment, and not least tailored interventions by healthcare professionals to ensure that 
needed medications are taken as prescribed. Unfortunately to date, many women with 
current psychiatric disorder are neither identified nor treated in the pregnancy and 
postpartum periods.300 Our findings about the maternal characteristics positively associated 
with use of psychotropics during pregnancy but also with no use of medications despite the 
presence of a psychiatric disorder, may assist clinicians in identifying these women and 
also in tailoring evidence-based counseling about the effect of pharmacotherapy versus that 
of undertreated maternal psychiatric illness in pregnancy.104,105,133,134,137,138 This may be of 
particular relevance in the context of pharmacotherapy discontinuation at conception.  
Our findings about the high burden of psychiatric comorbidity, the extensive use of 
psychotropics in the time around pregnancy, and not least the direct association between 
specific eating disorders and (incident) use of psychotropics during pregnancy and 
postpartum deserve attention. Clinicians are encouraged to query female patients about 
their medication-taking behavior and provide evidence-based counseling about the risk of 
medication exposure versus the risk of untreated psychiatric illness during pregnancy and 
postpartum. To date very little is known about the distinct effects of treated versus 
untreated eating disorders on perinatal outcomes;110,111 however the detrimental impact of 
untreated maternal depression, which is highly comorbid with eating disorders, on 
maternal-fetal health has been documented.104,105 Future research should attempt to 
establish whether pharmacotherapy with psychotropics during pregnancy among women 
with eating disorders may be of benefit in reducing the risk of a relapse of the disorder 

 
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itself as well as of depression in the postpartum period, but also in reducing the risk of 
specific perinatal and long-term neurodevelopmental outcomes.54 Efforts should be made 
to not let women with eating disorders or other psychiatric disorders go unrecognized 
during pregnancy. 
Awareness of the high burden of low adherence to psychotropics during pregnancy and 
that the most severely depressed women are at greater risk of non-adherence may assist 
clinicians when following-up pregnant patients with psychiatric disorders. Understanding 
ZRPHQ¶V EHOLHIV DERXW WKHLU psychotropic medications and the perceived risk of 
antidepressant exposure may assist clinicians in identifying women who are most likely to 
demonstrate low adherence. Also, since pregnant women overestimate the risk of the 
medications they take and recall negative information far more often than reassuring 
information,7,35 proper risk communication and information framing may represent 
HIIHFWLYH WRROV LQ DWWHQXDWLQJ ZRPHQ¶V QHJDWLYH EHOLHIV DQG SHUFHSWLRQV WKHUHE\
heightening medication adherence during pregnancy.6,301 Future research should test 
whether interventions proven to be effective in improving antidepressant adherence in the 
general population would be so also in the pregnant population.50 There is also the need to 
objectively measure adherence to psychotropic medication in pregnancy (i.e., via the 
plasma concentration of the drug in question) and to estimate the effect of poor medication  
adherence on important clinical outcomes, namely relapse of the psychiatric disorder at 
different times during gestation and/or in the postpartum period. Not least, researcher 
should attempt to develop a feasible and reliable medication adherence scale suited to 
pregnant women; this scale should be able to measure intentional and unintentional 
barriers WR PHGLFDWLRQ DGKHUHQFH EXW DOVR ZRPHQ¶V KHVLWDQF\ WR IROORZ WKH SUHVFULEHG
regimen because of fear of teratogenicity.  
Although our findings about the risk of vaginal bleeding after gestational exposure to 
antidepressants were reassuring, they need to be corroborated by future studies. Focus 
should also be given to the role of not medicated depression in relation to bleeding 
complications during gestation, and test whether vaginal bleeding may simply represent an 
intermediate on the path from depression to premature delivery. The controversial findings 
about the risk of postpartum hemorrhage associated with antidepressants should be settled 
by further studies. It would be particularly interesting to explore the relationship between 
bleeding complications postpartum and the maternal plasma concentrations of 

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antidepressants at the beginning of labor, or even the concentration of these drugs in 
umbilical cord blood samples.  
So far very little research has been done in relation to maternal safety after exposure to 
antidepressant during gestation. For instance, it is still not elucidated whether use of these 
medications during pregnancy may increase the risk of cardiovascular disorders such as 
preeclampsia or gestational hypertension,145,147,148,150 and for other conditions (e.g. 
gestational diabetes, weight gain) the literature is very scarce. It is also worth mentioning 
that to date, there is no evidence about the benefit and effectiveness of pharmacological 
treatment of depression or eating disorders during pregnancy.302 No randomized 
comparative study has evaluated the effectiveness of evidence-based psychiatric treatments 
during pregnancy, and few observational studies have assessed maternal benefit outcomes 
of SSRI treatment during pregnancy versus no treatment.181,303 On top of this, sound 
research data are needed to understand how pregnancy alters the pharmacokinetics and 
pharmacodynamics of antidepressants and therefore guide required dose adjustments 
during pregnancy.304 
At present, the study size and data availability in the Multinational Medication Use in 
Pregnancy Study give the opportunity to assess on a multinational level the fetal risk of 
those medications - on individual substance level - most commonly used by the pregnant 
population during the first trimester of pregnancy, and add to the current literature so far 
restricted to individual country level.26,43 These data material will also consent to explore 
medication adherence during pregnancy for treatment of other important chronic 
conditions such as asthma and hypothyroidism. The amount of data available in the MoBa 
study, along with the possibility to link such data with population-based registries such as 
the MBRN, the Norwegian Prescription Database and the Norwegian Patient Registry, 
offer an unique possibility to study the effects of numerous medications on immediate 
perinatal outcomes and on long-term neurodevelopmental outcomes in children until the 
age of 8 years. The availability of biological material in the MoBa offers the exceptional 
possibility to rely on maternal drug concentrations as exposure variable and therefore 
increase the exposure reliability, but also to explore whether specific perinatal and long-
term neurodevelopmental outcomes are associated with epigenetic changes acted by drug 
exposures during fetal life. Integration of biology and pregnancy-related epidemiology is 
indeed an important step forward in research, which will probably have an important 
impact on public health and prevention. Similarly, application of new statistical 

 
ϭϭϬ
methodologies in the field of epidemiology and pregnancy-related research will enable 
researchers to overcome, at least in those instances where the study design allows doing so, 
the mere concept of associations and infer causality.  


 
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7. References 
1. The ESHRE Capri Workshop Group. Europe the continent with the lowest fertility. 
Hum Reprod Update 2010;16:590-602. 
2. Balasch J, Gratacos E. Delayed childbearing: effects on fertility and the outcome of 
pregnancy. Curr Opin Obstet Gynecol 2012;24:187-93. 
3. World Health Organization (WHO). Depression. Fact Sheet n. 3692012. 
4. Hendrick V. Psychiatric Disorders in Pregnancy and the Postpartum: Principles and 
Treatment. Totowa, NJ: Humana Press; 2006. 
5. Baggley A, Navioz Y, Maltepe C, Koren G, Einarson A. Determinants of women's 
decision making on whether to treat nausea and vomiting of pregnancy pharmacologically. 
J Midwifery Womens Health 2004;49:350-4. 
6. Jasper JD, Goel R, Einarson A, Gallo M, Koren G. Effects of framing on 
teratogenic risk perception in pregnant women. Lancet 2001;358:1237-8. 
7. Mulder E, Davis A, Gawley L, Bowen A, Einarson A. Negative impact of non-
evidence-based information received by women taking antidepressants during pregnancy 
from health care providers and others. J Obstet Gynaecol Can 2012;34:66-71. 
8. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk 
perceptions of teratogenicity: a survey of pregnant Canadian women and their health 
professionals. J Clin Pharmacol 2000;40:573-7. 
9. Hameen-Anttila K, Jyrkka J, Enlund H, Nordeng H, Lupattelli A, Kokki E. 
Medicines information needs during pregnancy: a multinational comparison. BMJ Open 
2013;3. 
10. Thalidomide. The history of thalidomide. (Accessed February 3, 2015, at 
http://www.thalidomide.ca/history-of-thalidomide/.) 
11. McBride W. Thalidomide and congential abnormalities. Lancet Infect Dis 
1961;278:1358. 
12. Lenz W. Thalidomide and congential anomalies. Lancet 1962;279:45. 
13. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference 
guide to fetal and neonatal risk: Lippincott Williams & Wilkins; 2012. 
14. Smithells RW. Defects and disabilities of thalidomide children. BMJ 1973;1:269-
72. 

 
ϭϭϮ
15. FDA. Guidance for Industry. General Considerations for the Clinical Evaluation of 
Drugs. 1977. 
16. Brent R. Bendectin and birth defects: Hopefully, the final chapter. Birth Defects 
Res A Clin Mol Teratol 2003;67:79-87. 
17. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by 
counselling women on drug, chemical, and radiation exposure during the first trimester. 
Teratology 1990;41:657-61. 
18. FDA. Women's Health. FDA Needs to Ensure More Study of Gender Differences 
in Prescription Drug Testing. 1992. 
19. CIOMS. International Ethical Guidelines for Biomedical Research Involving 
Human Subjects WHO. Geneva 2002. 
20. Retningslinjer for inklusjon av kvinner i medisinsk forskning. 2001. (Accessed 
June 26, 2011, at http://www.etikkom.no/no/Forskningsetikk/Etiske-
retningslinjer/Medisin-og-helse/Inklusjon-av-kvinner/.) 
21. Somers GS. Thalidomide and congenital abnormalities. Lancet 1962;1:912-3. 
22. Pooja Mittal M, Deborah A. Wing, MDb. Urinary Tract Infections in Pregnancy. 
Clin Perinatol 2005;32:749-64. 
23. Lacroix R EE, Melzack R. Nausea and vomiting during pregnancy: a prospective 
study of its frequency, inten- sity, and patterns of change. Am J Obstet Gynecol 
2000;182:931-7. 
24. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during 
pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 
2011;20:895-902. 
25. Medication during pregnancy: an intercontinental cooperative study. Collaborative 
Group on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992;39:185-96. 
26. Odalovic M, Vezmar Kovacevic S, Ilic K, Sabo A, Tasic L. Drug use before and 
during pregnancy in Serbia. Int J Clin Pharm 2012;34:719-27. 
27. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use 
during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin 
Pharmacol 2008;64:1125-32. 
28. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. 
Prescription drug use among fathers and mothers before and during pregnancy. A 
population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin 
Pharmacol 2008;65:653-60. 

 
ϭϭϯ
29. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van 
Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, 
occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;113:559-68. 
30. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a 
study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65:839-46. 
31. Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during 
pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 
2003;59:127-33. 
32. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. 
Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. 
Am J Obstet Gynecol 2011;205:51 e1-8. 
33. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am 
J Obstet Gynecol 2004;191:398-407. 
34. Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: 
data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 
2004;60:355-61. 
35. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of 
medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66:207-14. 
36. Nordeng H, Hansen C, Garthus-Niegel S, Eberhard-Gran M. Fear of childbirth, 
mental health, and medication use during pregnancy. Arch Womens Ment Health 
2012;15:203-9. 
37. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-
counter medications during pregnancy. Am J Obstet Gynecol 2005;193:771-7. 
38. Bercaw J, Maheshwari B, Sangi-Haghpeykar H. The use during pregnancy of 
prescription, over-the-counter, and alternative medications among Hispanic women. Birth 
2010;37:211-8. 
39. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications 
and Herbal Remedies in Pregnancy. Amer J Perinatol 2005;22:321,4. 
40. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a 
potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 
2006;15:546-54. 
41. Irvine L, Flynn RW, Libby G, Crombie IK, Evans JM. Drugs dispensed in primary 
care during pregnancy: a record-linkage analysis in Tayside, Scotland. Drug Saf 
2010;33:593-604. 

 
ϭϭϰ
42. Kulaga S, Zargarzadeh AH, Berard A. Prescriptions filled during pregnancy for 
drugs with the potential of fetal harm. BJOG 2009;116:1788-95. 
43. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester 
of pregnancy: most common exposures and critical gaps in understanding fetal risk. 
Pharmacoepidemiol Drug Saf 2013;22:1013-8. 
44. Gaynes B, Gavin N, Meltzer-Brody S, et al. Perinatal Depression: Prevalence, 
Screening Accuracy, and Screening Outcomes. Summary, Evidence Report/Technology 
Assessment: Number 119. AHRQ Publication Number 05-E006-1, February 2005: Agency 
for Healthcare Research and Quality, Rockville (MD). 
45. Gotlib IH, Whiffen VE, Mount JH, Milne K, Cordy NI. Prevalence rates and 
demographic characteristics associated with depression in pregnancy and the postpartum. J 
Consult Clin Psychol 1989;57:269-74. 
46. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood 
during pregnancy and after childbirth. BMJ 2001;323:257-60. 
47. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of 
depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709. 
48. Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, Verdoux H. Women 
with anxiety disorders during pregnancy are at increased risk of intense postnatal 
depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry 
2004;19:459-63. 
49. Morgan JF. Eating disorders and gynecology, knowledge and attitudes among 
clinicians. Acta Obstet Gynecol Scand 1999;78:233-9. 
50. Association AP. American Psychiatric Association. Diagnostic and Statistical 
Manual of Mental Disorders (DSM) Washington, DC: American Psychiatric Press; 1994. 
51. American Psychiatric A. Desk reference to the diagnostic criteria from DSM-5. 
Washington, D.C: American Psychiatric Publishing; 2013. 
52. Easter A, Bye A, Taborelli E, et al. Recognising the symptoms: how common are 
eating disorders in pregnancy? Eur Eat Disord Rev 2013;21:340-4. 
53. Bulik CM, Von Holle A, Hamer R, et al. Patterns of remission, continuation and 
incidence of broadly defined eating disorders during early pregnancy in the Norwegian 
Mother and Child Cohort Study (MoBa). Psychol Med 2007;37:1109-18. 
54. Micali N, Treasure J. Biological effects of a maternal ED on pregnancy and foetal 
development: a review. Eur Eat Disord Rev 2009;17:448-54. 

 
ϭϭϱ
55. Braun DL, Sunday SR, Halmi KA. Psychiatric comorbidity in patients with eating 
disorders. Psychol Med 1994;24:859-67. 
56. Micali N, Simonoff E, Treasure J. Pregnancy and post-partum depression and 
anxiety in a longitudinal general population cohort: the effect of eating disorders and past 
depression. J Affect Disord 2011;131:150-7. 
57. ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: 
Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 
(replaces practice bulletin number 87, November 2007). Use of psychiatric medications 
during pregnancy and lactation. Obstet Gynecol 2008;111:1101-020. 
58. Claudino AM, Hay P, Lima MS, Bacaltchuk J, Schmidt U, Treasure J. 
Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006:Cd004365. 
59. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia 
nervosa. Cochrane Database Syst Rev 2003:Cd003391. 
60. Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating 
disorders. Int J Neuropsychopharmacol 2012;15:189-207. 
61. Summary of Product Characteristics (SPC), Fontex. Felleskatalogen. 
Felleskatalogen AS 2015. 
62. Food and Drug Administration (FDA). Medication Guide. Vyvanse. 
63. Fazeli PK, Calder GL, Miller KK, et al. Psychotropic medication use in anorexia 
nervosa between 1997 and 2009. Int J Eat Disord 2012;45:970-6. 
64. Mitchell JE, Roerig J, Steffen K. Biological therapies for eating disorders. Int J Eat 
Disord 2013;46:470-7. 
65. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. 
Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last 
decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 
2008;65:600-6. 
66. Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication 
use in early pregnancy-prevalence and determinants of use in a prospective cohort of 
women. Pharmacoepidemiol Drug Saf 2010;19:408-17. 
67. Checa MA, Peiro R, Pascual J, Carreras R. Drug intake behaviour of immigrants 
during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;121:38-45. 
68. De Las Cuevas C, de la Rosa MA, Troyano JM, Sanz EJ. Are psychotropics drugs 
used in pregnancy? Pharmacoepidemiol Drug Saf 2007;16:1018-23. 

 
ϭϭϲ
69. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. Patterns of antidepressant 
medication use among pregnant women in a United States population. J Clin Pharmacol 
2011;51:264-70. 
70. Axelsdottir TO, Sigurdsson EL, Gudmundsdottir AM, Kristjansdottir H, 
Sigurdsson JA. Drug use during early pregnancy: cross-sectional analysis from the 
Childbirth and Health Study in Primary Care in Iceland. Scand J Prim Health Care 
2014;32:139-45. 
71. Ystrom E, Vollrath ME, Nordeng H. Effects of personality on use of medications, 
alcohol, and cigarettes during pregnancy. Eur J Clin Pharmacol 2012;68:845-51. 
72. Roberson EK, Hurwitz EL. Prescription Drug Use During and Immediately Before 
Pregnancy in Hawai'i - Findings from the Hawai'i Pregnancy Risk Assessment Monitoring 
System, 2009-2011. Hawaii J Med Public Health 2014;73:382-6. 
73. Sawicki E, Stewart K, Wong S, Leung L, Paul E, George J. Medication use for 
chronic health conditions by pregnant women attending an Australian maternity hospital. 
Aust N Z J Obstet Gynaecol 2011;51:333-8. 
74. Petersen I, McCrea RL, Osborn DJ, et al. Discontinuation of antipsychotic 
medication in pregnancy: a cohort study. Schizophr Res 2014;159:218-25. 
75. Margulis AV, Kang EM, Hammad TA. Patterns of prescription of antidepressants 
and antipsychotics across and within pregnancies in a population-based UK cohort. Matern 
Child Health J 2014;18:1742-52. 
76. Cea-Soriano L, Garcia Rodriguez LA, Fernandez Cantero O, Hernandez-Diaz S. 
Challenges of using primary care electronic medical records in the UK to study 
medications in pregnancy. Pharmacoepidemiol Drug Saf 2013;22:977-85. 
77. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major 
determinant for discontinuation of antidepressants: an analysis of data from The Health 
Improvement Network. J Clin Psychiatry 2011;72:979-85. 
78. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications 
prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK 
General Practice Research Database. Pharmacoepidemiol Drug Saf 2006;15:555-64. 
79. Yamamoto A, McCormick MC, Burris HH. Disparities in antidepressant use in 
pregnancy. J Perinatol 2014. 
80. Meunier MR, Bennett IM, Coco AS. Use of antidepressant medication in the 
United States during pregnancy, 2002-2010. Psychiatr Serv 2013;64:1157-60. 

 
ϭϭϳ
81. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in 
pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-
2006). Clin Ther 2012;34:239-49.e2. 
82. Askaa B, Jimenez-Solem E, Enghusen Poulsen H, Traerup Andersen J. Maternal 
Characteristics of Women Exposed to Hypnotic Benzodiazepine Receptor Agonist during 
Pregnancy. Obstet Gynecol Int 2014;2014:945621. 
83. Jimenez-Solem E, Andersen JT, Petersen M, et al. Prevalence of antidepressant use 
during pregnancy in Denmark, a nation-wide cohort study. PLoS One 2013;8:e63034. 
84. Munk-Olsen T, Gasse C, Laursen TM. Prevalence of antidepressant use and 
contacts with psychiatrists and psychologists in pregnant and postpartum women. Acta 
Psychiatr Scand 2012;125:318-24. 
85. Bjorn AM, Norgaard M, Hundborg HH, Nohr EA, Ehrenstein V. Use of prescribed 
drugs among primiparous women: an 11-year population-based study in Denmark. Clin 
Epidemiol 2011;3:149-56. 
86. Artama M, Gissler M, Malm H, Ritvanen A. Nationwide register-based 
surveillance system on drugs and pregnancy in Finland 1996-2006. Pharmacoepidemiol 
Drug Saf 2011;20:729-38. 
87. Riska BS, Skurtveit S, Furu K, Engeland A, Handal M. Dispensing of 
benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based 
cohort study. Eur J Clin Pharmacol 2014;70:1367-74. 
88. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, 
Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin 
Pharmacol 2006;62:863-70. 
89. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use 
during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical 
Birth Register. Clin Epidemiol 2011;3:43-50. 
90. Charlton R, Jordan S, Pierini A, et al. Selective serotonin reuptake inhibitor 
prescribing before, during and after pregnancy: a population-based study in six European 
regions. BJOG 2014. 
91. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the 
United States from 2006 to 2011 among women with private insurance. BMC Pregnancy 
Childbirth 2014;14:242. 

 
ϭϭϴ
92. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic 
medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 
deliveries. Arch Womens Ment Health 2013;16:149-57. 
93. Epstein RA, Bobo WV, Shelton RC, et al. Increasing use of atypical antipsychotics 
and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf 2013;22:794-801. 
94. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant 
medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry 
2013;35:265-71. 
95. Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse 
outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012;207:49.e1-9. 
96. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during 
pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194 e1-5. 
97. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in 
pregnancy. Am J Obstet Gynecol 2007;196:544.e1-.e5. 
98. Berard A, Sheehy O. The Quebec Pregnancy Cohort--prevalence of medication use 
during gestation and pregnancy outcomes. PLoS One 2014;9:e93870. 
99. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Are women with major depression 
in pregnancy identifiable in population health data? BMC Pregnancy Childbirth 
2013;13:63. 
100. Julio-Pieper M, Dinan TG. The hypothalamic-pituitary-adrenal axis in depression.  
Modern Trends in Pharmacopsychiatry 2010:20-31. 
101. Seckl JR. Glucocorticoids, developmental 'programming' and the risk of affective 
dysfunction. Prog Brain Res 2008;167:17-34. 
102. Alder J, Fink N, Bitzer J, Hosli I, Holzgreve W. Depression and anxiety during 
pregnancy: A risk factor for obstetric, fetal and neonatal outcome? A critical review of the 
literature. J Matern Fetal Neonatal Med 2007;20:189±209. 
103. Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum 
period: A systematic review. J Clin Psychiatry 2006;67:1285-98. 
104. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal 
depression during pregnancy on perinatal outcomes: A systematic review and meta-
analysis. J Clin Psychiatry 2013;74:e321-e41. 
105. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-
analysis of depression during pregnancy and the risk of preterm birth, low birth weight, 
and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24. 

 
ϭϭϵ
106. Norhayati MN, Nik Hazlina NH, Asrenee AR, Wan Emilin WM. Magnitude and 
risk factors for postpartum symptoms: A literature review. J Affect Disord 2014;175c:34-
52. 
107. Beck CT. Revision of the postpartum depression predictors inventory. J Obstet 
Gynecol Neonatal Nurs 2002;31:394-402. 
108. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during 
pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 
2006;295:499-507. 
109. Bulik CM, Von Holle A, Siega-Riz AM, et al. Birth outcomes in women with 
eating disorders in the Norwegian Mother and Child cohort study (MoBa). Int J Eat Disord 
2009;42:9-18. 
110. Micali N, De Stavola B, dos-Santos-Silva I, et al. Perinatal outcomes and 
gestational weight gain in women with eating disorders: a population-based cohort study. 
BJOG 2012;119:1493-502. 
111. Linna MS, Raevuori A, Haukka J, Suvisaari JM, Suokas JT, Gissler M. Pregnancy, 
obstetric, and perinatal health outcomes in eating disorders. Am J Obstet Gynecol 
2014;211:392 e1-8. 
112. Solmi F, Sallis H, Stahl D, Treasure J, Micali N. Low birth weight in the offspring 
of women with anorexia nervosa. Epidemiol Rev 2014;36:49-56. 
113. Carter FA, McIntosh VVW, Joyce PR, Frampton CM, Bulik CM. Bulimia nervosa, 
childbirth, and psychopathology. J Psychosom Res 2003;55:357-61. 
114. Abraham S. Sexuality and reproduction in bulimia nervosa patients over 10 years. J 
Psychosom Res 1998;44:491-502. 
115. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005;353:487-
97. 
116. Sabaté E. Adherence to long-term therapies: evidence for action: World Health 
Organization; 2003. 
117. Matsui D. Adherence with drug therapy in pregnancy. Obstet Gynecol Int 
2012;2012:Article ID 796590, 5 pages. 
118. Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, adherence and 
compliance in medicine taking. Report for the National Co-ordinating Centre for NHS 
Service Delivery and Organisation R & D (NCCSDO). London: National Institute for 
Health Research Service Delivery and Organisation R&D; 2005. 

 
ϭϮϬ
119. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. 
Understanding Patients' Adherence-Related Beliefs about Medicines Prescribed for Long-
Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework. PLoS 
One 2013;8:e80633. 
120. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in 
adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67. 
121. Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs 
about medications: measurement and relationship to adherence in patients with severe 
mental disorders. Acta Psychiatr Scand 2009;119:78-84. 
122. Lupattelli A, Spigset O, Nordeng H. Adherence to medication for chronic disorders 
during pregnancy: results from a multinational study. Int J Clin Pharm 2014;36:145-53. 
123. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective 
serotonin reuptake inhibitors in pregnancy and congenital malformations: population based 
cohort study. Br Med J 2009;339. 
124. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin 
reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701. 
125. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin 
reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289. 
126. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and 
venlafaxine in early pregnancy and risk of birth defects: population based cohort study and 
sibling design. BMJ 2015;350:h1798. 
127. Bérard A, Ramos É, Rey É, Blais L, St.-André M, Oraichi D. First trimester 
exposure to paroxetine and risk of cardiac malformations in infants: the importance of 
dosage. Birth Defects Research Part B: Developmental and Reproductive Toxicology 
2007;80:18-27. 
128. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester 
and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 
2007;16:1075-85. 
129. Kallen B. Neonate Characteristics After Maternal Use of Antidepressants in Late 
Pregnancy. Arch Pediatr Adolesc Med 2004;158:312-6. 
130. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective Serotonin-
Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. N 
Engl J Med 2006;354:579-87. 

 
ϭϮϭ
131. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal Outcome Following Third 
Trimester Exposure to Paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32. 
132. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth 
outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000. 
133. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the 
relationship between antidepressant use in pregnancy and the risk of preterm birth and low 
birth weight. Gen Hosp Psychiatry 2014;36:13-8. 
134. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant 
medication use during pregnancy: a systematic review and meta-analysis. PLoS One 
2014;9:e92778. 
135. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery 
outcomes after exposure to antidepressant medication: a systematic review and meta-
analysis. JAMA Psychiatry 2013;70:436-43. 
136. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to 
antidepressants and persistent pulmonary hypertension of the newborn: systematic review 
and meta-analysis. BMJ 2014;348:f6932. 
137. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal 
antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J 
Clin Psychiatry 2013;74:e309-20. 
138. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure 
during pregnancy and congenital malformations: is there an association? A systematic 
review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74:e293-308. 
139. El Marroun H, White T, Verhulst FC, Tiemeier H. Maternal use of antidepressant 
or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a 
systematic review. Eur Child Adolesc Psychiatry 2014;23:973-92. 
140. Hermansen TK, Melinder A. Prenatal SSRI exposure: Effects on later child 
development. Child Neuropsychol 2014:1-27. 
141. Chrousos GP, Torpy DJ, Gold PW. Interactions between the Hypothalamic-
Pituitary-Adrenal Axis and the Female Reproductive System: Clinical Implications. Ann 
Intern Med 1998;129:229-40. 
142. Sandman CA, Wadhwa PD, Chicz-DeMet A, Dunkel-Schetter C, Porto M. 
Maternal Stress, HPA Activity, and Fetal/Infant Outcome. Ann N Y Acad Sci 
1997;814:266-75. 

 
ϭϮϮ
143. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: 
mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 
2011;28:345-67. 
144. O'Donnell J, Shelton R. Drug Therapy of Depression and Anxiety Disorders. In: 
Chabner B, Brunton L, Knollman B, eds. Goodman & Gilman's The Pharmacological 
Basis of Therapeutics. 12 ed. New York: McGraw-Hill; 2011. 
145. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. 
Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. Am J 
Psychiatry 2009;166:320-8. 
146. De Vera MA, Bérard A. Antidepressant Use During Pregnancy and the Risk of 
Pregnancy Induced Hypertension. Br J Clin Pharmacol 2012:no-no. 
147. Palmsten K, Huybrechts KF, Michels KB, et al. Antidepressant use and risk for 
preeclampsia. Epidemiology 2013;24:682-91. 
148. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernandez-Diaz S. Elevated 
risk of preeclampsia in pregnant women with depression: depression or antidepressants? 
Am J Epidemiol 2012;175:988-97. 
149. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in 
pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33. 
150. Lopez-Yarto M, Ruiz-Mirazo E, Holloway AC, Taylor VH, McDonald SD. Do 
psychiatric medications, especially antidepressants, adversely impact maternal metabolic 
outcomes? J Affect Disord 2012;141:120-9. 
151. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding 
associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction 
with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen 
Psychiatry 2008;65:795-803. 
152. Castro VM, Gallagher PJ, Clements CC, et al. Incident user cohort study of risk for 
gastrointestinal bleed and stroke in individuals with major depressive disorder treated with 
antidepressants. BMJ Open 2012;2:e000544. 
153. Lee YC, Shau WY, Chang CH, Chen ST, Lin MS, Lai MS. Antidepressant use and 
the risk of upper gastrointestinal bleeding in psychiatric patients: a nationwide cohort study 
in taiwan. J Clin Psychopharmacol 2012;32:518-24. 
154. Linnebur SA, Saseen JJ, Pace WD. Venlafaxine-associated vaginal bleeding. 
Pharmacotherapy 2002;22:652-5. 

 
ϭϮϯ
155. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with 
selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 
2008;28:230-4. 
156. Palmsten K, Hernandez-Diaz S, Huybrechts KF, et al. Use of antidepressants near 
delivery and risk of postpartum hemorrhage: cohort study of low income women in the 
United States. BMJ 2013;347:f4877. 
157. Lindqvist PG, Nasiell J, Gustafsson LL, Nordstrom L. Selective serotonin reuptake 
inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a 
hospital-based cohort study. J Thromb Haemost 2014;12:1986-92. 
158. Joseph KS, Sheehy O, Mehrabadi A, et al. Can Drug Effects Explain the Recent 
Temporal Increase in Atonic Postpartum Haemorrhage? Paediatr Perinat Epidemiol 2015. 
159. ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 
2007;110:731-6. 
160. Strom BL. What is Pharmacoepidemiology?  Pharmacoepidemiology: Wiley-
Blackwell; 2012:1-22. 
161. W. H. O. Collaborating Centre for Drug Statistics Methodology. Introduction to 
drug utilization research. Geneva: World Health Organization; 2003. 
162. Lee D, Bergman U. Studies of Drug Utilization.  Pharmacoepidemiology: Wiley-
Blackwell; 2012:377-401. 
163. Hernandez-Diaz S. Prescription of medications during pregnancy: accidents, 
compromises, and uncertainties. Pharmacoepidemiol Drug Saf 2006;15:613-7. 
164. Strom BL. Basic Principles of Clinical Epidemiology Relevant to 
Pharmacoepidemiologic Studies.  Pharmacoepidemiology: Wiley-Blackwell; 2012:38-51. 
165. Mitchell AA. Studies of Drug-Induced Birth Defects.  Pharmacoepidemiology: 
Wiley-Blackwell; 2012:487-504. 
166. Dreyer NA, Velentgas P. Registries.  Pharmacoepidemiology: Wiley-Blackwell; 
2012:331-46. 
167. U.S. Food and Drug Administration. Science and Research Special Topics. List of 
Pregnancy Exposure Registries. (Accessed February 20, 2015, at 
http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm134848.
htm.) 
168. Huybrechts K, Mikkelsen E, Christensen T, et al. A successful implementation of 
e-HSLGHPLRORJ\ WKH 'DQLVK SUHJQDQF\ SODQQLQJ VWXG\ µ6QDUW-*UDYLG¶ (XU - Epidemiol 
2010;25:297-304. 

 
ϭϮϰ
169. Veierød M, Lydersen S, Laake P. Design and analysis.  Medical statistics in clinical 
and epidemiological research. Oslo: Gyldendal akademisk; 2012:23-47. 
170. Czeizel AE. First 25 years of the Hungarian congenital abnormality registry. 
Teratology 1997;55:299-305. 
171. Jaddoe VV, van Duijn C, Franco O, et al. The Generation R Study: design and 
cohort update 2012. Eur J Epidemiol 2012;27:739-56. 
172. Olsen J, Melbye M, Olsen SF, et al. The Danish National Birth Cohort - its 
background, structure and aim. Scand J Public Health 2001;29:300-7. 
173. Cleary BJ, Rice Ú, Eogan M, Metwally N, McAuliffe F. 2009 A/H1N1 influenza 
vaccination in pregnancy: uptake and pregnancy outcomes ± a historical cohort study. Eur 
J Obstet Gynecol Reprod Biol 2014;178:163-8. 
174. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant Use in Pregnancy and 
the Risk of Cardiac Defects. N Engl J Med 2014;370:2397-407. 
175. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia: 
Lippincott Williams & Wilkins; 2008. 
176. Hill AB. The Environment and Disease: Association or Causation? Proceedings of 
the Royal Society of Medicine. 1965. p. 295-300. 
177. 6KHSDUG7+³3URRI´RIKXPDQWeratogenicity. Teratology 1994;50:97-8. 
178. Scialli AR. The National Birth Defects Prevention Study: how to communicate data. 
Semin Fetal Neonatal Med 2014;19:170-6. 
179. Moore KL, Persaud TVN, Torchia MG. The developing human : clinically oriented 
embryology. 9th ed. ed. Philadelphia, Pa: Saunders Elsevier; 2013. 
180. Roca A, Garcia-Esteve L, Imaz ML, et al. Obstetrical and neonatal outcomes after 
prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J Affect 
Disord 2011;135:208-15. 
181. Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant 
treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557-66. 
182. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of 
timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: 
population-based study. Br J Psychiatry 2008;192:338-43. 
183. Berlin JA, Cepeda S, Kim CJ. The Use of Meta-analysis in Pharmacoepidemiology.  
Pharmacoepidemiology: Wiley-Blackwell; 2012:723-56. 

 
ϭϮϱ
184. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: 
inclusion of dispensed drugs before pregnancy may lead to underestimation of risk 
associations. J Clin Epidemiol 2013;66:964-72. 
185. Sarangarm P, Young B, Rayburn W, et al. Agreement between self-report and 
prescription data in medical records for pregnant women. Birth Defects Res A Clin Mol 
Teratol 2012;94:153-61. 
186. van Gelder MM, van Rooij IA, de Walle HE, Roeleveld N, Bakker MK. Maternal 
recall of prescription medication use during pregnancy using a paper-based questionnaire: 
a validation study in the Netherlands. Drug Saf 2013;36:43-54. 
187. Bjork MH, Veiby G, Reiter SC, et al. Depression and anxiety in women with 
epilepsy during pregnancy and after delivery: a prospective population-based cohort study 
on frequency, risk factors, medication, and prognosis. Epilepsia 2015;56:28-39. 
188. Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004;6:e34. 
189. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian Mother and 
Child Cohort Study (MoBa). Int J Epidemiol 2006;35:1146-50. 
190. Norwegian Institute of Public Health. What is the Norwegian Mother and Child 
Cohort Study? (Accessed 11 March 2015, at 
http://www.fhi.no/eway/default.aspx?pid=240&trg=MainContent_6894&Main_6664=689
4:0:25,7372:1:0:0:::0:0&MainContent_6894=6706:0:25,7373:1:0:0:::0:0.) 
191. Rønningen K, Paltiel L, Meltzer H, et al. The biobank of the Norwegian mother 
and child cohort Study: A resource for the next 100 years. Eur J Epidemiol 2006;21:619-25. 
192. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and 
surveillance throughout 30 years. Acta Obstet Gynecol Scand 2000;79:435-9. 
193. Norwegian Institute of Public Health. Medical Birth Registry of Norway (MBRN). 
(Accessed March 11, 2015, at 
http://www.fhi.no/eway/default.aspx?pid=240&trg=Main_6664&Main_6664=6898:0:25,7
840:1:0:0:::0:0) 
194. International Statistical Classification of Diseases and Related Health Problems 
10th Revision. (Accessed March 11, 2015, at 
http://apps.who.int/classifications/icd10/browse/2015/en) 
195. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a 
medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 
2008;10:348-54. 

 
ϭϮϲ
196. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 
2012. (Accessed 17 March, 2012, at http://www.whocc.no/atc_ddd_index/) 
197. Reichborn-Kjennerud T, Bulik CM, Kendler KS, et al. Gender differences in binge-
eating: a population-based twin study. Acta Psychiatr Scand 2003;108:196-202. 
198. Cox J, Holden J, Sagovsky R. Detection of postnatal depression. Development of 
the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782-6. 
199. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the 
development and evaluation of a new method for assessing the cognitive representation of 
medication. Psychol Health 1999;14:1-24. 
200. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health 
status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, 
SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003;57:113-8. 
201. Fink P, Orbol E, Hansen MS, Sondergaard L, De Jonge P. Detecting mental 
disorders in general hospitals by the SCL-8 scale. J Psychosom Res 2004;56:371-5. 
202. Sandanger I, Moum T, Ingebrigtsen G, Dalgard OS, Sorensen T, Bruusgaard D. 
Concordance between symptom screening and diagnostic procedure: the Hopkins 
Symptom Checklist-25 and the Composite International Diagnostic Interview I. Soc 
Psychiatry Psychiatr Epidemiol 1998;33:345-54. 
203. Tambs K, Moum T. How well can a few questionnaire items indicate anxiety and 
depression? Acta Psychiatr Scand 1993;87:364-7. 
204. Cox JL, Holden J. Perinatal mental health: a guide to the Edinburgh Postnatal 
Depression Scale (EPDS): RCPsych Publications; 2003. 
205. Hosmer DW, Lemeshow S, eds. Applied logistic regression. 2nd ed. New York: 
Wiley-Interscience; 2000. 
206. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal 
diagrams. Epidemiology 2011;22:745. 
207. Greenland S, Pearl J, Robins JM. Causal Diagrams for Epidemiologic Research. 
Epidemiology 1999;10:37-48. 
208. Center for DiseaseControl and Prevention (CDC). Epi InfoTM 7. (Accessed 31 Dec, 
2013, at http://wwwn.cdc.gov/epiinfo/) 
209. Hein Stigum hompage. University of Oslo. Utilities. Get programs or command 
files. Sample size calculator. (Accessed 3 January, 2015, at 
http://folk.uio.no/heins/Utilities/Utilities.html) 

 
ϭϮϳ
210. Dempster AP, Laird NM, Rubin DB. Maximum Likelihood from Incomplete Data 
via the EM Algorithm. J R Stat Soc Series B Stat Methodol 1977;39:1-38. 
211. Autret-Leca E, Deligne J, Leve J, Caille A, Cissoko H, Jonville-Bera AP. Drug 
exposure during the periconceptional period: a study of 1793 women. Paediatr Drugs 
2011;13:317-24. 
212. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of 
medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157:175-82. 
213. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women 
taking? A literature review. J Adv Nurs 2006;56:636-45. 
214. Banhidy F, Acs N, Puho E, Czeizel AE. A population-based case-control 
teratologic study of oral dipyrone treatment during pregnancy. Drug Saf 2007;30:59-70. 
215. Bar-Oz B, Clementi M, Di Giantonio E, et al. Metamizol (dipyrone, optalgin) in 
pregnancy, is it safe? A prospective comparative study. Eur J Obstet Gynecol Reprod Biol 
2005;119:176-9. 
216. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol 
exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol 
2013;42:1702-13. 
217. Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among 
Italian women. Eur J Clin Pharmacol 2000;56:323-8. 
218. Odalovic M, Vezmar Kovacevic S, Nordeng H, Ilic K, Sabo A, Tasic L. Predictors 
of the use of medications before and during pregnancy. Int J Clin Pharm 2013;35:408-16. 
219. Olesen C, Thrane N, Henriksen TB, Ehrenstein V, Olsen J. Associations between 
socio-economic factors and the use of prescription medication during pregnancy: a 
population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006;62:547-
53. 
220. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and Predictors of Antibiotic 
Administration during Pregnancy and Birth. PLoS One 2013;8:e82932. 
221. Eberhard-Gran M, Tambs K, Opjordsmoen S, Skrondal A, Eskild A. Depression 
during pregnancy and after delivery: a repeated measurement study. J Psychosom Obstet 
Gynaecol 2004;25:15-21. 
222. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. 
Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 
2005;106:1071-83. 

 
ϭϮϴ
223. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during 
pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194.e1-5. 
224. Bennett IM, Marcus SC, Palmer SC, Coyne JC. Pregnancy-related discontinuation 
of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv 
2010;61:386-91. 
225. Carpenter-Song E, Chu E, Drake RE, Ritsema M, Smith B, Alverson H. Ethno-
cultural variations in the experience and meaning of mental illness and treatment: 
implications for access and utilization. Transcult Psychiatry 2010;47:224-51. 
226. Vargas SM, Cabassa LJ, Nicasio A, et al. Toward a cultural adaptation of 
pharmacotherapy: Latino views of depression and antidepressant therapy. Transcult 
Psychiatry 2015;52:244-73. 
227. Stuart-Parrigon K, Stuart S. Perinatal depression: an update and overview. Curr 
Psychiatry Rep 2014;16:468. 
228. O'Hara MW, Wisner KL. Perinatal mental illness: definition, description and 
aetiology. Best Pract Res Clin Obstet Gynaecol 2014;28:3-12. 
229. Misri S, Eng AB, Abizadeh J, Blackwell E, Spidel A, Oberlander TF. Factors 
impacting decisions to decline or adhere to antidepressant medication in perinatal women 
with mood and anxiety disorders. Depress Anxiety 2013;30:1129-36. 
230. Kelly NR, Bulik CM, Mazzeo SE. Executive functioning and behavioral 
impulsivity of young women who binge eat. Int J Eat Disord 2013;46:127-39. 
231. Gable KN, Dopheide JA. Psychotropic medication use at a private eating disorders 
treatment facility: A retrospective chart review and descriptive data analysis. Curr Ther 
Res Clin Exp 2005;66:572-88. 
232. Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-controlled 
administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. 
Biol Psychiatry 2001;49:644-52. 
233. Weltzin TE, Bulik CM, McConaha CW, Kaye WH. Laxative withdrawal and 
anxiety in bulimia nervosa. Int J Eat Disord 1995;17:141-6. 
234. Dellava JE, Von Holle A, Torgersen L, et al. Dietary supplement use immediately 
before and during pregnancy in Norwegian women with eating disorders. Int J Eat Disord 
2011;44:325-32. 
235. Micali N, Northstone K, Emmett P, Naumann U, Treasure JL. Nutritional intake 
and dietary patterns in pregnancy: a longitudinal study of women with lifetime eating 
disorders. Br J Nutr 2012;108:2093-9. 

 
ϭϮϵ
236. Knoph C, Von Holle A, Zerwas S, et al. Course and predictors of maternal eating 
disorders in the postpartum period. Int J Eat Disord 2013;46:355-68. 
237. Zerwas SC, Von Holle A, Perrin EM, et al. Gestational and Postpartum Weight 
Change Patterns in Mothers with Eating Disorders. Eur Eat Disord Rev 2014. 
238. Wu J, Davis-Ajami ML. Antidepressant treatment persistence in low-income, 
insured pregnant women. J Manag Care Spec Pharm 2014;20:631-7. 
239. Cramer JA, Roy A, Burrell A, et al. Medication Compliance and Persistence: 
Terminology and Definitions. Value Health 2008;11:44-7. 
240. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur 
Neuropsychopharmacol 2003;13 Suppl 3:S69-75. 
241. ten Doesschate MC, Bockting CL, Schene AH. Adherence to continuation and 
maintenance antidepressant use in recurrent depression. J Affect Disord 2009;115:167-70. 
242. Battle CL, Salisbury AL, Schofield CA, Ortiz-Hernandez S. Perinatal 
antidepressant use: understanding women's preferences and concerns. J Psychiatr Pract 
2013;19:443-53. 
243. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. 
Am J Obstet Gynecol 2012;207:157-63. 
244. Dante G, Pedrielli G, Annessi E, Facchinetti F. Herb remedies during pregnancy: a 
systematic review of controlled clinical trials. J Matern Fetal Neonatal Med 2013;26:306-
12. 
245. Serna MC, Cruz I, Real J, Gasco E, Galvan L. Duration and adherence of 
antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 
2010;25:206-13. 
246. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: 
prospective study from general practice. BMJ 1997;315:32-4. 
247. Aslih N, Walfisch A. Clinical Approach to Pregnancy-Related Bleeding. In: 
Sheiner E, ed. Bleeding during pregnancy: Springer New York; 2011:3-21. 
248. Hossain R, Harris T, Lohsoonthorn V, Williams MA. Risk of preterm delivery in 
relation to vaginal bleeding in early pregnancy. Eur J Obstet Gynecol Reprod Biol 
2007;135:158-63. 
249. Yang J, Savitz DA, Dole N, et al. Predictors of vaginal bleeding during the first two 
trimesters of pregnancy. Paediatr Perinat Epidemiol 2005;19:276-83. 
250. Koifman A, Levy A, Zaulan Y, et al. The clinical significance of bleeding during 
the second trimester of pregnancy. Arch Gynecol Obstet 2008;278:47-51. 

 
ϭϯϬ
251. Paidas MJ, Hossain N. Hematologic Changes in Pregnancy. In: Paidas MJ, Hossain 
N, Shamsi TS, Rodger MA, Langhoff-Roos J, Lockwood CJ, eds. Hemostasis and 
Thrombosis in Obstetrics & Gynecology. Oxford, UK: Wiley-Blackwell; 2010:1-11. 
252. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and 
anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000;95:487-90. 
253. WHO. Department of Making Pregnancy SaferDepartment of Making Pregnancy 
Safer. WHO Recommendations for the Prevention of Postpartum Haemorrhage. Geneva, 
Switzerland 2007. 
254. Knight M, Callaghan W, Berg C, et al. Trends in postpartum hemorrhage in high 
resource countries: a review and recommendations from the International Postpartum 
Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 2009;9:55. 
255. Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM, Joseph KS. 
Epidemiological investigation of a temporal increase in atonic postpartum haemorrhage: a 
population-based retrospective cohort study. BJOG 2013;120:853-62. 
256. Hossain N, Langhoff-Roos J, Paidas MJ. Postpartum Hemorrhage. In: Paidas MJ, 
Hossain N, Shamsi TS, Rodger MA, Langhoff-Roos J, Lockwood CJ, eds. Hemostasis and 
Thrombosis in Obstetrics & Gynecology: Wiley-Blackwell; 2010:167-81. 
257. Cordeaux Y, Pasupathy D, Bacon J, Charnock-Jones DS, Smith GC. 
Characterization of serotonin receptors in pregnant human myometrium. J Pharmacol Exp 
Ther 2009;328:682-91. 
258. Payne JL, Meltzer-Brody S. Antidepressant Use During Pregnancy: Current 
Controversies and Treatment Strategies. Clin Obstet Gynecol 2009;52:469-82. 
259. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal 
trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013;209:449.e1-7. 
260. Ekman A, Dickman P, Klint Å, Weiderpass E, Litton J-E. Feasibility of Using 
Web-based Questionnaires in Large Population-based Epidemiological Studies. Eur J 
Epidemiol 2006;21:103-11. 
261. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future 
in epidemiology? Am J Epidemiol 2010;172:1292-8. 
262. Whitehead L. Methodological issues in Internet-mediated research: a randomized 
comparison of internet versus mailed questionnaires. J Med Internet Res 2011;13:e109. 
263. Ritter P, Lorig K, Laurent D, Matthews K. Internet versus mailed questionnaires: a 
randomized comparison. J Med Internet Res 2004;6:e29. 

 
ϭϯϭ
264. Touvier M, Mejean C, Kesse-Guyot E, et al. Comparison between web-based and 
paper versions of a self-administered anthropometric questionnaire. Eur J Epidemiol 
2010;25:287-96. 
265. Kongsved SM, Basnov M, Holm-Christensen K, Hjollund NH. Response rate and 
completeness of questionnaires: a randomized study of Internet versus paper-and-pencil 
versions. J Med Internet Res 2007;9:e25. 
266. O'Higgins A, Murphy OC, Egan A, Mullaney L, Sheehan S, Turner MJ. The use of 
digital media by women using the maternity services in a developed country. Ir Med J 
2014;107:313-5. 
267. Bert F, Gualano MR, Brusaferro S, et al. Pregnancy e-health: a multicenter Italian 
cross-sectional study on Internet use and decision-making among pregnant women. J 
Epidemiol Community Health 2013;67:1013-8. 
268. Kraschnewski JL, Chuang CH, Poole ES, et al. Paging "Dr. Google": does 
technology fill the gap created by the prenatal care visit structure? Qualitative focus group 
study with pregnant women. J Med Internet Res 2014;16:e147. 
269. Internet use in households and by individuals in 2011. Eurostat Statistics in focus. 
2011. (Accessed 13 November, 2012, at 
http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-066/EN/KS-SF-11-066-
EN.PDF) 
270. Internet World Stats. Usage and population statistics. 2012. (Accessed 13 
November, 2012, at http://www.internetworldstats.com/) 
271. Australian Bureau of Statistics. Household Use of Information Technology, 
Australia, 2010-11 (Accessed 13 November, 2012, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-
11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=) 
272. Statistics Canada. Individual Internet use and E-commerce (2010). 2011. (Accessed 
November 13th, 2012, at http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-
eng.htm) 
273. United States Census Bureau. The 2012 Statistical Abstract. Information & 
Communications: Internet Publishing and Broadcasting and Internet Usage. 2010. 
(Accessed 13 November, 2012, at 
http://www.census.gov/compendia/statab/cats/information_communications/internet_publi
shing_and_broadcasting_and_internet_usage.html) 

 
ϭϯϮ
274. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large 
prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol 2009;23:597-608. 
275. Tu Y-K, Greenwood DC. Modern Methods for Epidemiology. Dordrecht: 
Dordrecht: Springer; 2012. 
276. Leece P, Bhandari M, Sprague S, et al. Internet versus mailed questionnaires: a 
randomized comparison (2). J Med Internet Res 2004;6:e30. 
277. Balter KA, Balter O, Fondell E, Lagerros YT. Web-based and mailed 
questionnaires: a comparison of response rates and compliance. Epidemiology 
2005;16:577-9. 
278. Ekman A, Litton J-E. New times, new needs; e-epidemiology. Eur J Epidemiol 
2007;22:285-92. 
279. Bert F, Gualano MR, Brusaferro S, et al. Pregnancy e-health: a multicenter Italian 
cross-sectional study on internet use and decision-making among pregnant women. J 
Epidemiol Community Health 2013. 
280. West R, Gilsenan A, Coste F, et al. The ATTEMPT cohort: a multi-national 
longitudinal study of predictors, patterns and consequences of smoking cessation; 
introduction and evaluation of internet recruitment and data collection methods. Addiction 
2006;101:1352-61. 
281. Fleming CM, Bowden M. Web-based surveys as an alternative to traditional mail 
methods. J Environ Manage 2009;90:284-92. 
282. Smith B, Smith TC, Gray GC, Ryan MA. When epidemiology meets the Internet: 
Web-based surveys in the Millennium Cohort Study. Am J Epidemiol 2007;166:1345-54. 
283. de Jong-van den Berg LT, Waardenburg CM, Haaijer-Ruskamp FM, Dukes MN, 
Wesseling H. Drug use in pregnancy: a comparative appraisal of data collecting methods. 
Eur J Clin Pharmacol 1993;45:9-14. 
284. Simon GE, VonKorff M. Recall of psychiatric history in cross-sectional surveys: 
implications for epidemiologic research. Epidemiol Rev 1995;17:221-7. 
285. Matthey S, Ross-Hamid C. Repeat testing on the Edinburgh Depression Scale and 
the HADS-A in pregnancy: differentiating between transient and enduring distress. J 
Affect Disord 2012;141:213-21. 
286. Lydsdottir LB, Howard LM, Olafsdottir H, Thome M, Tyrfingsson P, Sigurdsson 
JF. The mental health characteristics of pregnant women with depressive symptoms 
identified by the Edinburgh Postnatal Depression Scale. J Clin Psychiatry 2014;75:393-8. 

 
ϭϯϯ
287. Spek V, Nyklicek I, Cuijpers P, Pop V. Internet administration of the Edinburgh 
Depression Scale. J Affect Disord 2008;106:301-5. 
288. Favaro A, Ferrara S, Santonastaso P. The spectrum of eating disorders in young 
women: a prevalence study in a general population sample. Psychosom Med 2003;65:701-
8. 
289. Bulik CM, Sullivan PF, Fear JL, Pickering A, Dawn A, McCullin M. Fertility and 
reproduction in women with anorexia nervosa: a controlled study. J Clin Psychiatry 
1999;60:130-5; quiz 5-7. 
290. Kvalvik LG, Nilsen RM, Skjaerven R, et al. Self-reported smoking status and 
plasma cotinine concentrations among pregnant women in the Norwegian Mother and 
Child Cohort Study. Pediatr Res 2012;72:101-7. 
291. Brantsaeter AL, Haugen M, Hagve TA, et al. Self-reported dietary supplement use 
is confirmed by biological markers in the Norwegian Mother and Child Cohort Study 
(MoBa). Ann Nutr Metab 2007;51:146-54. 
292. Roth C, Bjorke-Monsen AL, Reichborn-Kjennerud T, et al. Use of folic acid 
supplements in early pregnancy in relation to maternal plasma levels in week 18 of 
pregnancy. Mol Nutr Food Res 2013;57:653-60. 
293. Al-Zirqi I, Stray-Pedersen B, Forsen L, Daltveit AK, Vangen S. Validation study of 
uterine rupture registration in the Medical Birth Registry of Norway. Acta Obstet Gynecol 
Scand 2013;92:1086-93. 
294. Engeland A, Bjorge T, Daltveit AK, Vollset SE, Furu K. Validation of disease 
registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet 
Gynecol Scand 2009;88:1083-9. 
295. Greenland S, Robins JM, Pearl J. Confounding and Collapsibility in Causal 
Inference. Statist Sci 1999:29-46. 
296. U.S. Food and Drug Administration. Drugs. Development and Approval Process. 
Development Resurces. Labeling. Pregnancy and Lactation Labeling Final Rule. 2015. 
(Accessed 28 April, 2015, at 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labelin
g/ucm093307.htm) 
297. El-Ibiary SY, Raney EC, Moos MK. The pharmacist's role in promoting 
preconception health. J Am Pharm Assoc (2003) 2014;54:e288-301; quiz e-3. 
298. Samuel N, Einarson A. Medication management during pregnancy: role of the 
pharmacist. Int J Clin Pharm 2011;33:882-5. 

 
ϭϯϰ
299. Broussard CS, Frey MT, Hernandez-Diaz S, et al. Developing a systematic 
approach to safer medication use during pregnancy: summary of a Centers for Disease 
Control and Prevention--convened meeting. Am J Obstet Gynecol 2014;211:208-14.e1. 
300. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric 
disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 
2008;65:805-15. 
301. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs 
during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 
2001;26:44-8. 
302. McDonagh MS, Matthews A, Phillipi C, et al. Depression drug treatment outcomes 
in pregnancy and the postpartum period: a systematic review and meta-analysis. Obstet 
Gynecol 2014;124:526-34. 
303. Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of 
depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 
2004;7:193-200. 
304. Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. Gend Med 
2006;3:169-82. 



I

Medication use in pregnancy:
a cross-sectional, multinational
web-based study
A Lupattelli,1 O Spigset,2,3 M J Twigg,4 K Zagorodnikova,5 A C Mårdby,6
M E Moretti,7 M Drozd,8 A Panchaud,9 K Hämeen-Anttila,10 A Rieutord,11
R Gjergja Juraski,12 M Odalovic,13 D Kennedy,14 G Rudolf,15 H Juch,16
A Passier,17 I Björnsdóttir,1 H Nordeng1,18
To cite: Lupattelli A,
Spigset O, Twigg MJ, et al.
Medication use in pregnancy:
a cross-sectional,
multinational web-based
study. BMJ Open 2014;4:
e004365. doi:10.1136/
bmjopen-2013-004365
▸ Prepublication history and
additional material for this
paper is available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-004365).
Received 30 October 2013
Revised 20 January 2014
Accepted 21 January 2014
For numbered affiliations see
end of article.
Correspondence to
Angela Lupattelli; angela.
lupattelli@farmasi.uio.no
ABSTRACT
Objectives: Intercountry comparability between
studies on medication use in pregnancy is difficult due
to dissimilarities in study design and methodology.
This study aimed to examine patterns and factors
associated with medications use in pregnancy from a
multinational perspective, with emphasis on type of
medication utilised and indication for use.
Design: Cross-sectional, web-based study performed
within the period from 1 October 2011 to 29 February
2012. Uniform collection of drug utilisation data was
performed via an anonymous online questionnaire.
Setting: Multinational study in Europe (Western, Northern
and Eastern), North and South America and Australia.
Participants: Pregnant women and new mothers with
children less than 1 year of age.
Primary and secondary outcome measures:
Prevalence of and factors associated with medication use
for acute/short-term illnesses, chronic/long-term disorders
and over-the-counter (OTC) medication use.
Results: The study population included 9459 women,
of which 81.2% reported use of at least one medication
(prescribed or OTC) during pregnancy. Overall, OTC
medication use occurred in 66.9% of the pregnancies,
whereas 68.4% and 17% of women reported use of at
least one medication for treatment of acute/short-term
illnesses and chronic/long-term disorders, respectively.
The extent of self-reported medicated illnesses and types
of medication used by indication varied across regions,
especially in relation to urinary tract infections, depression
or OTC nasal sprays. Women with higher age or lower
educational level, housewives or women with an unplanned
pregnancy were those most often reporting use of
medication for chronic/long-term disorders. Immigrant
women in Western (adjusted OR (aOR): 0.55, 95% CI 0.34
to 0.87) and Northern Europe (aOR: 0.50, 95% CI 0.31 to
0.83) were less likely to report use of medication for
chronic/long-term disorders during pregnancy than non-
immigrants.
Conclusions: In this study, the majority of women in
Europe, North America, South America and Australia used
at least one medication during pregnancy. There was a
substantial inter-region variability in the types of medication
used.
INTRODUCTION
Ethical reasons preclude inclusion of preg-
nant women in the vast majority of premar-
keting clinical trials.1 As a consequence, most
medications are placed onto the market
without a directly established safety proﬁle in
human pregnancy.2 So far, few medications
have been shown to be major teratogens, yet
the risk of minor teratogenicity or of more
subtle effects on fetal development still have
to be determined for most of them.3 Despite
this, medication use during pregnancy is
common. Mitchell et al4 found that use of
medications, either prescribed or purchased
over the counter (OTC), occurred in 88.8%
of all pregnancies in the USA. In Europe,
prevalence estimates of prescribed medica-
tion use vary considerably across countries,
ranging from 26% in Serbia to 93% in
France.5–10 Such intercountry variability
could, at least in part, be caused by
Strengths and limitations of this study
▪ Uniform data collection of drug utilisation data
across all participating countries allows for inter-
country comparability of the prevalence of medi-
cation use during pregnancy, up to now impeded
by differences in study design and methodology.
▪ The study adds a multinational perspective on
over-the-counter medication use during preg-
nancy to the limited number of studies quantify-
ing the extent of self-medication during
pregnancy.
▪ Lack of validity of the self-reported diagnoses is
a limitation since all disorders and related medi-
cation use were self-reported by the study
participants.
▪ A web-based survey as a study method impedes
calculation of a conventional response rate and
may cause selection bias of the target
population.
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differences in study design, methodology and exposure
ascertainment across studies.11 Uniform collection of
drug utilisation data during pregnancy between coun-
tries may overcome such drawbacks, allowing for inter-
country comparability of prevalence estimates and
shedding light on differences in prenatal care in the
various countries.
Prior studies have addressed research priorities in this
area such as presenting results on an individual drug
level according to the indication of use, quantifying the
extent of OTC and prescribed medication use during
pregnancy, and taking into account intercountry com-
parability.4 Only a few studies have individually examined
maternal factors associated with speciﬁc types of medica-
tion use during pregnancy.11–14
The objectives of the current study were to examine
patterns of medication use in pregnancy from a multi-
national perspective, with special emphasis on type of
medication utilised, including OTC medications and
self-reported indications for use, and to identify mater-
nal background factors potentially associated with medi-
cation use for acute/short-term illnesses, medication use
for chronic/long-term disorders and OTC medication
use during pregnancy.
METHODS
Study design and data collection
This is a multinational, cross-sectional, web-based study.
Pregnant women at any gestational week and mothers with
children less than 1 year of age were eligible to participate.
Member countries of the European Network of Teratology
Information Services (ENTIS), the Organization of
Teratology Information Specialists (OTIS) in North
America, MotherSafe in Australia and European institu-
tions conducting public health research were invited to
take part in the project. Of these, 18 countries participated
(Australia, Austria, Canada, Croatia, Finland, France,
Iceland, Italy, the Netherlands, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, the UK and the
USA). Data originating from some South and Central
American countries were also collected through OTIS.
Owing to the low number of participants on the individual
country level, the region of Central America was excluded
and countries in South America were aggregated into one
region. Data selection to achieve the ﬁnal study sample
was performed as depicted in ﬁgure 1. Participants were
categorised according to the reported country of residency
and grouped into six regions: Western Europe, Northern
Europe, Eastern Europe, North America, South America
and Australia.
Data were collected through an anonymous online
questionnaire administered by Quest Back (http://www.
questback.com) and accessible for a period of 2 months
in each participating country within the period 1
October 2011 to 29 February 2012. The questionnaire
was open to the public via utilisation of banners (invita-
tions to participate in the study) on national websites
and/or social networks commonly visited and consulted
by pregnant women and/or new mothers. The complete
questionnaire is presented in online supplementary
appendix 1. Detailed information about recruitment
tools utilised and Internet penetration rates are sum-
marised in online supplementary appendix 2.
The questionnaire was ﬁrst developed in Norwegian
and English and then translated into the other relevant
languages. A pilot study was carried out in September
2011 (n=47) which elicited no major change to the
questionnaire. Collected data were scrutinised for the
presence of potential duplicates (based on reported
country of residency, sociodemographic characteristics,
date and exact time of questionnaire completion) but
none were identiﬁed.
Exposure variables
Maternal sociodemographics (ie, region of residency,
age, educational level, mother tongue, working status at
time of conception, previous children, marital status and
unplanned pregnancy) and lifestyle characteristics (ie,
smoking status before and during pregnancy and
alcohol consumption after awareness of pregnancy) con-
stituted the exposure variables. To assess external valid-
ity, we compared sociodemographic and lifestyle
characteristics of our study population on an individual
country level with those of the general birthing popula-
tion in the same country. Reports of National Statistics
Bureaus or previous national studies were utilised for
this purpose. The ratio between the number of respon-
dents and the estimated number of live births in the
2-month period was also examined for each country (see
online supplementary appendix 3).
Outcome variables
Use of any medication, medication for acute/short-term
illnesses, medication for chronic/long-term disorders
and OTC medication use during pregnancy constituted
the outcome variables. Participants were ﬁrst confronted
with a list of the most common acute/short-term ill-
nesses (ie, nausea, heartburn, constipation, common
cold, urinary tract infections (UTIs), other infections,
pain in the neck/back/pelvic girdle, headache and
sleeping problems) and the most prevalent chronic/
long-term disorders (ie, asthma, allergy, hypothyroidism,
rheumatic disorders, diabetes, epilepsy, depression,
anxiety, cardiovascular disease and other disorders) and
asked whether they suffered/had suffered from these
conditions during pregnancy. In case of an afﬁrmative
response, women were questioned about medication use
for each individual indication as a free-text entry. Use of
OTC medications was also recorded. Recall was aided
with a list of ﬁve OTC medication categories: painkillers,
nasal spray/drops, antinauseants, antacids and laxatives,
along with examples of brand name products of rele-
vance in each country. It was optional to report timing
of exposure for each of the medication use questions
(the alternatives were gestational weeks 0–12 (1st
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trimester), 13–24 (2nd trimester) and 25 to delivery
(3rd trimester)).
We deﬁned a medicine as a single product containing
one or more active ingredients. We initially identiﬁed
the main active ingredient(s) and formulation of the
reported medicinal products either in the relevant
national medicines database or in the ‘Martindale’ text-
book.15 All recorded medications were coded into the
corresponding Anatomical Therapeutic Chemical (ATC)
codes at the ATC 5th level (ie, the substance level)
whenever possible, otherwise into the 2nd–4th levels as
appropriate, in accordance with the WHO ATC index.16
The OTC status of medications was crosschecked with
the prescription policies within each country. Whenever
a prescription medication was reported under the OTC
question, this record was omitted from the analysis of
OTC use but counted in the estimation of total medica-
tion use (including prescription and OTC). Iron,
mineral supplements, vitamins, herbal remedies and any
type of complementary medicine were recorded separ-
ately and excluded from the estimation of medication
use.
The required sample size calculation for the outcome
variables on region and individual country levels is out-
lined in online supplementary appendix 4. The expected
prevalence estimates were set according to the results of
previous studies.5–10 17 18
Ethics
All participants gave informed consent by answering
‘Yes’ to the question ‘Are you willing to participate in
the study?’. All data were handled and stored
anonymously.
Statistical analysis
Descriptive statistics were utilised as appropriate.
Univariate and multivariate logistic regression analyses
were used to examine the association between maternal
characteristic and three categorical outcome measures
(yes/no): medication use for acute/short-term illnesses;
medication use for chronic/long-term disorders; OTC
medication use. p Values of <0.05 were considered statis-
tically signiﬁcant. Data are presented as adjusted ORs
(aOR) with 95% CI. The analysed explanatory variables
included all maternal sociodemographics and lifestyle
characteristics. After ﬁtting the univariate logistic regres-
sion model for all explanatory variables, the multivariate
model was built and adjusted for all remaining covari-
ates. The Hosmer and Lemeshow19 test was used to
assess goodness of ﬁt of the ﬁnal multivariate model.
Analogue subanalyses on individual region level were
performed. In these instances, region of residency was
not included in the model. All statistical analyses were
performed using the Statistical Package for the Social
Sciences (SPSS) V.20.0 (IBM SPSS Statistics).
RESULTS
Population characteristics
A total of 9615 women accessed the online question-
naire, of which 98.6% completed it. The participant
ﬂowchart to achieve ﬁnal study population (n=9459) is
depicted in ﬁgure 1. A total of 5089 women (53.8%)
Figure 1 The participant flowchart to achieve the final sample analysed.
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were pregnant at the time of completion of the ques-
tionnaire, whereas 4370 women (46.2%) had delivered
their babies within the previous year. Of the former
group, 1095 (21.5%), 1702 (33.4%) and 2291 (45%)
women were in the ﬁrst, second and third trimester of
pregnancy, respectively. Of the latter group, 1320
(30.2%), 947 (21.7%) and 2102 (48.1%) had a baby of
age ≤16 weeks, 17–28 weeks and ≥29 weeks, respectively.
For two women, the time of gestation/baby’s age was
unknown. Overall, the birthing population in each par-
ticipating country was reﬂected quite well by the sample
with respect to age, parity and smoking habits (see
online supplementary appendix 3). However, there was
a difference in terms of educational level; on average,
the women in the study had higher education than the
general birthing population in each country. In add-
ition, participants in Sweden, Austria, Iceland and Italy
were slightly more often primiparous, whereas the
responders in Australia, the USA, the Netherlands,
Slovenia and Croatia were somewhat older than the
general birthing population.
Total medication use
After exclusion of vitamins, mineral supplements and
iron, use of at least one medication either prescribed or
OTC at any time during pregnancy was reported by
7678 of 9459 women (81.2%). Figure 2 depicts preva-
lence estimates of total medication use during
pregnancy by region and country of residence. The
extent of OTC medication use, as well as medication use
for acute/short-term illnesses and chronic/long-term
disorders, is also outlined. The highest prevalence of
total medication use during pregnancy was observed in
the Netherlands (95.1%), Iceland (93%) and Finland
(92.3%). The overall prevalence estimates of medication
use in pregnancy according to timing and drug class
(ATC levels 1 and 2) are presented in online supplemen-
tary appendix 5. Medications for the nervous system
(ATC class N) were most commonly used during preg-
nancy (57.5%), mostly due to paracetamol (acetamino-
phen) and its combinations.
A corollary analysis according to pregnancy status
showed that pregnant women reported in a signiﬁcantly
lower degree than new mothers any medication use
during pregnancy (78.8% vs 84%, p<0.001), as well as
OTC medication use (63% vs 71.5%, p<0.001) and
medication use for acute/short-term illnesses (66.2% vs
70.9%, p<0.001). In contrast, the difference in medica-
tion use for chronic/long-term disorders was not signiﬁ-
cant (17.4% vs 16.5%, p=0.271). None of the rates
differed signiﬁcantly when women in the third trimester
of pregnancy were compared with new mothers.
Medication use according to indication
Headache, heartburn, pain, nausea and UTIs consti-
tuted the leading indications for use of medication
Figure 2 The proportion of respondents (%) reporting use of any medication, over-the-counter (OTC) medication, medication for
acute/short-term illnesses and medication for chronic/long-term disorders during pregnancy, according to region and country of
residency. The observed estimates do not include vitamins, mineral supplements, iron and herbal or complementary medicine
products.
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during pregnancy among the acute/short-term illnesses
analysed. Hypothyroidism, asthma, allergy and depres-
sion were the leading indications for chronic/long-term
medication use. Observed prevalence rates of these dis-
orders, overall and by region of residency, are presented
in online supplementary appendices 6 and 7, respect-
ively, along with rates of total and speciﬁc medication
use. Table 1 outlines prevalence estimates of OTC medi-
cation use during pregnancy by region and indication
for use. Only the most common medication groups
reported are presented. Inter-region variations in rates
and types of medication used during pregnancy were
observed for acute/short-term illnesses (eg, nausea and
UTIs), chronic/long-term disorders (eg, asthma and
depression) and OTC medications (eg, nasal spray).
Factors associated with medication use
Factors associated with medication use during pregnancy
according to type of medication utilised are presented
in table 2. Use of chronic/long-term medications during
pregnancy was reported in a signiﬁcantly larger extent
by women in Northern Europe (aOR: 1.68, 95% CI 1.46
to 1.94), North America (aOR: 1.80, 95% CI 1.42 to
2.28) and Australia (aOR: 2.76, 95% CI 2.03 to 3.76)
compared with women in Western Europe. Older
women or housewives, those with low education or with
an unplanned pregnancy, were the ones most often
reporting use of chronic/long-term medication.
Subanalysis on individual region level revealed that
women not having the ofﬁcial language of the country
of residency as mother tongue were less likely to report
chronic/long-term medication use in Western (aOR:
0.55, 95% CI 0.34 to 0.87) and Northern Europe (aOR:
0.50, 95% CI 0.31 to 0.83), but not in the other regions.
DISCUSSION
This is the ﬁrst web-based study examining patterns and
factors associated with medication use during pregnancy
on a multinational level. In all regions, approximately 8
of 10 women reported use of at least one medication,
either prescribed or OTC, during the course of their
pregnancy. This ﬁnding is in line with previous research
conducted in Europe, North America, South America
and Australia,4 20–25 though our estimates were some-
what higher in some of the Eastern European countries,
for example, Serbia, than those observed in a previous
study.5 Different recruitment strategies, that is, web
based in our study versus maternity care unit/commu-
nity pharmacy based in the previous study could explain
such discrepancy.
Overall, analgesics, antacids, nasal decongestants/anti-
allergics and systemic antibiotics were the medication
groups dominating the drug utilisation scenario, as also
shown by previous research.4 20–22 However, our study
also provides insights into the proportion of medicated
women among those suffering from a speciﬁc illness
during pregnancy across the six regions. We found that
approximately 7 of 10 women who reported UTIs were
treated with antibiotics during pregnancy. This related
to all regions, except Eastern Europe where it was only 4
of 10 women. Since women may perceive dysuria
without ascertainment of bacteriuria in the urine as
UTI, an over-reporting of the illness could have
occurred. Yet, a suboptimal treatment of UTIs during
pregnancy in Eastern Europe cannot be ruled out. The
intercountry variability in the types of antibiotics used
for UTIs could simply be explained by differences in
prescribing practice,26 presence of screening for bacteri-
uria in early pregnancy or speciﬁc antibiotic resistance
patterns.
Even though nausea was the condition affecting most
women in all six regions, the corresponding proportions
of medicated nausea were generally low. This scenario is
probably due to two main factors: (1) the predominantly
mild character of nausea and the possibility of non-
pharmacological management (eg, dietary advices) and
(2) the reluctance of general practitioners to prescribe
antinauseants even though safety proﬁle assessments are
in place.27 28 As also shown in previous studies,4 29 use of
serotonin antagonists during pregnancy in North America
and Australia is increasing compared with the other
regions, eliciting the need of sound studies assessing the
safety proﬁle of this drug group in pregnancy.
In most regions, the self-reported prevalence of hypo-
thyroidism was somewhat higher than the reported
hormone substitution rate. Owing to its known associ-
ation with adverse pregnancy outcomes,30 the unex-
pected ﬁnding of potential suboptimal treatment of
hypothyroidism during pregnancy deserves attention. It
could probably be due to lack of information about
hypothyroidism typology and its diagnostic ascertain-
ment in our study.
In our study, depression was self-reported and not
based on any psychometric assessment, thus the
observed substantial inter-regional variability in the
extent of this disorder and related medication use could
have certainly been affected by women’s attitudes in
reporting. Our estimate of medication use for depres-
sion in Australia was higher than that observed in a
recent study (10.6% vs 2.1%).31 However, the similarity
in self-reported depression itself (11.5% vs 15.6%) sug-
gests that our population might mostly comprise women
who did not discontinue their pharmacological therapy
once they became pregnant. Our estimates for North
America and Western Europe were in line with recent lit-
erature showing an increase in antidepressant use in
pregnancy during the past years.4 32 Selective serotonin
reuptake inhibitors (SSRIs) were the most widely used
antidepressant class. Recent meta-analyses have shown
that antidepressants, including SSRIs, do increase the
risk of poor neonatal adaptation syndrome, speciﬁc car-
diovascular malformations and persistent pulmonary
hypertension of the newborn.33–35 However, the clinical
impact of the latter two outcomes, in absolute terms, is
small and the risk of pharmacotherapy should always be
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weighted versus the risk of undertreated depression in
pregnancy.
In most regions, approximately 60–70% of women
reported use of at least one OTC medication during the
course of their pregnancies, mostly for pain conditions,
heartburn and upper airways disorders, indicating a sub-
stantially high rate of self-medication during pregnancy.
This estimate aligns with previous research carried out
in North America.17 Of note, self-medication with OTC
sympathomimetic nasal decongestants was more exten-
sive in Northern and Eastern Europe than in the
remaining regions; this could be explained by the time
of the year when the data collection was performed.
Region of residency was an important factor associated
with medication use during pregnancy. As also shown by
Cleary et al,36 we found that rates of medication use
among women originally from Eastern Europe and
South America were signiﬁcantly lower than those
observed in Western Europe, North America and
Australia. Such geographical differences could be due to
culture, variations in prenatal care assistance or access to
medications in the various regions and the related costs.
Women working as healthcare providers, consuming
alcohol during pregnancy or those already having chil-
dren were more likely to use short-term and OTC medi-
cations, possibly reﬂecting higher conﬁdence in
self-treatment and use of medications in general in the
former instance, and less anxiety for the pregnancy
outcome in the latter two instances.
Contrary to previous studies indicating an association
between higher maternal education and more prevalent
use of medication during pregnancy,14 17 23 we found
that lower education was associated with a higher use of
OTC medications as well as medication for chronic/
long-term disorders (30–50% increased risk). Results of
similar magnitude (30% increased risk) were also
observed by Olesen et al,37 whereas Stokholm et al38
identiﬁed a stronger association (2.3-fold increased risk)
between low maternal education and use of antibiotic
for respiratory tract infections during pregnancy. One
factor negatively associated with chronic/long-term
medication use was not having the ofﬁcial language of
the country of residency as mother tongue. This ten-
dency was detected in Western and Northern Europe,
raising concerns about the potential health risks for
immigrant women in these two regions. As shown by
Hämeen-Anttila et al,39 57% of pregnant women have
perceived information needs about medications during
pregnancy. Thus, identiﬁcation of potential users or
non-users of medication during pregnancy might be of
clinical relevance. Indeed, this may allow tailored
evidence-based information about medication safety or
outcome of suboptimal medication of severe medical
conditions in pregnancy.
Strengths and limitations
The main strength is that data collection was performed
uniformly across all participating countries, allowing for
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intercountry comparison of the prevalence of medica-
tion use during pregnancy. By quantifying the extent of
self-medication with OTC drugs and medication use
according to self-reported indication, it was possible to
determine the leading causes for medication use among
pregnant women. Categorisation of maternal character-
istics positively associated with the various types of medi-
cations used during pregnancy enabled us to identify
which groups of women are more likely to need infor-
mation about medication use during pregnancy. The
utilisation of an anonymous web-based questionnaire
enabled us to reach a large proportion of the birthing
population in several countries worldwide. However, we
cannot exclude the possibility that the women who
decided to participate in the study differed from the
general birthing population in other ways that our ana-
lysis could not control for. In most of the participating
countries, the study sample was large enough to warrant
calculation of prevalence estimates with a precision of
5%. However, less precise estimates were permitted by
the study sample in Austria, Iceland and the
Netherlands (precision of 9–11%), as well as in
Australia, Canada, Croatia, Serbia, Slovenia and the USA
(precision of 6–7%).
One main limitation of the study is the lack of validity
of the self-reported diagnoses. All disorders were self-
reported by the participants, and hence dependent on
the women’s perception of the medical condition.
Similarly, information about medication use during
pregnancy was dependent on the accuracy of the
women’s reporting and recall. For new mothers, data
were registered retrospectively; hence a risk of recall bias
cannot be ruled out. In speciﬁc countries (Australia,
Canada, France, Russia, the Netherlands and the USA),
the study sample was a small proportion of the general
birthing population; hence the generalisability of our
ﬁndings for these speciﬁc countries should be inter-
preted with caution.
The questionnaire was only available through Internet
websites; by using this kind of approach, a conventional
response rate cannot be calculated and a selection bias
of the target population cannot be ruled out. However,
recent epidemiological studies indicate reasonable valid-
ity of web-based recruitment methods.40 41 Also, the
penetration rate of the Internet either in households or
at work is relatively high among women in childbearing
age.42–46 Hence, the degree to which our ﬁndings can
be extrapolated to the target population is based on the
representativeness of the respondents to the general
birthing populations in each country. The sample in
each country had a somewhat higher educational level
than the general birthing populations. Such a limitation
might have led to an underestimation of the prevalence
of medication during pregnancy. Since many ailments
requiring pharmacotherapy occur in mid or late preg-
nancy, inclusion of women in the ﬁrst trimester of preg-
nancy in the total data material has somewhat inﬂated
the prevalence of non-users of medications during
pregnancy. Also, women with speciﬁc disorders or in
need of information about medication use during preg-
nancy might have been more likely to consult Internet
websites, and therefore participate in this study.
CONCLUSIONS
Use of medications for acute/short-term illnesses and
chronic/long-term disorders, as well as use of OTC med-
ications, was common during pregnancy. The extent of
medicated illnesses and types of medications used for
the different indications varied across the six regions.
This was especially relevant not only for acute/short-
term illnesses such as nausea and UTIs, but also for
chronic/long-term disorders such as hypothyroidism or
depression. Women with higher age or lower educa-
tional level, housewives or women with an unplanned
pregnancy were those most often reporting chronic/
long-term medication use, as opposed to immigrants res-
iding in Western and Northern Europe who reported
the least use of this medication category. Future research
should deﬁnitely focus on this speciﬁc group of women
and also address more insights into the outcome of sub-
optimal medication for severe conditions in pregnancy.
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Appendix 1: Survey questionnaire 
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Internet questionnaire 

Medication use in pregnancy with focus on attitudes, 
perception of risk and mental health 
 
The Multinational Medication Use in Pregnancy Study 
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INFORMATION ABOUT YOURSELF 
 
1. In which country do you live?                       In which region/provincedo you live?  
 
Country:________________                           Region: ________________ 
2. Are you pregnant right now?  
      Ƒ<HV                                                          Ƒ1R 
(If yes in Q2) In which pregnancy week are 
you?  
From 1 to 44       
 
 
 
(If yes in Q2) Is it a multiple pregnancy? 
            Ƒ1R 
            Ƒ<HV (e.g. twins, triplets, etc)  
(If No in Q2) How old is your newborn 
child (in weeks)?  
0-4 / 5-8 / 9-12 / 13-16 / 17-20 /               
21-24 / 25-28 / > 29 
 
 
(If No in Q2) Do you breast feed your 
child?  
ƑYes                                
ƑNo 
3. How many children do you already have from before? 
Ƒ None 
Ƒ2QH 
Ƒ7ZR 
Ƒ0RUHWKDQWZR 
4. What is your marital status?  
Ƒ Married                            
Ƒ&RKDELWDQW 
ƑSingle 
Ƒ'LYRUFHG6HSDUDWHG 
Ƒ2WKHU 
5. What is the highest education you have completed?  
Ƒ3ULPDU\VFKRRO(8-9 years of education) 
Ƒ+LJK-school (11-13 years of education) 
Ƒ8QLYHUVLW\ 
Ƒ2WKHUHGXFDWLRQ 
6. What was your work situation when you became pregnant? 
Ƒ6WXGHQW 
Ƒ+RXVHZLIH 
Ƒ Health care personnel, i.e., physician, nurse, or pharmacist 
Ƒ(PSOR\HGLQDQRWKHUVHFWRU 
Ƒ Job seeker 
Ƒ1RQHRIWKHDERYH 
7. Is English your mother tongue? 
Ƒ<HV 
Ƒ1R 
 
      (If No in Q7 above) What is your mother tongue? ____________________ 
8. Your age: Years, from 15 to 55 
 


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INFORMATION ABOUT YOUR PREGNANCY  
 
9. (If pregnant) Are you attending any pregnancy/birth preparation course or similar? 
Ƒ<HV 
Ƒ1REXW,DPSODQQLQJWRDWWHQG 
Ƒ1R,DPQRWJRLQJWRDWWHQGLW 
10. (If pregnant) What are your thoughts about how the experience of giving birth is going 
to be? 
 
Please indicate your thoughts in a scale from 1 to 6, where 1 corresponds to absolutely terrible 
and 6 to absolutely fantastic 
Absolutely terrible 
 
1 
Ƒ 
2 
Ƒ 
3 
Ƒ 
4 
Ƒ 
5 
Ƒ 
6 
Ƒ 
Absolutely fantastic
 
 
11. Was your pregnancy planned? 
Ƒ<HV 
Ƒ1REXWLWZDVQRWFRPSOHWHO\XQH[SHFWHG 
Ƒ1Rit was not planned 
12. Did you contact any healthcare provider due to infertility? 
ƑYes 
ƑNo 
 
(If Yes in Q12 above)  Did you, in this pregnancy, become pregnant secondarily to 
infertility treatment? 
Ƒ<HV 
Ƒ1R 
13. Have you taken folic acid? (alone or as part of multivitamins) 
Ƒ<HVEHIRUHpregnancy 
ƑYes, before and during pregnancy 
ƑYes, only during pregnancy  
ƑNo 
Ƒ cannot remember 
14. Did you smoke cigarettes before becoming pregnant? 
Ƒ<HVUHJXODUO\ 
Ƒ<HVRFFDVLRQDOO\ 
Ƒ1RQHYHU                                                                        
 
            (If yes in Q14 as regularly/occasionally) Do you/did you smoke during pregnancy?       
Ƒ<HVPRUHWKDQEHIRUH 
Ƒ<HVDSSUR[LPDWHO\WKHVDPH 
Ƒ<HVEXWless 
Ƒ1R 
 
           (If yes) How many cigarettes (on average) do you/did you smoke per day?  
Ƒ < 1  
Ƒ1-5 
Ƒ-10 
Ƒ! 
15. Did you drink any alcohol after finding out that you were pregnant? 
            Ƒ<HV 
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            Ƒ1R 
            Ƒ&DQQRWUHPHPEHU 
 
(If yes) How much did you drink (in units)? 
1 alcohol unit is equivalent to: 
one 25ml single measure of whisky (ABV 40%),  
or a third of a pint of beer (ABV 5-6%)  
or half a standard (175ml) glass of red wine (ABV 12%). 
            Ƒ0RUHWKDQ-2 units per week 
            Ƒ-2  units per week 
            Ƒ-4 units per month 
            Ƒ-2 units during the pregnancy 
            Ƒ&DQQRWUHPHPEHU 

  
Supplemental material - Paper I 


    
 
HEALTH DISORDERS AND MEDICATIONS DURING PREGNANCY 
 
16. Have you experienced any of the disorders listed below during this pregnancy? 
If you use or have used any medicines in relation to [each health disorder listed] 
please enter the names of the medicines.  
In which weeks of pregnancy have you used them? 
Health disorder Medicine  Period of use 
(pregnancy weeks) 
Nausea Ƒ<HV
Ƒ1R
(If Nausea ticked) If you use or 
have used any medicines in relation 
to nausea, please enter the names of 
the medicines 
ƑZHHN-12  
ƑZHHN-24 
ƑZHHN- delivery 
Heartburn or 
reflux problems 
Ƒ<HV
Ƒ1R
(If Heartburn ticked) If you use or 
have used any medicines in relation 
to heartburn or reflux problem, 
please enter the names of the 
medicines 
ƑZHHN-12 
Ƒweek 13-24 
ƑZHHN- delivery 
Constipation Ƒ<HV
Ƒ1R
(If Constipation ticked) If you use 
or have used any medicines in 
relation to constipation, please enter 
the names of the medicines 
ƑZHHN-12 
Ƒweek 13-24 
ƑZHHN- delivery 
Common cold Ƒ<HV
Ƒ1R
(If common cold ticked If you use 
or have used any medicines in 
relation to common cold, please 
enter the names of the medicines 
ƑZHHN-12 
ƑZHHN 13-24 
ƑZHHN- delivery 
Urinary tract 
infections 
 
Ƒ<HV
Ƒ1R
(If UTI ticked) If you use or have 
used any medicines in relation to 
urinary tract infections, please enter 
the names of the medicines 
Ƒweek 0-12 
ƑZHHN-24 
ƑZHHN- delivery 
Other infections Ƒ<HV
Ƒ1R
(If other infections ticked) If you 
use or have used any medicines in 
relation to other infections, please 
enter the names of the medicines 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Pain in neck or 
back or pelvic 
girdle 
Ƒ<HV
Ƒ1R
(If pain ticked) If you use or have 
used any medicines in relation to 
pain in neck or back or pelvic 
girdle, please enter the names of the 
medicines 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Headache Ƒ<HV
Ƒ1R
(If headache ticked) If you use or 
have used any medicines in relation 
to headache, please enter the names 
of the medicines 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Sleeping 
problems 
Ƒ<HV
Ƒ1R
(If sleeping problems ticked) If you 
use or have used any medicines in 
relation to sleeping problems, 
please enter the names of the 
medicines 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
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17. Have you been on sick leave during this pregnancy?                                       
Ƒ<HV Ƒ1R 
18.  (If yes in Q17) What was the reason for it? In which pregnancy weeks have you been 
on sick leave? 
Reason of the sick leave Sick leave period 
(pregnancy week) 
_________________________________________________________ 
_________________________________________________________ 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN-delivery 
 
19. Below, some common over-the-counter (OTC) medicines are mentioned.  
Please indicate whether you have used any of them during pregnancy.  
 
Please enter the name of all X medicines you have used.  
In which pregnancy weeks have you used them? 
 Name of the medicine(s) you have used Period of use 
(pregnancy week) 
Pain killers 
(e.g. paracetamol) 
Ƒ<HV 
Ƒ1R 
(If painkillers ticked) 
Please enter the name of all pain killers 
you have used during pregnancy. 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Nasal spray/drops 
(excluding salt 
water solution) 
(e.g. Otrivine, 
Vicks Sinex 
decongestant 
Nasal spray) 
Ƒ<HV 
Ƒ1R 
(If nasal spray ticked) 
Please enter the name of all nasal 
sprays/drops you have used during 
pregnancy. 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Medication against 
heartburn  
(e.g. Gaviscon or 
Rennie)  
Ƒ<HV 
Ƒ1R 
(If OTC for heartburn ticked) 
Please enter the name of all medications 
you have used against heartburn during 
pregnancy. 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Medication against 
nausea/travel 
sickness (e.g. 
Cetirizine, Sea-
Legs) 
Ƒ<HV 
Ƒ1R 
(If OTC for nausea ticked) 
Please enter the name of all medications 
you have used against nausea during 
pregnancy. 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 
Medication against 
constipation 
(e.g.Lactulose, 
Dulcolax) 
Ƒ<HV 
Ƒ1R 
(If OTC for constipation ticked) 
Please enter the name of all medications 
you have used against constipation during 
pregnancy. 
ƑZHHN-12 
ƑZHHN-24 
ƑZHHN- delivery 

 
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
20. Did you take any herbal preparations during pregnancy (e.g. ginger, echinacea, valerian, 
cranberries)?   
Ƒ<HVƑ1RƑCannot remember             
   
(If yes) Please provide the name of all herbal preparations you have taken during pregnancy. 
(If yes) What was the reason for taking herbal preparations (health disorder, illness)? 
(If yes) In which pregnancy weeks did you take herbal preparations? 
Name of herbal 
preparation used  
Reason for use (health disorder, 
illness) 
Period of use 
(pregnancy week 
______________________
______________________
______________________ 
_________________________________
_________________________________
_________________________________ 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN- delivery 
______________________
______________________
______________________ 
_________________________________
_________________________________
_________________________________ 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN- delivery 
21. (If you used herbal preparations during pregnancy) Who recommended to you to take 
herbal preparations during pregnancy? (You may tick more than one answer) 
Ƒ0\RZQLQLWLDWLYH  
Ƒ)DPLO\IULHQGV 
Ƒ3K\VLFLDQ 
Ƒ0LGZLIH/Nurse                                                 
Ƒ3KDUPDF\personnel                  
ƑHerbal shop personnel 
Ƒ,QWHUQHW 
Ƒ Magazines, media, etc. 
Ƒ2WKHU(please specify:____________ )                     
22. Did you use homeopathic products during pregnancy? 
Ƒ<HVƑ1RƑCannot remember  
 
(If yes in Q22 above) What was the reason for use?  
_________________________________________________________________________      
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A BIT MORE ABOUT MEDICATION USE DURING PREGNANCY 
 
23. Have you deliberately avoided taking an over-the-counter medicine during your 
pregnancy?  
Ƒ<HVƑ1RƑCannot remember  
 
      (If yes in Q23 above) Which medicine was it? 
__________________________________________________                                
 
      (If yes in Q23 above) What was the reason for doing so? 
_____________________________________ 
___________________________________________________________________________ 
 
24. Have you deliberately chosen not to use a medicine prescribed by a doctor because you 
were pregnant? 
Ƒ<HVƑ1R                        Ƒ&DQQRWUHPHPEHU 
 
      (If yes in Q24 above) Which medicine was it? 
__________________________________________________ 
      (If yes in Q24 above) What was the reason for doing so? 
_____________________________________ 
___________________________________________________________________________ 
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YOUR NEEDS FOR INFORMATION 

25. Did you need information about medicines during the course of your pregnancy? 
             Ƒ<HV                                      Ƒ1R
                                
Ƒ&DQQRW remember
                     
 
26. (If yes in Q25) Whom did you turn to for information? (You may tick more than one 
answer) 
           Ƒ)DPLO\IULHQGV 
           Ƒ3K\VLFLDQ 
           Ƒ0LGZLIH/Nurse                         
           Ƒ3KDUPDF\personnel 
           ƑHerbal shop personnel 
            Ƒ'UXJIRUPXODU\LQIRUPDWLRQOHDIOHW 
           Ƒ3RLVRQLQIRUPDWLRQFHQWUH 
           Ƒ7HUDWRORJ\ information service 
           Ƒ1DWLRQDOFHQWHURILQIRUPDWLRQRQPHGLFLQHV 
           ƑInternet 
           Ƒ0agazines, media, etc              
           Ƒ2WKHUplease specify:_______)                      
 
27. (if yes in Q25) If you have obtained information from various sources, was such 
information similar? 
Ƒ<HVFRPSOHWHO\VLPLODU 
Ƒ<HVDVDZKROHRQO\WKHZRUGLQJRUGHWDLOOHYHOZDVVRPHZKDWGLIIHUHQW 
Ƒ1RSDUWRIWKHLQIRUPDWLRQZDVGLIIHUHQW 
Ƒ1RWKHLQIRUPDWLRQZDVFRPSOHWHO\contradictory   
28. (If No ± last 2 options in Q27) If there were discrepancies among the sources, what did it 
mean to you? (You may tick more than one answer) 
Ƒ1RWKLQJ 
Ƒ,EHFDPHDQ[LRXV 
Ƒ,GHFLGHGQRWWRXVHWKHPHGLFDWLRQ 
Ƒ,sought for a new information source (Which new source have you consulted? 
_______________________) 
Ƒ,FKRVHWRUHO\RQRQHVRXUFHDQGLJQRUHWKHFRQIOLFWLQJRQH (On which source have you 
relied?  _______________________Which source have you ignored? ______________) 
29. How often do you have someone help you read hospital materials? 
Ƒ$OZD\V 
Ƒ2IWHQ 
Ƒ6RPHWLPHV 
Ƒ2FFDVLRQDOO\ 
Ƒ1HYHU 
30. How confident are you filling out medical forms by yourself?  
Ƒ Extremely 
Ƒ4XLWHDELW 
Ƒ6RPHZKDW 
Ƒ$OLWWOHELW 
Ƒ1RWDWDOO 
31. How often do you have problems learning about your medical condition because of 
difficulty understanding written information? 
Ƒ$OZD\V 
Ƒ2IWHQ 
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Ƒ6RPHWLPHV 
Ƒ2FFDVLRQDOO\ 
Ƒ1HYHU 

  
Supplemental material - Paper I 


    
 
The following section will pop-up only if the subject has reported to be suffering from a chronic disease

I. MEDICATIONS FOR CHRONIC DISEASES DURING 
PREGNANCY 
 
If you use or have used medicines for a chronic disease during your pregnancy fill 
out this part of the questionnaire (I, II, III) and provide some information about 
those medicines you use daily.   
 
Some chronic diseases are asthma, allergy, hypothyroidism (low thyroid hormone), 
rheumatic diseases (incl. rheumatoid arthritis, psoriatic arthritis), diabetes (type I or II), 
epilepsy, depression, anxiety, cardiovascular diseases (incl. hypertension, high 
cholesterol, and heart diseases) 
 
Do you suffer of any chronic disease?              ƑYes               ƑNo 
 
(If Yes above) Please indicate whether you suffer of any of the following chronic 
diseases.  
 If you use or have used 
medicines for X during 
your pregnancy, please 
enter the name of the 
medicines. 
In which weeks of 
pregnancy did you use 
them? 
Asthma Ƒ<HV 
ƑNo 
(If Asthma ticked) If you use or 
have used medicines for asthma 
during pregnancy, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Allergy Ƒ<HV 
Ƒ1R 
(If Allergy ticked) If you use or 
have used medicines for allergy 
during pregnancy, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Hypothyroidism (low 
thyroid hormone) 
Ƒ<HV 
Ƒ1R 
(If Hypothyroidism ticked) If you 
use or have used medicines for 
hypothyroidism during 
pregnancy, please enter the names 
of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Rheumatic disorders 
(incl. rheumatoid 
arthritis, psoriatic 
arthritis) 
Ƒ<HV 
Ƒ1R 
(If Rheumatic disorders ticked) If 
you use or have used medicines 
for rheumatic disorder during 
pregnancy, please enter the names 
of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Diabetes (type I or II) Ƒ<HV 
Ƒ1R 
(If Diabetes ticked) If you use or 
have used medicines for diabetes 
during pregnancy, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Epilepsy Ƒ<HV 
Ƒ1R 
(If Epilepsy ticked) If you use or 
have used medicines for epilepsy 
during pregnancy, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Depression Ƒ<HV 
Ƒ1R 
(If Depression ticked) If you use 
or have used medicines for 
depression, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
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 If you use or have used 
medicines for X during 
your pregnancy, please 
enter the name of the 
medicines. 
In which weeks of 
pregnancy did you use 
them? 
Anxiety ƑYes 
Ƒ1R 
(If Anxiety ticked) If you use or 
have used medicines for anxiety 
during pregnancy, please enter the 
names of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Cardiovascular 
diseases (incl.  
hypertension, high 
cholesterol, heart 
diseases) 
Ƒ<HV 
Ƒ1R 
(If Cardio disease ticked) If you 
use or have used medicines for 
cardiovascular diseases during 
pregnancy, please enter the names 
of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 
Others  
(If Others ticked) 
(Please specify which 
other disease(s): 
___________) 
 
Ƒ<HV 
Ƒ1R 
(If Other disease ticked) If you 
use or have used medicines for 
your chronic disease during 
pregnancy, please enter the names 
of the medicines. 
Ƒ week 0-12 
ƑZHHN-24 
ƑZHHN-delivery 






 
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Section II will pop-up only if the subject has reported to be suffering of a chronic disease 
 

II. YOUR VIEWS ABOUT PRESCRIBED MEDICINES 
 
In this section of the survey questionnaire, the Belief About Prescribed Medicine 
Questionnaire (BMQ-Specific) was presented (Horne R, Weinman J, Hankins M. The 
beliefs about medicines questionnaire: The development and evaluation of a new method for 
assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24). 








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Section III will pop-up only if the subject has reported to be suffering of a chronic disease.  
There will be one single scale for each chronic condition reported 
 

III. QUESTION ABOUT YOUR USE OF MEDICATIONS FOR X 
DURING PREGNANCY AND/OR POSTPARTUM 

 
In this section of the survey questionnaire, the 8-item Morisky Medication Adherence 
Questionnaire (MMAS-8) was presented (Morisky DE, Green LW, Levine DM. Concurrent 
and predictive validity of a self-reported measure of medication adherence. Medical care. 
1986;24(1):67-74; Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a 
medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 
2008;10:348-54) 








 
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
Do you have any other comments about your medication use during pregnancy? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 






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YOUR VIEWS ABOUT MEDICATIONS  
 
 
In this section of the survey questionnaire, the Belief About Medicine Questionnaire 
(BMQ-General) was presented (Horne R, Weinman J, Hankins M. The beliefs about 
medicines questionnaire: The development and evaluation of a new method for assessing the 
cognitive representation of medication. Psychol Health. 1999;14(1):1-24). 
 
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
32. Below are some statements about use of medicines in pregnancy.  
Please specify how much you agree or disagree with these statements by ticking where 
appropriate. (You may only tick once per line) 
 Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
I have a higher threshold for using 
medicines when I am pregnant than 
ZKHQ,¶PQRWSUHJQDQW 
ƕ ƕ ƕ ƕ ƕ 
Even though I am ill and could have 
taken medicines, it is better for the 
foetus that I refrain from using them   
ƕ ƕ ƕ ƕ ƕ 
Pregnant women should preferably 
use herbal remedies than 
conventional medicines 
ƕ ƕ ƕ ƕ ƕ 

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YOUR ASSESSMENT OF PREGNANCY RISKS 
 
33. Among 100 healthy women in a healthy environment, how many do you think will give 
birth to a child with a birth defect? 
_________________________________________________ 
 
34. Here below is a list with various medicines, food and other substances.  
Please indicate how harmful you think they are for the foetus in a scale from 0 to 10, where 0 
FRUUHVSRQGVWRµQRWKDUPIXO¶DQGWRµYHU\KDUPIXO¶.  
 
If you have not heard before about such substance, tick µuQNQRZQVXEVWDQFH¶. 
 
Unknown 
substance 0 1 2 3 4 5 6 7 8 9 10 
Paracetamol/acetaminophen ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Antibiotics (e.g. Penicillins) ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Antidepressants ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Thalidomide    ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Swine influenza vaccine ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
OTC medicines against 
nausea/travel sickness ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Ginger ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Cranberries ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Blue veined cheese                 
(e.g. Gorgonzola)  ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Eggs  ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Alcohol during the 1. 
trimester  
(e.g. wine, beer, spirits)      
ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Smoking 
(e.g. cigarettes) ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 
Dental X-ray  ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ ƕ 

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HOW YOU ARE FEELING NOW 
 
In this section of the survey questionnaire, the Edinburgh Postnatal Depression Scale 
(EPDS) was presented (Cox J, Holden J, Sagovsky R. Detection of postnatal depression. 
Development of the 10-item edinburgh postnatal depression scale. The British Journal of 
Psychiatry. 1987 June 1, 1987;150(6):782-6). 





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HOW YOU SEE YOURSELF 
 
In this section of the survey questionnaire, the Big Five Inventory (BFI) was presented (John 
OP, Srivastava S, editors. The big five trait taxonomy: History, measurement, and theoretical 
perspectives: New York: Guilford; 1999; John OP, Robins RW, Pervin LA. Handbook of 
personality: Theory and research: The Guilford Press; 2008). 
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Appendix 2: Websites used for recruitment and internet penetration rates in each country where data 
were collected 
Country Website used for recruitment Internet 
penetration 
rates (%) 
EUROPE 
Western Europe 
Austria  www.schwangerschaft.at; www.schwangerschafts-
blog.at; www.fratz.at; www.netdoctor.at; 
www.babycenter.at; www.baby-boom.at; www.ekiz-
dachverband.at; www.babyguide.at 
93* [1] 
 
France www.aufeminin.com (Including ipad application to 
website subscribers) 
91* [1] 
Italy Pregnancy Forums: www.gravidanzaonline.it; 
www.forumsalute.it; www.mammole.it; 
www.pianetamamma.it; www.miobambino.it 
 
Targeted email to pregnancy forum subscribers: 
www.gravidanzaonline.it 
70* [1] 
Switzerland www.bebe-bebe.com; www.swissmom.ch 84* [2] 
The Netherlands www.lareb.nl; www.gezondzwangerzijn.nl; 
www.babybytes.nl 
98* [1] 
United Kingdom Targeted email to pregnancy forum subscribers: 
www.bounty.com  
 
Pregnancy Forums: www.pregnancyforum.co.uk; 
www.pregnancyforum.org.uk 
93* [1] 
Northern Europe 
Finland www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi 99* [1] 
Iceland Pregnancy Forums: www.bland.is 100* [1] 
Norway www.barnimagen.com; www.klikk.no; 
www.jormorsiri.no; www.tryggmamamedisin.no 
99* [1] 
Sweden www.barntotal.se; www.minbebis.com; 
www.se.babycenter.com; www.socmed.gu.se 
99* [1] 
Eastern Europe 
Croatia www.cybermed.hr 80* [1] (data 
from 2010)  
Poland www.zzief.umlub.pl 
 
Pregnancy Forums: www.ebrzuszek.pl; 
www.babyboom.pl; www.zapytajpolozna.pl; 
www.planujemydziecko.pl; www.twoja-ciaza.com.pl 
84* [1] 
Russia www.babyblog.ru; www.littleone.ru 48* [2] 
Supplemental material ± Paper I 
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Country Website used for recruitment Internet 
penetration 
rates (%) 
 
Pregnancy Forums: www.woman.ru; www.9months.ru; 
www.bemam; www.280dney.ru; www.iampregnant.ru 
www.pregnancy.org.ua; www.baby.ru; 
www.mama66.ru; www.spuzom.ru 
Serbia www.ringeraja.rs 52* [1] (data 
from 2009) 
Slovenia Pregnancy Forums: www.med.over.net 92* [1] 
AMERICAS 
North America 
Canada www.otispregnancy.org; Facebook page of OTIS; 
www.babyontheway.com.ca 
 
Pregnancy Forums: www.babycentre.com.ca; 
www.thecradle.com; www.talk.sheknows.com; 
www.parenting.com 
94  [3] 
 
USA www.otispregnancy.org; Facebook page of OTIS; 
www.justmommies.com 
 
Pregnancy Forums: www.babyandbump.com 
www.thecradle.com; www.talk.sheknows.com; 
www.parenting.com 
80§ [4] 
 
Central America 
Belize www.otispregnancy.org; Facebook page of OTIS 23[2] 
Costa Rica 43[2] 
El Salvador 25[2] 
Guatemala 16[2] 
Honduras 16[2] 
Nicaragua 14[2] 
Panama 43[2] 
South America 
Argentina www.otispregnancy.org; Facebook page of OTIS 
 
Pregnancy Forums: www.semanaasemana.com; 
www.univision.com; www.elembarazo.net 
67[2] 
Bolivia 30[2] 
Brazil 46[2] 
Chile 59[2] 
Colombia 59[2] 
Ecuador 44[2] 
Paraguay 24[2] 
Peru 37[2] 
Uruguay 56[2] 
Supplemental material ± Paper I 

Country Website used for recruitment Internet 
penetration 
rates (%) 
Venezuela 41[2] 
AUSTRALIA 
Australia www.mothersafe.org.au; www.bubhub.com.au 
 
Pregnancy Forums: www.abds.org.au; 
www.birth.com.au 
83ȗ [5] 
 
*Indicates the frequency of internet access - at least once a week, including every day - among individuals aged 25- 34 years. Differences 
between men and women were relatively small. Slightly more than two thirds of men (70%) and 65% of women used the Internet regularly. 
Indicates individuals aged 16-45 years who used the internet for personal use.  
§Indicates individuals > 18 years old, access from anywhere; household internet for women is equal to 68.1%; higher percentages are 
observed for people aged 25-54 years. 
ȗIndicates households with access to the internet at home.  
 
Sources of internet penetration rates:  
1. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus; 2011. 
2. Internet World Stats. Usage and population statistics. Available at: http://www.internetworldstats.com/. 
Accessed 29 December, 2013. 
3. Statistics Canada. Individual Internet use and E-commerce (2010). Available at: 
http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 20 November, 2012. 
4. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications: Internet 
Publishing and Broadcasting and Internet Usage. Available at: 
http://www.census.gov/compendia/statab/cats/information_communications/internet_publishing_and_broadcasti
ng_and_internet_usage.html. Accessed 13 November, 2012. 
5. Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11 
Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-
11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed 13 
November, 2012. 
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Abstract 
Introduction: Little is known about medication use among women with eating disorders in relation 
to pregnancy.  
Aims: To explore patterns and associations between use of psychotropic, gastrointestinal and 
analgesic medications and eating disorders in the period before, during and after pregnancy.  
Method: This study is based on the Norwegian Mother and Child Cohort Study (MoBa). A total of 
62,019 women, enrolled at approximately 17 weeks' gestation, had valid data from the Norwegian 
Medical Birth Registry and completed three MoBa questionnaires. The questionnaires provided 
diagnostic information on broadly defined anorexia nervosa (AN), bulimia nervosa (BN), binge 
eating disorder (BED) and recurrent self-induced purging in the absence of binge eating (EDNOS-
P), along with self-reported use of medication six months before, during, and 0-6 months after 
pregnancy.  
Results: The prevalence of eating disorder subtypes before and/or during pregnancy was: 0.09% AN 
(n=54), 0.94% BN (n=585), 0.10% EDNOS-P (n=61) and 5.00% BED (n=3104). The highest over-
time prevalence of psychotropic use was within the AN (3.7-22.2%) and EDNOS-P (3.3-9.8%) 
groups. Compared to controls, BN was directly associated with incident use of psychotropics in 
pregnancy (adjusted RR: 2.25, 99% CI: 1.17-4.32). Having AN (adjusted RR: 5.11, 99% CI: 1.53-
17.01) or EDNOS-P (adjusted RR: 6.77, 99% CI: 1.41-32.53) was directly associated with use of 
anxiolytics/sedatives postpartum. The estimates of use of analgesics (BED) and laxatives (all eating 
disorders subtypes) were high at all time periods investigated.  
Conclusions: Use of psychotropic, gastrointestinal, and analgesic medications is extensive among 
women with eating disorders in the period around pregnancy. Female patients with eating disorders 
should receive evidence-based counseling about the risk of medication exposure versus the risk of 
untreated psychiatric illness during pregnancy and postpartum. 
  
 ϯ
Introduction 
Eating disorders are serious mental illnesses primarily affecting women of childbearing age. It is 
estimated that 0.9%, 1.5%, and 3.5% of the female population experience anorexia nervosa (AN), 
bulimia nervosa (BN), or binge eating disorder (BED), respectively, over the life time [1]. During 
pregnancy, up to 7.5% of women may meet the diagnostic criteria for an eating disorder [2]. Few 
clinical trials have tested pharmacotherapy options for treatment of patients with eating disorders. 
Although there is no evidence supporting general use of antidepressants or antipsychotics for the 
treatment of AN, selective serotonin reuptake inhibitor (SSRI) antidepressants seem to moderately 
reduce the symptoms of BN and BED, but exert little effect on full recovery [3-7]. Previous research 
in clinical settings has shown that 13% and 49% of women with AN use antipsychotics an 
antidepressants, respectively [8]. Nevertheless, little is known about the extent of use of 
psychotropics in a population-based setting.  
The use of medication in women with eating disorders has as far as we know not been explored in 
relation to pregnancy. Inadequate evidence-based counseling about medication safety in pregnancy 
and negative information framing may led women to discontinue needed medication once pregnant 
[9]. However, since pharmacotherapy with psychotropics might reduce pregnancy-related 
exacerbation of eating disorder symptoms such as dieting or vomiting, their effect would probably 
be beneficial for both mother and fetus rather than detrimental. Since extreme dieting, compensatory 
behaviors, or psychiatric comorbidity among patients with eating disorders are associated with 
several painful conditions, including gastrointestinal complaints [10,11], a comprehensive 
understanding of medication use beyond psychotropics including analgesics and gastrointestinal 
medication in women with eating disorders, is essential to ensure maternal-fetal health.  
Thus, this study investigated patterns of use of psychotropic, analgesic, and gastrointestinal 
medications before, during, and after pregnancy across eating disorder subtypes, and explored the 
relationship between eating disorders and use of these specific medications during pregnancy and 
the postpartum, including whether there was a direct association between eating disorders and 
medication use or whether the association was indirect, e.g. via an underlying maternal depression 
and anxiety. We hypothesized a higher extent of medication use in the pregnancy and postpartum 
periods among women with eating disorders compared to healthy controls. 
 ϰ
Materials and methods 
Study population and data collection 
This study is based on the Norwegian Mother and Child Cohort Study (MoBa) and on records in the 
Medical Birth Registry of Norway (MBRN). MoBa is a prospective population-based pregnancy 
cohort study conducted by the Norwegian Institute of Public Health [12]. Participants were recruited 
from all over Norway from 1999-2008. The women consented to participation in 40.6% of the 
pregnancies [13]. The cohort now includes 114.500 children, 95.200 mothers and 75.200 fathers. 
Participants were recruited through a postal invitation in connection with a routine ultrasound 
examination offered to all pregnant women in Norway at 17-18 weeks of gestation. The current 
study is based on version 7 of the quality-assured data files released for research including women 
who delivered between 1999 and 2009. Informed consent was obtained from each participant. The 
study was approved by The Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate.  
The MBRN is based on compulsory notification of all live births, stillbirths and induced abortions 
and includes information on pregnancy, delivery and neonatal health [14]. Data from MoBa was 
OLQNHGWRWKH0%51YLDWKHZRPHQ¶Vpersonal identification number. The analysis population for 
this study included women who had a record in MBRN, and had answered three self-administered 
MoBa questionnaires [15]. The first (Q1) and third (Q3) questionnaires were completed in 
gestational weeks 13-17 and 30, respectively; the fourth questionnaire (Q4), concerning the period 
from gestational week 30 and onwards, was distributed when the infant was six months old [12,15]. 
Among those who agreed to participate in the MoBa, the response rate was 95% for Q1, 92% for Q3, 
and 87% for Q4 [12]. The exclusion criteria and flow-chart to achieve the final population analysis 
are outlined in Fig. 1.  
  
 ϱ
Fig. 1. Flow-chart to achieve final study population 
 
Conditions may overlap: excluded participants are not mutually exclusive.  
*Weight either < 30 Kg or > 300 Kg; ^Height < 100 cm. 
 
 
Measures 
Eating disorder 
Q1 included items on eating disorders and disordered eating behaviors designed in accordance with 
the DSM-IV criteria [16]. These items have previously been used for studies on eating disorders in 
the Norwegian Institute of Public Health Twin Panel [17,18]. In our analysis population, 
respondents completed Q1 at a median of 17.1 weeks of gestation (interquartile range 16.0±18.6 
weeks). Diagnostic algorithms and hierarchies were constructed to define the presence of eating 
disorders in the six months prior to pregnancy (retrospective assessment) and during pregnancy. 
Broadly defined AN was defined as meeting the DSM-IV criteria for AN with the exception of 
amenorrhea. Our definition of AN is more in accordance with DSM-5 since the amenorrhea criterion 
is eliminated. It was not possible to classify AN during pregnancy because of the missing body mass 
index (BMI) criterion due to pregnancy-induced weight gain. The other eating disorder categories 
 ϲ
included: broadly defined BN, endorsing at least a weekly frequency of binge eating and either 
purging (vomiting, laxatives) or non-purging (exercise, fasting) compensatory behaviors; broadly 
defined BED, at least a weekly frequency of binge eating in the absence of compensatory behaviors; 
and eating disorder not otherwise specified-purging subtype (EDNOS-P), purging at least weekly in 
the absence of binge eating. Questions for binge eating included both eating an unusually large 
amount of food and the feeling of loss of control. The frequency criteria for binge eating and 
purging in BN, BED, and EDNOS-P differed from the DSM-IV criteria but reflect the new DSM-5 
criteria (once a week instead of twice a week). As the symptom profile for many women changed in 
the interval before pregnancy and during pregnancy, the following diagnostic hierarchy was applied 
in order to assign only one diagnosis to each woman: AN, BN, EDNOS-P, BED, and no eating 
disorder. All individuals who met AN criteria before pregnancy were categorized as AN regardless 
of presentation during pregnancy. Those who met BN criteria either before or during pregnancy and 
who did not meet AN criteria prior to pregnancy were categorized as BN. If not classified as AN or 
BN, those who met criteria for EDNOS-P before or during pregnancy and did not endorse binge 
eating at either time were categorized as EDNOS-P. Similarly, individuals who endorsed BED and 
did not endorse purging during or before pregnancy were included in the BED group. Group 
assignment was made only when all responses were available to ensure accurate classification. 
Outcome assessment 
Self-reported information about type and timing of medication use was available from the MoBa Q1, 
Q3 and Q4. Respondents were asked to report medication use for numerous chronic, short-term, and 
pregnancy-related conditions as free entry text, along with the timing of use (six months before 
pregnancy; first, second and third trimesters; and two time periods postpartum [0-3 and 4-6 months 
after childbirth]). All medications recorded in Q1, Q3 and Q4 were grouped according to the 
Anatomical Therapeutic Chemical (ATC)[19] codes, as outlined in S1 Table, into: psychotropics 
(i.e., antidepressants, antipsychotics, anxiolytics and sedatives), gastrointestinal medications (i.e., 
antacids, drugs for peptic ulcer and gastro-esophageal reflux disease, laxatives), and analgesics (i.e., 
opioids, acetaminophen and other antipyretics, and nonsteroidal anti-inflammatory drugs  
[NSAIDs ]). When multiple drugs were used and multiple timings checked, we considered the drugs 
WREHXVHGLQDOOWLPHSHULRGV2XURXWFRPHPHDVXUHVGLFKRWRPRXVµ<HV1R¶ZHUHDmedication 
XVHDWDQ\WLPH³GXULQJSUHJQDQF\´DQG³DIWHUSUHJQDQF\´VHSDUDWHO\LUUHVSHFWLYHRIWKH
 ϳ
rHVSRQGHQWV¶VPHGLFDWLRQXVHVWDWXVLQWKHRWKHUWLPHSHULRGVELQFLGHQWXVHRIPHGLFDWLRQV³GXULQJ
SUHJQDQF\RQO\´LHZRPHQZKRVWDUWHGWDNLQJWKHPHGLFDWLRQLQSUHJQDQF\DQGZHUHQRWXVLQJ
WKDWPHGLFDWLRQQHLWKHUEHIRUHQRUDIWHUSUHJQDQF\DQG³SRVWSDUWXPRQO\´LHZRPHQZKRVWDUWHG
taking the medication postpartum and were not using that medication neither before nor during 
pregnancy). 
Assessment of maternal mental health 
Symptoms of depression and anxiety during pregnancy and postpartum were measured via the short 
versions of The Hopkins Symptom Checklist-25 (SCL-25): the Symptom Checklist-5 (SCL- 5) in 
Q1, and the Symptom Checklist-8 (SCL-8) in Q3 and Q4 [20,21].The scale is considered a reliable 
screening instrument for depression and anxiety as defined by the ICD-10 [22]. Both SCL-5 and 
SCL-8 are highly correlated to the SCL-25 [21,23]. For each item of the scales, a score from 1 to 4 
can be assigned. Whenever the respondent completed more than a half of the items, imputed values 
were generated on both instruments via utilization of the estimation-maximization algorithm. Values 
were imputed for 1.4%, 5.4%, and 8.9% of the study population in SCL-5 (Q1), SCL-8 (Q3), and 
SCL-8 (Q4), respectively. For all three instruments, the mean score was separately computed. 
Presence of depressive and anxiety symptoms during pregnancy was defined by a score greater than 
2.0 in the SCL-5 and greater than 1.85 in the SCL-8 [20]. The mean scores for the SCL-5 in Q1 and 
the SCL-8 in Q3 were summed (mean sum score) in order to measure symptoms of depression and 
anxiety throughout the pregnancy.  
Assessment of potential confounders and mediators 
Maternal socio-demographics (i.e., age, educational level, socio-economic status, BMI at conception, 
weight gain during pregnancy, weight decrease after childbirth, illnesses during pregnancy), life-
style characteristics (i.e., smoking and alcohol intake during pregnancy) and the degree of maternal 
depressive and anxiety symptoms during pregnancy (mean sum score of SCL-5 and SCL-8) and 
postpartum (mean score of the SCL-8) were all analyzed as potential confounders or mediators. 
Confounding and mediating factors were identified with the aid of directed acyclic graphs (DAGs) 
using DAGitty version 2.2 (one DAG for each medication-outcome pair) [24]. Our assumptions 
were: eating disorder status before and/or during pregnancy precedes maternal symptoms of 
 ϴ
depression and anxiety during pregnancy; eating disorder status before and/or during pregnancy 
determines BMI at conception. These assumptions applied to all the eating disorder subtypes. 
Statistical analysis 
All statistical analyses were performed by using the Statistical Package for the Social Sciences 
(SPSS) version 22.0 (IBM® SPSS® Statistics). The Pearson chi-square or Fisher exact test, and the 
Student's t-test were utilized to compare proportions and mean scores between independent groups, 
respectively. Because of the numerous analyses, we undertook a conservative approach and 
considered p-YDOXHVRIVWDWLVWLFDOO\VLJQLILcant.  
The Generalized Estimating Equations (GEE) with a Poisson distribution [25] was used to test 
differences in medication use across the eating disorder subtypes. In the first set of analyses we 
H[SORUHGPHGLFDWLRQXVH³GXULQJSUHJQDQF\´DQG³DIWHUSUHJQDQF\´VHSDUDWHO\,QWKHVHFRQGVHWZH
DVVHVVHGLQFLGHQWXVHRIPHGLFDWLRQV³GXULQJSUHJQDQF\RQO\´DQG³SRVWSDUWXPRQO\´,QWKHWZR
sets of analyses we carried out the following steps: we first computed crude relative risks (RR) with 
99% CI. Then, we entered in Model 1 the minimal sufficient adjustment set of variables (i.e., age, 
socioeconomic, status and educational level for all medication groups) for estimating the total 
association between eating disorders and the outcomes of interest. In a sensitivity analysis we 
included BMI at conception as additional covariate in Model 1 (because of the uncertainty in the 
direction of the association between BMI and eating disorders); however, the observed results did 
not differ substantially from the main analyses. In Model 2 we entered the set of confounders from 
Model 1 plus additional covariates (e.g., maternal depressive and anxiety symptoms, BMI, weight 
gain in pregnancy) in order to estimate the direct association between eating disorders and the 
outcomes of interest. Data are presented as crude and adjusted RR if there were at least three cases 
of women with eating disorders exposed to the specific medication groups. 
Results 
Population characteristics 
A total of 62,019 women were included in this study (Fig. 1). Those excluded from the analysis 
because of missing eating disorder assessment (n=5,934, 9.6%) were significantly older, had less 
education, lower socio-economic status, and higher BMI at conception than those included. The 
 ϵ
prevalence of eating disorder subtypes before and/or during pregnancy was: 0.09% AN (n=54), 0.94% 
BN (n=585), 0.10% EDNOS-P (n=61) and 5.00% BED (n=3,104). The remaining 93.87% did not 
present with any eating disorders (reference group).  
Maternal socio-demographics, life-style factors, morbidities, and mental health characteristics across 
the eating disorder subtypes are outlined in Table 1. Women within the AN, BN, EDNOS-P, and 
BED groups more frequently had less education and lower socio-economic status than the reference 
group, and showed significantly higher rates of depressive and anxiety symptoms throughout the 
pregnancy (Table 1).  
Patterns of medication use 
Fig. 2 outlines the extent of psychotropic medication use overtime across the various eating disorder 
subtypes. Women with AN or EDNOS-P reported the highest rate of psychotropic medication use 
prior, during and after pregnancy. Use of psychotropics decreased during pregnancy across all eating 
disorders compared to the period before conception; at 4-6 months postpartum the AN and EDNOS-
P groups were characterized by a significant increase in such use (mainly anxiolytics and sedatives) 
(Fig. 2 and S2 table). The extent of use of the individual psychotropic medications overtime, 
including regular use at all time periods and across the various eating disorder subtypes is outlined 
in S2 table. Overall, antidepressants comprised the medication class most widely used before, during, 
and after pregnancy.  
S1 and S2 Figs. outline the extent of use of gastrointestinal drugs and analgesics, respectively, 
according to timing and across the eating disorder subtypes. Patterns of use for the individual 
subgroups within gastrointestinal drugs and analgesics are shown in S3 and S4 tables, respectively. 
Women with any eating disorder were characterized by a high use of gastrointestinal drugs during 
pregnancy (especially in the second and third trimester) and postpartum. Compared to the reference 
group, all eating disorder subtypes were characterized by a higher rate of laxative use at some point 
before, during, or after pregnancy (S3 table).  
Even though not always significantly different, use of analgesics was at almost all time points higher 
among women with AN than the reference counterpart (S2 Fig.). Women with BED were 
characterized by a significantly higher use of any type of analgesics before, as well as during and 
 ϭϬ
after pregnancy. Also, women with AN, BN or BED were more likely than the reference group to 
use acetaminophen and other antipyretics at all time periods (S4 table). 
Fig. 2: Use of psychotropic medications before, during, and after pregnancy by type of eating 
disorder
Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not otherwise specified, 
purging type), BED (binge-eating disorder), ED (eating disorder). Psychotropic medications include antidepressants, 
antipsychotics, anxiolytics and hypnotics and sedatives. *Indicates p-value 0.001; ЫIndicates p-value 0.01. 
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Association between eating disorders and medication use in pregnancy 
Table 2 outlines the measure of association between the eating disorder subtypes and use of 
specific medication groups during pregnancy. After adjusting for confounding factors (Model 1), 
women with AN, BN, EDNOS-P, and BED had a significant 5.6-, 4.0-, 3.6- and 1.7-fold 
increased likelihood, respectively, to use psychotropics during pregnancy. Having BN was 
directly associated with use of psychotropics during pregnancy (1.8-fold magnitude). In a sub-
analysis by psychotropic subgroup, BED was found to be significantly directly associated with 
use of antidepressants during pregnancy (aRR: 1.45, 99% CI: 1.01-2.08), while BN had such 
effect on use of anxiolytics and sedatives (aRR: 2.36, 99% CI: 1.26-4.41). Only BN was 
significantly directly associated with incident use of psychotropics during pregnancy (Model 2, 
aRR: 2.25, 99% CI: 1.17-4.32). 
Women with BN or BED presented a significant 1.3- and 1.2-fold increased likelihood, 
respectively, for taking gastrointestinal drugs during pregnancy compared to controls (Model 1). 
However, only the EDNOS-P subtype was significantly directly associated with this outcome 
(specifically for antacids and laxatives). The BN and BED subtypes presented a significant 
modest likelihood to use analgesics during pregnancy (Model 1, 11-19% increased risk); 
however, none of the eating disorder subtypes was directly associated with this outcome (Model 
2). In the second set of analysis, women with BED presented a small significant likelihood to be 
incident users of analgesics during pregnancy (Model 1, aRR: 1.14, 99% CI: 1.02-1.28), 
although the association was not direct.  
Association between eating disorders and medication use postpartum 
Table 3 outlines the measure of association between the eating disorder subtypes and use of 
specific medication groups postpartum. Women with AN, BN, EDNOS-P, and BED presented a 
significant 9.5-, 2.4-, 7.2- and 1.5-fold increased likelihood, respectively, to use psychotropics in 
the period 0-6 months after delivery compared to the reference group (Model 1). Only the 
EDNOS-P subtype was directly associated with this outcome (Model 2, 4.5-fold magnitude). In 
the sub-analysis on type of psychotropics, AN and EDNOS-P were directly associated with an 
increased likelihood of using anxiolytics/sedatives postpartum (Model 2, aRR: 5.11, 99% CI: 
1.53-17.01; aRR: 6.77, 99% CI: 1.41-32.53, respectively). 
 ϭϰ
In Model 1, BN was significantly associated with a 1.8-fold increased likelihood to take 
gastrointestinal drugs postpartum compared to controls, and also showed a direct association 
with this outcome (Model 2, 1.6-fold magnitude). Women with BED, even though in a modest 
magnitude, were more likely than the reference group to use analgesics postpartum (1.2-fold 
increased risk); however, the association was not direct. No eating disorder was significantly 
associated with incident use of gastrointestinal drugs or analgesics postpartum. 
Discussion 
To our knowledge this is the first population-based study addressing the extent of medication use 
among women with eating disorders in the period before, during, and after pregnancy. Several of 
our findings are important for clinical practice. First, knowledge that use of psychotropic 
medication, especially antidepressants, was common among women with any eating disorder in 
the preconception period as well as during pregnancy and postpartum may assist clinicians when 
following-up or counseling female patients with eating disorders. Indeed, women with eating 
disorders, either pregnant or planning a pregnancy, might be in special need of evidence-based 
counseling about the benefit-risk ratio of gestational exposure to antidepressants or other 
psychotropics, and that of untreated psychiatric illness. To date very little is known about the 
distinct effects of treated versus untreated eating disorders on perinatal outcomes [26,27]; 
however the detrimental impact of untreated maternal depression, which is highly comorbid with 
eating disorders, on maternal-fetal health has been documented [28,29]. 
Second, women with AN or EDNOS-P presented the highest rate of psychotropic drug use at all 
time periods investigated, which may be due to a high degree of psychiatric comorbidity 
compared to the other groups of women. Women with AN were also those with the highest 
extent of regular use (i.e., before, during and after pregnancy) of psychotropics (5.6%), which is 
not completely unexpected since more than one out of five women with AN presented symptoms 
of depression and anxiety during pregnancy. Kaye et al.[30] showed in a double-blind placebo-
controlled trial that use of fluoxetine may be useful in improving outcome and preventing relapse 
of patients with AN after weight restoration; since most women with AN are weight restored 
during the course of the pregnancy, SSRI antidepressants, and in particular fluoxetine, may 
actually be more beneficial in this setting than before conception.  

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Third, women with EDNOS-P or AN had a 6.8- and 5.1-fold increased likelihood to be on 
pharmacotherapy with sedatives/anxiolytics in the postpartum period, even after cancelling out 
the effect of factors such as weight decrease postpartum or depressive and anxiety symptoms. 
The substantial physical changes accompanying motherhood may represent a special challenge 
for women with AN, being characterized by a profound fear of gaining weight and by a distorted 
perception of body shape. Although about 50% of women with AN or EDNOS-P have been 
shown to remit at 18 months postpartum [31], little is known about the course of these disorders 
in the earlier postpartum period. Women with AN or EDNOS-P were found to lose the 
gestational weight more quickly than controls over the first six months postpartum [32], thus for 
these women a return to restrictive weight control behaviors and a worsening of the anxiety 
symptomatology in the early postpartum period, requiring use of sedatives/anxiolytics, cannot be 
excluded.  
Fourth, women with BED were characterized by an extensive use of analgesics before, during 
and after pregnancy. In the multivariate analysis, though, BED was not directly associated with 
analgesic use during pregnancy or postpartum, suggesting that other factors, namely depressive 
and anxiety symptoms, pain ailments, BMI, weight change during pregnancy and postpartum, 
rather than the binging behavior, might constitute the driving factors for using analgesics.  
Lastly, our study revealed that use of laxatives is high among women with any eating disorders 
not only before pregnancy, but also during pregnancy and the postpartum, raising concerns about 
the impact of this practice on their own health and that of their unborn children.   
Our observed rates of use of psychotropics in the preconception period were lower than those 
found in three previous studies among women with AN (53%), BED (18%), or all eating 
disorders (96.7%)[8,33,34]; different recruitment strategies, that is, population-based recruitment 
in the present study versus clinical research recruitment in others, country-specific therapeutic 
traditions and access to special care in different countries, could probably explain these 
discrepancies. Factors such as pregnancy planning might have also deflated our estimates; 
because of fear to harm the unborn child and elevated risk perception of medication exposure, 
many women may discontinue their needed pharmacotherapy during pregnancy or when 
attempting to conceive [35,36].  
Compared to controls, BN was directly associated with use and incident use of pychotropics 
during pregnancy (1.8- and 2.3-fold, respectively). Since antidepressants have shown some 
 ϭϴ
effects in reducing the binge-eating and vomiting behaviors and fluoxetine is the only medication 
approved for treatment of BN [37], this finding is expected. On the other hand, incident use of 
psychotropics might also represent a proxy of increased severity of a pre-existing or an incident 
case of BN. A previous study[38] using the same data source found that the most common 
pattern for BN was remission or partial remission of symptoms from the pre-pregnancy period to 
early pregnancy, and incident cases were rare. Given this scenario, we cannot exclude the 
possibility that pharmacotherapy with psychotropics might have contributed, at least to some 
extent, to remission of symptoms among women with BN. Also, women with BN might have 
sought specialist care and treatment once pregnant for the well-being of the fetus. Two previous 
studies have for example shown that use of dietary supplements and nutritional intake during 
pregnancy were similar among women with and without eating disorders [39,40], underscoring 
how these women do their utmost to ensure the well-being of the developing fetus.  
The extent of use of gastrointestinal medication observed in our study was high across all the 
eating disorders and raises several concerns. In particular, women with BED were more often 
users of gastrointestinal medications during pregnancy (antacids, laxatives, and drugs for 
gastroesophageal reflux disease [GERD]) and postpartum (drugs for GERD), though not prior to 
pregnancy, suggesting a possible augmentation in severity or frequency of bingeing episodes 
during these periods, or more intense pregnancy-related bothers in the gastrointestinal tract 
secondary to the binge. Prior research using the MoBa cohort [38] has in fact shown that most 
women with BED experienced continuation of symptoms rather than remission during pregnancy 
compared to the period before conception, and incident cases were not uncommon. In our 
multivariate model, though, no direct associations between BED and use of gastrointestinal 
medications during pregnancy and postpartum were found, implying the importance of indirect 
factors, namely depressive and anxiety symptoms, weight gain or decrease, BMI and 
gastrointestinal concerns, on these associations. EDNOS-P, on the other hand, was directly 
associated with use of gastrointestinal medications during pregnancy (mostly antacids), which 
may be secondary to regurgitation episodes or to an intensification of purging behavior (i.e., 
vomiting) during pregnancy or, as shown by Torgersen et al., to the higher odds for these women 
to experience pregnancy-related vomiting [41]. 
In line with prior research showing an association between moderate to severe pain and eating 
disorders [42], we found that use of analgesics before, during and after pregnancy was high 
across all eating disorder subtypes. However, the multivariate analysis showed that when 
 ϭϵ
accounting for factors such as depressive and anxiety symptoms, pain disorders and weight 
increase or decrease, none of the eating disorders were directly associated with any analgesic use 
neither during nor after pregnancy. The higher extent of use of NSAIDs in the third trimester 
among women with AN, BN or EDNOS-P, however, deserves attention. Women should be 
advised against use of NSAIDs in the third trimester since use of NSAIDs after week 32 has 
been associated with premature closure of the ductus arteriosus, oligohydramnios, and inhibition 
of labor [43]. 
Frequent follow-ups and support with treatment by a multidisciplinary team including 
obstetricians, psychiatrists, and therapists is of critical importance for women with eating 
disorders, especially in a vulnerable phase of life such as pregnancy and motherhood. The high 
burden of psychiatric comorbidity and the extensive medication use among these women 
deserves attention: clinicians are encouraged to query female patients about their medication-
taking behavior and provide evidence-based counseling about the risk of medication exposure 
versus the risk of untreated psychiatric illness during pregnancy and postpartum. Sub-optimal 
treatment of maternal psychiatric illness might lead to adverse outcomes such as a relapse of the 
disorder, poor life-style or inadequate compliance with prenatal care, which are all harmful 
factors for both mother and child. In moderate to severe cases of psychiatric illness 
pharmacotherapy may be necessary [44]. 
Strengths and Limitations of the Study 
The MoBa study encompasses several strengths and limitations. Data collection was carried out 
prospectively, avoiding the risk of recall bias. Use of medications in the period from gestational 
week 30 to childbirth was the only information collected retrospectively (in Q4), and may 
therefore suffer of recall bias. However, the impact of misclassification of use of SSRIs (the 
most common psychotropics in our sample) in late pregnancy on risk estimates was assessed as 
minimal [45]. The collection of a vast array of health-related and sociodemographic information 
enabled us to take into account several potential confounders and mediators. The utilization of 
DAGs permitted a proper selection of confounding factors for the multivariate models, thus 
diminishing the risk of over-adjustment. Symptoms of depression and anxiety were measured at 
two time points in pregnancy and at six months postpartum via utilization of validated 
instruments, i.e. the SCL-5 and SCL-8, which are reliable screening tools [20-23]. 
 ϮϬ
On the other hand, our study has several limitations that should be considered when interpreting 
the results. Assessment of broadly defined eating disorders was based on women´s self-report, 
however the questions posed to the study participants were consistent with diagnostic criteria 
[16]. Other psychometric instruments (e.g., the SCOFF questionnaire) could have been used to 
identify individuals with eating disorders; however, the eating disorder hierarchy employed in 
our study has been widely used [31,32,38,39,46]. The MoBa study has a low response rate 
(40.6% of all women invited), with a possible self-selection of the healthiest women to the study. 
On the other hand, among those who accepted the invitation, the response rate is high [12]. A 
previous study [13] has thoroughly examined self-selection and its potential for bias by 
comparing the MoBa study population with the total Norwegian birthing population, and 
concluded that although the prevalence estimates could not necessarily be generalized, the 
measures of associations tested were valid in the MoBa study. We cannot, however, rule out that 
some of the association found here could be influenced by selection bias.  
It is plausible that women with eating disorders who participated in MoBa may represent the 
healthier end of the eating disorder severity spectrum because they had to be well enough to 
conceive and participate, especially women with AN. Furthermore, in this specific study women 
were included in the analysis only if they had completed Q1, Q3 and Q4; hence, a risk of 
attrition bias cannot be ruled out. Indeed, the burden of eating disorder before and/or during 
pregnancy as well as the severity of the underlying depressive symptomatology around 
gestational week 17 were significantly higher among women lost to follow-up at gestational 
week 30 compared to the non-lost counterpart. Further, women excluded from the analysis 
because of missing items for the eating disorder assessment had a more unfavorable profile than 
the included counterpart, implying a plausible exclusion of women with more severe eating 
disorder symptoms. Our sample was small for the AN and EDNOS-P groups, limiting the 
statistical power of most analyses.  
Information on medication dosage is not available in the MoBa study and data about duration of 
exposure is not always adequate. Information about type and timing of medication use is self-
UHSRUWHGWKXVGHSHQGHQWRQWKHDFFXUDF\RIWKHZRPHQ¶VUHSRUWLQJ+RZHYHUWKHYDOLGLW\RI
self-reported use of antidepressants in the MoBa study has been found to be reliable [45]. 
Symptoms of depression and anxiety were measured by two self-assessment instruments; 
although such measurements cannot replace a clinical interview and are not designed to measure 
perinatal mood specifically, they provide a reliable measure of the severity of these psychiatric 
 Ϯϭ
conditions [20,22]. Lastly, we cannot rule out the presence of unmeasured factors confounding 
the association between eating disorders and medication use, and therefore cannot conclude with 
regard to whether the associations found reflect causal relationships. 
Future studies should evaluate the distinct effect of treated and untreated eating disorders on 
perinatal outcomes and should focus on how obstetricians, psychiatrists, pharmacists, and 
midwives can form multidisciplinary teams to ensure that women with eating disorders in 
pregnancy receive the care and support they need for themselves and their children during this 
important phase of life.  
Conclusions 
Our study indicated that psychotropics, especially antidepressants, are widely used by women 
with eating disorders in the period before, during, and after pregnancy. In particular, women with 
AN or EDNOS-P were those most often taking psychotropics, which could partly be related to 
the high psychiatric comorbidity. Women with BN were more likely than healthy controls to 
initiate pharmacotherapy with psychotropics during pregnancy, even after accounting for the 
effect of indirect factors. Similarly, AN or EDNOS-P were directly associated with incident use 
of anxiolytics/sedatives over the six month period after childbirth. While women with BED were 
characterized by an extensive use of analgesics before, during and after pregnancy, use of 
laxatives was high among women with any eating disorder at all time periods investigated.  
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PATTERNS AND FACTORS ASSOCIATED
WITH LOW ADHERENCE TO PSYCHOTROPIC
MEDICATIONS DURING PREGNANCY—A
CROSS-SECTIONAL, MULTINATIONAL
WEB-BASED STUDY
Angela Lupattelli, M.Sc.Pharm.,1∗ Olav Spigset, Ph.D.,2,3 Ingunn Bjo¨rnsdo´ttir, Ph.D.,1
Katri Ha¨meen-Anttila, Ph.D.,4 Ann-Charlotte Ma˚rdby, Ph.D.,5 Alice Panchaud, M.D.,6
Romana Gjergja Juraski, M.D.,7 Gorazd Rudolf, M.D.,8 Marina Odalovic, Ph.D.,9 Mariola Drozd, Ph.D.,10
Michael J Twigg, M.Sc.Pharm.,11 Herbert Juch, M.D.,12 Myla E Moretti, Ph.D.,13 Debra Kennedy, M.D.,14
Andre Rieutord, M.Sc.Pharm.,15 Ksenia Zagorodnikova, Ph.D.,16 Anneke Passier, Ph.D.,17
and Hedvig Nordeng, Ph.D.1,18
Background: No previous studies have explored how closely women follow their
psychotropic drug regimens during pregnancy. This study aimed to explore pat-
terns of and factors associated with low adherence to psychotropic medication
during pregnancy. Methods: Multinational web-based study was performed in
18 countries in Europe, North America, and Australia. Uniform data collection
was ensured via an electronic questionnaire. Pregnant women were eligible to
participate. Adherence was measured via the 8-item Morisky Medication Adher-
ence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire
(BMQ-speciﬁc), the Edinburgh Postnatal Depression Scale (EPDS), and a nu-
meric rating scale were utilized to measure women’s beliefs, depressive symptoms,
and antidepressant risk perception, respectively. Participants reporting use of psy-
chotropic medication during pregnancy (n = 160) were included in the analysis.
Results: On the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI:
41.1–56.4%) demonstrated low adherence during pregnancy. The rates of low
adherence were 51.3% for medication for anxiety, 47.2% for depression, and
42.9% for other psychiatric disorders. Smoking during pregnancy, elevated an-
tidepressant risk perception (risk6), and depressive symptoms were associated
with a signiﬁcant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medica-
tion adherence, respectively. Women on psychotropic polytherapy were less likely
to demonstrate low adherence. The belief that the beneﬁt of pharmacotherapy
outweighed the risks positively correlated (r = .282) with higher medication
adherence. Conclusions: Approximately one of two pregnant women using psy-
chotropic medication demonstrated low adherence in pregnancy. Life-style fac-
tors, risk perception, depressive symptoms, and individual beliefs are important
factors related to adherence to psychotropic medication in pregnancy. Depression
and Anxiety 0:1–11, 2015. C© 2014 Wiley Periodicals, Inc.
Key words: adherence; pharmacotherapy; antidepressants; depression; anxiety;
pregnancy
C© 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Psychiatric disorders, most commonly depression and
anxiety, may develop among women of childbearing
age.[1–3] Antenatal depressive and anxiety disorders,
which are strongly coexistent, occur in as many as 13 and
8.5% of women, respectively.[2,4, 5] Psychiatric disorders
frequently require pharmacological treatment, even in
pregnancy.[6] About 1–8%ofwomen use antidepressants
during pregnancy,[7–9] with selective serotonin reuptake
inhibitors (SSRIs) being the preferred therapeutic choice
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for antenatal depressive and anxiety disorders.[3] Phar-
macological treatment is however a special challenge
among pregnant women since both effective treatment
of the mother and prevention of harmful effects to the
unborn child have to be assured.
Even though untreated depression or anxiety may
pose harm to both mother and fetus and impair
mother–child bonding,[10–12] women’s overestimation
of the teratogenic risk of medication, fear of harming
the unborn child, and negative attitudes toward med-
ication may negatively affect adherence to a needed
pharmacotherapy.[13,14] Pregnancy has been described
to be the driving factor for discontinuation of antide-
pressant therapy,[15] nevertheless, no previous studies
have explored how closely pregnant women follow
their psychotropic regimens in the context of ongoing
use. Prior research has however indicated that overall
36–59% of women were poor adherers to their chronic
regimens during pregnancy.[16,17]
Since medication discontinuation or suboptimal drug
therapy of the underlying psychiatric disorder may lead
to a relapse of the disorder over the course of the preg-
nancy and to adverse pregnancy outcomes,[10,11,18] more
insight into the extent of and risk factors for low adher-
ence during pregnancy is warranted. This study aimed
to investigate the level of adherence to psychotropic
medication during pregnancy for treatment of depres-
sion, anxiety, and other psychiatric disorders, and to
explore whether maternal sociodemographics, mental
health, women’s beliefs, and risk perception are related
to medication adherence during pregnancy.
MATERIALS AND METHODS
STUDY DESIGN AND DATA COLLECTION
This is a multinational, cross-sectional, web-based
study performed in 18 countries in Western, Northern,
and Eastern Europe; North America; and Australia.
Pregnant women at any gestational week were eligible
to participate. Data were collected via an anonymous
electronic questionnaire (http://www.questback.com),
accessible online for a period of 2months in each partici-
pating country between October 1, 2011 and February
29, 2012. The complete questionnaire is presented
elsewhere.[19] The questionnaire was open to the public
via utilization of banners on national websites and/or
social networks commonly visited by pregnant women.
Websites were selected on the basis of the number of
daily users. Information about recruitment tools utilized
and Internet penetration rates in each participating
country are described in details elsewhere.[17]
The questionnaire was ﬁrst developed in Norwegian
and English and then translated into other relevant lan-
guages. A pilot study in Finland, Italy,Norway, and Swe-
den elicited no major changes. Data from the pilot study
were not included in the analysis. Collected data were
scrutinized for the presence of potential duplicates but
none were identiﬁed.
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Figure 1. Participant ﬂow-chart to achieve ﬁnal analysis sample.
aPsychiatric disorders include depression, anxiety and other psychiatric disorders (i.e. bipolar, panic and personality disorders).
bPsychotropic medications include antidepressats, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics and sedating anti-
histamines.
cMMAS-8 indicates the 8-item Morisky Medication Adherence Scale.
PSYCHOTROPIC MEDICATION USE
Participants were presented with a list of chronic
disorders, including depression and anxiety. A free-text
ﬁeld was also available, where any other condition not
previously listed could be speciﬁed. Women were then
asked about medication use for each individual chronic
disorder as free-text entry. All recorded medications
were coded into the corresponding Anatomical Ther-
apeutic Chemical (ATC) codes in accordance with the
World Health Organization (WHO) ATC index.[20]
Pregnant women reporting depression, anxiety, or other
psychiatric disorders (i.e., bipolar, panic, or personality
disorders) were considered to be suffering from a psy-
chotropic disorder and thus selected for the data analysis.
Women reporting use of antidepressants (ATC N06A),
antipsychotics (ATC N05A), anxiolytics (ATC N05B),
hypnotics and sedatives (ATC N05C), antiepileptics
(ATC N03A), or sedating antihistamines (ATC R06A)
for the treatment of any psychiatric disorder were
classiﬁed as psychotropic medication users (Fig. 1).
MEDICATION ADHERENCE
Adherence to medication was measured via the 8-item
Morisky Medication Adherence Scale (MMAS-8).[21]
The MMAS-8 is a structured, self-reported medication
adherence measure with a satisfactory internal consis-
tency (Cronbach’s alpha reliability) of .83.[21–23] The
MMAS-8 consists of seven yes/no items and one 5-point
Likert scale. Each item measures speciﬁc medication-
taking behavior, for example, “problems remembering
to take the medication,” “complexity of the therapeutic
regimen,” “feeling hassled about sticking to the treat-
ment plan,” and “stopping the regimen because the
medication make the patient feel worse.”[21] The predic-
tive validity of the MMAS-8 has been examined through
associations with blood pressure control among hyper-
tensive patients (correct classiﬁcation for high/medium
adherence was 80.3%).[21] The participants completed
one MMAS-8 for each self-reported psychiatric disor-
der. Validated translated versions of the original English
MMAS-8 were available in eight languages other than
English. For the remaining six languages, translation
into the relevant language and back translation to
English was done by two independent native speakers
and/or translators. Professor DE Morisky approved the
construct validity of all translated and/or adapted items
of theMMAS-8 (ProfessorDEMorisky, personal e-mail
communication).
For each disorder-speciﬁc MMAS-8, the sum score
(range 0–8) was calculated and then trichotomized into
low (sum score < 6), medium (sum score 6 or 7), and
high (sum score = 8) adherence.[21] Imputed values were
generated when respondents completed at least six of the
Depression and Anxiety
4 Lupattelli et al.
eight items on the MMAS-8 (75% completion), using
the estimation–maximization algorithm.[24] Values were
imputed for 1.9% of the study population.
MATERNAL SOCIODEMOGRAPHIC AND
MEDICAL FACTORS
Maternal sociodemographics included time of ges-
tation, previous children, marital status, folic acid use
before and/or during pregnancy, unplanned pregnancy,
country of residency, age, employment status at time of
conception, educational level, mother tongue, smoking
status during pregnancy, and alcohol consumption after
awareness of pregnancy. Assessment of the study’s exter-
nal validity was done by comparing sociodemographic
and life-style characteristics of the sample on an individ-
ual country level with those of the general birthing popu-
lation in the country, as described in detail elsewhere.[17]
Maternal mental health was measured via the
Edinburgh Postnatal Depression Scale (EPDS), a
screening questionnaire for symptoms of depression
during pregnancy and postpartum. The EPDS is a
self-rating 10-item scale validated for major and minor
depression in clinical settings and with satisfactorily
Cronbach’s alpha reliability (.87).[25] Each question was
scored 0–3, producing a total score of 0–30. The cut-off
for probable depression was set to 13.[25] Validated
translated versions of the original EPDS were available
for eight languages other than English.[26] For the
Serbian version, translation and back translation were
carried out by two independent linguistic experts and
any discrepancies between the back-translated and
original EPDS were settled. For the remaining ﬁve lan-
guages, we utilized translated versions used in previous
studies.[27–30]
MEASUREMENT OF BELIEFS AND
RISK PERCEPTION
Women’s beliefs about medicines were explored via
the Beliefs about Prescribed Medicines Questionnaire
(BMQ-speciﬁc) that comprises two subscales: the
BMQ-Necessity (ﬁve items) and BMQ-Concerns (ﬁve
items).[31,32] Respondents indicated their degree of
agreement with each statement on a 5-point Likert scale
(1 = strongly disagree, 2 = disagree, 3 = uncertain,
4 = agree, and 5 = strongly agree). Individual item
scores were added, giving a total score of 5–25. Higher
scores indicate stronger beliefs in the concepts repre-
sented by the subscales. The belief variables were used
as continuous in the analysis. The necessity–concerns
differential was also calculated. Validated versions of the
translated BMQ-speciﬁc subscales were used whenever
available.[31],[33–38] For seven languages, translation of
the original version and back translation were carried
out by two independent linguistic experts; any discrep-
ancies between the back-translated and original version
were settled. Imputed values were generated when
respondents completed at least four of the ﬁve items
on each subscale, using the estimation–maximization
algorithm.[24] Values were imputed for 2.5% of the
study population.
Three statements were additionally used to explore
women’s beliefs aboutmedication use during pregnancy:
(1) “I have a higher threshold for using medicines when
I am pregnant than when I am not pregnant,” (2) “Even
though I am ill and could have taken medicines, it is
better for the fetus that I refrain from using them,” (3)
“Pregnant women should preferably use herbal remedies
than conventional medicines.” Respondents could indi-
cate their degree of agreement with each statement on a
5-point Likert scale (0 = strongly disagree, 1 = disagree,
2 = uncertain, 3 = agree, 4 = strongly agree). The belief
variables were used as continuous (score range 0–4) in
the analysis.
The perceived risk of antidepressant exposure dur-
ing pregnancy was measured via a numeric scale ranging
from 0 (not harmful to the fetus) to 10 (very harmful to
the fetus). Exposure to antidepressants was not consid-
ered to increase the risk for congenital anomalies in the
offspring (3–6%).[39]
ETHICS
This study was carried out in compliance with the
HelsinkiDeclaration. Informed consentwas given by the
participants by ticking the answer “yes” to the question
“Are you willing to participate in the study?” Regional
Ethics Committee in Norway, region Southeast, ap-
proved the study. Ethical approval or study notiﬁcation
to the relevant national Ethics Boards was achieved in
speciﬁc countries as required by national legislation. All
data were handled and stored anonymously.
STATISTICAL ANALYSIS
The Pearson chi-square and McNemar tests were
used to compare proportions between independent and
dependent groups, respectively. Student’s t-test and
one-way analysis of variance (ANOVA) with post hoc
testing (Bonferroni correction) were utilized to compare
mean scores among two or more groups, respectively.
The Spearman’s rank correlation coefﬁcient was used to
explore the correlation within the medication adherence
sum scores and beliefs aboutmedications. A P-value of <
.05 was considered statistically signiﬁcant.
Factors associated with medication adherence
during pregnancy (dichotomous variable: low versus
medium/high adherence) were explored via theGeneral-
izedEstimatingEquations (GEE).[40] TheGEEwasused
to take into account clustering on region of residency.
Data are presented as adjusted odds ratios (aORs) with
95% conﬁdence intervals (CIs). A two-tailed P-value
of < .05 was considered statistically signiﬁcant. The
multivariate GEE model was built as follows: candidate
variables were selected based on a univariate P-value <
.15; variables having no role (P-value > .05) or yielding
a change smaller than 15% in the beta coefﬁcients of the
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retained variables were removed. Continuous variables
were checked for linearity in the logit link. Because of
nonlinearity, the variable antidepressant risk perception
was categorized according to the nonlinearity midpoints
(risk 0–3; 4–5; 6). The ﬁnal multivariate model
included statistically signiﬁcant independent variables
(smoking during pregnancy, number of psychotropic
medications, EPDS score, and antidepressant risk
perception) and potential confounders (i.e., week of
gestation, educational level, and employment status).
Internal consistency was assessed via reliability
analysis.[41] All statistical analyses were performed by us-
ing the Statistical Package for the Social Sciences (SPSS)
version 20.0 (IBM
R©
SPSS
R©
Statistics).
RESULTS
POPULATION CHARACTERISTICS
Five thousand one hundred sixty-six pregnant women
accessed the electronic questionnaire and 5,095 (98.6%)
completed it. Women with no eligible country of
residency were excluded, leaving 4,938 participants.
Among these, 262 (5.3%) pregnant women reported at
least one psychiatric disorder and 163 of these reported
use of psychotropic medications. Three of 163 women
did not ﬁll the MMAS-8 (<75% completion) and were
excluded from the analysis, leading to a ﬁnal study
population of 160 and 99 women reporting use and
nonuse, respectively, of psychotropic medications dur-
ing pregnancy. Women with missing information in the
MMAS-8 (<75% completion, n = 3) were more often
of immigrant status compared to women who did ﬁll the
MMAS-8 (66.7 vs. 4.4%; P = .008). The mean gesta-
tional week at time of questionnaire completion was 20.9
(standard deviation: 10.5, range: 4–40). Data selection
to achieve the ﬁnal study sample is outlined in Fig. 1.
Of the 259 women with a psychiatric disorder, 160
(61.8%) reported treatment with psychotropic medica-
tions during pregnancy.Maternal characteristics and be-
liefs about medications according to medication use are
shown in Tables 1 and 2, respectively. Most participants
(200/259; 77.2%) were European residents, with 16.6%
North American and 6.2% Australian residents, respec-
tively. Women who used psychotropic medications dif-
fered signiﬁcantly from nonusers in region of residency,
age, parity, alcohol use after awareness of pregnancy,
and pregnancy planning (Table 1). Women who did not
use psychotropic medications most strongly believed
that the necessity of medications did not outweigh their
concerns and that despite being ill, it was better for the
fetus to refrain from taking medications (Table 2).
Antidepressants (mainly SSRIs) were the most
commonly used medication group (144/259; 55.6%).
Speciﬁc estimates of psychotropic medication use are
outlined in Supporting Information Table 1. The sam-
ple contained 53 women with concomitant psychiatric
disorders, speciﬁcally depression/anxiety/other psychi-
atric disorders (n = 4), depression/other psychiatric
disorders (n = 2), and depression/anxiety (n = 47). The
majority of participants using psychotropic medication
(120/160, 75.0%) were on monotherapy, whereas 18.7,
4.4, and 1.9% were treated with two, three, or four
psychotropic medications, respectively.
ADHERENCE
Of the 160 psychotropic medication users, 78 (48.8%;
95% CI: 41.1–56.4%) demonstrated low adherence
during pregnancy. The level of medication adherence
by type of psychiatric disorder is outlined in Table
3. The rates of low adherence were 51.3% for anxi-
ety, 47.2% for depression, and 42.9% for other psy-
chiatric disorders. In corollary analyses, we observed
no signiﬁcant interdisorder difference (chi-square test,
P-value = .392) in the rates of medication adherence
among women concomitantly treated for depression
(low: 42.6%; medium: 46.8%; high: 10.6%) and anxi-
ety (low: 53.2%; medium: 38.3%; high: 8.5%). Among
women treated for a single psychiatric disorder (n=107),
no signiﬁcant difference in the mean adherence sum
score was found across the three disorder groups (mean
scores for depression/anxiety/other psychiatric disor-
ders: 5.54/5.58/6.03, respectively; ANOVA test, P =
.792). Also, the level of medication adherence did not
signiﬁcantly vary by trimester of pregnancy (mean scores
for ﬁrst/second/third trimester: 5.74/5.43/5.40, respec-
tively; ANOVA test, P = .624).
FACTORS ASSOCIATED WITH LOW ADHERENCE
In the multivariate analysis, smoking during preg-
nancy, psychotropic monotherapy, elevated risk percep-
tion of antidepressants, and depressive symptoms dur-
ing pregnancy were signiﬁcantly associated with low ad-
herence. The corresponding measures of association are
shown in Table 4.
The association between medication adherence and
the BMQ-Necessity andBMQ-Concerns by type of psy-
chiatric disorder is outlined in Table 5. Overall, there
was a positive correlation between increasing level of ad-
herence to psychotropic medication and perception that
the beneﬁt of pharmacotherapy outweighed the risks
(r = .282; P < .001).
DISCUSSION
This is the ﬁrst study to explore adherence to pre-
scribed psychotropic medication in pregnancy using a
validated instrument. The study is also novel in provid-
ing insight into the effect of pregnant women’s beliefs,
perceptions of teratogenic risk, anddepressive symptoms
on adherence to psychotropic medications during preg-
nancy. Several ﬁndings are important for clinical prac-
tice. First, many women did not adhere to psychotropic
medication during pregnancy; this may raise concerns
about suboptimal control of the underlying maternal
psychiatric disorder. Second, understanding women’s
beliefs about their psychotropic medications may
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TABLE 1. Characteristics of the study population according to psychotropic medication use during pregnancya (n =
259)
Use of No use of Use versus no use
Maternal Total study psychotropic psychotropic of psychotropic
characteristics population (n = 259) medication (n = 160) medication (n = 99) medication
n (%) n (%) n (%) P-value
Depressive symptomsb
No 124 (49.8) 78 (50.6) 46 (48.4) .733
Yes 125 (50.2) 76 (49.4) 49 (51.6)
EPDS score (mean ± SD) 12.8 ± 5.9 12.5 ± 6.0 13.3 ± 5.6 .288
Gestational week (mean ± SD) 21.1 ± 10.4 20.9 ± 10.5 21.4 ± 10.5 .729
Region of residencyc
Western Europe 68 (26.3) 42 (26.2) 26 (26.3) .008
Northern Europe 106 (40.9) 70 (43.8) 36 (36.4)
Eastern Europe 26 (10.0) 9 (5.6) 17 (17.2)
North America 43 (16.6) 25 (15.6) 18 (18.2)
Australia 16 (6.2) 14 (8.8) 2 (2.0)
Maternal age (years)
20 10 (3.9) 3 (1.9) 7 (7.1) .001
21–30 132 (51.0) 71 (44.4) 61 (61.6)
31 117 (45.2) 86 (53.8) 31 (31.3)
Previous children
No 129 (49.8) 71 (44.4) 58 (58.6) .026
Yes 130 (50.2) 89 (55.6) 41 (41.4)
Marital status
Married/cohabiting 221 (85.3) 137 (85.6) 84 (84.8) .864
Single/divorced/others 38 (14.7) 23 (14.4) 15 (15.2)
Folic acid used
Yes 241 (94.1) 147 (93.0) 94 (95.9) .340
No 15 (5.9) 11 (7.0) 4 (4.1)
Working status
Employed, but not as HCP 119 (58.8) 70 (43.8) 49 (49.5) .803
HCP 34 (13.1) 23 (14.4) 11 (11.1)
Student 23 (8.9) 15 (9.4) 8 (8.1)
Housewife 36 (13.9) 25 (15.6) 11 (11.1)
Job seeker 19 (7.3) 11 (6.9) 8 (8.1)
Other than above 28 (10.8) 16 (10.0) 12 (12.1)
Highest educational level
Lower than high school 32 (12.4) 20 (12.5) 12 (12.1) .970
High school 73 (28.2) 44 (27.5) 29 (29.3)
Higher than high school 122 (47.1) 77 (48.1) 45 (45.5)
Others, unspeciﬁed 32 (12.4) 19 (11.9) 13 (13.1)
Alcohol use after awareness of pregnancy
No 209 (80.7) 121 (75.6) 88 (88.9) .009
Yes 50 (19.3) 39 (24.4) 11 (11.1)
Smoking before pregnancy
No 139 (53.9) 87 (54.7) 52 (52.5) .731
Yes 119 (46.1) 72 (45.3) 47 (47.5)
Smoking during pregnancy
No 215 (83.3) 130 (81.8) 85 (85.9) .390
Yes 43 (16.7) 29 (18.2) 14 (14.1)
(Continued)
assist clinicians in identifyingwomenwho aremost likely
to demonstrate low adherence. Third, knowledge that
the most severely depressed women and those on psy-
chotropic monotherapy are at greater risk of nonadher-
ence may assist clinicians when following-up pregnant
patients with psychiatric disorders.
Of the women with psychiatric disorders included in
the study, 61.8% were taking psychotropics, suggesting
a signiﬁcant psychiatric morbidity. This factor would
however only affect the representativeness of the results
pertaining to the total study population (including users
and nonusers of psychotropics), but not the comparison
between these two groups or within the group of
psychotropic medication users. The observed rates of
low medication adherence during pregnancy were high
across the different psychiatric disorders (42.9–51.3%).
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TABLE 1. Continued
Use of No use of Use versus no use
Maternal Total study psychotropic psychotropic of psychotropic
characteristics population (n = 259) medication (n = 160) medication (n = 99) medication
n (%) n (%) n (%) P-value
Completely unplanned pregnancy
Yes 38 (14.7) 29 (18.2) 9 (9.1) .044
No 220 (85.3) 130 (81.8) 90 (90.9)
Immigrant statuse
No 247 (95.4) 153 (95.6) 94 (94.9) .802
Yes 12 (4.6) 7 (4.4) 5 (5.1)
HCP, health-care provider; EPDS, Edinburgh Postnatal Depression Scale; SD, standard deviation.
Statistically signiﬁcant results (i.e., P values < .05) are presented in bold.
Numbers may not add up to total due to missing values (<4%).
aPsychotropic medications include antidepressants, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics, and sedating antihistamines.
bDeﬁned as having a score 13 on the EPDS.
cWestern Europe includes Austria, France, Italy, Switzerland, The Netherlands, and United Kingdom; Northern Europe includes Finland, Iceland,
Norway, and Sweden; Eastern Europe includes Croatia, Poland, Russia, Serbia, and Slovenia; North America includes USA and Canada.
dIndicates folic acid use before and/or during pregnancy.
eWomen having the ﬁrst language different from the ofﬁcial main language in the country of residency.
The results are however in line with prevalence es-
timates of nonadherence in the general nonpregnant
population with psychiatric disorders (40–53%),[42,43]
but higher than what we previously found among
women with somatic illness during pregnancy, using
the same methodology.[17] The suboptimal treatment
of psychiatric disorders in pregnant women is, however,
of additional concern due to the potential risks of
maternal–fetal health. Indeed, maternal depression
during pregnancy may increase the risk of poor peri-
natal outcomes, such as premature delivery, low birth
weight, and decreased breastfeeding initiation.[10,44]
However, contradictory ﬁndings about the safety of
antidepressants during pregnancy have so far posed
signiﬁcant challenges on practicing clinicians when as-
sessing the risk of untreated depression versus the risk of
pharmacotherapy.[45]
In the current study, we found that women’s beliefs
about medications were a powerful determinant of low
adherence.Women’s perception that the beneﬁt of phar-
macotherapy outweighed the risks and that herbal reme-
dies should be preferred to conventional medications
TABLE 2. Beliefs about medications according to psychotropic medication use during pregnancya (n = 259)
Total study Use of psychotropic No use of psychotropic Use versus no use of
population (n = 259) medication (n = 160) medication (n = 99) psychotropic medication
Beliefs about medication Mean score ± SD Mean score ± SD Mean score ± SD P-value
BMQ-speciﬁcb
Necessity 15.84 ± 5.55 17.36 ± 5.06 13.28 ± 5.42 <.001
Concerns 13.95 ± 4.28 14.02 ± 3.96 13.85 ± 4.79 .763
Necessity–concerns differential 1.87 ±6.81 3.33 ± 6.71 -0.57 ± 6.28 <.001
Pregnancy-speciﬁc beliefsc
Statement 1 2.84 ± 1.45 2.79 ± 1.40 2.91 ± 1.53 .539
Statement 2 2.63 ± 1.27 2.48 ± 1.24 2.87 ± 1.28 .018
Statement 3 1.77 ± 1.24 1.70 ± 1.25 1.89 ± 1.21 .238
BMQ, Belief about Medicine Questionnaire; SD, standard deviation.
Statistically signiﬁcant results (i.e., P values < .05) are presented in bold. Missing values are <5%.
aPsychotropic medications include antidepressants, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics, and sedating antihistamines.
bTheBMQ-speciﬁc questionnaire comprises theBMQ-Necessity andBMQ-Concerns subscales (score range: 5–25).Higher scores indicate stronger
beliefs in the concepts represented by the subscales. The necessity–concerns differential is the difference between the BMQ-Necessity and BMQ-
Concerns scores (positive scores indicate that the patient perception of the beneﬁts of medication outweigh the risks, whereas a negative score
indicates the converse). The BMQ-speciﬁc is copyrighted ( C©Professor Robert Horne).
cStatement 1: “I have a higher threshold for using medicines when I am pregnant than when I am not pregnant,” Statement 2: “Even though I am
ill and could have taken medicines, it is better for the foetus that I refrain from using them,” Statement 3: “Pregnant women should preferably use
herbal remedies than conventional medicines.” Higher scores indicate stronger agreement with the statements.
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TABLE 3. Women’s level of adherence to psychotropic medications according to type of psychiatric disorder (n = 160)
Psychiatric No. of Adherence sum Low Medium High
disorder subjectsa n Cronbach’s α scoreb Mean ± SD adherence n (%) adherence n (%) adherence n (%)
Depression 127 .73 5.51 ± 2.08 60 (47.2) 48 (37.8) 19 (15.0)
Anxiety 76 .64 5.32 ± 1.92 39 (51.3) 29 (38.2) 8 (10.5)
Other psychiatric disordersc 14 .79 6.23 ± 2.07 6 (42.9) 2 (14.3) 6 (42.9)
Total 160 - 5.52 ± 1.96 78 (48.8) 57 (35.6) 25 (15.6)
MMAS-8, 8-Item Morisky Medication Adherence Scale; SD, standard deviation.
aNumber of subjects exceeds 160 due to overlapping psychiatric disorders and related medication use.
bMMAS-8 sum score can range from 0 to 8.
cOther psychiatric disorders include bipolar disorder, panic disorder, and personality disorders.
Use of the C©MMAS is protected by US copyright laws. Permission for use is required. A licensure agreement is available from: Donald E. Morisky,
Sc.D., Sc.M., M.S.P.H., Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive
South, Los Angeles, CA 90095-1772.
TABLE 4. Multivariate adjusted OR for low adherence
to psychotropic medicationa (n = 160)
Variable Adjusted OR (95% CI) P-value
Smoking during
pregnancy
No Reference
Yes 3.87 (1.86–8.02) <.001
Number of psychotropic
medications
= 1 Reference
>1 0.32 (0.17–0.60) <.001
Depressive symptoms
during pregnancyb
No Reference
Yes 2.53 (1.37–4.67) .003
Antidepressant risk
perception score
0–3 Reference
4–5 1.28 (1.01–1.63) .045
6 2.33 (1.38–3.93) .001
aSmoking during pregnancy, number of psychotropic medication,
symptoms of depression, and antidepressant risk perception were the
only signiﬁcant independent variables retained in the ﬁnal multivari-
ate model. Adjustment was done for clustering on region of residency,
educational level, employment status, and gestational week.
bDepressive symptoms were considered to be present whenever the
EPDS score was 13.
during pregnancy could in fact explain 28 and 26% of
the variance in adherence to psychotropic medications,
respectively. Since medication adherence represents a
composite and multifaceted medication-taking behavior
affected by several practical and perceptual factors, such
correlation estimates can be deemed noteworthy and
of importance in clinical settings. In the current study,
elevated risk perception of antidepressants was associ-
ated with low medication adherence, possibly reﬂecting
women’s fear that the needed medication might harm
the fetus. Since pregnant women overestimate the risk
of the medications, and recall negative information
far more often than reassuring information,[13,46]
proper risk communication and information framing
may represent effective tools in attenuating women’s
negative beliefs and perceptions, thereby heightening
medication adherence during pregnancy.[47,48]
Among the risk factors explored, we found that ma-
ternal depression in pregnancy was associated with a
signiﬁcant 2.5-fold increased likelihood of low adher-
ence to psychotropicmedication during pregnancy com-
pared to absence of depression. The lack of a tem-
poral component in this cross-sectional study unfortu-
nately impedes any substantiation of the relationship be-
tween low adherence to psychotropic medications and
depressive symptoms, that is, whether low adherence
led to poorer mental health or the converse. In align-
ment with prior research in the general nonpregnant
population,[49] we found that women on monotherapy
demonstrated poorer adherence than those on polyther-
apy; a more severe or longer history of psychiatric dis-
orders in the latter group, leading to better knowledge
of the medications that are regularly taken, and not least
higher awareness of the correct administration schedule
could explain such a ﬁnding. Future research should test
whether interventions proven to be effective in improv-
ing antidepressant adherence in the general nonpregnant
population[50] would be so also in the pregnant popula-
tion.
STRENGTHS AND LIMITATIONS
An important strength of the study is the use of a
validated self-reported questionnaire of medication ad-
herence, the MMAS-8. The internal consistency of the
MMAS-8 was satisfactory among women treated for de-
pression andother psychiatric disorders (Cronbach’sα
.7), however, it was borderline adequate for anxiety. Val-
idated instruments with reliable psychometric proper-
ties were also utilized to measure women’s beliefs about
medications and maternal mental health. With respect
to the latter instrument, we used a cut-off score with
high sensitivity and speciﬁcity in predicting probable
depression.[26] Restriction to pregnant women only di-
minished the risk for recall bias. Data collectionwas con-
ducted uniformly in all participating countries via uti-
lization of an anonymous electronic questionnaire that
Depression and Anxiety
Adherence to Psychotropic Medications during Pregnancy 9
TABLE 5. Correlation between beliefs about medications and adherence to psychotropic medications during pregnancy
(n = 160)
Medication adherence sum score (MMAS-8)
Beliefs about medication Depression (n = 127) Anxiety (n = 76) Other psychiatric disorders (n = 14) Total (n = 160)
Spearman rank correlation coefﬁcient
BMQ-speciﬁc
Necessity .190a .108 .057 .208b
Concerns −.206a −.037 −.500 −.213b
Necessity–concerns differential .262b .099 .588a .282c
Pregnancy-speciﬁc beliefs
Statement 1 −.091 −.003 .137 −.003
Statement 2 −.144 −.092 .004 −.130
Statement 3 −.237b −.184 −.293 −.243b
MMAS-8, 8-Item Morisky Medication Adherence Scale.
Statistically signiﬁcant results (i.e., P values < .05) are presented in bold.
aIndicates P values < .05.
bIndicates P values < .01.
cIndicates P values < .001.
Number of subjects exceeds 160 due to overlapping psychiatric disorders and related medication use.
The BMQ-speciﬁc questionnaire comprises the BMQ-Necessity and BMQ-Concerns subscales (score range: 5–25). Higher scores indicate stronger
beliefs in the concepts represented by the subscale. The necessity–concerns differential is the difference between the BMQ-Necessity and BMQ-
Concerns subscale (positive scores indicate that the patient perception of the beneﬁts of medication outweigh the risks, whereas a negative score
indicates the converse). The BMQ-speciﬁc is copyrighted ( C©Professor Robert Horne).
Statement 1: “I have a higher threshold for using medicines when I am pregnant than when I am not pregnant,” Statement 2: “Even though I am
ill and could have taken medicines, it is better for the foetus that I refrain from using them,” Statement 3: “Pregnant women should preferably use
herbal remedies than conventional medicines.”
Use of the C©MMAS is protected by US copyright laws. Permission for use is required. A licensure agreement is available from: Donald E. Morisky,
Sc.D., Sc.M., M.S.P.H., Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive
South, Los Angeles, CA 90095-1772.
enabled us to potentially reach a large proportion of the
birthing population.
One limitation of the study is the lack of medically
conﬁrmed diagnoses. The psychiatric disorders were
self-reported by the participants and hence dependent
on the woman’s perception of the medical condition;
the overall prevalence of psychiatric disorders observed
in the current study might in fact be an underestimation
of the true prevalence. We could however measure un-
derlying maternal depression via the EPDS, which has
been validated against clinical interview,[25] even though
two measurements from each subject separated in time
would have been preferable.[26] Information about med-
ication use during pregnancy was also dependent on the
accuracy of the woman’s reporting. The overall preva-
lence of low adherence is uncertain due to the small to-
tal study sample, but could nevertheless be estimated
with a precision of ±8%. The study sample was also
small for the individual psychiatric disorders, thus lim-
iting the statistical power of speciﬁc subanalyses. We
did not have information about history of psychiatric
disorders and prior treatments, ongoing nonpharmaco-
logical therapies, as well as the time of onset of the dis-
orders, that is, prior to or during pregnancy. Due to
the small study sample, individual countries had to be
combined into regions, thus restraining us from doing
country-speciﬁc analyses on the relationship between
beliefs and adherence. In a recent meta-analysis in a
nonpregnant sample,[51] it was found that the associa-
tion between patient’s beliefs and adherence seems to
exist across different countries, languages, and cultures.
The questionnaire was only available through Internet
websites that did not permit calculation of a conventional
response rate. However, recent epidemiological studies
indicate reasonable validity of web-based recruitment
methods.[52,53] Also, the penetration rate of the Inter-
net, either in households or at work, is relatively high
among women of childbearing age.[54–57] Hence, the de-
gree to which our ﬁndings can be extrapolated to the tar-
get population is based on the representativeness of the
respondents to the general birthing populations in each
country. On average, the women in the study had higher
education andwere slightlymore often primiparous than
the general birthing populations in the various countries.
Women with lower level of education might have been
less likely to participate in the present study, whereas im-
migrant womenmore often did not complete the utilized
adherence measure. These limitations should be borne
in mind when considering the representativeness of the
study.
CONCLUSION
In our study, we found that low adherence to
psychotropic medication regimens is common during
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pregnancy, raising concern about suboptimal control
of the underlying maternal psychiatric disorder. Indi-
vidual beliefs and risk perception are important factors
determining adherence to psychotropic medication in
pregnancy. Adequate counseling and proper teratogenic
risk communication will potentially attenuate women’s
negative beliefs about medication and heighten med-
ication adherence during pregnancy. Knowledge that
women being prescribed psychotropic medications are
at risk of nonadherence during pregnancy may assist
clinicians when following-up pregnant patients with
psychiatric disorders.
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Risk of Vaginal Bleeding and Postpartum Hemorrhage After
Use of Antidepressants in Pregnancy
A Study From the Norwegian Mother and Child Cohort Study
Angela Lupattelli, MscPharm,* Olav Spigset, MD, PhD,Þþ
Gideon Koren, MD,§ and Hedvig Nordeng, PhD*||
Abstract: This study aimed to examine obstetric bleeding outcomes
after exposure during pregnancy to selective serotonin reuptake inhibitors
(SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic
(TCAs), and other antidepressants (OADs).
The Norwegian Mother and Child Cohort Study and the Medical Birth
Registry of Norway constituted the data source for the present study. We
included 57,279 pregnant women, of which 1.02% reported use of anti-
depressants during pregnancy, mostly SSRIs/SNRIs (0.92%). We catego-
rized exposure according to antidepressant use in pregnancy (SSRIs/SNRIs,
n = 527; TCAs/OADs, n = 59; nonexposed, nondepressed, n = 55,411) with
inclusion of a disease comparison group (nonexposed, depressed, n = 1282).
We used logistic regression to estimate adjusted odds ratio (aOR) and 95%
confidence interval (CI) for vaginal bleeding outcomes in pregnancy and
postpartum hemorrhage.
Compared with nonexposed subjects, first trimester exposure to SSRIs/
SNRIs or TCAs/OADs did not confer any increased risk of vaginal bleed-
ing in early pregnancy (aOR, 0.91; 95% CI, 0.72Y1.16 and aOR, 0.83;
95% CI, 0.36Y1.92, respectively). No increased risk for vaginal bleeding
in midpregnancy was observed among users of SSRIs/SNRIs (aOR, 0.81;
95% CI, 0.50Y1.31) or TCAs/OADs (aOR, 0.96; 95% CI, 0.26Y3.53)
in second trimester. Exposure to SSRIs/SNRIs during gestational
week 30 to childbirth did not confer any increased risk of postpartum
hemorrhage after vaginal (aOR, 0.90; 95% CI, 0.47Y1.74) or cesarean
(aOR, 1.47; 95% CI, 0.51Y4.22) delivery. Women in the disease compar-
ison group presented a significant moderate increased risk of vaginal
bleeding in early pregnancy (aOR, 1.22; 95% CI, 1.06Y1.39) and mid-
pregnancy (aOR, 1.28; 95% CI, 1.07Y1.55) but not postpartum.
Among this Norwegian cohort of pregnant women, use of antide-
pressants in pregnancy was not associated with any obstetrical bleeding
outcome.
Key Words: pregnancy, antidepressants, vaginal bleeding, postpartum
hemorrhage, the Norwegian Mother and Child Cohort Study
(J Clin Psychopharmacol 2014;34: 143Y148)
Symptoms of depression are common in pregnancy
1 and up
to 8% of women use antidepressants during this phase of
life.2,3 Although untreated depression may pose harm to both
mother and fetus,4 there have been concerns about the safety of
antidepressant use during pregnancy, not least for the selective
serotonin reuptake inhibitors (SSRIs). Recent research findings
suggest SSRIs or antidepressants with high affinity to the sero-
tonin transporter to be implicated in bleeding-related outcomes
from the gastrointestinal tract among nonpregnant subjects.5
The pharmacological plausibility behind the association SSRI-
bleeding resides within the critical role played by serotonin in
hemostasis.6 However, little is known about bleeding outcomes
from other sites than the gastrointestinal tract, such as the female
genital tract.7
Vaginal bleeding is common in pregnancy and its clinical
significance depends on the gestational week and the bleeding
characteristic.8 Nonetheless, postpartum hemorrhage (PPH) is
a leading cause of maternal morbidity and mortality.9 To the
best of our knowledge, no previous studies have investigated the
relationship between use of SSRIs and other antidepressants,
and vaginal bleeding throughout pregnancy. On the other hand,
a single nested case-control study10 examined the association
SSRIs-PPH and detected no increased risk among women ex-
posed to SSRIs (odds ratio [OR], 1.30; 95% confidence interval
[CI], 0.98Y1.72) when compared with non-SSRIs. Because of
the severity of PPH and because vaginal bleeding is a marker of
an at-risk pregnancy, we aimed to investigate the putative as-
sociation between obstetric bleeding outcomes and exposure to
SSRIs and other antidepressants during pregnancy.
MATERIALS AND METHODS
Study Population and Data Collection
Data from the Norwegian Mother and Child Cohort Study
(MoBa) and records in the Medical Birth Registry of Norway
(MBRN) provided the data used in this study. MoBa is a
population-based prospective cohort study described in details
elsewhere.11 Pregnant women from Norway were recruited to
the study through a postal invitation in connection with the
routine ultrasound examination offered to all pregnant women
at 17 to 18 weeks of gestation. At an assessment of the MoBa
study in 2009, the participation rate was 43.5% of all women
invited.12 In the present study, information from MoBa was
retrieved from 3 self-administered questionnaires.13 The first
(Q1) and third (Q3) questionnaires were completed in preg-
nancy weeks 13 to 17 and 30, respectively, whereas the fourth
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questionnaire (Q4) was distributed when the infant was 6 months
old (covering the period from gestationalweek 30 and onward).11,13
Among those who agreed to participate in the MoBa, the response
rate was 95% for Q1, 92% for Q3, and 87% for Q4.11 The MBRN
is based on compulsory notification of all live births, stillbirths, and
induced abortions and includes information on pregnancy, delivery,
and neonatal health.14 Data from MoBa were linked to the MBRN
via the women’s personal identification number. The Regional
Committee for Ethics in Medical Research, Region South, and the
Norwegian Data Inspectorate approved the MoBa study. Informed
consent was obtained from each participant.
We used the MoBa quality assured data file released for
research (version 4) including 72,934 women who delivered
between 1999 and 2006. We included women who had both
a record in MBRN and had answered MoBa Q1, Q3, and Q4
(n = 59,577). We excluded multiple pregnancies (n = 2004),
users of unspecified medication for depression (n = 269), and
users of SSRIs or serotonin-norepinephrine reuptake inhibitors
(SNRIs) together with tricyclic antidepressants (TCAs) or other
antidepressants (OADs) (n = 25). The final study population
comprised 57,279 pregnant women and their live born babies.
Women could participate in the MoBa for more than 1 preg-
nancy, with each of them being counted as individual mother-
child pair.
Exposure Assessment
Information about type and timing of antidepressant use was
retrieved fromQ1, Q3, and Q4.13 Drug exposurewas classified and
grouped according to the Anatomical Therapeutic Chemical (ATC)
Classification System.15 We defined antidepressant exposure as
exposure to a drug belonging to the ATC group N06A, subdivided
into SSRIs (ATC codeN06AB), SNRIs (ATC codes N06AX16 and
N06AX21), TCAs (ATC code N06AA), and OADs (ATC codes
N06AX03, N06AX06, N06AX11, N06AX12, and N06AX18).
In each questionnaire, women could report use of 1 or more me-
dicinal products for specifically named indications (eating disor-
ders, depression, anxiety, and other mental health problems), along
with the corresponding periods of exposure. Exposure to each an-
tidepressant was classified as follows: 6 months before pregnancy,
gestational weeks 0 to 4, 5 to 8, and 9 to 12 (Q1); gestational weeks
13 to 16, 17 to 20, 21 to 24, 25 to 28, 29+ (until completion of Q3);
last part of pregnancy (gestational week 30 to childbirth) (Q4).
Exposure by gestational week was then aggregated into trimesters
and total use during pregnancy. In those instances where multiple
medications had been reported for the same indication for use and
several exposure windows have been recorded, it was assumed that
every medication has been taken at each time interval.
Exposure was categorized into 4 groups: the exposed group 1,
defined as exposure to SSRIs/SNRIs during pregnancy (n = 527); the
exposed group 2, defined as reported use of TCAs or OADs during
pregnancy (n = 59); the disease comparison group, defined as no
exposure to antidepressants but presence of depressive symptoms at
both gestational weeks 17 and 30 (n = 1282); the nonexposed group,
defined as no reported use of antidepressants during pregnancy and
no presence of depressive symptoms at gestational weeks 17 and/or
30 (n = 55,411).
Assessment of Maternal Mental Health
To define the disease comparison group, the short versions
of The Hopkins Symptom Checklist-25 (SCL-25) that is, the
Symptom Checklist-5 (SCL-5) and the Symptom Checklist-
8 (SCL-8), were used.16,17 The SCL-5 and SCL-8 were included
in Q1 and Q3, respectively, and detected depressive symptoms at
gestational weeks 17 and 30. The SCL-25 is a psychometric scale
designed to screen for symptoms of depression in population
survey16 and is considered a reliable screening instrument for
depression as defined by the International Classification of
Diseases, Tenth Revision.18 Both SCL-5 and SCL-8 are highly
correlated to the SCL-25.19,20 Presence of depression was de-
fined by a score greater than 2.0 in the SCL-5 and greater than
1.85 in the SCL-8.16
Outcome Assessment
Information on bleeding outcomes during pregnancy was
retrieved from Q1 and Q3. In here, women could report details
about 2 bleeding episodes; if such episodes differed in typology
(trace versus large/medium amount of blood loss), we based our
analysis onwoman’smost severe bleeding experience. The outcomes
‘‘bleeding in early pregnancy’’ and ‘‘bleeding in midpregnancy’’
were defined as any occurrence of vaginal bleeding during the
first and second trimester of pregnancy, respectively. Bleeding
type was subdivided into trace of blood or spotting, moderate/
large amount of blood loss or clots, and occurrence of multiple
episodes. The outcome ‘‘postpartum hemorrhage,’’ defined as
blood loss greater than 500 mL, stems from the MBRN records,
and is medically confirmed information. All outcome variables
concerning maternal vaginal bleeding were dichotomized as
‘‘yes/no.’’
Assessment of Potential Confounders
Maternal age, parity, marital status, educational level, prepreg-
nancy body mass index (BMI), smoking during pregnancy, and
a history of abortionswere assessed as potential confounders. Factors
related to maternal health before and/or during pregnancy (ie, con-
genital heart defects, placenta previa, abruption placentae, history
of obstetric bleeding) and comedications in pregnancy (ie, nonste-
roidal anti-inflammatory drugs and antithrombotics) were also
assessed as potential confounders. These variables were categorized
as shown in Supplemental Table A (Supplemental Digital Content
1, http://links.lww.com/JCP/A217). The degree of the underlying
maternal depression during pregnancy was also assessed as a po-
tential confounding factor. The sum scores for the SCL-5 at gesta-
tionalweek 17 (fromQ1) and the SCL-8 at gestationalweek 30 (from
Q3) were used for such purpose and used as continuous variables.
Statistical Analysis
The Pearson W2 test was used to identify any association
between the exposure groups and maternal characteristics, medi-
cal factors, and comedications during pregnancy. A P value of less
than 0.05 was considered statistically significant. Univariate and
multivariate logistic regression analysis was used to estimate the
impact of each exposure group on obstetric bleeding outcomes.
Data are presented as adjusted OR (aOR) with 95% CI if there
were at least 3 exposed cases. Subanalysis on individual antide-
pressants and by pregnancy week exposure was also conducted.
Forward purposeful selection of covariates was carried out.21
Goodness of fit of the final multivariate model was assessed
by using the Hosmer and Lemeshow test.21 All final models in-
cluded adjustment for the level of maternal depression as a con-
tinuous variable. By definition, the final model for the same
bleeding outcomes in the disease comparison group did not in-
clude adjustment for the level of maternal depression. The Pre-
dictive Analytics SoftWare PASW version 20 for Windows
(SPSS, Chicago, IL) was used in all analysis.
RESULTS
Population Characteristics
All women in the study population (n = 57,279) gave
birth to a live-born child. Of these, 587 (1.02%) reported
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antidepressant use during pregnancy, mostly SSRIs/SNRIs (0.92%)
(cf. Supplemental Table B, Supplemental Digital Content 2,
http://links.lww.com/JCP/A216). Maternal characteristics, comor-
bidities, and comedications by antidepressant treatment status
are shown in Supplemental Table A (Supplemental Digital Con-
tent 1, http://links.lww.com/JCP/A217). Overall, 5.9% and 6.3%
of the final study population presented depressive symptoms at
weeks 17 and 30, respectively. Interestingly, women in the disease
comparison group presented a significantly higher (P G 0.001)
mean score for SCL-5 and SCL-8 (2.48 and 2.31) than women
medicated with either SSRIs/SNRIs (1.82 and 1.73) or TCAs/
OADs (1.78 and 1.83).
Vaginal Bleeding in Early and Midpregnancy
Of all women in the study population, 20.0% and 9.4%
reported occurrence of vaginal bleeding in early and midpreg-
nancy, respectively. The aORs for vaginal bleeding outcomes
are shown in Table 1. Compared with nonexposed, use of SSRIs/
SNRIs during first and second trimester was not associated with
any increased risk of vaginal bleeding of any kind in early (aOR,
0.91; 95% CI, 0.72Y1.16) and midpregnancy (aOR, 0.81; 95% CI,
0.50Y1.31), respectively. Analog findings were observed in the
analysis of specific bleeding type outcomes (Table 1). Exposure to
TCAs/OADs during first or second trimester did not confer any
significant increased risk of vaginal bleeding in neither early nor
midpregnancy, respectively, although the analysis for this expo-
sure group is underpowered (Table 1). Subanalysis by gestational
week and individual antidepressants did not show different find-
ings than those observed for exposure by trimester or for the main
drug groups SSRIs/SNRIs and TCAs/OADs. Compared with
nonexposed, women in the disease comparison group were asso-
ciated with a statistically significant increased risk of bleeding of
any kind in early (aOR, 1.22; 95% CI, 1.06Y1.39) as well as
midpregnancy (aOR, 1.28; 95% CI, 1.07Y1.55) (Table 1).
Postpartum Hemorrhage
In our study population, 8242 women (14.4%) experienced
PPH. The aORs for PPH, overall and stratified by type of de-
livery, are shown in Table 2. Compared with nonexposed sub-
jects, exposure to SSRIs/SNRIs during gestational week 30
to childbirth did not confer any increased risk of PPH (aOR,
0.97; 95% CI, 0.57Y1.65) and upon stratification by type of
delivery. Exposure to TCAs/OADs during gestational week 30
to childbirth was associated with a 3.75-fold increased risk. Due
to low statistical power, no stratification by type of delivery
could be carried out and therefore this association cannot be
further examined. Subanalysis on individual drug level did not
reveal different findings than those observed for the main drug
group SSRIs/SNRIs. We had no power to investigate the role of
individual TCAs/OADs in relation to PPH. Women in the dis-
ease comparison group did not present any increased risk of
PPH overall (aOR, 1.14; 95% CI, 0.97Y1.34) and upon strati-
fication by type of delivery.
DISCUSSION
The findings of this large prospective cohort study are
reassuring: use of neither SSRIs/SNRIs nor TCAs/OADs during
the first and second trimesters seems to be implicated in vaginal
bleeding outcomes during pregnancy. However, our study also
provides relevant insights about the role of nonmedicated de-
pression in pregnancy. We found that women with depressive
symptoms but not medicated with any antidepressants presented
an increased risk of vaginal blood loss in early and midpregnancy.
Interestingly, these women present more severe symptoms of
depression than the treated counterpart, suggesting a potential
involvement of the maternal underlying depression in vaginal
bleeding outcomes. Nonetheless, they may present higher level of
anxiety and stress, as indicated by their higher rate of utilization
of ultrasound in pregnancy, potentially leading to different health
behaviors and accuracy in reporting. Also, in light of previous
research findings,22 it can be speculated that the higher rates of
vaginal bleeding observed in the disease comparison group could
be simply recognized as signs of threatened abortion.
In the present study, we also found that exposure to SSRIs/
SNRIs as a group during gestational week 30 to childbirth did
not confer any increased risk of PPH. The results for the SSRIs/
SNRIs as a group are, nevertheless, in line with previous find-
ings,10 although the impact of individual antidepressants on
PPH has not been previously addressed. In the postpartum set-
ting, processes other than clotting may prevail in securing blood
TABLE 2. Association (aOR, 95% CI) Between Exposure Groups and Postpartum Hemorrhage (n = 57,279)*
Any Type of Delivery Stratum 1: Cesarean Section Stratum 2: Vaginal Delivery
n (%) n (%) n (%)
8242 (14.4) 2607 (4.6) 5635 (9.8)
Postpartum Hemorrhage
(9500 mL Blood Loss at Delivery) n n (%) aOR† (95% CI) n (%) aOR† (95% CI) n (%) aOR† (95% CI)
Nonexposed in pregnancy 55,411 7937 (14.3) Reference 2485 (4.5) Reference 5452 (9.8) Reference
Disease comparison 1282 211 (16.5) 1.14 (0.97Y1.34) 84 (6.6) 1.18 (0.89Y1.58) 127 (9.9) 1.05 (0.86Y1.28)
Nonexposed (week 30-childbirth) 55,862 8009 (14.3) Reference 2515 (4.50) Reference 5494 (9.83) Reference
SSRIs/SNRIs (week 30-childbirth) 123 18 (14.6) 0.97 (0.57Y1.65) 6 (4.88) 1.47 (0.51Y4.22) 12 (9.76) 0.90 (0.47Y1.74)
TCAs/OADs (week 30-childbirth) 12 4 (33.3) 3.75 (1.09Y12.94) 2 (16.67) V 2 (16.67) V
In all models, the disease comparison group is adjusted for all confounders as SSRI/SNRI and TCA/OAD groups, except for maternal depressive
symptoms (‘‘SCL-8’’ at gestational week 30).
Statistically significant results (ie, when the aOR with its entire 95% CI is above 1.00) are presented in bold.
*The nonexposed group is the reference group in all models. The disease comparison group includes women using no antidepressants during
pregnancy but with symptoms of depression at both gestational weeks 17 and 30.
†Adjusted for maternal age, parity, BMI, educational level, smoking, coagulation defects, history of previous abortion/miscarriage, placental
abruption, placenta previa, and maternal depressive symptoms.
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loss.23,24 Nonetheless, tapering or stopping SSRI and SNRI
treatment toward the end of pregnancy is often considered as a
way to avoid neonatal withdrawal symptoms,25 and this may
prevent identification of any increased risk of PPH, if existing.
We also tried to regroup all antidepressants according to the
level of affinity to serotonin transporter, as done in previous
studies,5 and could not identify any relationship antidepressants-
obstetrical bleeding. The difficulties involved in objectively esti-
mating the amount of blood loss after delivery, as well as the
variability in the definition and diagnosis of PPH among coun-
tries, are factors that should be taken into account when evaluating
our results.
Strengths and Limitations of the Study
The MoBa study material encompasses several inherent
strengths and limitations. Data collection was carried out pro-
spectively, avoiding the risk of recall bias. Exposure to antide-
pressants in gestational week 30 to childbirth was collected
retrospectively (in Q4), and may therefore suffer of inaccuracy
and recall-bias. However, all women reporting antidepressant
use in Q4 did it also in Q3. The collection of a vast array of
health-related and sociodemographic information enables us to
adjust for several potential confounders, including maternal
level of depression at 2 time points during pregnancy and con-
comitant medication use. Moreover, inclusion of a disease com-
parison group enables us to compare and distinguish between
underlying maternal illness and pharmaceutical treatment.
The study has several limitations that should be considered
when interpreting the results. First, the MoBa study has a low
response rate (43% of all women invited), with a possible self-
selection of the healthiest women to the study. On the other
hand, among those who accepted the invitation, the response
rate is high.11 The prevalence of antidepressant use in our co-
hort was slightly lower than in the Norwegian Prescription
Database.26 However, our estimates may in fact be considered
more representative of the actual use of antidepressants among
pregnant women in Norway because not all prescribed antide-
pressants are actually taken during pregnancy. A previous study12
has thoroughly examined self-selection and its potential for
bias by comparing the MoBa study population with the total
Norwegian birthing population. The authors concluded that al-
though the prevalence estimates could not necessarily be gener-
alized, the estimates of exposure-outcome associations were valid
in the MoBa study.
Second, nondifferential misclassification of the exposure
status, especially in the last part of pregnancy, may have oc-
curred. However, the impact of misclassification of exposure to
SSRIs in late pregnancy on risk estimates was addressed by a
recent study and assessed as minimal.27 To ascertain the accu-
racy of reporting in Q4, we also compared the prevalence of
antidepressant use postpartum in our cohort (based upon data
from Q4) with that reported by Engeland et al,26 which includes
data on all antidepressants prescribed to women in Norway after
delivery. We did observe complete concordance (0.7% vs
0.7%). Information on antidepressant dosage is not available
in the MoBa study and information about duration of exposure
is not always adequate.
Third, information about exposure to antidepressants and
bleeding outcomes in early and midpregnancy are self-reported,
thus dependent on the accuracy of the women’s reporting. Fourth,
depression was measured by 2 self-assessment instruments; al-
though such measurements cannot replace a clinical interview,
they provide a reliable measure of the severity of depression.16,18
Finally, although this study included more than 57,000 women,
we still had low statistical power to detect moderate but never-
theless clinically significant increases in the occurrence of spe-
cific bleeding outcomes in midpregnancy as well as PPH for all
exposure groups. Also, wewere limited by low statistical power in
subanalyses on the individual antidepressant level and for the
TCA/OAD group.
To conclude, in this study, we identified no overall in-
creased risk of vaginal bleeding in pregnancy or PPH among
women exposed to antidepressants. On the other hand, women
not medicated with antidepressants but with depressive symp-
toms present a moderately increased risk of vaginal bleeding in
early and midpregnancy. This information will assist women
and their health care providers when discussing treatment op-
tions for depression during pregnancy.
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APPENDIX 1:  
MoBa questionnaires Q1, Q3 and Q4 

1. How old were you when you had your first menstrual period?
Years 
2.How many days are there usually between the first day in your
menstrual period and the first day in your next menstrual period?
Days
3. Are you usually depressed or irritable before your period?
No Yes, noticeably
Yes, but just slightly Yes, very much 
4. If yes, does this feeling disappear after you get your period?
No
Yes 
5. Were your periods regular the year before you became
pregnant?
No
Yes
6. During the last year before you became pregnant, did you
lose your period for more than three months?
No 
Yes, due to an earlier pregnancy   
Yes, for other reasons
7. Date of first day of last menstrual period.
Day Month Year
8. Did your last menstrual period come at the expected time?
No 
Yes
9. Are you certain about the date of first day of last menstrual     
period?
Certain  
Uncertain
10. Describe the duration, amount of bleeding and menstrual
pains of your last period ?
As More than Less than
usual usual usual
Duration
Amount of bleeding
Menstrual pains
Date on which the questionnaire was completed (write the year with 4 numbers, e.g. 2000)
Day Month Year 
This questionnaire will be processed by a computer. It is therefore important that you follow these instructions: 
• Please use a blue or black ballpoint pen.
• Put a cross in the box that is most relevant like this:
• Should you put a cross in the wrong box correct it by filling in the box completely like this:  
• In the large green boxes write a number or a capital letter
It is important that you only write in the white area of each box like this:
Number: Letter: 
• When filling in a single figure in boxes containing two or more squares, please use the square to the right. Example:  
• A number of questions in this questionnaire concern the week of pregnancy.  For example, fill in week 5 for something that occurred
5 weeks after your last period.
• Specific information concerning, for example, medication or profession should be written in the boxes or on the lines provided. 
Please write clearly in CAPITAL LETTERS.
• Remember to provide the date when you completed the questionnaire.
Please return the completed questionnaire in the stamped addressed envelope provided.
0
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11. Have you/your partner at any time during the last year used the
following methods to avoid becoming pregnant? (Fill in all that apply.)
Condom
Diaphragm
IUD 
Hormone IUD 
Hormone injection 
Mini pill  
Pill 
Spermicides (foam, suppositories, cream) 
Safe period 
Withdrawal 
No such methods
Other______________________________________________
12. If you have used the pill/mini-pill, how long altogether have
you used them?
Pill Mini-pill
Less than one year  . . . . . . . . . . . . . . . . .
1-3 years  . . . . . . . . . . . . . . . . . . . . . . . . .
4-6 years  . . . . . . . . . . . . . . . . . . . . . . . . .
7-9 years  . . . . . . . . . . . . . . . . . . . . . . . . .
10 years or more  . . . . . . . . . . . . . . . . . . .
13. If you have used the pill/mini-pill, how old were you when
you first used it?
Years old 
14. Were you taking the pill/mini-pill during the last 4 months
before this pregnancy?
No 
Yes
15. If yes, how long before your last menstrual period did you
stop taking the pill/mini-pill?
Weeks
16. Was this pregnancy planned?
No 
Yes
17. If yes, how many months did you have regular intercourse
without contraception before you became pregnant?
Less than I month
1-2 months
3 months or more
Number of months if more than 3
18. Did you become pregnant even though you or your partner
used contraceptives?
No (proceed to question 21)
Yes
19. If yes, which type? (Fill in all that apply.)
Condom
Diaphragm
IUD 
Hormone IUD 
Hormone injection 
Mini pill  
Pill 
Spermicides (foam, suppositories, cream) 
Safe period 
Withdrawal 
Other______________________________________________
20. If you became pregnant while using an IUD, has it now  been removed?
No 
Yes
21. How  long have you and the baby’s father had a sexual relationship?
months or years
22. How often did you have sexual intercourse during the four
weeks before you became pregnant and during the last four
weeks?
Before Now
Every day  . . . . . . . . . . . . . . . . . . . .
5-6 times a week  . . . . . . . . . . . . . .
3-4 times a week  . . . . . . . . . . . . . .
1-2 times a week  . . . . . . . . . . . . . .
1-2 times every two weeks . . . . . . .
Less than 1-2 times every 2 weeks
Never  . . . . . . . . . . . . . . . . . . . . . . .
23. Have you ever been treated for infertility?
No
Yes
24. If yes, was it in connection with this pregnancy or an earlier
pregnancy and what type of treatment did you have?
(Fill in all that apply.)
Earlier This
Pregnancy Pregnancy
Fallopian tube surgery . . . . . . . . . . . . . . . . .
Other surgery  . . . . . . . . . . . . . . . . . . . . . . .
Medication for endometriosis  . . . . . . . . . . .
Hormone treatment  . . . . . . . . . . . . . . . . . .
Insemination (injection of sperm)  . . . . . . . .
IVF (test tube) method . . . . . . . . . . . . . . . . .
Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25. Have you been given information about having an
amniocentesis performed?
No
Yes
26. What was your blood pressure at your first antenatal visit?
(Check your medical card.)
/       E.g.                     /
27. What did you weigh at the time you became pregnant and
what do you weigh now (in kilograms)?
When I
became pregnant : kg Now: kg
28. How tall are you?
cm
29. How tall is the baby’s father?
cm
30. How much does the baby’s father weigh (in kilograms)?
kg
2
Contraception and pregnancy
1 5 0 9 5
333. Have you had any of the following problems during previous
pregnancies? (Fill in all that apply.)
No Yes
1. Pelvic girdle pain requiring medical leave
2. Pelvic girdle pain requiring bed rest
3. Serious nausea and vomiting
4. Pre-eclampsia during pregnancy
5. Pregnancy diabetes
6. Sugar in urine
7. Problems with incontinence 
34. If you had pelvic girdle pain in a previous pregnancy that led
to bed rest or medical leave, when did the pain start?
months after start of pregnancy
35. When did the pain stop?
months after pregnancy  
still have pain
Previous pregnancies
31. Have you been pregnant before? (Include all pregnancies that ended in abortion, miscarriage or stillbirth as well)
No (proceed to question 36) 
Yes
32. If yes, fill in for all earlier pregnancies. Include all pregnancies that ended in abortion, miscarriage or stillbirth as well as ectopic pregnancies.
State the year the pregnancy began, how many kilos you gained during the pregnancy and the number of months you breast-fed each baby. 
State whether or not you smoked during earlier pregnancies.
Week of Number of Weight gain Smoked
Pregnancy Year Live Spontaneous Termination Ectopic pregnancy for months during during
Number pregnancy started infant abortion/ of pregnancy abortion/ breast pregnancy pregnancy
born stillbirth pregnancy still birth feeding (in kg)
1
2
3
4
5
6
7
8
9
10
Illnesses and health problems during this pregnancy
36. Have you had bleeding from the vagina once or more during this pregnancy? 
No
Yes
37. If yes, describe the first and last bleeding. Give the date the bleeding started, how many days the bleeding lasted and how much
you bled.
First bleeding Trace of blood More than just a trace Clots
Last bleeding Trace of blood More than just a trace Clots
Day Month Year
If more than two episodes of bleeding write in the number of times  
Date when bleeding started No. of days (Enter a cross in a box indicating the amount of blood (trace blood means a few drops)
variation Amount
41 Pelvic girdle pain  . . . . . . . . . . . . . .  _____________________________
2 Abdominal pain  . . . . . . . . . . . . . . .  _____________________________
3 Back pain  . . . . . . . . . . . . . . . . . . . .  _____________________________
4 Neck and shoulder pain  . . . . . . . . .  _____________________________
5 Nausea  . . . . . . . . . . . . . . . . . . . . . .  _____________________________
6 Nausea with vomiting  . . . . . . . . . . .  _____________________________
7 Vaginal thrush  . . . . . . . . . . . . . . . .  _____________________________
8 Vaginal catarrh/unusual discharge  . ____________________________
9 Pregnancy itch  . . . . . . . . . . . . . . . .  _____________________________
10 Constipation  . . . . . . . . . . . . . . . . .  _____________________________
11 Diarrhoea/gastric flu  . . . . . . . . . . .  _____________________________
12 Unusual tiredness/sleepiness  . . .  _____________________________
13 Sleeping problems  . . . . . . . . . . . .  _____________________________
14 Heartburn/reflux  . . . . . . . . . . . . . .  _____________________________
15 Oedema  . . . . . . . . . . . . . . . . . . . .  _____________________________
16 Fever with rash . . . . . . . . . . . . . . .  _____________________________
17 Fever over 38.5 C . . . . . . . . . . . . .  _____________________________
18 Common cold  . . . . . . . . . . . . . . .  _____________________________
19 Throat infection . . . . . . . . . . . . . . .  _____________________________
20 Sinusitis/ear infection  . . . . . . . . . .  _____________________________
21 Influenza  . . . . . . . . . . . . . . . . . . . .  _____________________________
22 Pneumonia/bronchitis  . . . . . . . . .  _____________________________
23 Sugar in urine  . . . . . . . . . . . . . . . .  _____________________________
24 Protein in urine  . . . . . . . . . . . . . . .  _____________________________
Illness/health problem during this pregnancy Use of medication during this pregnancy
Week of pregnancy Week of pregnancy
Illness/health problem 0-4 5-8 9-12 13+ Name of medicine taken 0-4 5-8 9-12 13+
Number
of days
taken
38. Have you experienced any of the following illnesses or problems during this pregnancy? If you have used medication in connection
with these problems give the name of the medicine, the weeks you took the medicines and how many days you took them. (Include all
types of medication, both prescription and over the counter medicines in addition to alternative and herbal remedies.  Do not include
vitamins and dietary supplements as these are discussed elsewhere.)
5Asthma/Allergy/Skin disorders
1 Asthma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
2 Hay fever, pollen allergy . . . . . . . . . . . . . . ____________________________
3 Animal hair allergy  . . . . . . . . . . . . . . . . . . . ____________________________
4 Other allergy . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
5 Atopic dermatitis (childhood eczema)  . . . . . ____________________________
6 Urticaria (hives)  . . . . . . . . . . . . . . . . . . . . . . ____________________________
7 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
8 Other eczema . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
9 Cold sores (herpes)  . . . . . . . . . . . . . . . . . . ____________________________
10 Acne/pimples (serious)  . . . . . . . . . . . . . . . ____________________________
Diabetes
11 Diabetes treated with insulin  . . . . . . . . . ____________________________
12 Diabetes not treated with insulin  . . . . . ____________________________
Heart/Blood/Metabolism/Blood vessels
13 Congenital heart defect  . . . . . . . . . . . . . . ____________________________   
14 Other heart disease  . . . . . . . . . . . . . . . . . . ____________________________
15 High cholesterol  . . . . . . . . . . . . . . . . . . . . . ____________________________
16  High blood pressure  . . . . . . . . . . . . . . . . . ____________________________
17 Hypothyroidism or hyperthyroidism . . . . . . . ____________________________
18 Anaemia/low haemoglobin  . . . . . . . . . . . ____________________________
19 B-12/folic acid insufficiency  . . . . . . . . . ____________________________
Gastrointestinal
20 Hepatitis/jaundice  . . . . . . . . . . . . . . . . . . . ____________________________
21 Gall stones  . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
22 Duodenal/stomach ulcer  . . . . . . . . . . . . . ____________________________
23 Crohn’s disease/ulcerative colitis  . . . . ____________________________
24 Celiac sprue (gluten sensitivity) . . . . . . . ____________________________
25 Other gastro-intestinal problems  . . . . . ____________________________
Muscle/Skeleton/Connective tissue
26   Arthritis (rheumatoid arthritis)/
Bechterev’s reflex . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
Illness/health problem during this pregnancy  Use of medication  
Number
of days
used
Before During 
Illness/health problem Pregnancy Pregnancy Name of medicines
Last 6
months
before
pregnancy
Pregnancy week
0-4 5-8 9-12 13+
39. Do you have or have you had any of the following illnesses or health problems? If you have taken medication (tablets, mixtures, suppositories,
inhalers, creams, etc.)  in conjunction with the illness or health problem give the name(s) of the medication(s) and when you took them. 
Previous and current illnesses and health problems
627 Lupus (SLE)  . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
28 Sciatica  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
29 Fibromyalgia  . . . . . . . . . . . . . . . . . . . . . . . ____________________________
Genital and urinary tract
30 Ovary/fallopian tube infection  . . . . . . . ____________________________
31 Endometriosis  . . . . . . . . . . . . . . . . . . . . . . ____________________________
32 Uterus prolaps  . . . . . . . . . . . . . . . . . . . . . . ____________________________
33 Ovarian cyst  . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
34 Myoma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
35 Cervical cell changes  . . . . . . . . . . . . . . . ____________________________
36 Herpes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
37 Venereal warts/condyloma  . . . . . . . . . . ____________________________
38 Gonorrhea  . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
39 Chlamydia  . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
40  Kidney stones  . . . . . . . . . . . . . . . . . . . . . . ____________________________
41 Kidney infection/pyelonephritis  . . . . . . ____________________________
42 Urinary tract infections/cystitis  . . . . . . ____________________________
43 Incontinence  . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
Other illnesses/health problems
44 Anorexia/bulimia/other eating disorders  . . ____________________________
45 Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
46  Other headache . . . . . . . . . . . . . . . . . . . . . ____________________________
47 Epilepsy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
48 Multiple sclerosis  . . . . . . . . . . . . . . . . . . . ____________________________
49 Cerebral palsy  . . . . . . . . . . . . . . . . . . . . . . ____________________________
50 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
51 Depression  . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
52 Anxiety  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ____________________________
53 Other long illiness or health problems . . . . ____________________________
Which . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Illness/health problem during this pregnancy  Use of medication  
Number
of days
used
Before During 
Illness/health problem                         Pregnancy Pregnancy Name of medicines
Last 6
months
before
pregnancy
Pregnancy week
0-4 5-8 9-12 13+
7When did you take the supplements?
26-9 8-5 4-0 0-4 5-8 9-12 13+
weeks weeks      weeks weeks weeks weeks weeks
1 Folate/folic acid  . . . . . . . . . . . . . .
2 Vitamin B1 (Thiamine)  . . . . . . . . . .
3 Vitamin B2 (Riboflavin) . . . . . . . . . .
4 Vitamin B6 (Pyridoxine)  . . . . . . . . .
5 Vitamin B12  . . . . . . . . . . . . . . . . . .
6 Niacin . . . . . . . . . . . . . . . . . . . . . . .
7 Pantothenic acid  . . . . . . . . . . . . . .
8 Biotin  . . . . . . . . . . . . . . . . . . . . . . .
9 Vitamin C  . . . . . . . . . . . . . . . . . . . .
10 Vitamin A  . . . . . . . . . . . . . . . . . . . .
11 Vitamin D  . . . . . . . . . . . . . . . . . . . .
12 Vitamin E  . . . . . . . . . . . . . . . . . . . .
13 Iron . . . . . . . . . . . . . . . . . . . . . . . . .
14 Calcium  . . . . . . . . . . . . . . . . . . . . .
15 Iodine . . . . . . . . . . . . . . . . . . . . . . .
16 Zinc  . . . . . . . . . . . . . . . . . . . . . . . .
17 Selenium  . . . . . . . . . . . . . . . . . . . .
18 Copper . . . . . . . . . . . . . . . . . . . . . .
19 Chromium  . . . . . . . . . . . . . . . . . . .
20 Magnesium  . . . . . . . . . . . . . . . . . .
21 Cod liver oil  . . . . . . . . . . . . . . . . . .
22 Omega-3 fatty acid  . . . . . . . . . . . .
44. Have you used other medication not previously mentioned?  If yes, which and when did you take them? 
Use of medication during pregnancy weeks
0-4        5-8        9-12 13+Name of medication 
(e.g. Valium, Rohypnol, Paracetamol)
_________________________________________________________
_________________________________________________________
_________________________________________________________
_________________________________________________________
_________________________________________________________
Last 6 months
before pregnancy
Number
of days used
Other medicines
46. If yes, fill in the table below for the vitamins and minerals found in the contents list on the vitamin package/bottle. (For instance, if you have
taken cod liver oil for the last six months before becoming pregnant, enter a cross for each period under “When” (i.e. 7 crosses) and enter a cross in “Daily” under “How often”).
Last 6 months before pregnancy         During pregnancy
40. Do you have a congenital malformation/birth defect?
No
Yes
41. If yes, which? ____________________________________
42. Do your gums bleed when you brush your teeth at present?
No, rarely or never
Yes, sometimes 
Yes, often
Yes, almost always
43. If you had diabetes before you became pregnant, what was
your last long-term blood sugar level (HbA1c) before you
became pregnant?
Less than 7.5
7.5 - 12
More than 12
Don’t Know
Vitamins, minerals and dietary supplements
45. Do you take vitamins, minerals or other dietary supplements? 
No (proceed to question 49) 
Yes
In this period how often 
did you take this?
Daily 4-6 times 1-3 times
a week a week
847. Give the complete name(s) of all vitamins and dietary supplements you take. Include alternative/herbal remedies and diet
products. (Write clearly in CAPITAL LETTERS.)
E.g.
1
2
3
4
5
6
48. If you use multivitamins (with or without minerals) do these contain folic acid? 
Yes
No
Don’t Know
49. What is your civil status? 
Married Divorced/separated 
Cohabitant Widow
Single Other
50. What education do you and the baby’s father have? (Enter a cross indicating the highest level of education you both have completed and
current studies if you are still studying.)
You Baby’s Father
Completed On-going Completed On-going
1 9-year secondary school  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 1-2 year high school  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Technical high school  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 3-year high school general studies, junior college  . . . . . . . . . . . . . . . . . . . . . . . .
5 Regional technical college, 4-year university degree (Bachelor’s degree, nurse, teacher, engineer)  .
6 University, technical college, more than 4 years (Master’s degree, medical doctor, PhD)
7 Other education  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51. What was your and the baby’s father’s work situation when you became pregnant? (Fill in one or several boxes for each.)
You Baby’s Father
1 Student . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 At home  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Intern/apprentice  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Military service  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Unemployed/laid off . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Rehabilitation/disabled  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Employed in public sector  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 Employed in private sector  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9 Self-employed  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 Family member without steady income in family company (e.g. Farming, business)  . . . . . . . . . . . . . . . . . . . . . .
11 Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Work and leisure
Civil status and education
V I T H IE X W I TA P L R O N
9(Questions about current work situation to be answered by anyone in paid employment, even if they are temporarily absent due to
illness, being on leave or for similar reasons.)
56. The usual number of paid working hours a week before you became pregnant and at present.
Before the pregnancy:
During the pregnancy :
57. Describe the type of work carried out
at your and the baby’s father’s place of
work as accurately as possible.
(Write for example, hospital department
for children with cancer, body shop at a
garage for diesel vehicles, farming with
grain and swine, work in the home.) 
58. Occupation/title at this workplace?
(Write for example, staff nurse, mechanic,
foreman, lecturer, student, cleaning
assistant, housewife/at home.) 
59. Indicate the appropriate answer for each of the following questions concerning your present work situation. (Fill in only one box in each line.)
Yes every day Yes every day Yes,
more than less than periodically Seldom
half of  the half of the but not or
working day working day daily never
Do you sometimes have so much to do that your work situation becomes taxing?  . . . . . . . . . .
Do you have to turn or bend many times in the course of an hour?  . . . . . . . . . . . . . . . . . . . . . . .
Do you work with your hands up at shoulder level or higher?  . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you work standing or walking?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Can you choose to work a little faster some days and a little slower on other days?  . . . . . . . . .
Are you subjected to a lot of uncomfortable background noise?  . . . . . . . . . . . . . . . . . . . . . . . . .
Are you subjected to a lot of background noise that makes you
have to raise your voice when talking to others, even at a distance of one metre?  . . . . . . . . . .
60. How do the following statements describe your work situation? (Fill in only one box in each line.)
Agree   Agree mostly  Disagree mostly     Disagree 
completely
I have physically heavy work.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
My work is very stressful  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I learn a lot at work  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
My work is very monotonous  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
My work demands a lot of me.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I am able to decide how my work is to be carried out. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
There is a good team spirit at my place of work.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I enjoy my work  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61. When are your working hours? (Fill in one or several boxes.)
Permanent day work
Permanent afternoon or evening work
Permanent night work
Shift work or shift rotations
No set times (extra help, extra shifts, temporary employment, etc.)
Other 
62. During your pregnancy do you lift anything that weighs more
than 10 kg (10 kilos is the equivalent of a full bucket of water.)
At Home At Work
Seldom or never  . . . . . . . . . . . . . . . . . . . . . . . .
Yes, less than 20 times a week  . . . . . . . . . . . .
Yes, more than 20 times a week  . . . . . . . . . . .
Yes, 10-20 times a day  . . . . . . . . . . . . . . . . . . .
Yes, more than 20 times a day  . . . . . . . . . . . .
You Baby’s Father
52. Did you have an extra job (with or without salary) when you
became pregnant? (For example, accountant, hair dresser, singer in a
dance band, club leader)
No
Yes, describe_______________________________________
53. Have you been absent from your usual work more than two
weeks altogether during this pregnancy?
No
Yes
54 Are you absent from your work at the present time?
No
Yes
55. If yes, what is the reason for your absence? (Fill in one or 
several boxes.)
Medical leave
Leave of absence
Sick child
Other _____________________________________________
,
, Hours
Hours
10
63. How often have you worked with radio transmitters or radar
after becoming pregnant?
Seldom/Never
A few times a week
Daily
On average more than an hour daily 
64. How often do you talk on a cell phone?
Seldom/Never
A few times a week
Daily
On average more than an hour daily 
65. Do your cell phone calls last more than 15 minutes?
Never
Seldom
Often
66. How often have you worked with a computer monitor, laser printer
or copying machine (at a distance of less than two metres) after
you became pregnant?
Computer Copying
monitor Laser printer machine
Seldom/Never  . . . . . . . . . .
A few times per week  . . . . .
Daily  . . . . . . . . . . . . . . . .
On average more than 
an hour daily  . . . . . . . . . . . . .
67. How often have you worked with X-ray equipment (at a
distance of less than two metres) after you became pregnant?
(This does not include treatment as a patient)
Seldom/Never
A few times a week
Daily
On average more than an hour daily 
69. How often have you been to a discotheque since you became pregnant?
1-2 times a week 
Less often
Never
70. Are you in contact with animals either at work or in your leisure time? 
No
Yes
68. Have you been in contact with any of the following substances either at work or in your leisure time during the last six months? (Fill in each line.)
If Yes, Fill in if you have Fill in if you 
number of days used a hood for have used
the last 6 months gases or protective
No Yes (daily = 180 days) breathing protection gloves
1 Lead vapours, lead dust, lead particles or lead alloys . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2 Chrome, arsenic, cadmium or combinations of these . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
3 Gasoline or exhaust (does not apply to filling gasoline in your own car) . . . . . . . . . . . . . . . 
4 Mercury vapours, mercury or work with amalgam fillings (does not apply to your own dental treatment) . . 
5 Disinfectants, vermin poisons. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
6 Weed killers, insecticides, fungicides. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
7 Oil-based paint . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8 Water-based or latex paint . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
9 Paint thinner, paint-lacquer-glue remover or other solvents 
(e.g. lynol, turpentine, toluene, carbon tetrachloride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
10 Industrial dyes or ink . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
11 Motor oil, lubrication oil or other types of oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
12 Photographic chemicals (fixatives or developers). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
13 Substances used in welding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
14 Substances used in soldering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
15 Formalin/formaldehyde. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
16 Chemotherapeutic substances/chemotherapy treatment (does not apply to your own medical treatment). 
17 Laughing gas or other anaesthetic gases (does not apply to your own treatment as a patient) . . . . . 
18 Other substances and conditions, describe______________________ . . . . . . . . . . . . . . . . 
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79. What is your and the baby’s father’s yearly gross income?
(Include child support, unemployment benefits and other
allowances.) 
Your gross income Child’s father’s gross income
No income No income
Under 150.000 NOK Under 150.000 NOK
150-199.999 NOK 150-199.999 NOK
200-299.999 NOK 200-299.999 NOK
300-399.999 NOK 300-399.999 NOK
400-499.999 NOK 400-499.999 NOK
over 500.000 NOK over 500.000 NOK
Don’t know
80. Is it possible for your household to manage financially without your income?
No
Yes, but with difficulty
Yes, without difficulty 
81. What type of house do you live in?
Detached house
Farm
Semi detached
Four-flat house
Maisonette
Terraced flat
Basement flat
Apartment building
Townhouse/tenement
Which floor? 
Other______________________________________________
82. Has there been damp damage, visible signs of
fungus/mildew or a smell of mildew in your home in the past 3
months? (Fill in one or several boxes.)
No
Yes, damp damage 
Yes, signs of fungus and mould 
Yes, a smell of mildew
83. Where does your drinking water come from?
Public or private water company
Water from a local source (e.g. own well) 
84. How many times have you moved in the last 3 years?
times
85.Has anyone in your home had influenza, a prolonged cough, childhood
disease or an illness with fever and a rash after you became pregnant?
No
Yes
86.  If yes, which illness? (fill in one or several boxes)
German measles
Chicken pox
Measles 
Roseola infantum
Other fever with rash
Influenza
Prolonged cough
Tuberculosis
Hand, foot and mouth disease
Other
Housing and household 
71. If yes, what sort of animals and how often are you in contact
with them on a weekly basis? Less than
3-6 times 1-2 times 1 time
Daily a week a week    a week
1 Dog  . . . . . . . . . . . . .
2 Cat  . . . . . . . . . . . . . .
3 Guinea pig  . . . . . . . .
4 Hamster  . . . . . . . . . .
5 Rabbit  . . . . . . . . . . .
6 Canary or other bird .
7 Aquarium fish . . . . . .
8 Cow  . . . . . . . . . . . . .
9 Pig  . . . . . . . . . . . . . .
10 Sheep, goat  . . . . . . .
11 Horse  . . . . . . . . . . . .
12 Poultry  . . . . . . . . . . .
13 Other  . . . . . . . . . . . .
72. With whom do you live? (Fill in one or several boxes.)
Spouse/partner
Parents
Parents-in-law
Children
No one
Other describe__________________________________________
73. How many people including you live in your home?
Number of people over 18 years  . . . . . . . . . . . . .
Number of people between 12 - 18 years  . . . . . .
Number of people between 6 - 11 years  . . . . . . .
Number of people under 6 years  . . . . . . . . . . . . .
74. How many children are at nursery school/day care?
children
75. Do you or the baby’s father have a mother tongue other than Norwegian?
No
Yes
76. If yes, which language?
You Baby’s Father
Sámi  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Urdu  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
English  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
If other, which?_________________________________________
77. Do your parents or the baby’s father’s parents have a mother
tongue other than Norwegian?
No
Yes
78. If yes, which language?
Your Your Mother of Father of
Mother Father the child’s the child’s
father father
Sámi  . . . . . . . . . . . . . .
Urdu  . . . . . . . . . . . . . .
English  . . . . . . . . . . . .
Other  . . . . . . . . . . . . .
If other, which? _________________________________________
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Living habits
87. Did your mother smoke when she was pregnant with you?
No
Yes
Don’t Know
88. Are you exposed to passive smoking at home?
No 
Yes
89. If yes, how many hours a day are you exposed to passive smoking?
hours per day
90. Are you exposed to passive smoking at work?
No
Yes
91. If yes, how many hours a day are you exposed to passive smoking?
hours per day
92. Did the baby’s father smoke before you became pregnant?
No
Yes
93. Does he smoke now?
No
Yes
94. Have you ever smoked?
No (proceed to question 104)
Yes
95. Do you smoke now (after you became pregnant)?
No
Sometimes cigarettes per week 
Daily cigarettes per day
96. Did you smoke during the last 3 months before you became pregnant this time?
No
Sometimes cigarettes per week
Daily cigarettes per day
97. How old were you when you started to smoke on a daily basis?
Years
98. Have you stopped smoking completely?
No
Yes
99. If yes, how old were you when you stopped smoking?
Years
100. If you stopped smoking after you became pregnant, in
which week of pregnancy did you stop?
week of pregnancy
101. How long after you get up in the morning until you light
your first cigarette?
5 minutes
6-29 minutes
30-60 minutes
More than one hour
102. Do you smoke when you are ill?
No
Yes
103. Do you smoke more often during the first few hours after
you wake up than you do during the rest of the day?
No
Yes
104. If you have used other kinds of nicotine indicate which and
when you used them.
Before pregnancy    During pregnancy
Chewing tobacco/snuff . . . . . . . . . . .
Nicotine chewing gum  . . . . . . . . . . .
Nicotine adhesive patch  . . . . . . . . . .
Nicotine inhaler  . . . . . . . . . . . . . . . . .
105. What was your fluid consumption (number of cups/glasses) per
day before and during pregnancy? (1 mug = 2 cups, 1 small plastic
bottle (0.5 litre) = 4 cups, 1 large plastic bottle (1.5 litres) = 12 cups)
Number of cups/glasses
Before Decaffeinated 
pregnancy Now (Enter a cross)
1 Filter coffee  . . . . . . . . .
2 Instant coffee  . . . . . . .
3 Boiled coffee . . . . . . . .
4   Tea . . . . . . . . . . . . . . . .
5 Herbal tea  . . . . . . . . . .
6 Coca Cola/Pepsi etc.  . . .
7 Other fizzy drinks  . . . .
8 Diet Coca Cola/Pepsi  .
9 Other diet fizzy drinks  .
10 Tap water  . . . . . . . . . .
11 Bottled water  . . . . . . . .
Before Ecological 
pregnancy Now (Enter a cross)
12 Juice/squash . . . . . . . .
13 Diet juice/squash  . . . .
14 Milk (skim, low fat, whole)
15 Yogurt, all types  . . . . .
16 Yogurt/active Lactobacillus  .
17 Other type of cultured milk -
Kefir  . . . . . . . . . . . . . . . . . . . .
18 Other  . . . . . . . . . . . . . .
106. Have you used any of the following substances?
Last month During
Never Previously before pregnancy     pregnancy
1 Hash  . . . . . . . .
2 Amphetamine  .
3 Ecstasy . . . . . .
4 Cocaine  . . . . .
5 Heroin . . . . . . .
107. Have you ever consumed alcohol?
No (proceed to question 117) 
Yes
108. How  often did you consume alcohol in the 3 months before you
became pregnant and how often do you consume alcohol during the
pregnancy?
Last 3 months
before During
pregnancy pregnancy
1 Approximately 6-7 times a week  . .
2 Approximately 4-5 times a week  . .
3 Approximately 2-3 times a week  . .
4 Approximately once a week  . . . . .
5 Approximately 1-3 times a month  .
6 Less than once a month  . . . . . . . .
7 Never  . . . . . . . . . . . . . . . . . . . . . . .
109. What type of alcohol do you usually drink? (Fill in one or
several boxes.)
1 Light beer  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Beer  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Red wine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 White wine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Low alcohol sodas  . . . . . . . . . . . . . . . . . . . . . . . .
6 Fortified wines (sherry, port, Madeira)  . . . . . . . . . .
7 Spirits (vodka, gin, snaps, cognac, whisky, liqueur)  . .
110. Did you drink 5 units or more at least once during the last
3 months before pregnancy or during pregnancy?
Last 3
months before During
pregnancy pregnancy
1 Several times per week  . . . . . . . . .
2 Once a week  . . . . . . . . . . . . . . . . .
3 1-3 times a month  . . . . . . . . . . . . .
4 Less than once a month  . . . . . . . .
5 Never  . . . . . . . . . . . . . . . . . . . . . . .
111. How many units of alcohol do you usually drink when you
consume alcohol? Last 3
months before During
pregnancy pregnancy
10 or more . . . . . . . . . . . . . . . . . . . . .
7-9  . . . . . . . . . . . . . . . . . . . .
5-6  . . . . . . . . . . . . . . . . . . . .
3-4  . . . . . . . . . . . . . . . . . . . .
1-2  . . . . . . . . . . . . . . . . . . . .
Less than 1  . . . . . . . . . . . . . . . . . . . .
112. How many units of alcohol do you have to drink before you
feel any effect?
units
113. Have other people irritated you or hurt your feelings by
criticising how much you drink?
No
Yes
114. Have you ever felt that you ought to drink less alcohol?
No
Yes
115. Have you ever drunk alcohol in the morning to calm your
nerves or to get rid of a hangover?
No
Yes
116. Have you ever experienced any of the following problems
during the last year in relation to your alcohol consumption?
Several
Never Once times
Argued with or had negative  
feelings for a family member . . . . . . . . . . .
Suddenly found yourself somewhere 
without knowing how you got there  . . . . .
Been absent from work or school . . . . . . .
Fainted or passed out suddenly  . . . . . . . .
Had a sad period  . . . . . . . . . . . . . . . . . . .
117. Do you think you were overweight just before this pregnancy?
Yes, a lot 
Yes, a little
No
118. Are you worried about putting on more weight than
necessary during this pregnancy?
Yes, very worried 
Somewhat worried  
No, not especially worried
119. Has anyone said that you were too thin while you felt that
you were overweight during the last 2 years?
Yes, often
Yes, occasionally
No
120. Have you ever felt that you lost control while eating and
were not able to stop before you have eaten far too much?
Last 6 months
before this pregnancy Now
No . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Infrequently  . . . . . . . . . . . . . . . . . . . .
Yes, at least once a week  . . . . . . . . .
121. Have you ever used any of the following methods to
control your weight?
Last 6 months
before this pregnancy Now
At least Seldom/ At least Seldom/
once a week Never once a week Never
Vomiting  . . . . . . . . . . .
Laxatives  . . . . . . . . . .
Fasting  . . . . . . . . . . . .
Hard physical exercise
122. Is it important for your self-image that you maintain a certain weight?
Yes, very important
Yes, quite important
No, not especially important
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Weight and weight control
Alcohol units are used to compare the different types of alcoholic
beverages. 1 alcohol unit (= 1.5 cl. pure alcohol) is equivalent to:
1 bottle/can energy drink or cider 
1 glass (1/3 litre) of beer                         
1 wine glass red or white wine 
1 sherry glass sherry or fortified wine  
1 snaps glass spirits or liqueur
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123. How often do you exercise? (Fill in each line for both before and during this pregnancy.)
Last 3 months before this pregnancy During this pregnancy
1-3 3 or more 1-3 3 or more 
times 1 time 2 times times times 1 time 2 times times
Never a month a week a week a week Never a month a week a week a week
1 Walking  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Brisk walking  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Running/jogging/orienteering  . . . . . . . . . . . . . . .
4 Bicycling  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Training studio/weight training  . . . . . . . . . . . . . .
6 Special gymnastics/aerobics for pregnant women
7 Aerobics/gymnastics/dance without running and jumping
8 Aerobics/gymnastics/dance with running and jumping
9 Dancing (swing/rock/folk)  . . . . . . . . . . . . . . . . . .
10 Skiing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 Ball sports  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 Swimming  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13 Riding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14 Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
124. How often do you do exercises for the following muscle groups? (Fill in each line for both before and during this pregnancy.)
Last 3 months before  pregnancy During pregnancy
1-3 3 or more 1-3 3 or more 
times 1 time 2 times times times 1 time 2 times times
Never a month a week a week a week Never a month a week a week a week
Abdominal muscles  . . . . . . . . . . . . . . . . . . . . . . . . . .
Back muscles  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pelvic floor muscles (muscles around the vagina, urethra, anus)
125. How often are you so physically active in your leisure and/or at work that you get out of breath or sweat?
Last 3 months before this pregnancy During this pregnancy
Leisure At work Leisure At work
Never  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less than once a week  . . . . . . . . . . . . . . . . . . . . . . .
Once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 times a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3-4 times a week . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 times a week or more  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Physical activity
126. Do you agree or disagree with the following statements? (Fill in only one box in each line.) Don’t agree
Disagree Disagree or Agree Agree
completely   Disagree somewhat disagree somewhat Agree   completely
My life is largely what I wanted it to be  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
My life is very good  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I am satisfied with my life  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
To date, I have achieved what is important for me in my life  . . . . . . . . . . . . . . . . . . . .
If I could start all over, there is very little I would do differently  . . . . . . . . . . . . . . . . . . .
A little more about yourself and how you are keeping now
127. How do these statements describe your relationship? (Only answer if you have a partner.) (Fill in only one box in each line.)
Agree   Agree         Disagree Disagree
Completely Agree somewhat  somewhat Disagree completely
My husband/partner and I have a close relationship  . . . . . . . . . . . . . . . . .
My partner and I have problems in our relationship  . . . . . . . . . . . . . . . . . .
I am very happy in my relationship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
My partner is usually understanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I often think about ending our relationship . . . . . . . . . . . . . . . . . . . . . . . . .
I am satisfied with my relationship with my partner  . . . . . . . . . . . . . . . . . .
We often disagree about important decisions  . . . . . . . . . . . . . . . . . . . . . .
I have been lucky in my choice of a partner  . . . . . . . . . . . . . . . . . . . . . . . .
We agree about how children should be raised  . . . . . . . . . . . . . . . . . . . . .
I think my partner is satisfied with our relationship  . . . . . . . . . . . . . . . . . .
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128. Do you have anyone other than your husband/partner you
can ask for advice in a difficult situation?
No
Yes 1-2 people 
Yes more than 2 people
129. How often do you meet or talk on the telephone with your
family (other than those you live with) or close friends?
Once a month or less
2-8 times a month
More than twice a week 
130. Do you often feel lonely?
Almost never
Seldom
Sometimes
Usually
Almost always
131. Have you been bothered by any of the following during
the last two weeks? (Enter a cross for each line.)
Not A little Quite Very
bothered bothered bothered bothered
Feeling fearful . . . . . . . . . . . .
Nervousness or shakeiness inside
Feeling hopeless about the future
Feeling blue  . . . . . . . . . . . . . . . .
Worrying too much about things
132. Have you ever in your adult life been slapped, hit,  kicked
or bothered in any way physically? (fill in one or several boxes)
Last 6
During this months before
pregnancy pregnancy Earlier
No  . . . . . . . . . . . . . . . .
Yes  . . . . . . . . . . . . . . . .
Don’t remember  . . . . . . . . . . . .
133. Have you ever been pressured or forced to have sexual
intercourse? (Fill in one or several boxes.)
Last 6
During this months before
pregnancy pregnancy Earlier
No, never  . . . . . . . . . . . . . . .
Yes, pressured  . . . . . . . . . . .
Yes, forced with violence  . . . .
Yes, raped  . . . . . . . . . . . . . .
134. How do you feel about yourself? (Enter a cross for each line.)
Agree Disagree
completely Agree Disagree completely
I have a positive 
attitude toward myself  . . . . . . . . . .
I feel completely 
useless at times  . . . . . . . . . . . . . . .
I feel that I do not have 
much to be proud about . . . . . . . . .
I feel that I am a 
valuable person,
as good as anyone else  . . . . . . . . .
135. Have you ever experienced the following for a continuous
period of 2 weeks or more? (Fill in each line.)
No Yes
Felt depressed, sad . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Had problems with appetite or eaten too much  . . . . . .
Been bothered by feeling weaker or a lack of energy . .
Really blamed yourself and felt worthless . . . . . . . . . . .
Had problems with concentration
or had problems making decisions  . . . . . . . . . . . . . . . .
Had at least 3 of the problems 
named above simultaneously  . . . . . . . . . . . . . . . . . . . .
136. If you have had 3 or more of these problems at the same
time, how many weeks did the longest period last?
weeks
137. Was there a particular reason for this?
No, no particular reason
Yes (e.g. death, divorce, miscarriage, accident) 
We would be grateful if you would write anything else you
would like to tell us about this pregnancy or previous
births/pregnancies that are not addressed in this
questionnaire on the next page.
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Have you remembered to fill in the date on which you completed the questionnaire on page 1?
Thank you very much for your help!
Please return the completed questionnaire in the stamped addressed envelope provided.
Avd. for medisinsk fødselsregister
Kalfarveien 31
5018 Bergen
Comments
This questionnaire will be processed by a computer. It is therefore important that you follow these instructions:
• Use a blue or black ballpoint pen.
• Put a cross in the box that is most relevant like this: ■
• If you put a cross in the wrong box, correct it by filling in the box completely like this: ■
• Write a number or capital letter in the large green boxes.
It is important that you only write in the white area of each box like this:
Number:                                                                                                         Letter:
• When entering a single-digit number in boxes containing two or more squares, use the square on the right.
For example: 5 is written like this:
• A number of questions in this questionnaire concern the week of pregnancy. For example: If you want to indicate something
that happened 14 weeks after your last period, enter a cross in the box for week 13-16.
• Specific information concerning, for example, medication or profession should be written in the boxes or on the lines provided.
Please write clearly in CAPITAL LETTERS.
• Remember to enter the date when you completed the questionnaire.
Please return the completed questionnaire in the stamped addressed envelope provided.
Antenatal care and health 
1
Questionnaire 3C
This questionnaire applies mainly to the period after week 12 of your pregnancy. We will ask you some questions which you may recognise
from the first questionnaire. We do this because we want to continue following your and your child’s progress. It would be useful for you to
consult your pregnancy health card before you start answering the questions so that you can use the information contained in it when
completing this questionnaire. If you feel uncomfortable with a question or it is difficult to answer, you can skip this question and go on to
the next one.
1. Where have you been to antenatal check- ups?
(Fill in one or more boxes.) Specify how many times.
■ Public health centre times
■ Doctor’s surgery times
■ Hospital (outpatients) clinic times
2. Who has examined you each time? (Fill in one or
more boxes.) Specify how many times.
■ Midwife times 
■ General practitioner times 
■ Gynaecologist times 
■ Public health nurse  times 
1 2 3 4 5 6 7 8 9 0
5
A B C D
3. Is your doctor male or female? 
How many times have you gone to him/her?
General practitioner ■ female times
■ male times
Gynaecologist ■ female times
■ male times
4. If you visit or have visited a gynaecologist or hospital
clinic for your antenatal check-ups, what is or was the
reason?
■ Referred due to complications during this pregnancy
■ Referred due to previous illness or complications in 
previous pregnancies 
■ On your own initiative without a referral
■ Referred for another reason 
Q
u
e
s
t
io
n
n
a
ir
e
 
3
c
 
M
&
B
 
2
0
,
0
0
0
 
1
1
0
1
X
Date when the questionnaire was completed                                                                       (write the year in full, e.g. 2001)
Day Month Year
5. Do you agree with the following statements concerning your
antenatal check-ups?
I have been given sufficient 
advice and information  . . . . . .■ ■ ■ ■ ■ ■
I have been well taken care of ■ ■ ■ ■ ■ ■
There was not enough
time during the consultations . .■ ■ ■ ■ ■ ■
I felt secure during these 
check-ups  . . . . . . . . . . . . . . . .■ ■ ■ ■ ■ ■
I have been able to discuss 
everything I needed to during
the check-ups . . . . . . . . . . . . . .■ ■ ■ ■ ■ ■
On the whole, I am satisfied  
with the way I have been 
followed up by the health service■ ■ ■ ■ ■ ■
6. Have you contacted a midwife or doctor in addition to your
normal check-ups?
No Yes
Midwife. . . . . . . . . . . . . . . . ■ ■
Doctor . . . . . . . . . . . . . . . . ■ ■
7.If yes, was it difficult to get an appointment? 
Midwife Doctor
Not difficult ■ ■
Somewhat difficult ■ ■
Very difficult ■ ■
8. Have you had a gynaecological examination during your
pregnancy (internal examination)? If so, how many times?
■ No         
■ Yes Times
9. How many ultrasound examinations have you had during
your pregnancy?
External ultrasound examination                 Times
Internal ultrasound examination Times
10. How many children are you expecting?
11. Have you been offered an amniocentesis or placenta biopsy?
■ No (go to question 16)
■ Yes
12. If yes, were any tests performed and what were the results?
Amniocentesis ■ ■ ■ ■
Placenta biopsy ■ ■ ■ ■
If the tests were abnormal, describe the findings: 
13. If an amniocentesis or placenta biopsy was performed, 
what was the reason?
■ Due to my age (normally 38 or older at the time of delivery)
■ Previous child with a chromosome disorder
■ Previous child with neural tube defect (spina bifida)
■ Epilepsy (medication for epilepsy)
■ Ultrasound findings
■ Other
2
Agree
completely Agree
Agree
somewhat
Disagree
somewhat
Disagree Disagree
completely
14. Were there complications during the first 2 weeks
following the amniocentesis?
■ No
■ Yes
15. If yes, what kind of complications?
■ Vaginal bleeding 
■ Leakage of amniotic fluid
■ Abdominal pain (similar to or stronger than menstrual pains)
■ Other  _______________________________________
16. Have you had an X-ray during pregnancy?
■ No
■ Yes
17. If yes, what part of your body was X-rayed? How many X-
rays were taken and in which week of pregnancy? (Fill in
one or more boxes.)
Teeth ■ ■ ■ ■ ■ ■
Lungs. ■ ■ ■ ■ ■ ■
Arms or legs ■ ■ ■ ■ ■ ■
Pelvis/abdomen/
back ■ ■ ■ ■ ■ ■
Other ■ ■ ■ ■ ■ ■
18. Have you received treatment to prevent a premature birth
during this pregnancy? (Fill in one or more boxes.)
■ No
■ Yes, relax or bed-rest 
■ Yes, medication 
Which medicines?
19. Have you been vaccinated during this pregnancy?
■ No
■ Yes
Which vaccine?__________________________________
20. Has the midwife or doctor told you that you have or have
had high blood pressure during this pregnancy?
■ No
■ Yes
21. If yes, what was the highest reading during this
pregnancy? (High blood pressure is over 140/90)
(Refer to your health card.)
■ Don’t know
22. Have you had high blood pressure without being
pregnant?
■ No
■ Yes
■ Don’t know
23. If yes, what was the highest reading before this
pregnancy?
■ Don’t know
/ /1 5 0 9 5E.g.
Week of pregnancy No. of
0-12     13-16    17-20    21-24    25-28     29+    times
/ /1 5 0 9 5E.g.
Was the test performed? 
Yes         No
Were the results normal? 
Yes         No
324. What was your blood percentage/haemoglobin (Hb) value dur-
ing this pregnancy? (Refer to your health card and note the
most recent, in addition to the highest and lowest values.)
Haemoglobin Week
(Hb) of preg
Value at last antenatal check-up 
during pregnancy
Highest value during pregnancy
Lowest value during pregnancy
■ Don’t know
,
,
,
25. How much did you weigh at your last antenatal check-up
and when was it? (Refer to your health card.)
Weight kg
Date of antenatal
check -up
Day Month Year
,
26. Have you been admitted to the hospital since you became pregnant?
■ No
■ Yes, which hospital(s) ____________________________________________________________________________________________
27. If yes, why and when were you hospitalised? (Fill in one or more boxes.)
In which week of pregnancy were you admitted?
0–4 5–8 9–12 13–16 17–20 21–24 25–28 29+
■ Prolonged nausea and vomiting  . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ 
■ Bleeding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
■ Leakage of amniotic fluid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
■ Threatening preterm labour  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
■ High blood pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
■ (Pre-)Eclampsia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
■ Other  _______________________________________________  . . . . . ■ ■ ■ ■ ■ ■ ■ ■
28. Do you have or have you ever had any of the following? 
If yes, how often have you had problems? How much at a time? 
1–4 1–6 More than
times times Once once Large
Before this pregnancy: No    Yes a month a week a day a day Drops amounts
Incontinence when coughing, sneezing or laughing ■ ■ ■ ■ ■ ■ ■ ■
Incontinence during physical activity 
(running / jumping) . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
Incontinence with a strong need to urinate. . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
Problems retaining faeces. . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
Problems with flatulence . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
In this pregnancy:
Incontinence when coughing, sneezing or laughing. 
Incontinence during physical activity 
(running / jumping) . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
Incontinence with a strong need to urinate. ■ ■ ■ ■ ■ ■ ■ ■
Problems retaining faeces. . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
Problems with flatulence . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
29. Do you have or have you had pain in any of the following parts of your body?  Where and when? 
(Fill in one or more boxes.)
During this pregnancy During earlier pregnancies Between pregnancies Prior to first pregnancy
Mild Severe Mild Severe  Mild Severe Mild Severe
No Pain Pain Pain Pain Pain Pain Pain Pain
Small of the back. . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
One of the pelvic/sacroiliac joints at the back ■ ■ ■ ■ ■ ■ ■ ■ ■
Both pelvic/sacroiliac joints at the back . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
Over the coccygeal bone. . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
In the buttocks. . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
Over the pubic bone . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
Groin . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
Other back pains . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■ ■
430. Do you wake up at night due to pelvic pain? 
■ Yes, frequently  
■ Yes, sometimes
■ No, never
31. Do you have to use a stick or crutches in order to walk
due to pelvic pain?
■ No, never
■ Yes, but not every day, the pain varies from day to day
■ Yes, I have to use a stick or crutches every day
32. Have you received an anaesthetic in connection with
surgery or dental treatment during this pregnancy?
■ No
■ Yes
33. If yes, what type of anaesthetic have you had? (Fill in one
or more boxes.)
■ General (full) anaesthetic
■ Spinal anaesthetic (epidural)
■ Local anaesthetic
■ Don’t know
34. Have you been to the dentist during this pregnancy?
■ No
■ Yes
35. If yes, did the dentist perform any of the following treat-
ments? (Fill in one or more boxes.)
Yes No
Put in new amalgam fillings (silver fillings) ■ ■ 
Removed or replaced amalgam fillings ■ ■
Put in new white fillings ■ ■
36. How many teeth do you have and how many have
fillings? (Look in the mirror and count.)
Total number of teeth
Number of teeth with amalgam fillings
Number of teeth with other types of fillings
37. At present, do your gums bleed when you brush your
teeth?
■ No, seldom or never
■ Yes, sometimes
■ Yes, frequently
■ Yes, nearly always
38. Have you had a tattoo or body piercing, including extra
holes in the ears?  (Do not include pierced ears if you
have one hole in each ear.)
■ No
■ Yes
39. If yes, where and when was it done?
(Fill in one or more boxes.)
Tattoo Body piercing
Before this pregnancy:
In Norway ■ ■
Abroad ■ ■
During this pregnancy:
In Norway ■ ■
Abroad ■ ■
40. Have you ever had a blood transfusion? If yes, give the
number of transfusions.
■  No
■  Yes, during this pregnancy Times
■  Yes, before this pregnancy Times
41. If yes, in which country and which year? (Give the last
2 transfusions.) YEAR
Country:
Country:
42. Have you ever had breast surgery?
■  No
■  Yes
43. If yes, was it:
■  Breast enlargement
■  Breast reduction
■  Cancer/biopsy
■  Other, describe:
44. Have you ever had cervical dysplasia?
■  No
■  Yes
Year the dysplasia was detected the first time
45. Have you had an operation on your cervix?
■  No
■  Yes
Year of operation
46. Have you ever had a gamma globulin injection? (used
to prevent infection of hepatitis A, primarily when
travelling abroad.)
■  No
■  Yes
If yes, which year?
5How have you been recently?
49. Do you know why you bled?
■  No
■  Yes
50. If yes, what was the reason? (Fill in one or more boxes.)
■  The placenta is too low/is in a difficult position/placenta previa
■  Premature separation of the placenta/abruptio/ablatio placenta 
■  Threatening miscarriage/premature birth
■  Cervical ulcer, bleeding of the mucous membrane in the vagina
■  Following intercourse
■  Other reason
Some questions about the time that has elapsed since the 13th week of pregnancy.
47. Have you had one or more episodes of vaginal bleeding after the 13th week of pregnancy?
■  No
■  Yes 
48. If yes, how much did you bleed, in which week(s) of pregnancy and how many days did the bleeding last? (If you have had
more than 2 episodes of bleeding, describe the last 2 only.)
In which week of pregnancy did the No. of days
The amount of blood bleeding occur? bleeding
(spotting means a few drops) 13–16 17–20 21–24 25–28 29+ lasted
1.■ Spotting ■ More than spotting ■ Large amounts ■ ■ ■ ■ ■
2.■ Spotting ■ More than spotting ■ Large amounts ■ ■ ■ ■ ■
■ Number of episodes of bleeding if more than 2
51. Have you been bothered by uterine contractions?
■  No
■  Yes, a little
■  Yes, a lot
52. Do you have or have you had any of the following illnesses or problems after the 13th week of pregnancy? If you have used tablets,
mixtures, suppositories, inhalers, creams, etc. in connection with the illness or problem, give the name(s) of the medication(s), when and
how long you took them. (Fill in one or more boxes.) (This applies to all types of medicines including alternative and herbal remedies, both
regular and occasional use. Do not include vitamins and nutritional supplements as these are asked about elsewhere.)
In which week of pregnancy In which week of pregnancy No.
did you have problems? did you take medication of days
13- 17- 21- 25- 29+ 13- 17- 21- 25- 29+ taken
16 20 24 28    The name of the medication taken 16 20 24 28
1 Pelvic girdle pain . . . 
2 Back pains . . . . . . . . 
3 Other pains in
muscles/joints . . . . . . 
4 Nausea . . . . . . . . . . . 
5 Long-term nausea
and vomiting . . . . . . . 
6 Vaginal thrush . . . . . . 
7 Vaginal catarrh,
unusual discharge. . . 
8 Pregnancy itch . . . . . . . 
9 Constipation . . . . . . . 
10 Diarrhoea/gastric flu. . . . 
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
Continued...
611 Unusual fatigue
/drowsiness. . . . . . . . . 
12 Heartburn . . . . . . . . . . 
13 Swelling of the body
(oedema) . . . . . . . . . . . 
14 Common cold . . . . . . . 
15 Throat infection . . . . . . 
16 Sinusitis/ear infection . . . . 
17 Influenza . . . . . . . . . . . 
18 Pneumonia
/bronchitis . . . . . . . . . . 
19 Other cough . . . . . . . . 
20 Sugar in urine . . . . . . . 
21 Protein in urine . . . . . . . . . 
22 Bladder infection/
cystitis . . . . . . . . . . . . . 
23 Incontinence . . . . . . . . 
24 High blood pressure . . 
25 Leg cramps . . . . . . . . . 
26 Asthma . . . . . . . . . . . . 
27 Hay fever/other allergy . . . 
28 Headache/migraine. . . 
29 Depression . . . . . . . . . 
30 Other psychological problems
31 Other . . . . . . . . . . . . . . 
53. If you have had a fever once or more since the 13th week of pregnancy, indicate in which week of pregnancy, name of any medication
taken to reduce the fever and the highest temperature measured. (If more than 3 times, indicate the last 3.)
Name any medication Highest recorded Temperature
Which week of pregnancy did you have a fever? taken to lower temperature not 
13–16 17–20 21–24 25–28 29+ the fever (e.g. 38.9° C) taken
1st time ■ ■ ■ ■ ■ °C ■
2nd time ■ ■ ■ ■ ■ °C ■
3rd time ■ ■ ■ ■ ■ °C ■
■ Fever more than 3 times
,
,
,
In which week of pregnancy In which week of pregnancy No.
did you have problems? did you take medication of days
13- 17- 21- 25- 29+ 13- 17- 21- 25- 29+ taken
16 20 24 28    The name of the medication taken 16 20 24 28
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■ ■ ■
Week of pregnancy supplement taken? How often did you take this supplement?
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■ ■
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54. Have you taken other medication after the 13th week of pregnancy not previously mentioned, for example, sleeping tablets or sedatives? Give
the name, when and how many days altogether the medication was taken for. (This applies to all types of medicines including alternative and herbal
remedies, both regular and occasional use. Do not include vitamins and nutritional supplements as these are discussed elsewhere.)
Name of medication Use of medication in week of pregnancy No. of days
(e.g. Valium, Rohypnol, Paracetamol) 13–16 17–20 21–24 25–28 29+ taken
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
55. During this pregnancy have you been involved in an accident or been 56. If yes, in which week of pregnancy?
injured (e.g. traffic accident, fall, hit in the stomach)?
■  No
■  Yes
57. Have you taken vitamins, minerals or other nutritional supplements after the 13th week of pregnancy?
■  No (go to question 61)
■  Yes
If you take supplements, please find the package/bottle.
58. Fill in the table below for the vitamins and minerals found on the vitamin package/bottle. Fill in when and
approximately how often you have taken them.
Vitamins, minerals and dietary supplements
1  Folate/folic acid  . . . . . . . . . . . . . . . . .
2  Vitamin B1 (Thiamine)  . . . . . . . . . . .
3  Vitamin B2 (Riboflavin)  . . . . . . . . . . .
4  Vitamin B6 (Pyridoxine)  . . . . . . . . . .
5  Vitamin B12   . . . . . . . . . . . . . . . . . . .
6  Niacin  . . . . . . . . . . . . . . . . . . . . . . . .
7 Pantothenic acid  . . . . . . . . . . . . . . . .
8  Biotin  . . . . . . . . . . . . . . . . . . . . . . . .
9  Vitamin C  . . . . . . . . . . . . . . . . . . . . .
10  Vitamin A  . . . . . . . . . . . . . . . . . . . . .
11  Vitamin D  . . . . . . . . . . . . . . . . . . . . .
12  Vitamin E  . . . . . . . . . . . . . . . . . . . . .
13  Iron  . . . . . . . . . . . . . . . . . . . . . . . . . .
14  Calcium  . . . . . . . . . . . . . . . . . . . . . .
15  Iodine  . . . . . . . . . . . . . . . . . . . . . . . .
16  Zinc  . . . . . . . . . . . . . . . . . . . . . . . . . .
17  Selenium  . . . . . . . . . . . . . . . . . . . . . .
18  Copper  . . . . . . . . . . . . . . . . . . . . . . .
19  Chromium  . . . . . . . . . . . . . . . . . . . . .
20  Magnesium  . . . . . . . . . . . . . . . . . . . .
21  Cod liver oil  . . . . . . . . . . . . . . . . . . .
22  Omega-3 fatty acid  . . . . . . . . . . . . .
13–16 17–20 21–24 25–28 29+
4-6 1-3
Daily times times
a week a week
8V I T A P L E X  M E D  J E R N  1
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5 
6 
e.g.
59. Give the complete name(s) of all the vitamins and nutritional supplements you take. Include also herbal remedies and diet
products. (Write clearly using CAPITAL LETTERS since this will be read by a computer.)
60. If you take multivitamins (with or without minerals), do these contain folate/folic acid?
■  No
■  Yes
■  Don’t know
WORK
61. Have you been in paid employment during this
pregnancy?
■  No (go to question 76 )
■  Yes
62. Do you have the same job conditions now after the
13th week of pregnancy that you described in the first
questionnaire?
■  No
■  Yes (go to question 66)
63. If no, in which week of your pregnancy did your work
situation change?
Week of pregnancy
64.  How has your work situation changed?
■  I have stopped working 
■  I have gone over to a part-time position
■  Other
65. If you have stopped working, why did you stop?
■  I handed in my notice
■  The work was temporary (seasonal, short-term contract)
■  I was fired
■  Other
66. Have your working arrangements been changed during
this pregnancy making your job more suitable for you
now that you are pregnant?
■  No
■  Yes
67. If no, why have your working conditions not been
changed to make them more suitable for you?
■  Not necessary
■  Impossible or nearly impossible
■  I have asked for changes but no changes have been made
■  It is difficult to ask
■  None of the above (explain why)
68. What are your working hours? (Fill in one or more boxes.)
■  Permanent day work 
■  Permanent afternoon or evening work
■  Permanent night work
■  Shift work or shift rotas
■  No set times (extra work, extra shifts, temporary employment, etc.)
■  Other
69. Answer each of the following questions for your present work. (Fill in each item.)
Yes daily, Yes daily,             Yes
more than less than periodically,    Seldom
half of half of but not              or
working hours working hours daily             never
Do you ever have so much to do that your work situation becomes stressful and annoying? . . ■  ■  ■  ■  
Do you have to bend or turn many times a day? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
Do you work with your hands at shoulder level or higher?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
Do you work standing or walking about?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
In some jobs it is possible to decide yourself how much and how quickly you work. You can, for example, work
a little faster one day and take it a little easier the next. Do you have this opportunity?  . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
Is there so much noise at your workplace that it is uncomfortable?  . . . . . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
Is there so much noise that you have to raise your voice to speak
with others even at a distance of one metre?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■  ■  ■  ■
973. Are you absent from regular work at the present
time?
■ No
■ Yes, part time
■ Yes
74. If yes, why are you currently absent from work?
(Fill in for only one item.)
■ Sick leave (with sick compensation pay)
■ Absent due to sick child
■ Made redundant with compensation
■ Absent with maternity allowance due to the working environment
■ Started maternity leave (with allowance)
■ Service leave
■ Other (describe)
70. How often have you worked with a radio transmitter
or radar after the 13th week of pregnancy?
■ Seldom/never
■ A few times a week
■ Daily
■ On average, more than 1 hour a day
71. How often have you worked with X-ray equipment (at
a distance of less than 2 metres) after the 13th week
of pregnancy? (Do not include treatment as a patient.)
■ Seldom/never
■ A few times a week
■ Daily
■ On average, more than 1 hour a day
72. Have you been absent from your normal job for more
than two weeks after the 13th week of pregnancy?
■ No
■ Yes, part time
■ Yes
75. Complete the table below if you were on sick leave (full or part time) after the 13th week of pregnancy. Fill in the reason (e.g.
pelvic girdle pain, pneumonia), which weeks you were on sick leave, the number of days and the percentage of time each peri-
od of sick leave represents. (Give one reason for sick leave per line.)
Reason for sick leave
Example: Pelvic girdle pain ■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
76. Do you currently lift anything over 10 kilos while you are
pregnant? (10 kilos is equivalent to a full bucket of water)
Home Work
Seldom or never . . . . . . . . . . . . . . . . . . . . ■ ■
Yes, less than 20 times a week . . . . . . . . ■ ■
Yes, more than 20 times a week . . . . . . . . ■ ■
Yes, 10-20 times a day . . . . . . . . . . . . . . . ■ ■
Yes, more than 20 times a day . . . . . . . . . ■ ■
77. Have others helped you with housework or childcare
more than they usually do to relieve you during this preg-
nancy?
■ Yes, considerably
■ Yes, to a fair extent
■ No, no one has offered
■ No, it has not been necessary
78. If you are on maternity leave for this pregnancy, when
did it start?
Date: 
day           month year
Sick leave during week of
pregnancy:
13- 17- 21- 25- 29+
16 20 24 28
Number of
days
%
sick leave
1  4 5  0
Habits
79. How often do you talk on a mobile phone?
■ Seldom/never
■ A few times a week
■ Daily
■ On average, more than 1 hour a day
80. Do you talk on your mobile phone for longer than 15
minutes at a time?
■ Never
■ Seldom
■ Frequently
81. How frequently have you worked with a computer monitor, laser
printer or photocopy machine (at a distance of less than 2 metres)
after the 13th week of pregnancy?
Computer Laser Photocopy
monitor printer machine
Seldom/never . . . . . . . . ■ ■ ■
A few times a week . . . ■ ■ ■
Daily. . . . . . . . . . . . . . . . . . ■ ■ ■
On average, more than
1 hour a day . . . . . . . . ■ ■ ■
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83. How often have you been to a discotheque since
you answered the previous questionnaire?
■ Never
■ At least 1-2 times a week
■ Less often
82. Do you live close to high-voltage power lines?
■ No
■ Yes, closer than 50 metres
■ Yes, between 50 - 100 metres
■ Yes, more than 100 metres
84. How often do you exercise at present? (Fill in for each item.)
1-3 3 times
times Once Twice or more
Never a month a week a week a week
1. Walking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
2. Brisk walking  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
3. Running/jogging/orienteering  . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
4. Cycling  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
5. Training studio/weight training  . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
6. Special gymnastics/aerobics for pregnant women  . . . . . . . . . ■ ■ ■ ■ ■
7. Aerobics/gymnastics/dance without running and jumping  . . . ■ ■ ■ ■ ■
8. Aerobics/gymnastics/dance with running and jumping  . . . . . ■ ■ ■ ■ ■
9. Dancing (swing/rock/folk)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
10. Skiing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
11. Ball sports  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
12. Swimming  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
13. Riding  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
14. Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
85. How often do you do exercises at home or at a gym for the following groups of muscles? (Fill in for each item.)
1-3
times Once Twice 3 times
Never a month a week a week a week or more
Abdominal muscles ■ ■ ■ ■ ■
Back muscles ■ ■ ■ ■ ■
Pelvic floor muscles
(Muscles around the vagina, urethra, anus) ■ ■ ■ ■ ■
86. How often at the moment are you so physically active in your spare time and/or at work that you get out of breath or
sweat? (Fill in for both spare time and work.)
Spare time At work
Never  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Less than once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Twice a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
3-4 times a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
5 or more times a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
87. How often on average have you had sexual intercourse
during the last month?
■ Daily
■ 5-6 times a week
■ 3-4 times a week
■ 1-2 times a week
■ Less frequently
■ Never
88. Have you been abroad during the last year?
■ No
■ Yes 
89. If yes, which countries did you visit and when?
Country                                      Month             Year
90. Have you come into contact with animals either at
work or in your free time?
■ No
■ Yes
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91. If yes, which animals have you come into contact with and
how often?
3–6 1-2
Daily times times Less
a week a week often
Dog . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Cat . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Guinea pig/hamster/rabbit/rat, etc. . ■ ■ ■ ■
Canary or other caged birds. . . ■ ■ ■ ■
Hens and other poultry . . . . . . . ■ ■ ■ ■
Cow/sheep/goat . . . . . . . . . . . . ■ ■ ■ ■
Horse . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Pig. . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Other . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
92. How many hours a day do you usually sleep now when
you are pregnant?
■ Over 10 hours
■ 8–9 hours
■ 6-7 hours
■ 4-5 hours
■ Less than 4 hours
93. Do you currently sleep on a waterbed or use an electric
blanket?
Yes No
Waterbed . . . . . . . . . . . . . ■ ■
Electric blanket . . . . . . . . . ■ ■
94. Can you rest during the day (both at home and at work)?
■ No
■ Yes
95. Have you been in a sauna while you have been pregnant?
■ No
■ 1–5 times
■ 6-10 times
■ More than 10 times
96. Have you been in a solarium while you have been
pregnant?
■ No
■ 1-5 times
■ 6-10 times
■ More than 10 times
97. Are you exposed to passive smoking either at home or at
work? If yes, how many hours a day?
No Yes No. of hrs
Home . . . . . . . . ■ ■
Work. . . . . . . . . ■ ■
98. Do you smoke at present? If yes, how many cigarettes?
■ No
■ Sometimes Cigarettes per week
■ Daily Cigarettes per day
99. Does the baby’s father smoke at present? If yes, how
many cigarettes?
■ No
■ Sometimes Cigarettes per week
■ Daily Cigarettes per day
100. If one or both of you have stopped smoking during the
pregnancy, in which week of pregnancy did you stop?
■ You Week of pregnancy
■ Baby’s father Week of pregnancy
101. If you or the baby’s father have smoked during the
pregnancy, were there periods during which you or the
baby’s father did not smoke? (Fill in the weeks during
pregnancy when you did not smoke.)
Weeks of pregnancy without smoking
0–4 5–8 9–12 13–16 17–20 21–24 25–28 29+
You . . ■ ■ ■ ■ ■ ■ ■ ■
Baby’s 
father . . . ■ ■ ■ ■ ■ ■ ■ ■
102. Have you used other forms of nicotine after the 13th week
of pregnancy?
No Yes
Nicotine chewing gum  . . . . . . . .■ ■
Nicotine patches  . . . . . . . . . . . . .■ ■
Nicotine inhaler  . . . . . . . . . . . . . .■ ■
Chewing tobacco/snuff  . . . . . . . .■ ■
103. Have you used any of the following substances after the
13th week of pregnancy?
No Yes
Hash . . . . . . . . . . . . . . . . . . . . . . ■ ■
Amphetamine . . . . . . . . . . . . . . . ■ ■
Ecstasy . . . . . . . . . . . . . . . . . . . . ■ ■
Cocaine . . . . . . . . . . . . . . . . . . . ■ ■
Heroin. . . . . . . . . . . . . . . . . . . . . ■ ■
104. Have you ever used any of the following substances? (Fill in for each item.)
Last 6 months During
before this
No Previously pregnancy pregnancy
Anabolic steroids  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■
Testosterone products  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■
Growth hormones (e.g. genotropin/somatropin)  . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■
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Food and drink
105. How often do you eat the following foods? (Fill in for each item.)
Before the pregnancy During the pregnancy
A few 1–3 Once a 1–3 Once a 
Never times times a week Never times a week
a year Month or more                                   month        or more  
1 Crab  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
2 Shrimps  . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
3  Shellfish (e.g. mussels, oysters)  . . ■ ■ ■ ■ ■ ■ ■
4 Fish liver  . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
5  Tuna fish or halibut  . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
6  Flounder/other flat fish  . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
7 Pike or perch . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
8 Other fresh water fish  . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
9 Reindeer meat . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
10 Mutton . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
11 Liver or kidney from game  . . . . . . ■ ■ ■ ■ ■ ■ ■
12 Wild mushrooms  . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
106.  How often do you eat the following types of food? (Fill in for each item.)
A few 1-3 times Once a week
Never times a year a month or more
Food from restaurant/street vendors/canteen or the like  . . . . . . . . . . . . . . . ■ ■ ■ ■
Meat (not including tinned) bought in other countries  . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Meat (including poultry) that is raw or undercooked (pink near the bone)  . . . . . . . . . . ■ ■ ■ ■
Raw minced meat/meat mixtures (even to taste)  . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Smoked or cured salmon or trout (uncooked)  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Soft cheeses (e.g. cream cheese, camembert, blue cheese, etc.) . . . . . . . . ■ ■ ■ ■
Unwashed raw vegetables, unwashed fruit  . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
107. Do you avoid eating the following foods during this
pregnancy?
No Yes
Fish ■ ■
Eggs ■ ■
Nuts ■ ■
Oranges, lemons ■ ■
Strawberries ■ ■
Other, specify
108. What type of drinking water do you have where you live?
■ Own water source (e.g. well)
■ Water company (public or private)
■ Other source
Name of water company
■ Don’t know the name of the water company
109. Is your water treated (chlorinated or UV-radiated)?
■ No
■ Yes, UV radiation
■ Yes, chlorinated
■ Don’t know
110.What was your fluid consumption (number of
cups/glasses) per day after the 13th week of
pregnancy? (1 mug = 2 cups, 1 small plastic bottle (0.5
litre) = 4 cups, 1 large plastic bottle (1.5 litres) = 12 cups)
Number of Decaffeinated
cups / glasses      (fill in)
1. Filter coffee . . . . . . . . . . . . ■
2. Instant coffee . . . . . . . . . . ■
3. Boiled coffee. . . . . . . . . . . ■
4. Other coffee . . . . . . . . . . . ■
5. Tea . . . . . . . . . . . . . . . . . . ■
6. Coca Cola/Pepsi, etc.. . . . ■
7. Other fizzy drinks . . . . . . . ■
8. Diet Coca Cola, diet Pepsi ■
9. Other diet fizzy drinks. . . . ■
10. Tap water . . . . . . . . . . . . . 
11. Bottled water. . . . . . . . . . . 
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Number of Organic
cups/glass (fill in)
12. Juice/squash . . . . . . . . . . ■
13. Diet juice/squash . . . . . . . ■
14.  Milk (skimmed, low fat, whole) ■
15.  Yogurt, all types.. . . . . . . . ■
16.  Yogurt with active Lactobacillus all types ■
17.  Other type of cultured milk (kefir) ■
18. Other. . . . . . . . . . . . . . . . . ■
111. How often did you consume alcohol before and how
often do you consume it now?
Last 3 months In this pregnancy
before last week of pregnancy
period 0–12 13–24 25+
Roughly 6-7 times a week . ■ ■ ■ ■
Roughly 4–5  times a week ■ ■ ■ ■
Roughly 2-3  times a week . ■ ■ ■ ■
Roughly 1 time a week . . . . ■ ■ ■ ■
Roughly 1–3 times a month ■ ■ ■ ■
Less then once a month . . . ■ ■ ■ ■
Never. . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Alcohol units
Alcohol units are used to compare the different types of alcoholic
beverages. 1 alcohol unit = 1.5 cl. pure alcohol.
1 glass of beer = 1 alcohol unit
1 wine glass of red or white wine = 1 alcohol unit
1 sherry glass of sherry or other fortified wine = 1 alcohol unit
1 spirit glass of spirits or liqueur = 1 alcohol unit
1 bottle/can breezer or cider = 1 alcohol unit
You and your life now
119. Do you often feel lonely?
■ Almost never
■ Seldom
■ Sometimes
■ Usually
■ Almost always
120. If you have given birth before, in general, how was the
experience of giving birth?
■ Very good
■ Good
■ Alright
■ Bad
■ Very bad
116. What is your current civil status?
■ Married
■ Cohabiting
■ Single
■ Divorced/separated 
■ Widowed
■ Other
117. Do you have anyone other than your husband/partner you
can ask for advice in a difficult situation?
■ No.
■ Yes, 1 or 2 people
■ Yes, more than 2 people
118. How frequently do you meet or talk on the telephone with
your family (other than your husband/partner and
children) or close friends?
■ Once a month or less
■ 2-8 times a month
■ More than twice a week
112. In the period just before you became pregnant and during this
pregnancy, how many times have you consumed 5 units or
more of alcohol? (See the explanation for units.)
Last 3 mths
In this pregnancy
before last week of pregnancy
period 0–12 13–24 25+
Several times a week  . . . . . ■ ■ ■ ■
Once a week . . . . . . . . . . . . ■ ■ ■ ■
1-3 times a month  . . . . . . . ■ ■ ■ ■
Less than once a month  . . . ■ ■ ■ ■
Never  . . . . . . . . . . . . . . . . . ■ ■ ■ ■
113. How many units do you usually drink when you consume
alcohol? (See the above explanation.)
Last 3 mths
In this pregnancy
before last week of pregnancy
period 0–12 13–24 25+
10 or more  . . . . . . . . . . . . ■ ■ ■ ■
7–9  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
5–6  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
3–4  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
1–2  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Less than 1 . . . . . . . . . . . . ■ ■ ■ ■
114. If you have changed your drinking habits before this
pregnancy, when did the change occur? (Fill in one or more boxes.)
Reduced intake Increased intake
Last 3 months before last period ■ ■
During pregnancy weeks 0-6 ■ ■
During pregnancy weeks 7-12 ■ ■
During pregnancy weeks 13-24 ■ ■
After pregnancy week 25 ■ ■
115. If you have modified your consumption of alcohol, how
important were the following factors? (Fill in one or more boxes.)
Not Not very Quite Important Very
relevant important important important
Nausea, discomfort  . . ■ ■ ■ ■ ■
Altered taste  . . . . . . . . ■ ■ ■ ■ ■
For the baby’s sake  . . ■ ■ ■ ■ ■
Depression/problems  . ■ ■ ■ ■ ■
Other reasons . . . . . . . ■ ■ ■ ■ ■
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121. Do you agree or disagree with the following statements relating to the forthcoming birth of your baby?
(Fill in for each statement.)
Agree Agree Disagree Disagree 
completely Agree somewhat somewhat Disagree completely
I want to give birth as naturally as possible without painkillers or intervention . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am really dreading giving birth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I want to have enough medication so that the birth will be painless. . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I want to have an epidural regardless . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I want to have an epidural if the midwife agrees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
If I could choose I would have a caesarean. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I think the woman herself should decide whether or not to have a caesarean . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I worry all the time that the baby will not be healthy or normal. . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am really looking forward to the baby coming. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
122. How do these statements describe your relationship? (Only answer if you have a partner.)
(Fill in for each statement.)
Agree Agree Agree Disagree Disagree Completely
completely somewhat somewhat disagree
My husband/partner and I have a close relationship. . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
My partner and I have problems in our relationship . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am very happy in my relationship . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
My partner is usually understanding . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I often think about ending our relationship . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am satisfied with my relationship with my partner . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
We often disagree about important decisions . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I have been lucky in my choice of a partner . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
We agree on how children should be raised . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I think my partner is satisfied with our relationship . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
123. Have you been bothered during the last 2 weeks by any of the following? (Enter a cross in a box for each item.)
Fairly         Very
Not Slightly much much
bothered bothered bothered bothered
1. Feeling fearful  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
2. Nervousness or shakiness inside  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
3. Feeling hopeless about the future  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
4. Feeling blue  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
5. Worrying too much about things  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
6. Feeling everything is an effort  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
7. Feeling tense or keyed up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
8. Suddenly scared for no reason  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
124. How often do you experience the following in your everyday life? (Fill in for each statement.)
Seldom/ Fairly seldom Sometimes Often Very often
never
Feel pleased about something . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
Feel happy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
Feel joyful, as though everything is going your way . . . . . . . . . . . . . ■ ■ ■ ■ ■
Feel that you will scream at someone or hit something . . . . . . . . . . ■ ■ ■ ■ ■
Feel angry, irritated or annoyed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
Feel mad at someone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
125. How well do these statements describe you? (Fill in for each statement.)
Incorrect Partly Almost Completely
correct correct correct
I always manage to solve difficult problems if I try hard enough  . . . . . . . . . . ■ ■ ■ ■
If anyone opposes me, I find a way to get what I want  . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I am sure that I can cope with unexpected events  . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I am calm when I encounter difficulties because I trust my ability to cope  . . ■ ■ ■ ■
When I am in a difficult situation, I usually find a solution  . . . . . . . . . . . . . . . ■ ■ ■ ■
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126. Do you agree or disagree with the following statements? (Fill in for each statement.)
Disagree Disagree Disagree Don’t agree Agree Agree Agree
completely somewhat or disagree somewhat completely
My life is largely what I wanted it to be  . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
My life is very good  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
I am satisfied with my life  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
I have achieved so far what is important for me in my life  . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
If I could start all over, there is very little I would do differently . . . . . . ■ ■ ■ ■ ■ ■ ■
127. How do you feel about yourself? (Fill in for each statement.)
Agree Disagree
completely Agree Disagree completely
I have a positive attitude toward myself . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel completely useless at times . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel that I do not have much to be proud about. . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel that I am a valuable person, as good as anyone else . . . . . . . . . . . . . . ■ ■ ■ ■
128. Have you experienced any of the following during the last 12 months? If yes, how painful or difficult was it for you?
(Fill in for each statement.)
IF YES
Not too Painful/ Very painful/
No Yes bad difficult difficult
Have you had problems at work or where you study?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Have you had financial problems?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Have you been divorced, separated or ended your relationship with your partner? . . . . . . .■ ■ ■ ■ ■
Have you had problems or conflicts with your family, friends or neighbours?  . . . . . . . . . . .■ ■ ■ ■ ■
Have you been seriously ill or injured?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Has anyone close to you been seriously ill or injured?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Have you been involved in a serious accident, fire or robbery?  . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Have you lost someone close to you?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■
129. Have you ever experienced any of the following? (Fill in for each statement.)
Someone has over a long period of time
systematically tried to subdue, degrade or humiliate you  . .■ ■ ■ ■ ■ ■ ■ ■
Someone has threatened to hurt you
or someone close to you  . . . . . . . . . . . . . . . . . . . . .■ ■ ■ ■ ■ ■ ■ ■
You have been subjected to physical abuse  . . . . . .■ ■ ■ ■ ■ ■ ■ ■
You have been forced to have sexual intercourse  . .■ ■ ■ ■ ■ ■ ■ ■
Miscellaneous
130. Has anyone living with you had any of the following ill-
nesses during this pregnancy? (Enter a cross and specify the period)
In which week of pregnancy?
0–9 10–19 20–29 30+
■ Influenza. . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
■ Childhood diseases (fever and rash) . . . . . . ■ ■ ■ ■
■ Prolonged cough . . . . . . . . . . . . . . . . ■ ■ ■ ■
■ Other infectious disease . . . . . . . . . . ■ ■ ■ ■
131. Have there been any instances of cot death in your family
or your partner’s family?
■ No
■ Don’t know
■ Yes, in my family (see question 132) 
■ Yes, in the baby’s father’s family (see question 133) 
132. The child that died of cot death in my family was:
■ My sister
■ My brother
■ My sister’s child . . . . . . . . . . ■ Boy ■ Girl
■ My brother’s child . . . . . . . . ■ Boy ■ Girl
■ My mother’s sibling . . . . . . . . ■ Boy ■ Girl   ■ Sex unknown
■ My father’s sibling . . . . . . . . ■ Boy ■ Girl   ■ Sex unknown
■ Other
Has this
occurred during
the last year?
No Yes
Who was responsible for this?
A Family or Another
stranger relative known person
Yes, as Yes, as
a child an adult
No, (under (over
never 18) 18)
16
133. The child that died of cot death in the baby’s father’s family was:
■ Baby’s father’s sister
■ Baby’s father’s brother
■ Baby’s father’s sister’s child ■ Boy ■ Girl
■ Baby’s father’s brother’s child ■ Boy ■ Girl
■ Baby’s paternal grandmother’s sibling ■ Boy ■ Girl ■ Sex unknown
■ Baby’s paternal grandfather’s sibling ■ Boy ■ Girl ■ Sex unknown
■ Other
134. Have you ever lost a child?
■ No (if no, you are finished with the questionnaire)
■ Yes
135. If yes, what was the cause of death and when did the
death occur?
■ Stillbirth (Birth after the 16th week of pregnancy.)
■ Cot death
■ Accident
■ Illness/birth defect
Which illness/birth defect:
■ Other
Year Child’s age
Child 1
Child 2
Years Months
136. Did you receive counselling from healthcare staff or other
persons after the death? How many sessions did you
have with healthcare staff, and/or parent support group,
family and friends? How many weeks did you receive
support?
Healthcare Parent support group, 
staff family, friends
Number of meetings
(approximately):
Number of sessions via
telephone (approximately):
Weeks of support
(approximately):
137. Do you feel that the follow -up you received after your
child’s death was adequate?
■ No follow-up was provided
■ Very good
■ Good enough
■ Should have been better
■ Bad
138. Has the death made you more anxious during this
pregnancy?
■ No, not at all
■ No, not very much
■ Yes, to a fair extent
■ Yes, very much
139. Do you feel that the health care staff at the antenatal
clinics took into consideration this painful experience in
their contact with you?
■ Yes, very much
■ Yes, to a fair extent
■ No, not at all
Have you remembered to fill in the date on which you completed the
questionnaire on page 1?
Thank you very much for your help!
Please return the completed questionnaire in the stamped addressed
envelope provided.
Questionnaire 4  - When your child is around 6 months old
This questionnaire comes in two parts. The first part is about your child, while the other part is about yourself. It will help if you have your
childʼs health card to hand before you start answering the questions so that you can use the information contained in it when completing
this questionnaire. If you find a question difficult to answer, you can skip it and go onto the next question.
If you have had twins or triplets, complete one questionnaire for each child.
The questionnaire will be processed by a computer. It is therefore important that you follow these
instructions when completing it:
Use a blue or black ballpoint pen.
In the small check boxes, enter a cross to indicate what you think is the most appropriate answer like this: ■
If you make a mistake you can delete the cross by filling in the box completely like this: ■
Write numbers in the large green boxes.
It is important that you only write in the white area of each box like this:
Number:
In the case of numbered boxes with more than one square, enter a one-digit number in the right box. Example: 5 is entered as follows
Date boxes are split into 3 sections, with the first one for the day of the month, the second one for the month and the last one for the year.
So, enter the date as follows:
Day           Month Year
Specific information concerning, for example, medication should be written on the lines provided. Please write clearly!
As soon as you have completed the questionnaire, return it to us in the enclosed stamped addressed envelope.
X
•
•
•
•
•
•
Day Month Year
About your child’s birth
1
+
+
+
Specify the day, month and year when the questionnaire
was completed (write the year in full, e.g. 2005)
1. Is your child a boy or girl?
■ Boy
■ Girl
2. How big was your child when he/she was born?
Birth weight:  g
Length:         cm
3. In which week of your pregnancy did you give birth?
week
4. How long was your child in hospital after the birth?
Number of days                    or weeks 
5. Was your child transferred to another department or
hospital after the birth?
■ No
■ Yes
If yes, specify  
–––––––––––––––––––––––––––––––––––––––––––
6. Was your child delivered by caesarean section? 
■ No
■ Yes+ +
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15. What did you give your child to drink during the first
week of life?
(You can enter a cross in more than one box.)
■ Breast milk
■ Water
■ Sugar water
■ Formula
■ Other, specify: ___________________________________________
■ Donʼt know/donʼt remember 
7. If yes, was the caesarean section planned?
■ No
■ Yes
If yes, why?
■ Breech presentation
■ Previous caesarean
■ Pregnancy complication or mother taken ill
■ Poor growth or other factor relating to the foetus
■ Own preference
■ Other
8. Were there any complications during the birth?
■ No
■ Yes
If so, describe:_______________________________________________
9. Were you admitted or transferred to another department
or other hospital due to complications in connection with
the birth? (Applies both before and after the birth.)
■ No
■ Yes
10. If yes, where?
Department:
____________________________________________________
Hospital: ____________________________________________________
11. How many days were you in hospital in connection with
the birth?
Before the birth  Number of days
After the birth Number of days
12. Did the birth go as you had expected?
■ Yes, as expected
■ No, it went better
■ Neither/nor
■ No, it was worse
■ Donʼt know
13. How true do you think the following descriptions are of
the birth? (Enter a cross in a box for each item.)
Fairly Partially Not
true true true
I felt safe and in good hands  . . . . . . . ■ ■ ■
I was in a lot of pain  . . . . . . . . . . . . . . ■ ■ ■
I received too few pain-killing
drugs . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
14. Was anyone from your close family present at the birth?
■ Yes, childʼs father
■ Yes, someone else
■ No
16. What has your child been given to drink during the first
6 months of his/her life?
(Enter a cross for each month you gave your child the relevant drink.)
Childʼs age in months
0 1 2 3 4 5 6
Breast milk . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
Standard Collett formula  . ■ ■ ■ ■ ■ ■ ■
Collett formula with Omega 3 ■ ■ ■ ■ ■ ■ ■
Standard NAN formula  . . ■ ■ ■ ■ ■ ■ ■
Nan HA1 formula . . . . . . . ■ ■ ■ ■ ■ ■ ■
Other milk, specify:
________________________ ■ ■ ■ ■ ■ ■ ■
Water  . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
Squash/Juice  . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
About your child
Nutrition
+
+
+
+
17. How often do you give your child the following to drink at the
moment? (Enter a cross in a box for each item.)
Never / 1-3 times 4-6 times At least
seldom a week a week once a day
1. Breast milk  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
2. Breast milk supplement  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
3. Normal sweet milk, any type  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
4. sour milk (yogurt, buttermilk, etc.)  . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
5. Organic milk products (milk, yogurt)  . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
6. Boiled water  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ Cont.+
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7. Tap water  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
8. Bottled water  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
9. Bottled baby cordial  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
10. Other type of cordial, sweetened  . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
11. Cordial, artificially sweetened  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
12. Juice  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
13. Other, specify: __________________________________________________ ■ ■ ■ ■
Instant porridge 
1. Rice porridge, maize porridge  . . . . . . . . ■ ■ ■ ■
2. Oatmeal porridge, different types  . . . . . ■ ■ ■ ■
3. Wheat porridge, all types, rusk porridge ■ ■ ■ ■
Home-made porridge using:
4. Wheat flour (rough/fine), rusk, semolina, oats ■ ■ ■ ■
5. Iron-enriched wheat flour  . . . . . . . . . . . . ■ ■ ■ ■
6. Helios baby flour  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
7. Millet  . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Processed dinner in a jar:
8. Vegetables  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
9. Vegetables and meat  . . . . . . . . . . . . . . . ■ ■ ■ ■
Home-made dinner:
10. Potato/vegetable puree  . . . . . . . . . . . . . ■ ■ ■ ■
11. Meat and vegetables/potatoes  . . . . . . . . ■ ■ ■ ■
12. Fish and vegetables/potatoes  . . . . . . . . ■ ■ ■ ■
13. Other type of home-made dinner  . . . . . ■ ■ ■ ■
Snack/dessert:
14. Home-made fruit puree  . . . . . . . . . . . . . ■ ■ ■ ■
15. Fruit/berry puree in a jar  . . . . . . . . . . . . ■ ■ ■ ■
16. Rusks/biscuits/bread  . . . . . . . . . . . . . . . ■ ■ ■ ■
17. Other, specify: _______________________ ■ ■ ■ ■
How often do you give this to your child?
Never/ 1-3 times 4-6 times At least
seldom a week a week once a day
18. How often does your child eat the following food at the moment, and how old was your child when you started giving him/her this food?
How old was your child
when you gave him/her
this foodfor the first time?
months
months
months
months
months
months
months
months
months
months
months
months
months
months
months
months
months
++
+
+
+ Never / 1-3 times 4-6 times At leastseldom a week a week once a day
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19. Do you think or do you know that your
child has a reaction to milk/dairy products?
■ No
■ Yes
21. Do you give your child cod liver oil, vitamins, iron or any other dietary supplement?
■  No             ■  Yes
Growth, health and use of medication
23. How many times have you been to the mother
and child health centre with your child?
■ Never
■ 1-2 times
■ 3-5 times
■ 6-10 times
■ more than 10 times
24. Has your child been given the vaccinations recommended
by the health centre?
■ Yes
■ No, donʼt want vaccination
■ No, your child has been often ill
■ No, vaccinations postponed for practical reasons
■ Donʼt know +
+
+
You will find the information to help you answer the following questions on your childʼs health card.
22. If you give your child cod liver oil, vitamins, iron or another dietary supplement, specify how much you give your child each
time and how often. How old was your child in months and weeks when you gave him/her the product for the first time?
How many How old was your child when you
Name of product teaspoons each time? How often do you give your child this?  started giving the product?
1. Cod liver oil  . . . . . . . . . . . . . . . . . . . . . . . . teaspoons . . . . . ■ daily . . . ■ sometimes . . . . . months and   . . weeks
2. Biovit  . . . . . . . . . . . . . . . . . . . . . . . . . . . . teaspoons . . . . . ■ daily . . . ■ sometimes . . . . . months and   . . . weeks
3. Sanasol  . . . . . . . . . . . . . . . . . . . . . . . . . . teaspoons . . . . . ■ daily . . . ■ sometimes . . . . . months and   . . weeks
4. Nycoplus Multi-Vitamin mixture for children teaspoons . . . . . ■ daily . . . ■ sometimes . . . . . months and   . . . weeks
5. Fluoride  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ daily . . . ■ sometimes . . . . . months and   . . . weeks
6. Iron supplement, specify:
__________________________________________________________________ ■ daily . . . ■ sometimes . . . . . months and   . . . weeks
7. Other dietary supplement, specify: 
__________________________________________________________________ ■ daily . . . ■ sometimes . . . . . months and   . . . weeks
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25. Referring to your child’s health card, enter a cross for the vaccinations which your child has received and whether the
vaccinations had any side-effect. (Enter a cross in a box for each item.)
Was there any Was there any
Has your Was there any side-effect resulting in side-effect resulting in
child received side-effect after contact with hospital
the vaccination? the vaccination? a doctor? admission?
Vaccinations No        Yes No        Yes No         Yes No        Yes
1. DTP (Infanrix)  . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
2. DT (diphtheria/tetanus)  . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
3. Polio – Hib (Act-Hib polio)  . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
4. Hepatitis B (Engerix-B)  . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
5. BCG (tuberculosis)  . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
6. Pneumococcus (Prevenar)  . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■ ■
7. Other vaccination:_______________________ ■ ■ ■ ■ ■ ■ ■ ■
20. If yes, which products?
■ Whole milk
■ Low-fat milk/skimmed milk
■ Cream/whipped cream/ice cream
■ Yogurt/sour milk
■ Breast milk when mother is drinking milk
■  Other
+
+
26. Referring to your child’s health card, enter below your child’s weight, length and head circumference when he/she was
around 6 weeks, 3 months and 6 months.
Date of examination
Day Month           Year Length Head circumference Weight
Approx. 6 weeks
Approx. 3 months
5-6 months
cm
cm
cm
g
g
g
cm
cm
cm
,
,
,
,
,
,
+
+
+
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27. Does your child have or has he/she had any of the following health problems? If yes, has the mother and child health centre
or someone else referred your child for further specialist investigation? (Enter a cross in a box for each item.)
Has your child been referred for a
Has(had) your child specialist investigation?
problems?
No Yes No Yes, referred Yes, referred
from health centre by someone else
1. Hip disorder/dislocated hip ■ ■ ■ ■ ■
2. Impaired hearing ■ ■ ■ ■ ■
3. Impaired vision ■ ■ ■ ■ ■
4. Delayed motor development (movement development) ■ ■ ■ ■ ■
5. Too little weight gain ■ ■ ■ ■ ■
6. Too much weight gain ■ ■ ■ ■ ■
7. Abnormal head circumference ■ ■ ■ ■ ■
8. Heart defect ■ ■ ■ ■ ■
9. Testicles not descended into scrotum ■ ■ ■ ■ ■
10. Asthma ■ ■ ■ ■ ■
11. Atopic eczema (childhood eczema) ■ ■ ■ ■ ■
12. Hives ■ ■ ■ ■ ■
13. Food allergy/intolerance ■ ■ ■ ■ ■
14. Delayed psychomotor development (several functions) ■ ■ ■ ■ ■
15. (Other) malformations: _______________________________ ■ ■ ■ ■ ■
16. Other:______________________________________________ ■ ■ ■ ■ ■
+
28. If your child was referred for a specialist investigation,
what did this investigation show?
■ Everything was fine
■ Still some doubts/further investigations needed
■  Donʼt know
■ Given the following diagnosis: ___________________________
________________________________________________________
________________________________________________________
29. Is you child suspected of having a syndrome or chromo-
somal defect?
■ No
■ Yes, a syndrome
■ Yes, a chromosomal defect
■ If yes, specify the name or describe the problem:_________
________________________________________________________
________________________________________________________
30. Has your child been treated for a hip problem (hip dysplasia)?
■ No ■ Yes, treated with a plaster cast
■ Yes, treated with a cushion ■ Yes, treated with braces
If yes, how long did the treatment go on for?            months
+
The following questions concern any illnesses or health problems your child has had. We will first ask you about more
longterm problems, then about illnesses and problems of a more acute nature.
631. Has your child had the following illness/health problem? If yes, did you go to a doctor or hospital about it? (Enter a cross in a box for each item.)
Has your child had Number Did you go to a Has your child been
health problems?of times doctor/clinic admitted to hospital
for this?for this?
No Yes No Yes No Yes
1. Common cold  . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
2. Throat infection  . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
3. Ear infection  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
4. Pseudocroup  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
5. Bronchitis/RS virus/pneumonia . . . . . . . . . ■ ■ ■ ■ ■ ■
6. Gastric flu/diarrhoea  . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
7. Urinary tract infection  . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
8. Conjunctivitis  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
9. Febrile convulsions  . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
10. Other convulsions (without any fever) . . . . ■ ■ ■ ■ ■ ■
11. Colic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
12. Nappy rash  . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
13. Other, describe ___________________________ ■ ■ ■ ■ ■ ■
32. Have your child ever been given any medication?
■ No
■ Yes
33. If yes, give the name of the medicines and when they were given. (Include all types of medication, as well as natural medicines,
taken both on a regular and occasional basis.)
How old was your child when you
Name of medicine gave the medicine?
(e.g. Apocilin, Paracetamol) <1 1-2 3-4 5-6 Number of days
Month months months months given in total
________________________________________________________________ ■ ■ ■ ■
________________________________________________________________ ■ ■ ■ ■
________________________________________________________________ ■ ■ ■ ■
________________________________________________________________ ■ ■ ■ ■
+
+
+
+
+
+Development, childcare and life style
36. The following questions concern your child’s development. If you haven’t actually observed your child, spend a little time
looking at what he/she can actually do. (Enter a cross in a box for each question.)
Yes Yes, but No, not Donʼt
often seldom yet know
1. When your child is lying on his/her back, does he/she play by grabbing hold of his/her feet? ■ ■ ■ ■
2. When your child is lying on his/her tummy, does he/she raise his/her upper body off the
ground with straight arms? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
3. Does your child roll over from his/her back onto his/her tummy? . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
4. When you “chat” to your child, does he/she try to “chat” back to you? . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
5. Does your child babble and make sounds when he/she is lying on his/her own?. . . . . . . . . . ■ ■ ■ ■
6. Can you tell how your child is just by listening to the sounds he/she is making (e.g.
contented, hungry, angry,in pain)? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
7. Do you get a smile from your child when you just smile at him/her (without touching or
tickling him/her and without holding up a toy)? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
8. When you call your child, does he/she turn towards you one of the first times
you say his/her name? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
9. Does your child grab hold of a toy you give him/her and then put it in his/her mouth or hold it? . . . . ■ ■ ■ ■
10. When your child is sitting on your lap, does he/she stretch out for a toy or something else on
the table in front of you?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
11. Does your child hold onto a toy with both hands when he/she is examining it? . . . . . . . . . . . ■ ■ ■ ■
37. Where is your child cared for during the day?
■ At home with mother/father/other family member
■ At home with an unqualified childminder
■ At a childminderʼs/family creche
■ In an outdoor nursery
■ In a nursery
38. How many other children are there usually along with
your child during the day?
children   children
39. Does your child go to baby swimming?
■ No
■ Yes
If yes, indicate the number of times during the
last 2 months
40. How often is your child outside? (Enter just one cross.)
■ Seldom
■ Often, but less than 1 hour a day
■ 1-3 hours a day
■ More than 3 hours a day
41. Does your child use a dummy/pacifier?
■ Seldom or never
■ Only when he/she goes to sleep
■ Often
■ Most of the time
42. How many hours in total does your child sleep per 24
hours?
■ Less than 8 hours
■ 8 - 10 hours
■ 11 - 13 hours
■ 13 - 14 hours
■ More than 14 hours +
+
+
35. Has your child been operated on or does he/she have a
condition requiring an operation?
■ No
■ Yes, specify:
______________________________________________
34. Has your child been examined at or admitted to hospital
(since returning home from hospital after birth)?
■ No
■ Yes, specify: ______________________________________________
+
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45. Enter a cross to indicate whether you agree or disagree with the following statements about your child’s mood and tempera-
ment. Think about how he/she usually is. (Enter a cross in a box for each item.)
Neither
agree
Totally Slightly or Slightly Totally
disagree Disagree disagree disagree agree Agree agree
1. Your child whimpers and cries a lot  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
2. Your child is usually easy to pacify when he/she is crying . . . . . . ■ ■ ■ ■ ■ ■ ■
3. It doesnʼt take much for your child to become upset and start crying ■ ■ ■ ■ ■ ■ ■
4. When your child is crying, he/she usually screams angrily and loudly ■ ■ ■ ■ ■ ■ ■
5. Your child is very easy to deal with  . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
6. Your child demands an awful lot of attention  . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
7. When your child is left alone, he/she usually plays contentedly
on his/her own  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
8. Your child is so demanding that he/she would pose a major
problem for most parents  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
9. Your child smiles and laughs often  . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■ ■
10. Your child is easy to put down and goes to sleep quickly  . . . . . . ■ ■ ■ ■ ■ ■ ■
46. Currently how often does your child usually wake up during the night? (Enter just one cross.)
■ 3 or more times every night
■ Once or twice every night
■ A few times a week
■ Seldom or never
Comments
+ +
++
+
43. How do you put your child down when he/she is going to sleep?
(Enter a cross in a box for each item.)
On back On side On tummy
After the birth ■ ■ ■
At 2 months ■ ■ ■
At 4 months ■ ■ ■
At 6 months ■ ■ ■
44. Does your child share a bed with his/her mother/father
(at least half the night)? (Enter a cross in a box for each item.)
No sometimes Often
After the birth ■ ■ ■
At 2 months ■ ■ ■
At 4 months ■ ■ ■
At 6 months ■ ■ ■
8
About yourself
The last time you completed a questionnaire was around week 30 of your pregnancy. The questions we are asking you
now are mainly about the period after this up until your child was 6 months old.
47. Did you go to your doctor/midwife/health visitor for your
own health problems during the first month after the birth?
■ No
■ Yes                      times  
48. If yes, what was the reason for this?
■ Perninealwound/stitches
■ Caesarean section wound
■ Mastitis
■ Sore nipples
■ Breastfeeding problems
■ Other, specify: __________________________________________
49. When you think back to the time just after the birth, did
you feel depressed during that period?
■ No
■ Yes, specify how long: weeks
50. Apart from being in hospital for the birth, have you been admit-
ted to hospital since you completed the previous questionnaire?
■ No
■ Yes, specify hospital: ______________________________________
51. Do you have a chronic/long-term illness which has started
since you completed the previous questionnaire?
■ No
■ Yes, specify: _____________________________________________
52. Overall, how would you describe your physical health at
the moment?
■ Very good
■ Good
■ Poor
■ Very poor
Health and use of medication
53. Have you had any of the following problems/illnesses since you completed the previous questionnaire? If yes, are you taking or have you
taken medication for these problems? (This includes every type of medication, including natural medicines, taken on both a regular and occasional basis.)
(Enter a cross in a box for each item.)
Have you suffered from? If you have taken medication
Yes, last Yes, Last After the birth Numberpart of after part of of days
during the this 0-3 4-6 taken
Illness / problem No pregnancy birth Name of medication taken pregnancy mth   mth in total
1. Sugar in urine . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
2. Protein in urine . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
3. High blood pressure . . ■ ■ ■ _______________________________________ ■ ■ ■
4. Swelling (oedema) . . . . ■ ■ ■ _______________________________________ ■ ■ ■
5. Cystitis . . . . . . . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
6. Sluggish bowels/constipation ■ ■ ■ _______________________________________ ■ ■ ■
7. Diarrhoea/vomiting . . . . ■ ■ ■ _______________________________________ ■ ■ ■
8. Heartburn/acidity . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
9. Common cold/influenza ■ ■ ■ _______________________________________ ■ ■ ■
10. Sore throat/sinusitis/earinfection■ ■ ■ _______________________________________ ■ ■ ■
cont. next page
+
+
+
+
+
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54. Have you taken medicines other than those mentioned in Question 52? (For instance, sleeping tablets, sedatives or analgesics.)
■ No           ■ Yes
55. If yes, give the name of the medicines and when you took them. (Include all types of medication, as well as natural medicines, taken
both on a regular and occasional basis.)
Last part of 0-3 months 4-6 months
pregnancy after the birth after the birth
Name of medicine Taken Number Taken Number Taken Number
(e.g. Valium, Rohypnol, Paracetamol) medication of days medication of days medication of days
__________________________________________________________ ■ ■ ■
__________________________________________________________ ■ ■ ■
__________________________________________________________ ■ ■ ■
56. Do you take or have you taken cod liver oil, vitamins or other dietary supplements since the previous questionnaire?
■ No        ■ Yes
57.  If yes, which product, when did you take it and how often? (One line for each product.)
When did you take the product? How often?
Last part of 0-3 months 4-6 months Taken Taken
Name of product pregnancy after the birth after the birth daily sometimes
_____________________________________________ ■ ■ ■ ■ ■
_____________________________________________ ■ ■ ■ ■ ■
_____________________________________________ ■ ■ ■ ■ ■
+
+
+
+
+
Have you suffered from? If you have taken medication
Yes, last Yes, Last After the birth Numberpart of after part of of days
during the this 0-3 4-6 taken
Illness / problem No pregnancy birth Name of medication taken pregnancy mth mth in total
11. Pneumonia/bronchitis . . ■ ■ ■ _______________________________________ ■ ■ ■
12. Asthma . . . . . . . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
13. Hay fever/other allergy. ■ ■ ■ _______________________________________ ■ ■ ■
14. Headache/other pains . ■ ■ ■ _______________________________________ ■ ■ ■
15. Vaginitis . . . . . . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
16. Mental health problems ■ ■ ■ _______________________________________ ■ ■ ■
17. Mastitis. . . . . . . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
18. Fever . . . . . . . . . . . . . . ■ ■ ■ _______________________________________ ■ ■ ■
19. Other, specify:
__________________________ ■ ■ ■ _______________________________________ ■ ■ ■
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58. Have you experienced any pain in your back or pelvis since you completed the previous questionnaire?
■  No 
■  Yes
59. If yes, enter a cross to indicate where you have experienced pain, when and how much.
Last part of
pregnancy
0-3 months
after the birth
4-6 months
after the birth
Some Major Some Major Some Major
pain pain pain pain pain pain
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
Where was the pain?
Small of the back . . . . . . . . . . . . . . . . 
One of the pelvic/sacroiliac joints at the back
Both pelvic/sacroiliac joints at the back
Over the coccygeal bone . . . . . . . . . . 
In the buttocks . . . . . . . . . . . . . . . . . . 
Over the pubic bone . . . . . . . . . . . . . . 
Groin . . . . . . . . . . . . . . . . . . . . . . . . . . 
Other back pains . . . . . . . . . . . . . . . . 
Problem
Incontinence when coughing, sneezing or laughing . . . 
Incontinence during physical activity (running/jumping)
Incontinence with a strong need to urinate . . . . . . . . . . 
Problems retaining faeces. . . . . . . . . . . . . . . . . . . . . . . 
Problems with flatulence . . . . . . . . . . . . . . . . . . . . . . . . 
60. Currently, do you wake up at night because of pelvic
pain?
■ No, never 
■ Yes, but only sometimes
■ Yes, often
61. Do you have such problems walking at the moment due
to pelvic pain that you have to use a stick or crutches?
■ No, never 
■ Yes, but not every day
■ Yes, every day
62. Have you ever received treatment for pelvic pain?
■ No
■ Yes
63. If yes, enter a cross to indicate the type of treatment and
when it was.
Physiotherapy  . . . . . . .
Chiropractic . . . . . . . . .
Medication  . . . . . . . . .
Other, specify:
_____________________
Before During After
this this this
pregnancy pregnancy birth
■ ■ ■
■ ■ ■
■ ■ ■
■ ■ ■
65. Do you have any of the following problems at the moment; if so, how often and to what extent? (Enter a cross in a box for each item.)
How often do you have these problems? How much at a time?
64, How long was it before you resumed sexual intercour-
se after the birth?
■ Have not had sexual intercourse
weeks
+
+
+
66. How many times did you go for an ultrasound scan
during your pregnancy?
times
67. Was everything OK with the ultrasound scan(s)?
■ Yes 
■ No 
68. If no, what was the problem?
■ The baby was not growing enough.
■ Suspected malformation,describe: 
________________________________________________________
■ Other, specify: __________________________________________
+
+
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1-4 1-6 More than
times times Once Once Large
Never a month a week a day a day Drops amounts
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
69. How much did you weigh at the end of your pregnancy
and how much do you weigh now?
At end of pregnancy kg
Now kg
70. Were you completely or partly on sick leave after week
30 of your pregnancy? (Don’t include maternity leave)
■ No 
■ Yes,partly on sick leave
■ Yes,completely on sick leave
71. If you were on sick leave after week 30 of your pregnancy, complete the table below with a line for each time you were on sick
leave. Give the reason and enter a cross indicating which weeks of your pregnancy you were on sick leave. Specify how many
days and what percentage of the period you were on sick leave each time.
Was on sick leave during pregnancy weeks
Reason for sick leave: 30- 34- Number %
33 37 38+ of days sick leave
___________________________________ ■ ■ ■
___________________________________ ■ ■ ■
___________________________________ ■ ■ ■
___________________________________ ■ ■ ■
X
Finances – lifestyle
+
+ +
1  0 5  0Example: pelvic girdle pains
,
,
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75. If yes, which type(s)? (You can enter a cross in more than one box.)
■ Dog
■ Cat
■ Guinea pig, rabbit, mouse, rat, etc.
■ Budgie, other type of bird
■ Other type of animal:
_____________________________________________
76. Do you have heating based on electrical heating cables
under the floor in rooms where you child is? (Do not include
waterborne heating)
■ No
■ Yes
77. If yes, in which rooms? (You can enter a cross in more than one box.)
■ Living room
■ Kitchen
■ Childʼs room
■ Bedroom
■ Hall 
■ Bathroom
■ Other rooms
72. Would your current financial situation allow you to
cope with an unexpected bill of NOK 10,000 for a dental
visit or a repair, for a instance?
■ No
■ Yes
■ Donʼt know
73. Have you found it difficult sometimes during the last
six month to cope with running expemces for food,
transport, rent etc.?
■ No, never
■ Yes, but infrequently
■ Yes, sometimes
■ Yes, often
74. Are there pets in the child’s home?
■ No
■ Yes
78. How often do you exercise these muscle groups at home or at the gym at present? (Enter a cross in a box for each item.)
1-3 times Three times
times Once Twice or more
Never a month a week a week a week
Stomach muscles  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
Back muscles  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
Pelvic floor muscles (muscles around the vagina, urethra, rectum)  . . . . . ■ ■ ■ ■ ■
+82. Is your child ever present in a room where someone smokes?
■ No
■ Yes, sometimes
■ Yes, several times a week
■ Yes, every day
If every day, number of hours per day
81. What were your and your partner/husband’s smoking habits during the last 3 months of your pregnancy and in the period
after the birth? (Enter a cross in a box for each period.)
Yourself Your partner/husband
Last 3 0-3 4-6 Last 3 0-3 4-6
mths during mths after mths after mths during mths after mths after
pregnancy birth birth pregnancy birth birth
Didnʼt smoke  . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
Smoked sometimes  . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
Smoked every day . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
If every day, number of cigarettes per day
If sometimes, number of cigarettes per week
79. How often are you physically active at present? (Enter a cross in a box for each item.)
Three times
1-3 times Once Twice or more
Never a month a week a week a week
1 Didnʼt smoke  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
2 Brisk walking  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
3 Running/jogging/orienteering  . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
4 Cycling  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
5 Training studio/weight training  . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
6 Special gymnastics/aerobics for pregnant women  . . . . . . . . . . . ■ ■ ■ ■ ■
7 Aerobics/gymnastics/dancing without running and jumping  . . . . ■ ■ ■ ■ ■
8 Aerobics/gymnastics/dancing with running and jumping  . . . . . . ■ ■ ■ ■ ■
9 Dancing (swing, rock, folk)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
10 Skiing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
11 Ball sport  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
12 Swimming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
13 Riding  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
14 Other  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■
80. Currently how often are you physically active (during your spare time or at work) that you get out of breath or sweat?
Spare time At work
Never  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Less than once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
Twice a week . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
3-4 times a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
5 times or more a week  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■
+
+
+
+
83. Did you take any of the following substances during the
last 3 months of your pregnancy and after the birth?
(Enter a cross in a box for each item.)
Yes, last 3 Yes
month of after
No pregnancy birth
Hanish  . . . . . . . . . . . . . ■ ■ ■
Amphetamines . . . . . . . ■ ■ ■
Ecstasy  . . . . . . . . . . . . ■ ■ ■
Cocaine  . . . . . . . . . . . . ■ ■ ■
Heroin  . . . . . . . . . . . . . ■ ■ ■
Other, specify:
–––––––––––––––––––––– ■ ■ ■
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84. Have you taken any of the following substances during the last 3 months of your pregnancy and after the birth? (Enter a cross
in a box for each item.)
Yes, last 3 Yes,
months of after
No pregnancy birth
Anabolic steroids  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Testosterone preparations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Growth hormone (e.g. genotropin/somatropin)  . . . . . . . . . . . . . . . . . . . . ■ ■ ■
85. How often did you drink alcohol during the last 3 months of your pregnancy and how often do you drink now?
(Enter a cross in a box for each period.)
After the birth
Last 3 months 0-3 4-6
of pregnancy months months
Roughly 6-7 times a week . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Roughly 4-5 times a week . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Roughly 2-3 times a week . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Roughly once a week  . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Roughly 1-3 times a month  . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Less often than once a month . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Never  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
86. How many units of alcohol do you usually drink when you consume alcohol (complete both for the last 3 months of your pregnancy
and afterwords)? (See explanation about alcohol units.) (Enter a cross in a box for each period.)
After the birth
Last 3 months 0-3 4-6
Number of alcohol units of pregnancy months months
10 or more . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
7-9  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
5-6  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
3-4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
1-2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
Less than 1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■
A little more about yourself and how you are keeping now
87. Do you have a boyfriend/
husband/partner?
■Yes
■ No
+
+
+
+
+
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Alcohol units
In order compare different types of alcohol, we ask for
the number of alcohol units (= 1.5 cl of pure alcohol).
In practice, this means the following:
1 glass (1/3 litre) of beer = 1 alcohol unit
1 wine glass of red or white wine = 1 alcohol unit
1 sherryglass of sherry = 1 alcohol unit
1 brandy glass of spirits or liquer = 1 alcohol unit
1 bottle of alcopop/cider = 1 alcohol unit
88. If yes, to what extent do you agree with the following descriptions? (Enter just one cross in a box for each item.)
Totally Slightly Slightly Totally
agree Agree agree disagree Disagree disagree
My husband/partner and I have a close relationship . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
My partner and I have problems in our relationship . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am very happy in my relationship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
My partner is usually understanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I often think about ending our relationship. . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I am satisfied with my relationship with my partner . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
We often disagree about important decisions . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I have been lucky in my choice of partner . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
We agree on how children should be raised . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
I think my partner is satisfied with our relationship . . . . . . . . . . . . . . . . . ■ ■ ■ ■ ■ ■
89. In your daily life, how often do you (Enter just one cross in a box for each item.)
Seldom Fairly A few Very
never seldom times Often often
Feel pleased about something ■ ■ ■ ■ ■
Feel happy ■ ■ ■ ■ ■
Feel joyful, as though everything is going your way ■ ■ ■ ■ ■
Feel that you will scream at someone or hit something ■ ■ ■ ■ ■
Feel angry, irritated or annoyed ■ ■ ■ ■ ■
Feel mad at somebody ■ ■ ■ ■ ■
+
+
+
+
+
Have you had problems at work or where you study? . . . . . . . . . . . . . . 
Have you had financial problems?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Have you been divorced, separated or ended your relationship with your partner?
Have you had problems or conflicts with family, friends or neighbours?. 
Have you been seriously worried that there is something wrong with your child?
Have you been seriously ill or injured? . . . . . . . . . . . . . . . . . . . . . . . . . . 
Has anyone close to you been seriously ill or injured? . . . . . . . . . . . . . . 
Have you been involved in a serious accident, fire or robbery? . . . . . . . 
Have you lost someone close to you?. . . . . . . . . . . . . . . . . . . . . . . . . . . 
Have you been pressurized into having sexual intercourse? . . . . . . . . . 
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Neither
agree
Totally Slightly or Slightly Totally
disagree Disagree disagree disagree agree Agree agree
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■ ■
Not so Painful/ Very painful/
No Yes bad difficult difficult
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
■ ■ ■ ■ ■
If yes
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90. Indicate with a cross whether you agree or disagree with the following statements.
(Enter just one cross in a box for each item.)
My life is largely what I wanted it to be . . . . . . . . . . . . . . . . . . . . . . . . . . 
My life is very good . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
I am satisfied with my life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
I have achieved so far what is important for me in my life . . . . . . . . . . . 
If I could start all over, there is very little I would do differently . . . . . . . . 
91. Have you experienced any of the following situations since the previous questionnaire? If yes, how painful or difficult was
this for you? (Enter a cross in a box for each item.)
++
92. Have you experienced any of the following feelings during the last week? (Enter just one cross in a box for each item.)
Yes, almost Yes, now Not very No,
all the time and then often never
Really reproached yourself when something went wrong . . . . . . . . . . . . ■ ■ ■ ■
Have been anxious or worried for no reason. . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Have been afraid or panicked for no reason . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Have been so unhappy that youʼve had problems sleeping . . . . . . . . . . ■ ■ ■ ■
Felt down or unhappy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Have been so unhappy that youʼve cried . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
93. How do you feel about yourself? (Enter just one cross in a box for each item.)
Totally Totally
agree Agree Disagree disagree
I have a positive attitude towards myself  . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel completely useless at times  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel that I do not have much to be proud about . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
I feel that I am a valuable person, as good as anyone else  . . . . . . . . . . ■ ■ ■ ■
94. Have you been bothered by any of the following feelings during the past 2 weeks? (Enter just one cross in a box for each item.)
Not A little Quite Very 
bothered bothered bothered bothered
Feeling fearful  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Nervousness or shakiness inside  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Feeling hopeless about the future  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Feeling blue  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Worrying too much about things  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Feeling everything is an effort  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Feeling tense or keyed up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Suddenly scared for no reason  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ■ ■ ■ ■
Thank you very much for your help!
Insert the completed questionnaire in the stamped addressed envelope.
+
+
+
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APPENDIX 3:  
Directed Acyclic Graphs (paper II) 
  


 
&ŝŐƵƌĞĂ͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐĂƚĐŽŶĐĞƉƚŝŽŶ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚ
ĚĞůŝǀĞƌǇ͕^DK<ͬ>KŝƐƐŵŽŬŝŶŐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇƵŶƚŝůŐĞƐƚĂƚŝŽŶĂůǁĞĞŬϯϬĂŶĚĂůĐŽŚŽůƵƐĞĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕
t'ŝƐǁĞŝŐŚƚŐĂŝŶĚƵƌŝŶŐĞŶƚŝƌĞƉƌĞŐŶĂŶĐǇ͕^>ŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐ
ƚŚƌŽƵŐŚŽƵƚƚŚĞƉƌĞŐŶĂŶĐǇ͕zŝƐƚŚĞŽƵƚĐŽŵĞ͗ƉƐǇĐŚŽƚƌŽƉŝĐŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶƉƌĞŐŶĂŶĐǇ͘hͬ^^ĂŶĚ^DK<ͬ>K
ǁĞƌĞĐŽŵďŝŶĞĚŝŶƚŚĞƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇƉƵƌƉŽƐĞƐ͘dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ
;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘
 
 
&ŝŐƵƌĞď͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚĚĞůŝǀĞƌǇ͕
^DK<ͬ>KŝƐƐŵŽŬŝŶŐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇƵŶƚŝůŐĞƐƚĂƚŝŽŶĂůǁĞĞŬϯϬĂŶĚĂůĐŽŚŽůƵƐĞĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕t'ŝƐ
ǁĞŝŐŚƚŐĂŝŶĚƵƌŝŶŐĞŶƚŝƌĞƉƌĞŐŶĂŶĐǇ͕^>ŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐƚŚƌŽƵŐŚŽƵƚƚŚĞ
ƉƌĞŐŶĂŶĐǇ͕'/ŝƐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůĚŝƐŽƌĚĞƌƐĂŶĚŝŶĐůƵĚĞƐŚĞĂƌƚďƵƌŶͬƌĞĨůƵǆ͕ĚƵŽĚĞŶĂůͬƐƚŽŵĂĐŚƵůĐĞƌƐ͕ƌŽŚŶ
ĚŝƐĞĂƐĞͬƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐĂŶĚŽƚŚĞƌŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƉƌŽďůĞŵƐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕zŝƐƚŚĞŽƵƚĐŽŵĞ͗ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶƉƌĞŐŶĂŶĐǇ͘hͬ^^ĂŶĚ^DK<ͬ>KǁĞƌĞĐŽŵďŝŶĞĚŝŶƚŚĞƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇƉƵƌƉŽƐĞƐ͘
dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘
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

&ŝŐƵƌĞĐ͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚĚĞůŝǀĞƌǇ͕
^DK<ͬ>KŝƐƐŵŽŬŝŶŐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇƵŶƚŝůŐĞƐƚĂƚŝŽŶĂůǁĞĞŬϯϬĂŶĚĂůĐŽŚŽůƵƐĞĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕t'ŝƐ
ǁĞŝŐŚƚŐĂŝŶĚƵƌŝŶŐĞŶƚŝƌĞƉƌĞŐŶĂŶĐǇ͕^>ŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐƚŚƌŽƵŐŚŽƵƚƚŚĞ
ƉƌĞŐŶĂŶĐǇ͕WŝƐƉĂŝŶĚŝƐŽƌĚĞƌƐĂŶĚŝŶĐůƵĚĞƐƉĞůǀŝĐŐŝƌĚůĞ͕ďĂĐŬĂŶĚŽƚŚĞƌƉĂŝŶƐ͕ŚĞĂĚĂĐŚĞͬŵŝŐƌĂŝŶĞĚƵƌŝŶŐ
ƉƌĞŐŶĂŶĐǇ͕zŝƐƚŚĞŽƵƚĐŽŵĞ͗ĂŶĂůŐĞƐŝĐŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶƉƌĞŐŶĂŶĐǇ͘hͬ^^ĂŶĚ^DK<ͬ>KǁĞƌĞĐŽŵďŝŶĞĚŝŶ
ƚŚĞƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇƉƵƌƉŽƐĞƐ͘dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘
 
 
&ŝŐƵƌĞĚ͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚĚĞůŝǀĞƌǇ͕tŝƐ
ǁĞŝŐŚƚĚĞĐƌĞĂƐĞĂƚƐŝǆŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕^>ͲWŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐĂƚƐŝǆ
ŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕&ŝƐďƌĞĂƐƚĨĞĞĚŝŶŐŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͕zŝƐƚŚĞŽƵƚĐŽŵĞ͗ƉƐǇĐŚŽƚƌŽƉŝĐ
ŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͘hͬ^^ǁĂƐĐŽŵďŝŶĞĚŝŶƚŚĞƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇ
ƉƵƌƉŽƐĞƐ͘dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘
 



&ŝŐƵƌĞĞ͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚĚĞůŝǀĞƌǇ͕tŝƐ
ǁĞŝŐŚƚĚĞĐƌĞĂƐĞĂƚƐŝǆŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕^>ͲWŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐĂƚƐŝǆ
ŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕&ŝƐďƌĞĂƐƚĨĞĞĚŝŶŐŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͕zŝƐƚŚĞŽƵƚĐŽŵĞ͗ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͘hͬ^^ǁĂƐĐŽŵďŝŶĞĚŝŶƚŚĞƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇ
ƉƵƌƉŽƐĞƐ͘dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘


&ŝŐƵƌĞĨ͗ŝƌĞĐƚĞĚĐǇĐůŝĐ'ƌĂƉŚ;'ͿǁŚĞƌĞŝƐĞĂƚŝŶŐĚŝƐŽƌĚĞƌďĞĨŽƌĞĂŶĚͬŽƌĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ͕hͬ^^ŝƐ
ĞĚƵĐĂƚŝŽŶĂŶĚƐŽĐŝŽĞĐŽŶŽŵŝĐƐƚĂƚƵƐ͕D/ŝƐďŽĚǇŵĂƐƐŝŶĚĞǆĂƚĐŽŶĐĞƉƚŝŽŶ͕ĂŐĞŝƐŵĂƚĞƌŶĂůĂŐĞĂƚĚĞůŝǀĞƌǇ͕tŝƐ
ǁĞŝŐŚƚĚĞĐƌĞĂƐĞĂƚƐŝǆŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕^>ͲWŝƐŵĂƚĞƌŶĂůƵŶĚĞƌůǇŝŶŐĚĞƉƌĞƐƐŝǀĞĂŶĚĂŶǆŝĞƚǇƐǇŵƉƚŽŵƐĂƚƐŝǆ
ŵŽŶƚŚƐƉŽƐƚƉĂƌƚƵŵ͕&ŝƐďƌĞĂƐƚĨĞĞĚŝŶŐŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͕ͲƐĞĐƚŝŽŶŝƐĐĞƐĂƌĞĂŶƐĞĐƚŝŽŶ͕zŝƐ
ƚŚĞŽƵƚĐŽŵĞ͗ĂŶĂůŐĞƐŝĐŵĞĚŝĐĂƚŝŽŶƵƐĞŝŶŝŶƚŚĞϬͲϲŵŽŶƚŚƐƉĞƌŝŽĚƉŽƐƚƉĂƌƚƵŵ͘hͬ^^ǁĂƐĐŽŵďŝŶĞĚŝŶƚŚĞ
ƐĂŵĞŶŽĚĞĨŽƌƌĞĂĚĂďŝůŝƚǇƉƵƌƉŽƐĞƐ͘dŚĞǇǁĞƌĞƚǁŽƐĞƉĂƌĂƚĞŶŽĚĞƐŝŶ'ŝƚƚǇ;ŚƚƚƉ͗ͬͬǁǁǁ͘ĚĂŐŝƚƚǇ͘ŶĞƚͬͿ͘

 


APPENDICES 4a-4b:  
Additional analyses (paper III) 
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Psychotropic medication use 
 Analysis 1 Analysis 2 
  
aOR (95% CI) 
 
aOR (95% CI) 
Region of residence*   
Western Europe 
Northern Europe 
Eastern Europe 
North America 
South America 
Australia 
Reference 
2.05 (1.54-2.79) 
0.38 (0.23-0.65) 
3.03 (1.98-4.65) 
0.25 (0.08-0.82) 
4.35 (2.61-7.25) 
NA 
Maternal age (years)   
<=20 
21-30  
31-40 
>=41 
0.20 (0.07-0.56) 
Reference 
1.80 (1.37-2.37) 
2.75 (1.47-5.12) 
0.22 (0.09-0.52) 
Reference 
1.91 (1.42-2.57) 
2.84 (1.36-5.92) 
Previous children   
No  
Yes 
Reference 
0.92 (0.71-1.21) 
Reference 
0.96(0.83-1.12) 
Marital status   
Married/cohabiting 
Single/divorced/others 
Reference 
1.73 (1.13-2.63) 
Reference 
1.82 (1.09-3.04) 
Working status   
Employed, but not as HCP 
HCP 
Student 
Housewife 
Job seeker 
Other than above 
Reference 
1.10 (0.75-1.64) 
1.69 (1.06-2.68) 
2.20 (1.51-3.21) 
1.53 (0.89-2.63) 
2.19 (1.39-3.45) 
Reference 
1.32 (1.02-1.69) 
1.86 (1.31-2.65) 
2.31 (1.73-3.07) 
1.66 (1.08-2.56) 
2.26 (1.57-3.28) 
Educational level   
High school 
< High school 
> High school 
Others, unspecified 
Reference 
2.99 (1.93-4.63) 
0.92 (0.68-1.26) 
0.99 (0.64-1.54) 
Reference 
2.67 (1.31-5.42) 
0.90 (0.66-1.24) 
0.91 (0.65-1.47) 
Alcohol use after awareness of pregnancy 
No 
Yes 
Reference 
1.66 (1.22-2.25) 
Reference 
1.48 (1.19-1.85) 
Smoking during pregnancy   
No 
Smoking < than before pregnancy 
6PRNLQJWKDQEHIRUHSUHJQDQF\ 
Reference 
1.69 (1.16-2.45) 
2.10 (1.03-4.30) 
Reference 
1.65 (1.37-1.99) 
2.16 (0.98-4.78) 
Planned pregnancy   
Yes 
No 
Reference 
1.55 (1.08-2.21) 
Reference 
1.60 (1.18-2.16) 
First language different from the official  
main language in the country of residency 
No 
Yes 
Reference 
0.72 (0.40-1.27) 
Reference 
0.78 (0.46-1.32) 
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APPENDICES 5a-5b:  
Results of sensitivity analyses restricted to women with a single participation in the 
MoBa study (paper IV) 
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APPENDICES 6a-6b:  
Results of sensitivity analyses restricted to women with a single participation in the 
MoBa study or participating with only the first pregnancy in case of multiple 
participations (paper IV) 
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